<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML>
<HEAD>
<!-- Created by: EDGAR Online, Inc. EDGAR Filing HTML Converter, Version: 4.66, http://www.edgar-online.com -->
<TITLE> SEATTLE GENETICS INC /WA (Form: 10-K, Received: 02/21/2017 17:10:29) </TITLE>
<META NAME="TABLES" CONTENT="FIS_FORM **FIS_PART_I **FIS_BUSINESS **FIS_RISK_FACTORS **FIS_UNRESOLVED_STAFF_COMMENTS **FIS_PROPERTIES **FIS_LEGAL_PROCEEDINGS **FIS_MINE_SAFETY_DISCLOSURE **FIS_PART_II **FIS_MARKET **FIS_FINANCIAL_DATA **FIS_MANAGEMENTS_DISCUSSION **FIS_RESULTS_OF_OPERATIONS **FIS_MARKET_RISK **FIS_FINANCIAL_STATEMENTS **FIS_AUDITORS_OPINION **FIS_BALANCE_SHEET **FIS_STOCKHOLDERS_EQUITY **FIS_CASH_FLOW **FIS_NOTES_TO_FINANCIAL_STATEMENT **FIS_ACCOUNTING_CHANGES **FIS_CONTROL_AND_PROCEDURES **FIS_OTHER_INFORMATION **FIS_PART_III **FIS_DIRECTORS_AND_OFFICERS **FIS_COMPENSATION **FIS_SECURITY_OWNERS **FIS_OFFICER_TRANSACTIONS **FIS_ACCOUNTANT_FEES **FIS_PART_IV **FIS_EXHIBITS **FIS_SIGNATURES FIS_EXHIBIT_10 FIS_EXHIBIT_10_2 FIS_EXHIBIT_10_3 FIS_EXHIBIT_10_4 FIS_EXHIBIT_10_5 FIS_EXHIBIT_21 **FIS_SUBSIDIARIES FIS_EXHIBIT_23 **FIS_EXPERTS_CONSENT FIS_EXHIBIT_31 **FIS_CERTIFICATION FIS_EXHIBIT_31_2 **FIS_CERTIFICATION_2 FIS_EXHIBIT_32 **FIS_CERTIFICATION_3 FIS_EXHIBIT_32_2 **FIS_CERTIFICATION_4 ">
<META NAME="DETECTED PAGES" CONTENT="167">
<STYLE TYPE="text/css">
<!--
	body          { background-color: white; color: black }
	.eolNewPage   { page-break-after: always; line-height: 0; height: 0; margin: 0; padding: 0 }
	.eolLeftAlign { text-align: left; margin-left: auto; margin-right: auto }
	.eolCenter    { text-align: center }
	a:link        { color: blue }
	a:active      { color: red }
	a:visited     { color: purple }
	
	@media print
	{
		@page           { margin: 0.25in }
		body            { font-size: 10pt }
		a               { text-decoration: none }
		thead           { display: table-header-group }
		tfoot           { display: table-footer-group }
		hr.eolPageBreak { display: none }
		.eolPrint50pt   { font-size: 5pt }
		.eolPrint55pt   { font-size: 5.5pt }
		.eolPrint60pt   { font-size: 6pt }
		.eolPrint65pt   { font-size: 6.5pt }
		.eolPrint70pt   { font-size: 7pt }
		.eolPrint75pt   { font-size: 7.5pt }
		.eolPrint80pt   { font-size: 8pt }
		.eolPrint85pt   { font-size: 8.5pt }
		.eolPrint90pt   { font-size: 9pt }
		.eolPrint95pt   { font-size: 9.5pt }
	}
-->
</STYLE>
</HEAD>
<BODY>
<A NAME="eolPage1"></A>
<A NAME="FIS_TOP_OF_DOCUMENT"></A>

<A NAME="D481013D10K_HTM"></A>
<EFX_FORM>
<A NAME="FIS_FORM"></A>
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="LINE-HEIGHT:3PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX;BORDER-BOTTOM:3PT SOLID #000000">
	&nbsp;
</P>
<P STYLE="LINE-HEIGHT:3PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:2PX;BORDER-BOTTOM:1PT SOLID #000000">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="5">
<B>
	UNITED STATES
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="5">
<B>
	SECURITIES AND EXCHANGE COMMISSION
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Washington, D.C. 20549
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<CENTER>
<P STYLE="LINE-HEIGHT:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:2PX;BORDER-BOTTOM:0.5PT SOLID #000000;WIDTH:26%">
	&nbsp;
</P>
</CENTER>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="5">
<B>
	Form 10-K
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	(Mark One)
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="6%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="3">
<B>
</B>
	&#9746;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="3">
<B>
	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	For the fiscal year ended December&nbsp;31, 2016
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	OR
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="6%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="3">
<B>
</B>
	&#9744;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="3">
<B>
	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	For the transition period from
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Commission file number: 0-32405
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<CENTER>
<P STYLE="LINE-HEIGHT:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:2PX;BORDER-BOTTOM:0.5PT SOLID #000000;WIDTH:26%">
	&nbsp;
</P>
</CENTER>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2017/02/21/0001193125-17-050543_G481013G67K80.JPG" ALT="LOGO">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="5">
<B>
	Seattle Genetics, Inc.
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(Exact name of registrant as specified in its charter)
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="49%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD WIDTH="47%">
</TD>
</TR>
<TR>
<TD VALIGN="TOP" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Delaware
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	91-1874389
</B>
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	(State or other Jurisdiction of
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	incorporation or organization)
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	(I.R.S. Employer
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	Identification No.)
</FONT>
</P>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX;PADDING-BOTTOM:0PX; " ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	21823
	30
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	th
</SUP>
</FONT>
	Drive SE
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Bothell, WA 98021
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(Address of principal executive offices, including zip
	code)
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Registrant&#146;s telephone number, including area code:
<B>
	(425)&nbsp;527-4000
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Securities registered pursuant to Section&nbsp;12(b) of the Act:
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="49%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD WIDTH="47%">
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<P STYLE="BORDER-BOTTOM:1PX SOLID #000000;WIDTH:42PT" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Title of class
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<P STYLE="BORDER-BOTTOM:1PX SOLID #000000;WIDTH:148PT" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Name of each exchange on which registered
</B>
</FONT>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Common Stock, par value $0.001
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	The NASDAQ Stock Market LLC
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Securities registered pursuant to Section&nbsp;12(g) of the Act:
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	None
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<CENTER>
<P STYLE="LINE-HEIGHT:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:2PX;BORDER-BOTTOM:0.5PT SOLID #000000;WIDTH:26%">
	&nbsp;
</P>
</CENTER>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:3%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities
	Act.&nbsp;&nbsp;YES&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;NO&nbsp;&nbsp;&#9744;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:3%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Indicate by check mark if the registrant is not required to file reports pursuant to Section&nbsp;13 or Section&nbsp;15(d) of the
	Act.&nbsp;&nbsp;YES&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;NO&nbsp;&nbsp;&#9746;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:3%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Indicate by check mark whether the registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for
	such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements for the past 90 days.&nbsp;&nbsp;YES&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;NO&nbsp;&nbsp;&#9744;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:3%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Indicate by check mark whether the registrant has submitted
	electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was
	required to submit and post such files).&nbsp;&nbsp;YES&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;NO&nbsp;&nbsp;&#9744;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:3%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Indicate by check mark if disclosure of delinquent filers pursuant to Item&nbsp;405 of Regulation S-K is not contained herein, and will
	not be contained, to the best of registrant&#146;s knowledge, in definitive proxy or information statements incorporated by reference in Part&nbsp;III of this Form&nbsp;10-K or any amendment to this Form 10-K.&nbsp;&nbsp;&#9746;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:3%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Indicate by check mark whether the registrant is a large
	accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule 12b-2 of
	the Exchange Act.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="17%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="58%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="21%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="1%">
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Large&nbsp;accelerated&nbsp;filer
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&#9746;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Accelerated&nbsp;filer
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#9744;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Non-accelerated filer
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;(Do not check if smaller reporting company)
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Smaller&nbsp;reporting&nbsp;company
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#9744;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:3%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Indicate by check mark
	whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&nbsp;&nbsp;YES&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;NO&nbsp;&nbsp;&#9746;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:3%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The aggregate market value of the voting and non-voting
	common equity held by non-affiliates of the registrant was approximately $3,833,493,519 as of the last business day of the registrant&#146;s most recently completed second fiscal quarter, based upon the closing sale price on The NASDAQ Global Select
	Market reported for such date. Excludes an aggregate of 45,611,169 shares of the registrant&#146;s common stock held as of such date by officers, directors and stockholders that the registrant has concluded are or were affiliates of the registrant.
	Exclusion of such shares should not be construed to indicate that the holder of any such shares possesses the power, direct or indirect, to direct or cause the direction of the management or policies of the registrant or that such person is
	controlled by or under common control with the registrant.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:3%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	There were 142,493,676 shares of the registrant&#146;s Common Stock issued and outstanding as of February&nbsp;16, 2017.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	DOCUMENTS INCORPORATED BY REFERENCE
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:3%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Part III incorporates information by reference from the
	registrant&#146;s definitive proxy statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A, not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, in connection with
	the Registrant&#146;s 2017 Annual Meeting of Stockholders.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="LINE-HEIGHT:1PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX;BORDER-BOTTOM:1PT SOLID #000000">
	&nbsp;
</P>
<P STYLE="LINE-HEIGHT:4PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:2PX;BORDER-BOTTOM:2PT SOLID #000000">
	&nbsp;
</P>
<A NAME="eolPage2"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	SEATTLE GENETICS, INC.
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	FORM 10-K
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	FOR THE YEAR ENDED DECEMBER 31, 2016
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D481013D10K_HTM_TOC">
</A>
	TABLE OF CONTENTS
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="7%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="88%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Page
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP" COLSPAN="6" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	PART I
</B>
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	&nbsp;
</B>
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Item&nbsp;1.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D481013D10K_HTM_TOC481013_1">
	Business
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Item&nbsp;1A.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D481013D10K_HTM_TOC481013_2">
	Risk Factors
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	35
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Item 1B.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D481013D10K_HTM_TOC481013_3">
	Unresolved Staff Comments
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	71
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Item 2.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D481013D10K_HTM_TOC481013_4">
	Properties
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	71
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Item 3.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D481013D10K_HTM_TOC481013_5">
	Legal Proceedings
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	71
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Item 4.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D481013D10K_HTM_TOC481013_6">
	Mine Safety Disclosures
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	72
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP" COLSPAN="3" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	PART II
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Item 5.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D481013D10K_HTM_TOC481013_7">
	Market for Registrant&#146;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	73
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Item 6.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D481013D10K_HTM_TOC481013_8">
	Selected Financial Data
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	75
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Item 7.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D481013D10K_HTM_TOC481013_9">
	Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	76
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Item 7A.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D481013D10K_HTM_TOC481013_10">
	Quantitative and Qualitative Disclosures About Market Risk
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	98
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Item 8.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D481013D10K_HTM_TOC481013_11">
	Financial Statements and Supplementary Data
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	99
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Item 9.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D481013D10K_HTM_TOC481013_12">
	Changes in and Disagreements With Accountants on Accounting and Financial Disclosure
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	131
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Item 9A.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D481013D10K_HTM_TOC481013_13">
	Controls and Procedures
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	131
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Item 9B.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D481013D10K_HTM_TOC481013_14">
	Other Information
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	131
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP" COLSPAN="3" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	PART III
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Item 10.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D481013D10K_HTM_TOC481013_15">
	Directors, Executive Officers and Corporate Governance
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	132
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Item 11.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D481013D10K_HTM_TOC481013_16">
	Executive Compensation
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	132
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Item 12.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D481013D10K_HTM_TOC481013_17">
	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	132
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Item 13.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D481013D10K_HTM_TOC481013_18">
	Certain Relationships and Related Transactions, and Director Independence
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	132
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Item 14.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D481013D10K_HTM_TOC481013_19">
	Principal Accounting Fees and Services
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	132
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8" COLSPAN="3">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP" COLSPAN="3" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	PART IV
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="TOP">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Item 15.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D481013D10K_HTM_TOC481013_20">
	Exhibits, Financial Statement Schedules
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	133
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Item&nbsp;16.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D481013D10K_HTM_TOC481013_21">
	Form 10-K Summary
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	137
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D481013D10K_HTM_TOC481013_22">
	Signatures
</A>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	138
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	i
</FONT>
</P>
<A NAME="eolPage3"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<EFX_PART_I>
<A NAME="FIS_PART_I"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	PART I
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	This Annual Report on Form 10-K contains
	forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act of 1933 and Section&nbsp;21E of the Securities Exchange Act of 1934. Forward-looking statements are based on our management&#146;s beliefs and assumptions and on
	information currently available to our management. All statements other than statements of historical facts are &#147;forward-looking statements&#148; for purposes of these provisions, including those relating to future events or our future
	financial performance and financial guidance. In some cases, you can identify forward-looking statements by terminology such as &#147;may,&#148; &#147;might,&#148; &#147;will,&#148; &#147;should,&#148; &#147;expect,&#148; &#147;plan,&#148;
	&#147;anticipate,&#148; &#147;project,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;predict,&#148; &#147;potential,&#148; &#147;intend&#148; or &#147;continue,&#148; the negative of terms like these or other comparable terminology, and
	other words or terms of similar meaning in connection with any discussion of future operating or financial performance. These statements are only predictions. All forward-looking statements included in this Annual Report on Form 10-K are based on
	information available to us on the date hereof, and we assume no obligation to update any such forward-looking statements. Any or all of our forward-looking statements in this document may turn out to be wrong. Actual events or results may differ
	materially. Our forward-looking statements can be affected by inaccurate assumptions we might make or by known or unknown risks, uncertainties and other factors. We discuss many of these risks, uncertainties and other factors in this Annual Report
	on Form 10-K in greater detail under the heading &#147;Item 1A&#151;Risk Factors.&#148; We caution investors that our business and financial performance are subject to substantial risks and uncertainties.
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<EFX_BUSINESS>
<A NAME="FIS_BUSINESS"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D481013D10K_HTM_TOC481013_1">
</A>
	Item&nbsp;1. Business
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Overview
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%;PADDING-BOTTOM:0PX; ">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Seattle Genetics is a biotechnology company focused on the development and
	commercialization of targeted therapies for the treatment of cancer. Our marketed product ADCETRIS
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	&reg;
</SUP>
</FONT>
	, or
	brentuximab vedotin, is now approved by the United States Food and Drug Administration, or FDA, and the European Commission for three indications, encompassing several settings for the treatment of relapsed Hodgkin lymphoma and relapsed systemic
	anaplastic large cell lymphoma, or sALCL. ADCETRIS is commercially available in 66 countries around the world, including in the United States, Canada, members of the European Union and Japan. We are collaborating with Takeda Pharmaceutical Company
	Limited, or Takeda, to develop and commercialize ADCETRIS on a global basis. Under this collaboration, Seattle Genetics retains commercial rights for ADCETRIS in the United States and its territories and in Canada, and Takeda has commercial rights
	in the rest of the world.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Beyond our current
	labeled indications, we and Takeda have a broad development strategy for ADCETRIS evaluating its therapeutic potential in earlier lines of therapy for patients with Hodgkin lymphoma or mature T-cell lymphoma, or MTCL, also known as peripheral T-Cell
	lymphoma, or PTCL, including sALCL, and in other CD30-expressing malignancies. We and Takeda are currently conducting three phase 3 clinical trials of ADCETRIS: ALCANZA, ECHELON-1 and ECHELON-2. All of these trials are being conducted under Special
	Protocol Assessment, or SPA, agreements with the FDA and pursuant to scientific advice from the European Medicines Agency, or EMA. An SPA is an agreement with the FDA regarding the design of the clinical trial, including size and clinical endpoints,
	to support an efficacy claim in a new drug application or a Biologics License Application, or BLA, submission to the FDA if the trial achieves its primary endpoints. We plan to submit a supplemental Biologics License Application, or sBLA, to the FDA
	in mid-2017 to seek approval for a new indication in CD30-expressing relapsed CTCL. We have also completed enrollment of 1,334 patients in our ECHELON-1 trial and expect to report data in 2017. In November 2016, we completed enrollment of 452
	patients in our ECHELON-2 trial, and expect to report data in 2018.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We are also advancing the development of SGN-CD33A, or vadastuximab talirine. A phase 3 clinical trial, called the CASCADE trial, was initiated in the second quarter of 2016 based on data from our phase 1
	clinical trial for patients with acute myeloid leukemia, or AML. The CASCADE trial is evaluating SGN-CD33A in
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1
</FONT>
</P>
<A NAME="eolPage4"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	combination with hypomethylating agents, or HMAs, in previously untreated older patients with AML who are not candidates for intensive induction chemotherapy. We also have been evaluating
	SGN-CD33A in additional treatment settings, and overall, more than 300 patients have been treated with SGN-CD33A to date in clinical trials across these multiple treatment settings. On December&nbsp;27, 2016, we announced that we had received notice
	from the FDA that a full clinical hold or partial clinical hold had been placed on several early stage trials of
<FONT STYLE="WHITE-SPACE:NOWRAP">
	SGN-CD33A
</FONT>
	in AML to evaluate the potential risk of hepatotoxicity following adverse medical
	events, including fatal events. We are working diligently with the FDA to determine whether there is any association between hepatotoxicity and treatment with SGN-CD33A and to promptly identify appropriate measures for patient safety with the goal
	of addressing the FDA&#146;s concerns.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In
	addition, in collaboration with Astellas Pharma, Inc., or Astellas, we are developing ASG-22ME, or enfortumab vedotin. We and Astellas are planning discussions with regulatory agencies during 2017 to advance the program into potential registrational
	trials in urothelial cancer patients, including patients who have been previously treated with a checkpoint inhibitor therapy.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our clinical-stage pipeline also includes six other antibody-drug conjugate, or ADC, programs consisting of SGN-LIV1A, SGN-CD19A, or
	denintuzumab mafodotin, SGN-CD19B, SGN-CD123A, SGN-CD352A, and ASG-15ME, as well as two immuno-oncology agents, SEA-CD40, which is based on our sugar-engineered antibody, or SEA, technology, and SGN-2FF, which is a novel small molecule. In addition,
	we have multiple preclinical and research-stage programs that employ our proprietary technologies, including SGN-CD48A, a preclinical ADC that is a candidate for investigational new drug, or IND, submission in 2017.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We announced on February&nbsp;10, 2017 that we had entered
	into a development and license agreement, or the Immunomedics License, with Immunomedics, Inc., or Immunomedics, pursuant to which, upon the terms and subject to the conditions set forth in the Immunomedics License, we would receive exclusive
	worldwide rights to develop, manufacture and commercialize sacituzumab govitecan, or IMMU-132. IMMU-132 is an ADC targeted to TROP-2, which is expressed in several solid tumors, and is in a pivotal phase 1/2 trial for patients with triple negative
	breast cancer, or TNBC, and is being investigated in other solid tumors. IMMU-132 received Breakthrough Therapy Designation, or BTD, from the FDA for the treatment of patients with TNBC who have failed prior therapies for metastatic disease. In
	connection with the closing of the transactions contemplated by the Immunomedics License, Immunomedics would receive an upfront payment of $250 million. In addition, Immunomedics would also be eligible to receive development, regulatory and
	sales-dependent milestone payments across multiple indications and geographical regions of up to a total maximum of approximately $1.7 billion, as well as royalties which are based on a percentage of annual net sales of the licensed products, if
	any, beginning in the teens and rising to twenty percent based on sales volume. The closing of the transactions contemplated by the Immunomedics License is subject to customary closing conditions, including the expiration of the applicable waiting
	period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, or the HSR Act, there being no pending court or administrative challenges to the Immunomedics License and there being no court or administrative orders blocking the
	closing. On February&nbsp;20, 2017, Immunomedics and we entered into a letter agreement pursuant to which Immunomedics irrevocably waived to the extent applicable to Immunomedics the condition precedent to the closing and effectiveness of the
	Immunomedics License that there be no pending court or administrative challenges to the transaction. Additionally, under the terms of the Immunomedics License, Immunomedics had the right to continue discussions with a small number of parties that
	previously expressed interest in licensing IMMU-132 until 11:59 p.m. New York City time on February&nbsp;19, 2017. If a third party had provided Immunomedics with a financially superior licensing offer, we would have had the right to match any such
	offer, and if we had decided not to match, Immunomedics would have had the right to accept the superior offer and terminate the Immunomedics License upon payment of a termination fee to us. We have not received notice from Immunomedics of any such
	third party offers during this limited time period, and on February 21, 2017, Immunomedics announced that it is subject to customary &#147;no-shop&#148; restrictions on its and its representatives&#146; ability to solicit, discuss or negotiate
	alternative licensing agreement proposals from third parties with regard to IMMU-132.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2
</FONT>
</P>
<A NAME="eolPage5"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On February&nbsp;13, 2017, we were named a co-defendant in a lawsuit filed by venBio Select
	Advisors LLC, or venBio, in the Delaware Chancery Court against the members of the board of directors of Immunomedics pursuant to which, among other things, venBio seeks to enjoin the closing of the transactions contemplated by the Immunomedics
	License. As a result of the pending litigation challenging the transactions contemplated by the Immunomedics License, Immunomedics and we have committed to the Court not to close the transactions contemplated by the Immunomedics License prior to
	March&nbsp;10, 2017. We cannot predict the timing or outcome of this lawsuit or the impact it may have on the Immunomedics License or the closing of the transactions contemplated by the Immunomedics License. See &#147;License
	Agreements&#151;Immunomedics License&#148; below for more information.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We have collaborations for our ADC technology with a number of biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd., or AbbVie; Bayer Pharma AG, or Bayer; Celldex Therapeutics,
	Inc., or Celldex; Genentech, Inc., a member of the Roche Group, or Genentech; GlaxoSmithKline LLC, or GSK; Pfizer, Inc., or Pfizer; and PSMA Development Company LLC, a subsidiary of Progenics Pharmaceuticals Inc., or Progenics. In addition, we have
	entered into a 50/50 co-development agreement with Agensys, Inc., an affiliate of Astellas, for the development of ADCs, including ASG-22ME. We also have an option for an ADC co-development agreement with Genmab A/S, or Genmab, and a collaboration
	with Unum Therapeutics, Inc., or Unum, to develop and commercialize novel antibody-coupled T-cell receptor, or ACTR, therapies incorporating our antibodies for the treatment of cancer.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Our Antibody-Drug Conjugate (ADC) Technologies
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	ADCETRIS and many product candidates in our pipeline of
	clinical-stage monoclonal antibody-based product candidates utilize our ADC technology. ADCs are monoclonal antibodies that are linked to cytotoxic or cell-killing agents. Our ADCs utilize monoclonal antibodies that internalize within target cells
	after binding to a specified cell-surface receptor. Enzymes present inside the cell catalyze the release of the cytotoxic agent from the monoclonal antibody, which then results in the desired activity, specific killing of the target cell.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	A key component of our ADCs are the linkers that
	attach the cell-killing agent to the monoclonal antibody, which are designed to hold the cytotoxic agent to the monoclonal antibody until it binds to the cell surface receptor on the target cell and then to release the cytotoxic agent upon
	internalization within the target cell. This targeted delivery of the cell-killing agent is intended to maximize delivery of the cytotoxic agent to targeted cells while minimizing toxicity to normal tissues. Our ADCs use proprietary auristatins,
	which are microtubule disrupting agents, or pyrrolobenzodiazepine, or PBD, dimers, which are DNA cross-linkers, as cell-killing agents. The PBD dimer cell-killing agent is stably linked to an antibody using our proprietary, site-specific conjugation
	technology, resulting in uniform drug-loading of two PBD dimers per antibody. We call this engineered antibody an EC-mAb. In contrast to natural products that are often more difficult to produce and link to antibodies, the cytotoxic drugs used in
	our ADC&#146;s are synthetically produced and easier to scale for manufacturing. ADCETRIS, SGN-CD33A (vadastuximab talirine), ASG-22ME (enfortumab vedotin), SGN-LIV1A, SGN-CD19A (denintuzumab mafodotin), SGN-CD19B, SGN-CD123A, SGN-CD352A, and
	ASG-15ME, each utilize our proprietary, auristatin-based or PBD-based ADC technologies. These technologies are also the basis of our corporate collaborations. In addition, we are advancing a preclinical product candidate, SGN-CD48A, which utilizes a
	novel linker technology, PEG-Glucuronide linker, attached to an auristatin. We own or hold exclusive or partially-exclusive licenses to multiple issued patents and patent applications covering our ADC technology. We continue to evaluate new linkers,
	antibody formats, and cell-killing agents for use in our ADC programs.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Our Sugar-Engineered Antibody (SEA) Technology
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our proprietary SEA technology is a method to selectively reduce fucose incorporation in monoclonal antibodies as they are produced in cell line-based manufacturing. We believe that this may result in
	increased effector function and antitumor activity. Our SEA technology is a novel approach to modify the activity of monoclonal antibodies that is complementary to our ADC technology.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	3
</FONT>
</P>
<A NAME="eolPage6"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	A key feature of our SEA technology is that no genetic modification of the
	antibody-producing cell line is necessary and standard cell culture conditions can be used while maintaining the underlying manufacturing processes, yields and product quality. We believe the SEA approach may be simpler and more cost-effective to
	implement as compared to existing technologies for enhancing antibody effector function, most of which require development of new cell lines.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	SEA-CD40 is a clinical-stage non-fucosylated monoclonal antibody developed using SEA technology. Enhanced binding to effector cells
	results in crosslinking and activation of CD40 signaling in immune cells. We hypothesize that this increased stimulation of the patient&#146;s own immune cells may result in meaningful antitumor activity. We are developing SEA-CD40 as a novel
	immuno-oncology agent. A phase 1 clinical trial of SEA-CD40 for solid tumors and hematologic malignancies is ongoing.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Other Technologies
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In addition, we utilize other technologies designed to maximize antitumor activity and reduce toxicity of antibody-based therapies.
	Genetic engineering enables us to produce antibodies that are optimized for their intended uses. For ADCs, we screen and select antibodies that bind to antigens that are differentially expressed on tumor cells versus vital normal tissues, rapidly
	internalized within target cells and utilize native or engineered conjugation sites to optimize drug attachment. In some cases, we evaluate the use of our monoclonal antibodies and ADCs in combination with conventional chemotherapy and other
	anticancer agents, which may result in increased antitumor activity.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Our Strategy
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our strategy is to become a leading developer and marketer of targeted therapies for cancer. Key elements of our strategy are to:
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Successfully Execute our ADCETRIS Commercial Plan.
</I>
	&nbsp;&nbsp;&nbsp;&nbsp;An important near-term objective is to continue to execute our
	ADCETRIS commercial plan by driving market penetration and duration of therapy consistent with the current ADCETRIS label. We continue to focus our efforts on commercializing ADCETRIS in the United States and Canada through the coordinated efforts
	of our sales, marketing, reimbursement and market planning groups. In addition, as of January&nbsp;31, 2017, ADCETRIS had received marketing authorizations in relapsed Hodgkin lymphoma and sALCL from regulatory authorities in 66 countries, and we
	are continuing to support Takeda&#146;s efforts to obtain regulatory approvals and conduct commercial launches in additional countries worldwide.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Expand the Therapeutic Potential of ADCETRIS.
</I>
	&nbsp;&nbsp;&nbsp;&nbsp;We believe ADCETRIS may have applications in earlier lines of therapy for
	Hodgkin lymphoma and MTCL and in other types of CD30-expressing lymphomas. In this regard, during 2016 we reported data from the ALCANZA trial and intend to submit an sBLA to the FDA in mid-2017 to seek approval for a new indication in
	CD30-expressing relapsed CTCL. We also have ongoing clinical trials evaluating ADCETRIS in frontline therapy for Hodgkin lymphoma (the ECHELON-1 trial) and MTCL (the ECHELON-2 trial). Clinical trials are also being conducted by us, by our
	collaborators and as investigator sponsored trials in different CD30-expressing indications, including salvage therapy for patients with Hodgkin lymphoma prior to autologous hematopoietic stem cell transplant, or auto-HSCT, novel combinations of
	ADCETRIS plus immuno-oncology or other anticancer agents and in other areas of medical and scientific interest.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Advance Clinical Pipeline of Oncology Drugs.
</I>
	&nbsp;&nbsp;&nbsp;&nbsp;We are employing our clinical, development, regulatory and manufacturing
	expertise with the goal of advancing our clinical stage product candidates towards regulatory approval and commercialization on a global basis. Our efforts in this regard include:
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="9%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="3%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Evaluate SGN-CD33A in AML and Myelodysplatic Syndrome Patient Populations.
</I>
	&nbsp;&nbsp;&nbsp;&nbsp;In the second quarter of 2016, we initiated
	the phase 3 CASCADE trial evaluating SGN-CD33A in combination with HMAs in previously untreated older patients with AML who are not candidates for intensive induction chemotherapy. We are also evaluating SGN-CD33A in additional treatment settings.
	On December 27, 2016, we announced that we had received notice from the FDA that a full clinical
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	4
</FONT>
</P>
<A NAME="eolPage7"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="13%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<P>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	hold or partial clinical hold had been placed on several early stage trials of SGN-CD33A in AML to evaluate the potential risk of hepatotoxicity following adverse medical events, including fatal
	events. We are working diligently with the FDA to determine whether there is any association between hepatotoxicity and treatment with SGN-CD33A, and to promptly identify appropriate measures for patient safety with the goal of addressing the
	FDA&#146;s concerns. No new studies of SGN-CD33A will be initiated unless and until the clinical holds are lifted. Our phase 3 CASCADE trial in older AML patients and our phase 1/2 trial in myelodysplastic syndrome, or MDS, are currently proceeding
	with enrollment.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="9%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="3%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Advance ASG-22ME into Registrational Trials for Urothelial Cancer.&nbsp;&nbsp;&nbsp;&nbsp;
</I>
	We and Astellas are planning discussions with
	regulatory agencies during 2017 to advance the program into potential registrational trials of ASG-22ME in urothelial cancer patients, including patients who have been previously treated with a checkpoint inhibitor therapy.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Global Expansion.
</I>
	&nbsp;&nbsp;&nbsp;&nbsp;We have established operations in Zug, Switzerland to support clinical trials, regulatory, medical
	affairs and manufacturing and future potential commercial activities for our pipeline. In 2017, we will continue to develop our European presence in support of our global expansion.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Continue to Develop our Other Pipeline Programs.
</I>
	&nbsp;&nbsp;&nbsp;&nbsp;We believe that it is important to maintain a diverse pipeline of
	product candidates to sustain our future growth. To accomplish this, we are continuing to advance the development of our other clinical product candidates, including SGN-LIV1A, SGN-CD19A, SEA-CD40, SGN-CD19B, SGN-CD123A, SGN-CD352A, SGN-2FF and
	ASG-15ME, as well as other preclinical and research-stage programs that employ our proprietary technologies. In addition, we have an ADC co-development agreement with Genmab that provides us with a future ADC product opportunity and we are
	co-developing several preclinical immuno-oncology programs with Unum Therapeutics.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Continue to Leverage our Industry-Leading ADC Technology.&nbsp;&nbsp;&nbsp;&nbsp;
</I>
	We have developed proprietary ADC technology designed to
	empower monoclonal antibodies. We are currently developing multiple product candidates that employ our ADC technology and we have also licensed this technology to biotechnology and pharmaceutical companies to generate collaboration revenues and
	funding, as well as potential milestones and potential future royalties. Presently, we have active ADC collaborations with AbbVie, Bayer, Celldex, Genentech, GSK, Pfizer, and Progenics, as well as ADC co-development agreements with Astellas and
	Genmab. These ADC collaboration and co-development agreements have generated over $350 million as of December&nbsp;31, 2016 through a combination of upfront payments, research support, and other fees, milestone payments and equity purchases.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Support Future Growth of our Pipeline through Internal Research Efforts and Strategic In-Licensing.&nbsp;&nbsp;&nbsp;&nbsp;
</I>
	We have internal
	research programs directed toward identifying novel antigen targets, monoclonal antibodies and other targeting molecules, creating new antibody engineering techniques and developing new classes of stable linkers and cell-killing agents for our ADC
	technology. In addition, we supplement these internal efforts through ongoing initiatives to identify product candidates, products and technologies to in-license from biotechnology and pharmaceutical companies and academic institutions. In this
	regard, we recently announced our entry into the Immunomedics License, pursuant to which, if the transactions contemplated by the Immunomedics License are consummated, we would receive exclusive worldwide rights to develop, manufacture and
	commercialize IMMU-132.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Enter into Strategic Product Collaborations to Supplement our Internal Resources.&nbsp;&nbsp;&nbsp;&nbsp;
</I>
	We enter into collaborations to broaden
	and accelerate clinical trial development and potential commercialization of our product candidates. Collaborations can generate significant capital, supplement our own internal expertise in key areas such as manufacturing, regulatory affairs and
	clinical development, and provide us with access to our collaborators&#146; marketing, sales and distribution capabilities in specific territories. When establishing strategic collaborations, we seek beneficial financial terms and endeavor to retain
	significant product rights, particularly in the United States, Canada and Europe.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	5
</FONT>
</P>
<A NAME="eolPage8"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_2"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	ADCETRIS and Product Candidate Development Pipeline
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The following table summarizes our ADCETRIS and product
	candidate development pipeline:
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="14%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="20%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="19%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="44%">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Name&nbsp;of&nbsp;Product&nbsp;or
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX;BORDER-BOTTOM:1PX SOLID #000000;WIDTH:67PT" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Product Candidate
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Description
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Commercial Rights
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Status
</B>
</FONT>
</P>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	ADCETRIS
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	&reg;
</SUP>
</FONT>
	(brentuximab vedotin)
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Anti-CD30 ADC
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Seattle Genetics in United States and Canada; Takeda in rest of world
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	ADCETRIS has regular approval in the United States for the treatment of patients with (i)&nbsp;relapsed classical Hodgkin lymphoma or
	(ii)&nbsp;classical Hodgkin lymphoma at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation, or post-auto-HSCT consolidation. ADCETRIS also has accelerated approval in the United States for the treatment of
	patients with relapsed sALCL. In addition, ADCETRIS has approval with conditions in Canada for the treatment of patients with relapsed Hodgkin lymphoma or sALCL.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	As of January 31, 2017, ADCETRIS had received marketing authorizations in
	relapsed Hodgkin lymphoma or relapsed sALCL from regulatory authorities in 66 countries. In particular, ADCETRIS has conditional marketing authorization in the European Union and marketing authorization in Japan for patients with relapsed Hodgkin
	lymphoma or relapsed sALCL. In January 2016, Takeda received an additional approval from the European Commission for retreatment of adult patients with relapsed or refractory Hodgkin lymphoma or sALCL who previously responded to ADCETRIS and who
	later relapse. In June 2016, the European Commission approved ADCETRIS for the treatment of adult patients with CD30-positive Hodgkin lymphoma at increased risk of relapse or progression following autologous stem cell transplant, or ASCT.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Ongoing trials of ADCETRIS include:
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The ALCANZA phase 3 randomized trial for relapsed CD30-expressing CTCL
	patients, comparing ADCETRIS versus investigator&#146;s choice of methotrexate or bexarotene. In 2016, we reported that the ALCANZA phase 3 trial met its primary endpoint. Based on the results of the trial, we expect to submit an sBLA to the FDA in
	mid- 2017 for approval of a new indication in CD30-expressing relapsed CTCL.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	6
</FONT>
</P>
<A NAME="eolPage9"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="12%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="20%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="19%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="46%">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The ECHELON-1 phase 3 randomized trial ongoing for patients with newly diagnosed advanced stage classical Hodgkin lymphoma comparing
	adriamycin, bleomycin, vinblastine and dacarbazine, or ABVD, versus AVD plus ADCETRIS. We expect to report data in 2017.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The ECHELON-2 phase 3 randomized trial ongoing for patients with newly diagnosed CD30-expressing MTCL, including sALCL, comparing
	cyclophosphamide, doxorubicin, vincristine and prednisone, or CHOP, versus CHP plus ADCETRIS. Enrollment was completed in November 2016 and we expect to report data in 2018.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Phase 2 trial ongoing for patients age 60 or older with newly diagnosed Hodgkin lymphoma evaluating ADCETRIS as frontline monotherapy or
	in combination with other agents, including bendamustine or dacarbazine. In late 2016, the trial was amended to evaluate the combination of ADCETRIS and nivolumab.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Phase 1/2 second-line trial ongoing for patients with relapsed Hodgkin
	lymphoma evaluating ADCETRIS in combination with bendamustine.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Phase 2 trial ongoing for patients with relapsed or refractory CD30-expressing diffuse large B-cell lymphoma, or DLBCL, evaluating rituximab and
	bendamustine either with or without ADCETRIS.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Phase 1/2 trial
	ongoing for patients with relapsed or refractory Hodgkin lymphoma after failure of frontline therapy evaluating ADCETRIS in combination with nivolumab.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Phase 1/2 trial ongoing for patients with relapsed or refractory B-cell and T-cell non-Hodgkin lymphomas, including DLBCL, evaluating ADCETRIS in
	combination with nivolumab. In 2016, the trial was amended to also evaluate the combination in rare B-cell lymphomas.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Phase 2 monotherapy trial ongoing for patients with systemic lupus erythematosus.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<A NAME="FIS_UNIDENTIFIED_TABLE_3"></A>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	SGN-CD33A (vadastuximab talirine)
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Anti-CD33 ADC
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Seattle Genetics
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Phase 3 CASCADE trial ongoing to evaluate SGN-CD33A in combination with HMAs in previously untreated older AML patients.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	7
</FONT>
</P>
<A NAME="eolPage10"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="13%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="20%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="19%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="45%">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Phase 1/2 trial ongoing for patients with previously untreated MDS evaluating SGN-CD33A in combination with azacitidine.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Several early stage trials of SGN-CD33A are on a full or partial clinical
	hold. See
<FONT STYLE="WHITE-SPACE:NOWRAP">
	&#147;SGN-CD33A
</FONT>
	(Vadastuximab Talirine)&#148; below for more information on these trials.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<A NAME="FIS_UNIDENTIFIED_TABLE_4"></A>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	ASG-22ME (enfortumab vedotin)
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Anti-Nectin-4 ADC
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	50: 50
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	co-development and
	commercialization with Astellas
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Phase 1 trial ongoing for Nectin-4-positive solid tumors, including urothelial cancers such as bladder cancer.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	SGN-LIV1A
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Anti-LIV-1 ADC
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Seattle Genetics
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Phase 1 trial ongoing for patients with LIV-1-positive metastatic breast cancer, in particular triple negative disease. In addition, the
	trial was expanded to include patients who are LIV-1 positive and HER2 positive to evaluate SGN-LIV1A in combination with trastuzumab.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	SGN-CD19A (denintuzumab mafodotin)
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Anti-CD19 ADC
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Seattle Genetics
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Phase 2 randomized trial ongoing for patients with relapsed DLBCL evaluating SGN-CD19A in combination with rituximab, ifosfamide,
	carboplatin and etoposide, or RICE, to RICE alone.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Phase 2
	randomized trial ongoing for patients with newly diagnosed DLBCL comparing a combination therapy that includes SGN-CD19A versus standard frontline therapy.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	SEA-CD40
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Anti-CD40 SEA empowered antibody
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Seattle Genetics
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Phase 1 trial ongoing for patients with solid tumors. In 2016, the trial was amended to include patients with hematologic
	malignancies.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	SGN-CD19B
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Anti-CD19 ADC
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Seattle Genetics
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Phase 1 trial ongoing for patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	SGN-CD123A
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Anti-CD123 ADC
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Seattle Genetics
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Phase 1 trial ongoing for patients with relapsed or refractory AML.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	SGN-CD352A
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Anti-CD352 ADC
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Seattle Genetics
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Phase 1 trial ongoing for patients with relapsed or refractory multiple myeloma.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	SGN-2FF
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Small molecule
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Seattle Genetics
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Phase 1 trial ongoing for patients with advanced solid tumors.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	ASG-15ME
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Anti-SLITRK6 ADC
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	50: 50
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	co-development and
	commercialization with Astellas
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Phase 1 trial ongoing for patients with urothelial cancer.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8
</FONT>
</P>
<A NAME="eolPage11"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	ADCETRIS
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	ADCETRIS is an ADC comprised of an anti-CD30 monoclonal
	antibody attached by a protease-cleavable linker to a proprietary microtubule disrupting agent, monomethyl auristatin E, or MMAE. ADCETRIS employs a linker system that is designed to be stable in the bloodstream and to release MMAE upon
	internalization into CD30-expressing cells. We believe that the CD30 antigen is an attractive target for cancer therapy because it is expressed on multiple types of cancer, but has limited expression on normal tissues. We are collaborating with
	Takeda on the global development and commercialization of ADCETRIS. Under this collaboration, we retain commercial rights in the United States and Canada. Takeda has exclusive rights to commercialize ADCETRIS in the rest of the world. ADCETRIS has
	received regulatory approvals as follows:
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
	United States
</U>
	.&nbsp;&nbsp;&nbsp;&nbsp;ADCETRIS
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	&reg;
</SUP>
</FONT>
	(brentuximab vedotin) injection for intravenous infusion has received approval from the FDA for three indications: (1)&nbsp;regular approval for the treatment of
	patients with classical Hodgkin lymphoma after failure of auto-HSCT or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates, (2)&nbsp;regular approval for the treatment of classical
	Hodgkin lymphoma patients at high risk of relapse or progression as post-auto-HSCT consolidation, and (3)&nbsp;accelerated approval for the treatment of patients with sALCL after failure of at least one prior multi-agent chemotherapy regimen. The
	sALCL indication is approved under accelerated approval based on overall response rate. Continued approval for the sALCL indication is contingent upon verification and description of clinical benefit in confirmatory trials.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
	Canada
</U>
	.&nbsp;&nbsp;&nbsp;&nbsp;Health Canada has issued a Notice of Compliance with conditions, authorizing marketing of ADCETRIS for two
	lymphoma indications: (1)&nbsp;the treatment of patients with Hodgkin lymphoma after failure of ASCT, or after failure of at least two multi-agent chemotherapy regimens in patients who are not ASCT candidates, and (2)&nbsp;the treatment of patients
	with sALCL after failure of at least one multi-agent chemotherapy regimen. The indications for ADCETRIS were authorized based on promising response rates demonstrated in single-arm trials.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
	European Union
</U>
	.&nbsp;&nbsp;&nbsp;&nbsp;ADCETRIS was granted conditional marketing authorization by the European Commission in October 2012 for
	two indications: (1)&nbsp;for the treatment of adult patients with relapsed or refractory CD30-positive Hodgkin lymphoma following ASCT, or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option, and
	(2)&nbsp;the treatment of adult patients with relapsed or refractory sALCL. The European Commission extended the current conditional approval of ADCETRIS and approved ADCETRIS for the treatment of adult patients with CD30-positive Hodgkin lymphoma
	at increased risk of relapse or progression following ASCT.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<U>
	Worldwide
</U>
	.&nbsp;&nbsp;&nbsp;&nbsp;As of January&nbsp;31, 2017, ADCETRIS is commercially available in 66 countries for relapsed or refractory
	Hodgkin lymphoma and relapsed or refractory sALCL.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:2%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Required ADCETRIS Post-approval Clinical Study
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	ADCETRIS was granted approval for the treatment of patients with sALCL after failure of at least one prior multi-agent chemotherapy regimen under the FDA&#146;s accelerated approval regulations, which
	allows the FDA to approve products for cancer or other serious or life-threatening illnesses based on surrogate endpoints or on a clinical endpoint other than survival or irreversible morbidity. Under the FDA&#146;s accelerated approval regulations,
	we are subject to certain post-approval requirements pursuant to which we are conducting an additional confirmatory phase 3 trial to verify and describe the clinical benefit of ADCETRIS. In addition, we are subject to extensive ongoing obligations
	and continued regulatory review from the FDA and other applicable regulatory agencies, such as continued adverse event reporting requirements and the requirement to have our promotional materials pre-cleared by the FDA.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Successful completion of our AETHERA trial converted our
	accelerated approval to regular approval in the relapsed Hodgkin lymphoma indication. ECHELON-2 is a required post-approval study to convert the approval of ADCETRIS in the United States from accelerated approval to regular approval in its currently
	approved relapsed sALCL indication; however, the FDA has indicated that positive results from either the ECHELON-1 or
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	9
</FONT>
</P>
<A NAME="eolPage12"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	the ECHELON-2 trial could form the basis for such a conversion. Post-approval clinical studies similar to those required by the FDA are required in many other countries, including in Canada and
	the European Union. The requirements of these post-approval clinical studies vary from country to country and may in some cases involve testing in addition to the post-approval studies required by the FDA.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:2%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Market Opportunities
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	According to the American Cancer Society, more than 8,500
	cases of Hodgkin lymphoma were expected to be diagnosed in the United States during 2016, and an estimated 1,120 people were expected to die of the disease. Approximately 1,800 additional patients per year in the United States are diagnosed with
	sALCL, a type of MTCL that expresses the CD30 antigen. The use of combination chemotherapy as frontline therapy for malignant lymphomas has resulted in high remission rates; however, these frontline chemotherapy regimens have substantial associated
	toxicities and a significant number of lymphoma patients relapse and require additional treatments including other chemotherapy regimens and ASCT. For the reasons discussed in &#147;Item 1A&#151;Risk Factors&#148;, we may not be able to obtain
	regulatory approvals to market ADCETRIS for frontline Hodgkin lymphoma or MTCL, or otherwise continue to expand its labeled indications of use.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:2%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Clinical Development Status and Plan
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In collaboration with Takeda, we are pursuing a broad development strategy that includes clinical trials of ADCETRIS both as a single
	agent and in combination with standard therapies for CD30-expressing cancers. These ongoing clinical trials include:
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Phase 3 Cutaneous T-Cell Lymphoma (ALCANZA).&nbsp;&nbsp;&nbsp;&nbsp;
</I>
	The ALCANZA trial is a randomized, open-label, phase 3 trial of
	ADCETRIS versus investigator&#146;s choice of methotrexate or bexarotene in patients with
<FONT STYLE="WHITE-SPACE:NOWRAP">
	CD30-expressing
</FONT>
	CTCL, including those with pcALCL or mycosis fungoides. The ALCANZA trial enrolled 131&nbsp;patients
	and is being conducted under an SPA agreement with the FDA and also received EMA scientific advice. In August 2016, we reported that the ALCANZA phase 3 trial met its primary endpoint and showed that treatment with ADCETRIS resulted in a
	statistically significant improvement in the rate of objective response lasting at least four months (ORR4) versus the control arm as assessed by an independent review committee
<FONT STYLE="WHITE-SPACE:NOWRAP">
	(p-value
</FONT>
	&lt;0.0001).
	Additional data were reported at the December 2016 American Society of Hematology, or ASH, annual meeting showing that the median progression free survival, or PFS, in the ADCETRIS arm was 16.7 months compared to 3.5 months in the control arm
	(p-value &lt;0.0001). The most common adverse events of any grade occurring in 15 percent or more of patients in the ADCETRIS and control arms were peripheral neuropathy (67 and six percent, respectively), nausea (36 and 13 percent, respectively),
	diarrhea (29 and six&nbsp;percent, respectively), fatigue (29 and 27 percent, respectively), vomiting (17 and five percent, respectively), alopecia (15 and three percent, respectively), pruritis (17 and 13 percent respectively), fever (17 and 18
	percent, respectively), decreased appetite (15 and five percent, respectively) and hypertriglyceridemia (2 and 18 percent, respectively). We plan to submit a sBLA to the FDA in mid-2017 to seek approval for a new indication in
<FONT STYLE="WHITE-SPACE:NOWRAP">
	CD30-expressing
</FONT>
	relapsed CTCL. ADCETRIS is included in National Comprehensive Cancer Network, or NCCN, treatment guidelines for patients with certain types of CTCL.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Phase 3 Frontline Hodgkin Lymphoma
	(ECHELON-1)
</I>
	.&nbsp;&nbsp;&nbsp;&nbsp;We and Takeda have completed patient enrollment of 1,334 patients in a randomized, open-label, phase 3 trial investigating ADCETRIS plus AVD versus ABVD as frontline therapy in patients with advanced classical
	Hodgkin lymphoma, or the ECHELON-1 trial. The study enrolled patients who have histologically-confirmed diagnosis of Stage III or IV classical Hodgkin lymphoma and who have not been previously treated with systemic chemotherapy or radiotherapy. The
	primary endpoint of this trial is modified PFS per independent review facility assessment. Secondary endpoints include overall survival, complete remission rate and safety. The trial is being conducted under an SPA agreement with the FDA and also
	received scientific advice from the EMA. We expect to report data from this trial in 2017.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Data from a phase 1 trial in frontline Hodgkin lymphoma that evaluated ADCETRIS combined with ABVD or combined with AVD supported our decision to initiate the ECHELON-1 phase 3 trial. In November 2013,
	data
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10
</FONT>
</P>
<A NAME="eolPage13"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	from the phase 1 trial were published in the medical publication
<I>
	Lancet Oncology
</I>
	. Among the 25 evaluable patients in the ADCETRIS plus AVD cohorts, 24 patients who completed frontline
	therapy on study achieved a complete remission. Follow-up data were reported at the December 2014 ASH annual meeting showing that in the ADCETRIS plus AVD arm, three-year overall survival was 100 percent and three-year failure-free survival was 92
	percent. In the ADCETRIS plus ABVD arm, three-year overall survival was 92 percent and three-year failure-free survival was 79 percent. Grade 3 or higher adverse events occurring in more than one patient overall noted in the ABVD and AVD cohorts,
	respectively, were neutropenia (80 percent, 77 percent), anemia (20 percent, 12 percent), febrile neutropenia (20 percent, 8 percent) and pulmonary toxicity (24 percent, 0 percent).
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Phase 3 Frontline Mature T-Cell Lymphoma (ECHELON-2).&nbsp;&nbsp;&nbsp;&nbsp;
</I>
	We and Takeda have
	completed patient enrollment of 452 patients in a global randomized, double-blind, placebo-controlled multi-center phase 3 clinical trial known as ECHELON-2. This trial is evaluating ADCETRIS in combination with CHP versus CHOP for the treatment of
	newly diagnosed CD30-expressing MTCL patients, including patients with sALCL and other types of peripheral T-cell lymphomas. The primary endpoint of the trial is PFS per independent review facility assessment. Secondary endpoints include overall
	survival, complete remission rate and safety. We expect to report data in 2018. A molecular companion diagnostic test is being used in this trial to identify eligible patients based on CD30-expression. We are developing a companion diagnostic under
	a collaboration agreement with Ventana Medical Systems, or Ventana, and Takeda. The ECHELON-2 trial is being conducted under an SPA agreement with the FDA and also received scientific advice from the EMA. We are required to conduct this trial as
	part of our ADCETRIS post-marketing requirement for the relapsed sALCL indication, and the trial is designed to be confirmatory in the United States, Canada and Europe.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Data from a phase 1 trial that evaluated ADCETRIS plus
	chemotherapy for frontline sALCL, which was subsequently amended to include patients with any CD30-expressing MTCL, supported our decision to initiate the ECHELON-2 trial. Among the 26 patients who received the combination regimen of ADCETRIS plus
	CHP, 88 percent achieved a complete remission. At the December 2016 ASH annual meeting, follow-up data were reported showing that the estimated four-year PFS rate was 52 percent, with no patients receiving a consolidative stem cell transplant in
	first remission. The estimated four-year overall survival rate was 80 percent. There were no progression events or deaths in the trial since the previous presentation at the 2015 ASH annual meeting. The most common adverse events of any grade
	occurring in more than 30 percent of patients were nausea and peripheral sensory neuropathy (69 percent each), diarrhea (62 percent), fatigue (58 percent) and hair loss (54 percent). ADCETRIS is included in NCCN treatment guidelines for patients
	with relapsed CD30-expressing PTCL.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Frontline
	Therapy for Hodgkin Lymphoma Patients Age 60 and Over
</I>
	.&nbsp;&nbsp;&nbsp;&nbsp;In October 2012, we initiated a phase 2 clinical trial evaluating ADCETRIS monotherapy as a frontline therapy for patients age 60 or older with newly diagnosed Hodgkin
	lymphoma. The trial was subsequently amended to include the administration of ADCETRIS in combination with bendamustine or dacarbazine. The phase 2 open-label clinical trial is evaluating the activity and tolerability of ADCETRIS in patients age 60
	or older with newly diagnosed Hodgkin lymphoma. The primary endpoint of the trial is the objective response rate, with key secondary endpoints of safety and tolerability, duration of response, complete remission rate and PFS. At the October 2016
	International Symposium on Hodgkin Lymphoma, or ISHL, meeting, we presented updated data from this study. Of 21 evaluable patients in the dacarbazine combination arm, all patients (100 percent) had an objective response, including 62 percent with a
	complete remission. Of 17 evaluable patients in the bendamustine combination arm, all patients (100 percent) had an objective response, including 88 percent with a complete remission. The most common adverse events of any grade occurring in at least
	25 percent of patients in the dacarbazine combination arm were peripheral sensory neuropathy (77 percent); constipation (45 percent); fatigue and nausea (41 percent each), peripheral edema (32 percent) and diarrhea (27 percent). The most common
	adverse events of any grade occurring in at least 25 percent of patients in the bendamustine combination arm were diarrhea (85 percent), nausea (65 percent), fatigue (50 percent), decreased appetite (45 percent) and peripheral sensory neuropathy and
	fever (40 percent each). Enrollment on the bendamustine arm was closed given the tolerability of the combination did not meet study goals for this fragile patient population. In 2016, the trial was amended to
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	11
</FONT>
</P>
<A NAME="eolPage14"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	evaluate the combination of ADCETRIS and nivolumab. ADCETRIS monotherapy is included in NCCN guidelines for older patients with newly diagnosed Hodgkin lymphoma.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Relapsed or Refractory CD30-expressing
	DLBCL
</I>
	.&nbsp;&nbsp;&nbsp;&nbsp;In October 2015, we announced the initiation of a randomized phase 2 open-label, multi-center clinical trial of rituximab and bendamustine with or without ADCETRIS in relapsed or refractory patients with
	CD30-expressing DLBCL. The primary endpoint is to compare the objective response rates between the two study arms. Secondary endpoints include PFS, complete remission rate, duration of response and overall survival. ADCETRIS is included in NCCN
	guidelines for patients with second-line or beyond CD30-expressing DLBCL.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Combination trials with nivolumab (OPDIVO).
</I>
	&nbsp;&nbsp;&nbsp;&nbsp;In January 2015, we and BMS announced a clinical trial collaboration agreement to evaluate the investigational combination of
	ADCETRIS and BMS&#146; immunotherapy nivolumab in two phase 1/2 clinical trials. Nivolumab is a programmed death-1, or PD-1, immune checkpoint inhibitor that is designed to harness the body&#146;s own immune system to help restore antitumor immune
	response.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	One ongoing trial is evaluating the
	combination of ADCETRIS and nivolumab for patients with second line Hodgkin lymphoma. At the 2016 ASH annual meeting, data were reported from 42 patients with relapsed or refractory Hodgkin lymphoma after failure of frontline therapy who received
	the combination regimen. Patients were treated with up to four cycles of combination therapy. After completion of the fourth cycle of treatment, patients were eligible to undergo an ASCT. Of 29 response-evaluable patients, 90 percent had an
	objective response, including 62 percent with a complete metabolic response. The most common adverse events of any grade occurring prior to ASCT in more than 20 percent of patients were fatigue, nausea, infusion related reaction, or IRR, pruritus
	and rash. IRRs were observed in 38 percent of patients and most symptoms included flushing and nausea (14 percent each); chest discomfort, dyspnea, urticaria (12 percent each); cough and pruritis (10 percent each). The protocol was amended to
	require premedication with low-dose corticosteroids and antihistamine.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The second ongoing trial is evaluating the combination of ADCETRIS and nivolumab in patients with relapsed or refractory B-cell and T-cell non-Hodgkin lymphomas, including DLBCL. This trial has been
	subsequently amended to evaluate the combination in rare B-cell lymphomas, including gray zone and mediastinal B-cell lymphomas.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Investigator-Sponsored Trials.
</I>
	&nbsp;&nbsp;&nbsp;&nbsp;In addition to our corporate-sponsored trials, as of December&nbsp;31, 2016,
	there were more than 35 reported investigator-sponsored trials of ADCETRIS in the United States. In addition, we and Takeda are reviewing proposals from multiple clinical investigators and cooperative groups in the United States, Canada and Europe
	about potential investigator-sponsored trials of ADCETRIS. The investigator-sponsored trials to date include the use of ADCETRIS in a number of malignant hematologic indications such as CTCL, DLBCL, untreated limited stage Hodgkin lymphoma, salvage
	therapy for patients with Hodgkin lymphoma prior to auto-HSCT and graft versus host disease. There are also numerous other investigator-sponsored trials for the use of ADCETRIS in other CD30-expressing and select CD30-undetectable settings, and in
	solid tumors such as mesothelioma and testicular germ cell tumors. One cooperative group investigator-sponsored trial is currently evaluating ADCETRIS with immuno-oncology compounds in Hodgkin lymphoma, and we expect additional
	investigator-sponsored trials might evaluate ADCETRIS in novel combination regimens.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	SGN-CD33A (Vadastuximab Talirine)
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	SGN-CD33A is an ADC composed of an anti-CD33 monoclonal antibody linked to a potent PBD dimer using our proprietary ADC technology. We are developing this product candidate as a potential treatment of AML
	and MDS. SGN-CD33A targets CD33, a protein that is expressed on most AML cells. SGN-CD33A employs our newest proprietary ADC technology. This technology is comprised of a PBD dimer, which is a potent cell-killing agent that works by a different
	mechanism than auristatins, linked to an engineered antibody called EC-mAb, resulting in uniform drug-loading of two PBD dimers per antibody.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	12
</FONT>
</P>
<A NAME="eolPage15"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On December&nbsp;27, 2016, we announced that we had received notice from the FDA that a full
	clinical hold or partial clinical hold had been placed on several early stage trials of SGN-CD33A in AML to evaluate the potential risk of hepatotoxicity following adverse medical events, including fatal events. Our phase 1/2 trial of SGN-CD33A
	monotherapy in pre- and post- allogeneic transplant AML patients has been placed on full clinical hold. Additionally, clinical trials evaluating SGN-CD33A monotherapy, and including a subset of older AML patients in combination with HMAs, and
	SGN-CD33A combination treatment with 7+3 chemotherapy in newly diagnosed younger AML patients have been placed on partial clinical hold. Our phase 3 CASCADE trial in older AML patients and our phase 1/2 trial in MDS are proceeding with enrollment.
	No new studies of SGN-CD33A will be initiated unless and until the clinical holds are lifted. We are working diligently with the FDA to determine whether there is any association between hepatotoxicity and treatment with SGN-CD33A and to promptly
	identify appropriate measures for patient safety with the goal of addressing the FDA&#146;s concerns.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In May 2016, we initiated a phase 3, randomized, double-blind, placebo-controlled, global clinical trial called CASCADE. The CASCADE trial
	is designed to evaluate if SGN-CD33A in combination with the HMAs azacitidine or decitabine can extend overall survival compared to either HMA alone in older patients with newly diagnosed AML. Patients will be randomized on a 1:1 ratio to be treated
	with an HMA plus SGN-CD33A or an HMA plus placebo. The secondary endpoints include the comparison of composite complete remission rate (complete remission and complete remission with incomplete hematologic recovery), event-free and leukemia-free
	survival, duration of response, safety, and 30- and 60-day mortality rates. Treatment and patient enrollment in this trial is ongoing.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our decision to initiate the CASCADE trial was supported by interim data from a phase 1 open-label, multi-center, dose-escalation clinical
	trial of SGN-CD33A as monotherapy or in combination with other standard treatments. In addition, the trial was evaluating anti-leukemic activity, pharmacokinetics, PFS and overall survival in patients with CD33-positive AML. At the December 2016 ASH
	annual meeting, we reported updated data from a cohort of this trial that evaluated SGN-CD33A in combination with an HMA. Of 49 patients evaluable for response, 73 percent of patients achieved a complete remission or complete remission with
	incomplete platelet or neutrophil recovery. With a median follow-up of 14.7 months, median overall survival for all patients was 11.3 months and 28 percent of patients remained alive and on study as of last follow-up. The 30- and 60-day mortality
	rates were two and eight percent, with no treatment-related deaths occurring during that time. The most common Grade 3 or 4 treatment-emergent adverse events occurring in 20 percent or more of patients were thrombocytopenia, febrile neutropenia,
	anemia and neutropenia. The most common Grade 1 and 2 treatment-emergent adverse events occurring in 20 percent or more of patients were fatigue, nausea, constipation, peripheral edema and decreased appetite. In December 2016, this phase 1 trial was
	placed on a partial clinical hold by the FDA. Under the partial clinical hold, existing patients in the trial may continue treatment with
<FONT STYLE="WHITE-SPACE:NOWRAP">
	SGN-CD33A
</FONT>
	following execution of an additional informed consent form,
	but no new patients may be enrolled in the trial.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In February 2016, we initiated a phase 1/2, open label, multi-center clinical trial of SGN-CD33A in combination with azacitidine in
	patients with previously untreated Intermediate-2 or high risk MDS. Phase 1 of the study will identify the recommended dose of SGN-CD33A when combined with azacitidine in this patient population. The phase 2 portion of the trial will be a
	randomized, double-blind, placebo-controlled study evaluating azacitidine with or without SGN-CD33A. The primary endpoint in phase 1 is determination of the recommended SGN-CD33A dose in combination with azacitidine. The primary endpoint in phase 2
	is to compare the overall response rate between the two treatment arms. The secondary endpoints include evaluation of safety, best response, duration of response, PFS and overall survival. Treatment and patient enrollment in this trial is ongoing.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In December 2014, we initiated a phase 1b,
	open-label, multi-center, dose-escalation clinical trial designed to evaluate SGN-CD33A administered in combination with frontline standard of care regimens for induction (cytarabine and daunorubicin, also known as 7+3) for younger patients with
	newly diagnosed AML. The trial was also designed to evaluate SGN-CD33A in the consolidation setting for AML, both in combination with
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	13
</FONT>
</P>
<A NAME="eolPage16"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	cytarabine and as a single-agent maintenance regimen. The primary endpoints are determination of the maximum tolerated dose and safety profile of SGN-CD33A. In addition, the trial was evaluating
	anti-leukemic activity, pharmacokinetics, PFS and overall survival. At the ASH 2016 annual meeting, we reported interim data showing that of 42 patients evaluable for response, 76 percent achieved a complete remission or complete remission with
	incomplete platelet or neutrophil recovery. Among patients who achieved a remission, 78 percent were negative for minimal residual disease. Median OS had not yet been reached. The 30-day mortality rate was two percent. The most common Grade 3 or 4
	treatment-emergent adverse events occurring in 20 percent or more of patients were febrile neutropenia, thrombocytopenia, anemia and neutropenia. The most common Grade 1 and 2 treatment-emergent adverse events occurring in 20 percent or more of
	patients were nausea, diarrhea, constipation, hypokalemia and decreased appetite. In December 2016, this phase 1b trial was placed on partial clinical hold by the FDA. Under the partial clinical hold, existing patients in the trial may continue
	treatment with SGN-CD33A following execution of an additional informed consent form, but no new patients may be enrolled in the trial.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In November 2015, we initiated a phase 1/2 clinical trial of SGN-CD33A in patients with relapsed or refractory AML. The trial was designed
	to evaluate SGN-CD33A monotherapy as a pre-conditioning regimen prior to an allogeneic stem cell transplant and also for use as maintenance therapy following transplant. In December 2016, this trial was placed on full clinical hold by the FDA. Under
	the full clinical hold, all patients in the trial were required to discontinue treatment with SGN-CD33A immediately and no new patients may be enrolled in the trial.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We may be unable to submit to the FDA all required clinical
	follow-up information to respond to the clinical holds. Even if we are able to provide such information, the FDA may not deem the information to be sufficient to lift any or all of the clinical holds. In addition, we may encounter delays in reaching
	an agreement with the FDA regarding the terms under which these trials may be resumed, or we may elect to discontinue one or more of these trials for safety or any other reasons. Furthermore, the FDA may require us to implement additional,
	potentially burdensome pharmacovigilance procedures or conduct additional pre-clinical studies before it will consider lifting the clinical holds, if at all. In addition, although the FDA has not placed a clinical hold on the CASCADE trial or our
	phase 1/2 trial in MDS and we continue to enroll patients in these trials, we cannot assure you that the FDA or another regulatory authority will not place a clinical hold on one or both of these trials. If we are unable to submit required
	information to the FDA in a timely manner, or at all; if the FDA does not lift the clinical holds in a timely manner, or at all; if the FDA does not permit us to initiate additional trials of SGN-CD33A and/or the FDA imposes clinical holds on the
	CASCADE trial or our phase 1/2 trial in MDS; or if there are additional safety results, including from our ongoing trials of SGN-CD33A, that alter the benefit-risk profile of SGN-CD33A or cause it to become unacceptable, we would be further delayed
	or prevented from advancing the clinical development of SGN-CD33A, which would adversely affect our business, results of operations and prospects.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	ASG-22ME (Enfortumab Vedotin)
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	ASG-22ME is an ADC composed of an anti-Nectin-4 monoclonal antibody linked to a potent auristatin compound using our proprietary ADC
	technology. Nectin-4 is a novel target expressed in multiple cancers including urothelial cancers, such as bladder cancer, as well as ovarian and lung cancers. We are developing ASG-22ME as a potential treatment of solid tumors under our
	co-development collaboration with Astellas.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In
	October 2016, we reported interim data from a phase 1, open-label, dose-escalation, multi-center clinical trial of ASG-22ME at the European Society for Medical Oncology, or ESMO, annual meeting. Of the 49 metastatic urothelial cancer patients
	evaluable for response, 37 percent had an objective response, including two percent who achieved a complete response. The preliminary estimate of median PFS was 16.6 weeks. At the recommended phase 2 dose of 1.25 mg/kg, 17 patients were treated of
	which 59 percent had a partial response. In the 16 patients across dose levels who had previously been treated with checkpoint inhibitors, 38 percent achieved a partial response. Among the seven patients treated at the recommended phase 2 dose that
	had
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	14
</FONT>
</P>
<A NAME="eolPage17"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	previously been treated with checkpoint inhibitors, 57 percent achieved a partial response. The most common treatment related adverse events of any grade occurring in 20 percent or more of
	patients were pruritis (31 percent), fatigue (30 percent), diarrhea (29 percent), nausea (28 percent), rash (26 percent) and alopecia (21 percent).
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Based on these interim phase 1 data, we and Astellas are planning discussions with regulatory agencies during 2017 to advance the program
	into potential registrational trials of ASG-22ME in urothelial cancer patients, including patients who have been previously treated with a checkpoint inhibitor therapy.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	SGN-LIV1A
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	SGN-LIV1A is an ADC composed of an anti-LIV-1 monoclonal
	antibody linked to a potent auristatin compound using our proprietary ADC technology, and is being developed as a potential treatment of LIV-1-positive metastatic breast cancer.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In October 2013 we initiated a phase 1, open-label,
	dose-escalation clinical trial to evaluate the safety and antitumor activity of SGN-LIV1A in patients with LIV-1-positive metastatic breast cancer. At the December 2016 San Antonio Breast Cancer Symposium annual meeting, updated interim data were
	reported showing that among 30 evaluable patients with triple negative disease, 37 percent achieved a partial response. The estimated median PFS for these patients was 12 weeks with seven patients remaining on treatment. The maximum tolerated dose
	was not reached among doses ranging from 0.5 to 2.8 mg/kg. For all patients in the study, the most common adverse events of any grade occurring in 20 percent or more of patients included fatigue (57 percent), nausea (53 percent), alopecia (42
	percent), decreased appetite (34 percent) and constipation (32 percent). The incidence of grade 3/4 neutropenia at the 2.5 mg/kg dose was 50 percent. Two patients (seven percent) experienced febrile neutropenia, and there was one treatment-related
	death due to sepsis. Based on these safety data, a separate expansion cohort at 2.0 mg/kg is currently being evaluated. In addition, enrollment is ongoing for patients with HER2 positive breast cancer to evaluate SGN-LIV1A in combination with
	trastuzumab.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	SGN-CD19A (Denintuzumab Mafodotin)
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	SGN-CD19A is an ADC composed of an
	anti-CD19 monoclonal antibody linked to a potent auristatin compound using our proprietary ADC technology. CD19 is a B-cell antigen that is expressed in non-Hodgkin lymphoma, chronic lymphocytic leukemia and acute lymphoblastic leukemia.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In October 2015, we announced the initiation of a phase 2
	randomized, open-label, multi-center clinical trial of SGN-CD19A in combination with the second-line salvage regimen of rituximab, ifosfamide, carboplatin and etoposide, or RICE, for patients with relapsed or refractory DLBCL. The primary endpoint
	is to compare the complete remission rates between the two study arms. Secondary endpoints include safety of the combination regimen, PFS, overall survival and the number of patients who are able to undergo ASCT.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In October 2016, we announced the initiation of a phase 2
	clinical trial of SGN-CD19A in patients with newly-diagnosed DLBCL. The trial will assess the activity and tolerability of adding SGN-CD19A to the standard frontline regimen, R-CHOP, as well as a modified regimen, R-CHP. The primary endpoints are to
	evaluate the complete remission rate and tolerability profile of the combinations. Secondary endpoints include event-free survival, PFS, overall survival and duration of response.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	SEA-CD40
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	SEA-CD40 utilizes our novel proprietary SEA technology to
	produce a non-fucosylated antibody targeting CD40, which is believed to work as an immuno-oncology molecule, activating certain immune cells. It builds on our extensive experience targeting CD40. In February 2015, we announced initiation of a phase
	1, open-label, multi-center, dose-escalation clinical trial of SEA-CD40 in patients with advanced solid tumors who have failed current standard of care treatments. Expansion cohorts are planned to evaluate SEA-CD40 across up to three
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	15
</FONT>
</P>
<A NAME="eolPage18"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	cancer indications that will be determined based on data from the dose escalation portion of the study. The primary endpoints are determination of the maximum tolerated dose and safety profile of
	SEA-CD40. In addition, the trial will evaluate antitumor activity, pharmacokinetics and immunological pharmacodynamic effects. In 2016, the phase 1 trial was expanded to evaluate patients with hematologic malignancies.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	SGN-CD19B
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	SGN-CD19B is a proprietary ADC composed of an anti-CD19
	monoclonal antibody utilizing our proprietary EC-mAb technology linked to a potent PBD dimer. We are developing this product candidate as a potential treatment of non-Hodgkin lymphoma. In February 2016, we announced initiation of a phase 1,
	open-label, multi-center, dose-escalation clinical trial of SGN-CD19B for patients with relapsed or refractory DLBCL or grade 3 follicular lymphoma. The primary endpoints are the estimation of the maximum tolerated dose and evaluation of the safety
	of SGN-CD19B. In addition, the trial will evaluate antitumor activity, pharmacokinetics, objective response rate and PFS.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	SGN-CD123A
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	SGN-CD123A is a proprietary ADC composed of an anti-CD123 monoclonal antibody utilizing our proprietary EC-mAb technology linked to a
	potent PBD dimer. We are developing this product candidate as a potential treatment of AML. In September 2016, we announced initiation of a phase 1, open-label, multi-center, dose-escalation clinical trial of SGN-CD123A for patients with relapsed or
	refractory AML. It will initially evaluate the maximum tolerated dose of SGN-CD123A, followed by an expansion cohort to further define safety and estimate anti-leukemic activity. In addition, the trial will assess pharmacokinetics, remission rate,
	duration of complete remission and overall survival.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	SGN-CD352A
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	SGN-CD352A is a proprietary ADC composed of an anti-CD352 monoclonal antibody utilizing our proprietary EC-mAb technology linked to a
	potent PBD dimer. In January 2017, we announced initiation of a phase 1, open-label, multi-center, dose-escalation clinical trial of SGN-CD352A for patients with relapsed or refractory multiple myeloma. The trial will be conducted in two parts, with
	a dose escalation part to identify the maximum tolerated dose of SGN-CD352A followed by an expansion part to further define safety and antitumor activity.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	SGN-2FF
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	SGN-2FF is a novel small molecule immuno-oncology agent. It is an oral agent that has been shown in preclinical models to inhibit
	fucosylation of proteins, which may make tumors more visible to the immune system, and thereby slow the growth and spread of cancer cells. In January 2017, we initiated an open-label, multi-center, dose-escalation clinical trial of SGN-2FF for
	patients with relapsed or refractory solid tumors, including non-small cell lung cancer.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	ASG-15ME
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	ASG-15ME is an ADC composed of an anti-SLITRK6 monoclonal antibody linked to a potent auristatin compound using our proprietary ADC technology. We are developing ASG-15ME under our co-development
	collaboration with Astellas. A phase 1 clinical trial of ASG-15ME for the treatment of metastatic urothelial cancer, notably bladder cancer, was initiated in October 2013. This trial is evaluating the safety, tolerability, pharmacokinetic profile
	and antitumor activity of escalating doses of ASG-15ME. We and Astellas are focusing our development activities on ASG-22ME for metastatic urothelial cancer, while evaluating next development steps for ASG-15ME.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Research Programs
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In addition to our pipeline of product candidates and
	antibody-based and SEA technologies, we have internal research programs directed toward developing new classes of potent, cell-killing agents and stable
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	16
</FONT>
</P>
<A NAME="eolPage19"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	linkers, identifying novel antigen targets, monoclonal antibodies and other targeting molecules, and advancing our antibody engineering initiatives.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	New Cell-Killing Agents.
</I>
	&nbsp;&nbsp;&nbsp;&nbsp;We
	continue to study new cell-killing agents that can be linked to antibodies, such as the auristatins and PBDs that we currently use in our ADC technology, and new classes of cell-killing agents.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	New Stable Linkers.
</I>
	&nbsp;&nbsp;&nbsp;&nbsp;We are
	conducting research with the intent to develop new linker systems that are more stable in the bloodstream and more effective at releasing the cell-killing agent once inside targeted cancer cells.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Novel Monoclonal Antibodies and Antigen
	Targets.
</I>
	&nbsp;&nbsp;&nbsp;&nbsp;We are actively engaged in internal efforts to identify and develop monoclonal antibodies and other targeting molecules and ADCs with novel specificities and activities against selected antigen targets. We focus
	on antigen targets that are highly expressed on the surface of cancer cells that may serve as targets for monoclonal antibodies or ADCs. We may then create and screen panels of cancer-reactive monoclonal antibodies in our laboratories to identify
	those with the desired specificity. We supplement these internal efforts by evaluating opportunities to in-license targets and antibodies from academic groups and other biotechnology and pharmaceutical companies, such as our ongoing co-development
	collaboration with Genmab.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Antibody
	Engineering.
</I>
	&nbsp;&nbsp;&nbsp;&nbsp;We have substantial internal expertise in antibody engineering, both for antibody humanization and non-fucosylation, as well as engineering of antibodies to improve drug linkage sites for use with our ADC
	technology. By modifying the number and type of drug-linkage sites found on our antibodies, we believe that we can improve the robustness and cost-effectiveness of our manufacturing processes for conjugation of ADCs.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Research and Development Expense
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Since inception, we have devoted a significant amount of
	resources to develop ADCETRIS, our product candidates and our antibody-based technologies. For the years ended December&nbsp;31, 2016, 2015, and 2014, we recorded $379.3 million, $294.5 million, and $230.7 million, respectively, in research and
	development expenses.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Corporate Collaborations
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We enter into collaborations with biotechnology and
	pharmaceutical companies to advance the development and commercialization of our product candidates and to supplement our internal pipeline. We seek collaborations that will allow us to retain significant future participation in product sales
	through either profit-sharing or royalties paid on net sales. We also license our ADC technology to collaborators to be developed with their own antibodies. These ADC collaborations benefit us in many ways, including generating cash flow and
	revenues that partially offset expenditures on our internal research and development programs, expanding our knowledge base regarding ADCs across multiple targets and antibodies provided by our collaborators and providing us with future pipeline
	opportunities through co-development or opt-in rights to new ADC product candidates.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Takeda ADCETRIS Collaboration
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In December 2009, we entered into a collaboration agreement with Takeda to develop and commercialize ADCETRIS, under which Seattle Genetics retains commercial rights in the United States and its
	territories and in Canada, and Takeda and its Takeda affiliates have commercial rights in the rest of the world. As of December&nbsp;31, 2016, we had received an upfront payment of $60 million and had achieved milestone payments totaling $70 million
	related to regulatory and commercial progress by Takeda. As of December&nbsp;31, 2016, we were entitled to receive additional progress- and sales-dependent milestone payments of up to $165 million based on Takeda&#146;s achievement of significant
	events under the collaboration in addition to tiered royalties with percentages starting in the mid-teens and escalating to the mid-twenties based on net sales of ADCETRIS within Takeda&#146;s licensed
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	17
</FONT>
</P>
<A NAME="eolPage20"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	territories. Takeda also bears a portion of third-party royalty costs owed on sales of ADCETRIS in its territory. We and Takeda equally co-fund the cost of development activities conducted under
	the collaboration. Although we are funding half of the development activities conducted under the collaboration, Takeda is responsible for the achievement of the progress- and sales-dependent milestone payments that we may receive. Either party may
	terminate the collaboration agreement if the other party materially breaches the agreement and such breach remains uncured. Takeda may terminate the collaboration agreement for any reason upon prior written notice to us and we may terminate the
	collaboration agreement in certain circumstances. The collaboration agreement can also be terminated by mutual written consent of the parties. If neither party terminates the collaboration agreement, then the agreement automatically terminates on
	the expiration of all payment obligations.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Astellas
	Co-Development Collaboration
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In January
	2007, we entered into an agreement with Astellas to jointly research, develop and commercialize ADCs for the treatment of several types of cancer. The collaboration encompasses combinations of our ADC technology with fully-human antibodies developed
	by Astellas to proprietary cancer targets.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Under
	the collaboration agreement, we and Astellas are co-funding all development and commercialization costs for ASG-22ME and ASG-15ME, and will share on a 50/50 basis in any profits that may come from these product candidates if successfully
	commercialized. Costs associated with co-development activities are included in research and development expense.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Astellas has the right to develop and commercialize certain other ADC product candidates on its own, subject to paying us annual
	maintenance fees, milestones, royalties and support fees for research and development services and material provided under the collaboration agreement. We are entitled to receive progress- and sales-dependent milestone payments of up to
	approximately $96 million based on Astellas&#146; achievement of significant events under the collaboration in addition to mid-single digit royalties on net sales of any of these other ADC product candidates by Astellas. Either party may opt out of
	co-development and profit-sharing in return for receiving milestones and royalties from the continuing party. Either party may terminate the collaboration agreement if the other party becomes insolvent or the other party materially breaches the
	agreement and such breach remains uncured. Subject to certain restrictions, either party may terminate the collaboration agreement for any reason upon prior written notice to the other party. The collaboration agreement can also be terminated by
	mutual written consent of the parties. If neither party exercises its option to terminate the collaboration agreement, then the agreement will automatically terminate on the later of: (a)&nbsp;the expiration of all payment obligations pursuant to
	the collaboration agreement, or (b)&nbsp;the day upon which we and Astellas cease to develop and commercialize products under the agreement.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Unum Therapeutics Collaboration
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In June 2015, we entered into a strategic collaboration and license agreement with Unum to develop and commercialize novel ACTR therapies
	incorporating our antibodies for cancer. Unum&#146;s proprietary ACTR technology enables programming of a patient&#146;s T-cells to attack tumor cells when co-administered with tumor-specific therapeutic antibodies. Through our research and
	development in the field of ADCs, we have a substantial portfolio of cancer targets and tumor-specific monoclonal antibodies from which programs will be selected for the collaboration with Unum. Under the terms of the agreement, we and Unum will
	initially develop two ACTR product candidates that combine Unum&#146;s ACTR technology with our antibodies, and we have an option to expand the collaboration to include a third ACTR product candidate upon payment of an additional fee. Unum is
	obligated to conduct preclinical research and clinical development activities through phase 1 clinical trials and we are obligated to provide funding for these activities. The agreement calls for us to work together to co-develop and jointly fund
	programs after phase 1 clinical trials unless either company opts out. We and Unum would co-commercialize any successfully developed product candidates and share any profits 50/50 on any co-developed programs in the United States. We retain
	exclusive commercial rights outside of the United States, paying Unum a royalty that is a high single digit to mid-teens percentage of ex-U.S. sales, if any. The potential future licensing and progress-dependent milestone payments to Unum under the
	collaboration may total up to
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	18
</FONT>
</P>
<A NAME="eolPage21"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$615 million across all three ACTR programs, payment of which is triggered by the achievement of development, regulatory and commercial milestones. As of the date of this filing, this agreement
	is not material to us.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Genmab Co-Development Collaboration
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In September 2010, we entered into an
	ADC research collaboration agreement with Genmab. Under the agreement, Genmab has rights to utilize our ADC technology with its HuMax-TF antibody targeting the Tissue Factor, or TF, antigen, which is expressed on numerous types of solid tumors.
	Under this agreement, we received an upfront payment and have the right to exercise a co-development option for any resulting ADC products at the end of phase 1 clinical development. Genmab is responsible for research, manufacturing, preclinical
	development and phase 1 clinical trials under the collaboration. We receive research support payments for any assistance provided to Genmab. If we opt into the anti-TF ADC product at the end of phase 1, we and Genmab would co-develop and share all
	future costs and profits for the product on a 50/50 basis. If we do not opt in, then Genmab would pay us fees, milestones and mid-single digit royalties on worldwide net sales of the product. As of the date of this filing, this agreement is not
	material to us.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	ADC Collaborations
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We have active collaborations with a number of companies to
	allow them to use our proprietary ADC technology with their monoclonal antibodies. Under our ADC collaborations, which we enter into in the ordinary course of business, we receive or are entitled to receive upfront cash payments, progress-dependent
	milestones and single digit royalties on net sales of products incorporating our ADC technology, as well as annual maintenance fees and support fees for research and development services and materials provided under the agreements. Our ADC
	collaborators are responsible for development, manufacturing and commercialization of any ADC product candidates that result from the collaborations and are solely responsible for the achievement of any of the potential milestones under these
	collaborations.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	19
</FONT>
</P>
<A NAME="eolPage22"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our current ADC collaborations are at various stages of clinical and preclinical
	development. Our ability to generate significant future revenues from our current ADC collaboration agreements will largely depend on a product that incorporates our ADC technology entering late-stage clinical development and receiving marketing
	approval from the FDA at which point the milestone payments, royalties or other rights and benefits would become more substantial and material to our company. Below is a table setting forth our active ADC collaborations and current development
	status:
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2017/02/21/0001193125-17-050543_G481013G64T04.JPG" ALT="LOGO">
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	License Agreements
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We have in-licensed antibodies, targets and enabling
	technologies from pharmaceutical and biotechnology companies and academic institutions for use in our pipeline programs and ADC technology, including the following:
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Bristol-Myers Squibb
	License.
</I>
	&nbsp;&nbsp;&nbsp;&nbsp;In March 1998, we obtained rights to some of our technologies and product candidates, portions of which are exclusive, through a license agreement with Bristol-Myers Squibb. Through this license, we secured rights
	to use various targeting technologies. Under the terms of the license agreement, we are required to pay royalties in the low single digits on net sales of products, including ADCETRIS, which incorporate various technologies owned by Bristol-Myers
	Squibb.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	University of Miami
	License.
</I>
	&nbsp;&nbsp;&nbsp;&nbsp;In September 1999, we entered into an exclusive license agreement with the University of Miami, Florida, covering an anti-CD30 monoclonal antibody that is the basis for the antibody component of ADCETRIS. Under
	the terms of this license, we made an upfront payment and are required to pay annual maintenance fees, progress-dependent milestone payments and royalties in the low single digits on net sales of products, including ADCETRIS, incorporating
	technology licensed from the University of Miami.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Immunomedics License
</I>
<B>
<I>
	.&nbsp;&nbsp;&nbsp;&nbsp;
</I>
</B>
	On February&nbsp;10, 2017, we entered into the Immunomedics License.
	Pursuant to the Immunomedics License, Immunomedics granted us, subject to the terms and conditions of the Immunomedics License, exclusive worldwide rights to develop, manufacture and commercialize IMMU-132 and second generation ADCs targeting TROP-2
	for all human therapeutics uses in any and all indications. IMMU-132 is an ADC targeted to TROP-2, which is expressed in several solid tumors, and is in a pivotal phase 1/2 trial for patients with TNBC, and is being investigated in other solid
	tumors. Under the Immunomedics License, we
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	20
</FONT>
</P>
<A NAME="eolPage23"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	agreed to pay Immunomedics an up-front payment of $250 million following closing of the Immunomedics License. In addition, we agreed to pay development, regulatory and sales-dependent milestone
	payments to Immunomedics across multiple indications and geographic regions of up to a total maximum of approximately $1.7 billion. Immunomedics would also be eligible to receive royalties on worldwide annual net sales of licensed products at tiered
	royalty rate percentages beginning in the teens and rising to twenty percent, subject to customary reductions, during the royalty term specified in the Immunomedics License. We would bear the future costs of worldwide development and
	commercialization of licensed products, subject to specified exceptions. We agreed to use commercially reasonable efforts to develop IMMU-132. Following regulatory approval (and pricing and reimbursement approvals, as applicable) of any licensed
	product in any of the major market countries specified in the Immunomedics License, we agreed to use commercially reasonable efforts to commercialize such licensed product in each major market country where it has been approved. Under the
	Immunomedics License, Immunomedics would have the right to exercise a co-promotion option to provide up to 50% of the sales efforts for the commercialization of IMMU-132 in the United States, subject to certain parameters set forth in the
	Immunomedics License. We may terminate the Immunomedics License for convenience upon at least two hundred seventy (270)&nbsp;days prior written notice to Immunomedics. Either we or Immunomedics may terminate the Immunomedics License if the other
	party is in material breach of the Immunomedics License and fails to cure such breach within specified cure periods. Upon a termination of the Immunomedics License by us for convenience or by Immunomedics for our material breach, all licenses
	granted by Immunomedics to us terminate (other than specified exceptions), and all payment obligations that accrued prior to the date of such termination shall survive the termination, among other effects of termination. The Immunomedics License
	also provides us the right to terminate specified portions of the Immunomedics License in the event of certain fundamental breaches by Immunomedics that are not cured in accordance with specified cure periods and procedures. In connection with our
	entry into the Immunomedics License, we purchased 3,000,000 shares of Immunomedics common stock from Immunomedics at an aggregate purchase price of $14.7 million, and also received a warrant from Immunomedics to purchase up to 8,655,804 additional
	shares of Immunomedics common stock.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The closing
	of the transactions contemplated by the Immunomedics License is subject to customary closing conditions, including the expiration of the applicable waiting period under the HSR Act, there being no pending court or administrative challenges to the
	Immunomedics License and there being no court or administrative orders blocking the closing. On February 20, 2017, Immunomedics and we entered into a letter agreement pursuant to which Immunomedics irrevocably waived to the extent applicable to
	Immunomedics the condition precedent to the closing and effectiveness of the Immunomedics License that there be no pending court or administrative challenges to the transaction. Additionally, under the terms of the Immunomedics License, Immunomedics
	had the right to continue discussions with a small number of parties that previously expressed interest in licensing IMMU-132 until 11:59 p.m. New York City time on February&nbsp;19, 2017. If a third party had provided Immunomedics with a
	financially superior licensing offer, we would have had the right to match any such offer, and if we had decided not to match, Immunomedics would have had the right to accept the superior offer and terminate the Immunomedics License upon payment of
	a termination fee to us. We have not received notice from Immunomedics of any such third party offers during this limited time period, and on February 21, 2017, Immunomedics announced that it is subject to customary &#147;no-shop&#148; restrictions
	on its and its representatives&#146; ability to solicit, discuss or negotiate alternative licensing agreement proposals from third parties with regard to IMMU-132. On February&nbsp;13, 2017, we were named a co-defendant in a lawsuit filed by venBio
	in the Delaware Chancery Court against the members of the board of directors of Immunomedics pursuant to which, among other things, venBio seeks to enjoin the closing of the transactions contemplated by the Immunomedics License. As a result of the
	pending litigation challenging the transactions contemplated by the Immunomedics License, Immunomedics and we have committed to the Court not to close the transactions contemplated by the Immunomedics License prior to March&nbsp;10, 2017. We cannot
	predict the timing or outcome of this lawsuit or the impact it may have on the Immunomedics License or the closing of the transactions contemplated by the Immunomedics License. However, it is possible that, in connection with this lawsuit, the
	Immunomedics License could be rescinded or reformed in a way that is disadvantageous to us, including by requiring us to increase the transaction consideration payable to Immunomedics under the Immunomedics License, or that otherwise adversely
	affects the anticipated benefits to us of the Immunomedics License.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	21
</FONT>
</P>
<A NAME="eolPage24"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Patents and Proprietary Technology
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our owned and licensed patents and patent applications are directed to ADCETRIS, our product candidates,
	monoclonal antibodies, our ADC and SEA technologies and other antibody-based and/or enabling technologies. We commonly seek patent claims directed to compositions of matter, including antibodies, ADCs, and drug-linkers containing highly potent
	cell-killing agents, as well as methods of using such compositions. When appropriate, we also seek claims to related technologies, such as methods of using certain sugar analogs utilized in our SEA technology. For ADCETRIS and each of our product
	candidates, we have filed or expect to file multiple patent applications. We maintain patents and prosecute applications worldwide for technologies that we have out-licensed, such as our ADC technology. Similarly, for partnered products and product
	candidates, such as ADCETRIS, ASG-22ME, and ASG-15ME, we seek to work closely with our development partners to coordinate patent efforts, including patent application filings, prosecution, term extension, defense and enforcement. As ADCETRIS and our
	development product candidates advance through research and development, we seek to diligently identify and protect new inventions, such as combination therapies, improvements to methods of manufacturing, and methods of treatment. We also work
	closely with our scientific personnel to identify and protect new inventions that could eventually add to our development pipeline.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	For ADCETRIS and our related ADC technology, we own nine patents in the United States and Europe that will expire between 2020 and 2031.
	For SGN-CD33A and our related ADC technology, we own, co-own or have licensed rights to six patents in the United States and Europe that will expire between 2027 and 2032. For ASG-22ME and our related ADC technology, we own, co-own or have licensed
	rights to nine patents in the United States and Europe that will expire between 2022 and 2031. Of these nine patents, we own or co-own seven patents and have licensed rights to two patents. For SGN-LIV1A and our related ADC technology, we own or
	have licensed rights to seven patents in the United States and Europe that will expire between 2020 and 2032. Of these seven patents, we own rights to five patents and have licensed rights to two patents. Of these six patents, we own or co-own four
	patents and have licensed rights to two patents. For SGN-CD19A and our related ADC technology, we own eleven patents in the United States and Europe that will expire between 2024 and 2029. For SEA-CD40 and our related SEA technology, we own or have
	licensed rights to eleven patents in the United States and Europe that will expire between 2020 and 2030. Of these eleven patents, we own eight patents and have licensed rights to three patents. For ASG-15ME and our related ADC technology, we own or
	co-own five patents in the United States and Europe that will expire between 2022 and 2033. In some cases, our U.S. patents may be eligible for patent term extension, and our European patents may be eligible for supplemental protection in one or
	more countries. The length of any such extension would vary by country.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Patents expire, on a country by country basis, at various times depending on various factors, including the filing date of the corresponding patent application(s), the availability of patent term
	extension and supplemental protection certificates and requirements for terminal disclaimers. Although we believe our owned and licensed patents and patent applications provide us with a competitive advantage, the patent positions of biotechnology
	and pharmaceutical companies can be uncertain and involve complex legal and factual questions. We and our corporate collaborators may not be able to develop patentable products or processes or obtain patents from pending patent applications. Even if
	patent claims are allowed, the claims may not issue. In the event of issuance, the patents may not be sufficient to protect the proprietary technology owned by or licensed to us or our corporate collaborators. Our or our collaborators&#146; current
	patents, or patents that issue on pending applications, may be challenged, invalidated, infringed or circumvented. In addition, changes to patent laws in the United States or other countries may limit our ability to defend or enforce our patents, or
	may applied retroactively to affect the term of our patents. Our patents have been and may in the future be challenged by third parties in post-issuance administrative proceedings or in litigation as invalid, not infringed or unenforceable under
	U.S. or foreign laws, or they may be infringed by third parties. As a result, we are or may be from time to time involved in the defense and enforcement of our patent or other intellectual property rights in a court of law, U.S. Patent and Trademark
	Office inter partes review or reexamination proceeding, foreign opposition proceeding or related legal and administrative proceeding in the United States and elsewhere. The costs of defending our patents or enforcing our proprietary rights in
	post-issuance administrative proceedings or litigation may be substantial and
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	22
</FONT>
</P>
<A NAME="eolPage25"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	the outcome can be uncertain. An adverse outcome may allow third parties to use our proprietary technologies without a license from us or our collaborators. Our and our collaborators&#146;
	patents may also be circumvented, which may allow third parties to use similar technologies without a license from us or our collaborators.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our commercial success depends significantly on our ability to operate without infringing patents and proprietary rights of third parties.
	Organizations such as pharmaceutical and biotechnology companies, universities and research institutions may have filed patent applications or may have been granted patents that cover technologies similar to the technologies owned, optioned by or
	licensed to us or to our collaborators. In addition, we are monitoring the progress of multiple pending patent applications of other organizations that, if granted, may require us to license or challenge their validity or enforceability in order to
	continue commercializing ADCETRIS or to commercialize our product candidates. Our challenges to patents of other organizations may not be successful, which may affect our ability to commercialize ADCETRIS or our product candidates. We cannot
	determine with certainty whether patents or patent applications of other parties may materially affect our or our collaborators&#146; ability to make, use or sell ADCETRIS or any other products.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We require our scientific personnel to maintain laboratory
	notebooks and other research records in accordance with our policies, which are designed to strengthen and support our intellectual property protection. In addition to our patented intellectual property, we also rely on trade secrets and other
	proprietary information, especially when we do not believe that patent protection is appropriate or can be obtained. Our policy is to require each of our employees, consultants and advisors to execute a proprietary information and inventions
	assignment agreement before beginning their employment, consulting or advisory relationship with us. These agreements provide that the individual must keep confidential and not disclose to other parties any confidential information developed or
	learned by the individual during the course of their relationship with us except in limited circumstances. These agreements also provide that we will own all inventions conceived or reduced to practice by the individual in the course of rendering
	services to us. Our agreements with collaborators require them to have a similar policy and agreements with their employees, consultants and advisors. Our policy and agreements and those of our collaborators may not sufficiently protect our
	confidential information, or third parties may independently develop equivalent information.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Government Regulation
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries impose substantial requirements upon the clinical development, pre-market approval, manufacture,
	marketing and distribution of biopharmaceutical products. These agencies and other regulatory agencies regulate research and development activities and the testing, approval, manufacture, quality control, safety, efficacy, labeling, storage,
	distribution, import, export, recordkeeping, advertising and promotion of products and product candidates. Failure to comply with applicable FDA or other requirements may result in Warning Letters, civil or criminal penalties, suspension or delays
	in clinical development, recall or seizure of products, partial or total suspension of production or withdrawal of a product from the market. The development and approval process requires substantial time, effort and financial resources, and we
	cannot be certain that any approvals for our product candidates will be granted on a timely basis, if at all. We must obtain approval of our product candidates from the FDA before we can begin marketing them in the United States. Similar approvals
	are also required in other countries.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Product
	development and approval within this regulatory framework is uncertain, can take many years and requires the expenditure of substantial resources. The nature and extent of the governmental review process for our product candidates will vary,
	depending on the regulatory categorization of particular product candidates and various other factors.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The necessary steps before a new biopharmaceutical product may be sold in the United States ordinarily include:
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	preclinical
<I>
	in vitro
</I>
	and
<I>
	in vivo
</I>
	tests, some of which must comply with Good Laboratory Practices, or GLP;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	23
</FONT>
</P>
<A NAME="eolPage26"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	submission to the FDA of an IND which must become effective before clinical trials may commence, and which must be updated at least annually with a
	report on development;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	development of a drug formulation and manufacture of the drug product for clinical trials, and commercial sale, if approved;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	completion of adequate and well controlled human clinical trials to establish the safety and efficacy of the product candidate for its intended use;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	submission to the FDA of a marketing authorization application in the form of a BLA, which must be accompanied by a substantial user fee unless the fee
	is waived;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	FDA pre-approval inspection of manufacturing facilities for current Good Manufacturing Practices, or GMP, compliance and FDA inspection of select
	clinical trial sites for Good Clinical Practice, or GCP, compliance; and
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	FDA review and approval of the marketing authorization application and product prescribing information prior to any commercial sale.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The results of preclinical
	tests (which include laboratory evaluation as well as preclinical GLP studies to evaluate toxicity) for a particular product candidate, together with related manufacturing information and analytical data, and a clinical protocol are submitted as
	part of an IND to the FDA. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30 day time period, raises concerns or questions about the conduct of the clinical trial, including concerns that human
	research subjects will be exposed to unreasonable health risks. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. IND submissions may be authorized by the FDA, for example, to
	commence a clinical trial. A separate submission to an existing IND must also be made for each successive clinical trial conducted during product development. Further, an independent institutional review board, or IRB, for each medical center
	proposing to conduct the clinical trial must review and approve the plan for any clinical trial before it commences at that center and it must monitor the study until completed. The FDA, the IRB or the sponsor may suspend a clinical trial at any
	time on various grounds, including a finding that the subjects or patients are being exposed to an unacceptable health risk. Clinical testing also must satisfy extensive GCP regulations and regulations for informed consent and privacy of
	individually-identifiable information.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Clinical
	trials generally are conducted in three sequential phases that may overlap or in some instances, be skipped. In phase 1, the initial introduction of the product into humans, the product candidate is tested to assess safety, metabolism,
	pharmacokinetics and pharmacological actions associated with increasing doses. Phase 2 usually involves trials in a limited patient population to evaluate the efficacy of the potential product for specific, targeted indications, determine dosage
	tolerance and optimum dosage and further identify possible adverse reactions and safety risks. Phase 3 and pivotal trials are undertaken to evaluate further clinical efficacy and safety often in comparison to standard therapies within a broader
	patient population, generally at geographically dispersed clinical sites. Phase 4, or post-marketing, trials may be required as a condition of commercial approval by the FDA and may also be voluntarily initiated by us or our collaborators. Since we
	received accelerated approval for ADCETRIS from the FDA for the relapsed sALCL indication, we are subject to certain post-approval requirements pursuant to which we are conducting an additional confirmatory phase 3 trial, the ECHELON-2 trial, to
	verify and describe the clinical benefit of ADCETRIS in the relapsed sALCL indication. Phase 1, phase 2 or phase 3 testing may not be completed successfully within any specific period of time, if at all, with respect to any of our product
	candidates. Similarly, suggestions of safety, tolerability or efficacy in earlier stage trials do not necessarily predict findings of safety and efficacy in subsequent trials. Furthermore, the FDA, an IRB or we may suspend a clinical trial at any
	time for various reasons, including a finding that the subjects or patients are being exposed to an unacceptable health risk. Clinical trials are subject to central registration and results reporting requirements, such as on www.clinicaltrials.gov.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The results of preclinical studies,
	pharmaceutical development and clinical trials, together with information on a product&#146;s chemistry, manufacturing, and controls, are submitted to the FDA in the form of a BLA, for approval of the manufacture, marketing and commercial shipment
	of the pharmaceutical product. Data from
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	24
</FONT>
</P>
<A NAME="eolPage27"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	clinical trials are not always conclusive and the FDA may interpret data differently than we or our collaborators interpret data. The FDA may also convene an Advisory Committee of external
	advisors to answer questions regarding the approvability and labeling of an application. The FDA is not obligated to follow the Advisory Committee&#146;s recommendation. The submission of a BLA is required to be accompanied by a substantial user
	fee, with few exceptions or waivers. The user fee is administered under the Prescription Drug User Fee Act, or PDUFA, which sets goals for the timeliness of the FDA&#146;s review. A standard review period is twelve months from submission of the
	application, while priority review is eight months from submission of the application. The testing and approval process is likely to require substantial time, effort and resources, and there can be no assurance that any approval will be granted on a
	timely basis, if at all. The FDA may deny review of an application by refusing to file the application or not approve an application by issuance of a complete response letter if applicable regulatory criteria are not satisfied, require additional
	testing or information, or require post-market testing and surveillance to monitor the safety or efficacy of the product. Approval may occur with significant Risk Evaluation and Mitigation Strategies, or REMS, that limit the clinical use in the
	prescribing information, distribution or promotion of a product. Accelerated approval of ADCETRIS for relapsed sALCL additionally requires the pre-submission of marketing materials to the FDA for the product until such time as the accelerated
	approval requirements have been fulfilled. Once an approval is issued, the FDA may require safety-related labeling changes or withdraw product approval if ongoing regulatory requirements are not met or if safety problems occur after the product
	reaches the market. In addition, the FDA may require further testing of ADCETRIS, including phase 4 clinical trials, and surveillance programs to monitor the safety of ADCETRIS, and the FDA has the power to prevent or limit further marketing of
	ADCETRIS based on the results of these post-marketing programs or other information.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Products manufactured or distributed pursuant to FDA approvals are subject to continuing regulation by the FDA, including manufacture, labeling, distribution, advertising, promotion, recordkeeping, annual
	product quality review and reporting requirements. Adverse event experience with the product must be reported to the FDA in a timely fashion and pharmacovigilance programs to proactively look for these adverse events are mandated by the FDA.
	Manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with ongoing
	regulatory requirements, including cGMPs, which impose certain procedural and documentation requirements upon us and our third-party manufacturers. Following such inspections, the FDA may issue notices on Form FDA 483 and Warning Letters that could
	cause us to modify certain activities. A Form FDA 483 notice, if issued at the conclusion of an FDA inspection, can list conditions the FDA investigators believe may have violated cGMP or other FDA regulations or guidance. Failure to adequately and
	promptly correct the observations(s) can result in further regulatory enforcement action. In addition to Form FDA 483 notices and Warning Letters, failure to comply with the statutory and regulatory requirements can subject a manufacturer to
	possible legal or regulatory action, such as suspension of manufacturing, seizure of product, injunctive action or possible civil penalties. We cannot be certain that we or our present or future third-party manufacturers or suppliers will be able to
	comply with the cGMP regulations and other ongoing FDA regulatory requirements. If we or our present or future third-party manufacturers or suppliers are not able to comply with these requirements, the FDA may halt our clinical trials, not approve
	our products, require us to recall a product from distribution or withdraw approval of the BLA for that product. Failure to comply with ongoing regulatory obligations can result in delay of approval or Warning Letters, product seizures, criminal
	penalties, and withdrawal of approved products, among other enforcement remedies.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. These regulations include standards and restrictions for direct-to-consumer
	advertising, industry-sponsored scientific and educational activities, promotional activities involving the internet, and off-label promotion. While physicians may prescribe products for off label uses, manufacturers may only promote products for
	the approved indications and in accordance with the provisions of the approved label. The FDA has very broad enforcement authority under the Federal Food, Drug and Cosmetic Act, and failure to abide by these regulations can result in penalties,
	including the issuance of a Warning Letter directing entities to correct deviations from FDA standards, and state and federal civil and criminal investigations and prosecutions.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	25
</FONT>
</P>
<A NAME="eolPage28"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	FDA Regulation of Companion Diagnostics
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	ADCETRIS and certain of our product candidates may rely upon
	in vitro companion diagnostics for use in selecting the patients that we believe will respond to our therapeutics. If safe and effective use of a therapeutic product depends on an in vitro diagnostic, the FDA generally will require approval or
	clearance of the diagnostic at the same time that FDA approves the therapeutic product. This policy is described in an August 2014 FDA guidance document. The review of these in vitro companion diagnostics in conjunction with the review of our cancer
	treatments involves coordination of review by FDA&#146;s Center for Drug Evaluation and Research and by FDA&#146;s Center for Devices and Radiological Health. For example, we and Takeda have formed a collaboration with Ventana under which Ventana is
	working to develop, manufacture and commercialize a molecular companion diagnostic test with the goal of identifying patients who might respond to treatment with ADCETRIS based on CD30 expression levels in their tissue specimens, which companion
	diagnostic may be required by regulatory authorities to support regulatory approval of ADCETRIS in other CD30-expressing malignancies.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Regulation Outside of the United States
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In addition to regulations in the U.S., we and our collaborators are and will be subject to regulations of other countries governing
	clinical trials and commercial sales, manufacturing and distribution of our products. We must obtain approval by the regulatory authorities of countries outside of the U.S. before we can commence clinical trials in such countries and approval of the
	regulators of such countries or economic areas, such as Canada, before we may market products in those countries or areas. The approval process and requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement
	vary greatly from place to place, and the time may be longer or shorter than that required for FDA approval.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Healthcare Regulation
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Federal and state healthcare laws and regulations, including fraud and abuse and health information privacy and security laws and regulations, may also be applicable to our business. If we fail to comply
	with those laws, we could face substantial penalties and our business, results of operations, financial condition and prospects could be adversely affected. The healthcare laws and regulations that may affect our ability to operate include, without
	limitation, anti-kickback and false claims laws, data privacy and security laws, as well as transparency laws regarding payments or other items of value provided to healthcare providers.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully soliciting, receiving,
	offering or paying remuneration, directly or indirectly, to induce, or in return for, purchasing, leasing, ordering, or arranging for or recommending the purchase, lease, or order of any good, facility, item, or service reimbursable, in whole or in
	part, under a federal healthcare program, such as the Medicare and Medicaid programs. The term &#147;remuneration&#148; has been broadly interpreted to include anything of value. Although there are a number of statutory exceptions and regulatory
	safe harbors protecting some common activities from prosecution, the exceptions and safe harbors are drawn narrowly. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases or recommendations may be
	subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the
	Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all its facts and circumstances. Several courts have interpreted the statute&#146;s intent requirement to mean
	that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the Anti-Kickback Statute has been violated. Additionally, the intent standard under the Anti-Kickback Statute was
	amended by the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, collectively PPACA, to a stricter standard such that a person or entity no longer needs to have actual
	knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, PPACA codified case law that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute
	constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	26
</FONT>
</P>
<A NAME="eolPage29"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The federal civil and criminal false claims laws, including the federal civil False Claims
	Act, prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment to or approval by the federal government, including the Medicare, and Medicaid programs, or knowingly making, using,
	or causing to be made or used a false record or statement material to a false or fraudulent claim or to avoid, decrease, or conceal an obligation to pay money to the federal government.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, created additional federal
	criminal statutes that prohibit, among other actions, knowingly and willfully executing or attempting to execute a scheme to defraud any healthcare benefit program, including private third party payors, knowingly and willfully embezzling or stealing
	from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing, or covering up a material fact or making any materially false, fictitious or fraudulent
	statement in connection with the delivery of or payment for healthcare benefits, items, or services. Like the Anti-Kickback Statute, PPACA amended the intent standard for certain healthcare fraud under HIPAA such that a person or entity no longer
	needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The civil monetary penalties statute imposes penalties against any person or entity that, among other things, is determined to have
	presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	HIPAA, as amended by the Health Information Technology for
	Economic and Clinical Health Act, or HITECH, and their implementing regulations, imposes certain requirements on certain types of individuals and entities relating to the privacy and security of individually identifiable health information. Among
	other things, HITECH makes HIPAA&#146;s security standards directly applicable to business associates, independent contractors or agents of covered entities that receive or obtain protected health information in connection with providing a service
	for or on behalf of a covered entity. HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to
	file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#146; fees and costs associated with pursuing federal civil actions.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The federal Physician Payments Sunshine Act, created under PPACA and its implementing regulations, requires
	certain manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#146;s Health Insurance Program to annually report information related to certain payments or other
	transfers of value provided to physicians and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, the physicians and teaching hospitals, and to report annually certain ownership and investment interests
	held by physicians and their immediate family members. Failure to submit timely, accurately and completely the required information for all payments, transfers of value and ownership or investment interests may result in civil monetary penalties of
	up to an aggregate of $150,000 per year and up to an aggregate of $1 million per year for &#147;knowing failures.&#148; Covered manufacturers are required to submit reports on aggregate payment data to the Secretary of the U.S. Department of Health
	and Human Services on an annual basis.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Many
	states have similar statutes or regulations to the above federal laws and regulations that may be broader in scope than the aforementioned federal versions and apply regardless of payor, and many of which differ from each other in significant ways
	and may not have the same effect, further complicating compliance efforts. Additionally, our business operations in foreign countries and jurisdictions, including Canada and the European Union, may subject us to additional regulation.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Because of the breadth of these laws and the narrowness of
	the statutory exceptions and safe harbors available under such laws, it is possible that some of our business activities could be subject to challenge under one or more of such laws. If our operations are found to be in violation of any of the
	health regulatory laws described above or any other laws that apply to us, we may be subject to penalties, including potentially
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	27
</FONT>
</P>
<A NAME="eolPage30"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	significant criminal and civil and/or administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government healthcare programs, contractual damages,
	reputational harm, administrative burdens, diminished profits and future earnings additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance
	with these laws, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Coverage and Reimbursement
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Sales of ADCETRIS and any future products depend, in
	significant part, on the extent to which the costs of our products will be covered by third-party payors, such as government health programs, commercial insurance and managed healthcare organizations. Patients who are prescribed treatment for their
	conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Patients and providers are unlikely to use our products unless coverage is provided and
	reimbursement is adequate to cover a significant portion of the cost of our products. Pharmaceutical products are typically reimbursed based on FDA labeled indications, recognized compendia listings, available medical literature and determination of
	medical necessity.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Additionally, a third-party
	payor&#146;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors.
	Therefore, coverage and reimbursement for products can differ significantly from payor to payor. Decisions regarding the extent of coverage and amount of reimbursement to be provided for each of our product candidates is individual to each insurer,
	can vary based on provider contract, and will be affected by state and federal laws providing for reimbursement formulas based on acquisition cost. Third party payors continue to work diligently to control their spending on prescription drugs and
	medical service. The containment of healthcare costs has become a priority of the U.S. government and abroad, and the prices of drugs have been a focus in this effort. The U.S. government, state legislatures and foreign governments have shown
	significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of
	more restrictive policies in jurisdictions with existing controls and measures, could further limit our net revenue and results. Payors, commercial and public in the U.S. and abroad, must review the therapeutics value of our products before
	extending coverage under their plans to reimburse our products If third-party payors do not find a product to be of therapeutic value, they may not cover it or, if they do, the level of payment may not be sufficient to allow us to sell our products
	on a profitable basis.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Many of the patients in
	the U.S. who seek treatment with ADCETRIS may be eligible for Medicare or Medicaid benefits. The Medicare and Medicaid programs are administered by the Centers for Medicare and Medicaid Services, or CMS, and coverage and reimbursement for products
	and services under these programs are subject to changes in CMS regulations and interpretive policy determinations, in addition to statutory changes made by Congress. Federal budget decisions have and may result in reduced Medicare payment rates. In
	addition, as a condition of federal funds being made available to cover our products under Medicaid, we are required to participate in the Medicaid drug rebate program. The rebate amount under this program varies by quarter, and is based on pricing
	data we report to CMS. In addition, because we participate in the Medicaid drug rebate program, we must make ADCETRIS available to authorized users of the Federal Supply Schedule of the General Services Administration. This requires compliance with
	additional laws and requirements, including offering ADCETRIS at a reduced price to federal agencies including the United States Department of Veterans Affairs and United States Department of Defense, the Public Health Service and the Indian Health
	Service. We are also required to offer discounted pricing to certain eligible not for profit entities that are eligible for 340B pricing under the Public Health Services Act. Participation in these programs requires submission of pricing data and
	calculation of discounts and rebates pursuant to complex statutory formulas, as well as the entry into government procurement contracts governed by the Federal Acquisition Regulations and the guidance governing such calculations is not always clear.
	Compliance with such requirements can require significant investment in
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	28
</FONT>
</P>
<A NAME="eolPage31"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	personnel, systems and resources, but failure to properly calculate our prices, or offer required discounts or rebates could subject us to substantial criminal, civil and/or administrative
	penalties, as well as, administrative burdens and exclusion from or contract termination regarding these programs. The terms of these government programs could change in the future which may increase the discounts or rebates we are required to
	offer, possibly reducing the revenue derived from sales of ADCETRIS to these entities.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The requirements governing drug pricing vary widely from country to country. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products
	will allow favorable reimbursement and pricing arrangements for any of our products.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Healthcare Reform
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	PPACA substantially changes the way healthcare is financed by both governmental and private insurers and significantly affects the pharmaceutical industry. PPACA aims to, among other things, expand
	coverage for the uninsured while at the same time containing overall healthcare costs. With regard to biopharmaceutical products, PPACA is expected to, among other things, expand and increase industry rebates for products covered under Medicaid
	programs and make changes to the coverage requirements under the Medicare Part D program. We cannot yet predict the full impact of PPACA at this time for many reasons including that many of its provisions require the promulgation of detailed
	implementing regulations, which has not yet occurred.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Many provisions of PPACA may impact the biopharmaceutical industry, including that in order for a biopharmaceutical product to receive federal reimbursement under the Medicare Part B and Medicaid programs
	or to be sold directly to U.S. government agencies, the manufacturer must extend discounts to entities eligible to participate in the drug pricing program under the Public Health Services Act, or PHS. The required PHS discount on a given product is
	calculated based on the Average Manufacturers Price, or AMP, and Medicaid rebate amounts reported by the manufacturer. PPACA expanded the types of entities eligible to receive discounted PHS pricing, although, under the current state of the law,
	with the exception of children&#146;s hospitals, these newly eligible entities will not be eligible to receive discounted PHS pricing on orphan drugs when used for the orphan indication. In addition, as PHS drug pricing is determined based on AMP
	and Medicaid rebate data, revisions, including the recently published AMP rule, to the Medicaid rebate formula and AMP definition described above could cause the required PHS discount to increase.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Since its enactment, there have been judicial and
	Congressional challenges to certain aspects of PPACA. In January 2017, Congress voted to adopt a budget resolution for fiscal year 2017, or the Budget Resolution, that authorizes the implementation of legislation that would repeal portions of PPACA.
	The Budget Resolution is not a law; however, it is widely viewed as the first step toward the passage of legislation that would repeal certain aspects of PPACA. Further, on January&nbsp;20, 2017, President Trump signed an Executive Order directing
	federal agencies with authorities and responsibilities under PPACA to waive, defer, grant exemptions from, or delay the implementation of any provision of PPACA that would impose a fiscal or regulatory burden on states, individuals, healthcare
	providers, health insurers, or manufacturers of pharmaceuticals or medical devices. The potential impact of these efforts to repeal or defer and delay enforcement of PPACA on our business remains unclear. Congress also could consider subsequent
	legislation to replace elements of PPACA that are repealed. Because of the continued uncertainty about the implementation of the PPACA, including the potential for further legal challenges or repeal of PPACA, we cannot quantify or predict with any
	certainty the likely impact of the PPACA or its repeal on our business, prospects, financial condition or results of operations.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In addition, other legislative changes have been proposed and adopted since PPACA was enacted. The Budget Control Act of 2011, among other
	things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals in spending reductions. The Joint Select Committee did not achieve a targeted deficit reduction of at least $1.2 trillion for the years 2013 through
	2021, triggering the legislation&#146;s automatic reduction to several government programs. This includes reductions to Medicare payments to providers, which went into effect in April 2013 and, following passage of the Bipartisan Budget Act of 2015,
	will remain in effect
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	29
</FONT>
</P>
<A NAME="eolPage32"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	through 2025 unless additional congressional action is taken. The American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several providers and increased the
	statute of limitations period for the government to recover overpayments to providers from three to five years.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Further, the recently enacted Drug Supply Chain Security Act imposes on manufacturers of certain pharmaceutical products new obligations
	related to product tracking and tracing, among others, which will be phased in over several years beginning in 2015. Among the requirements of this new legislation, manufacturers subject to this federal law will be required to provide certain
	information regarding the drug product to individuals and entities to which product ownership is transferred, label drug product with a product identifier, and keep certain records regarding the drug product. The transfer of information to
	subsequent product owners by manufacturers will eventually be required to be done electronically. Covered manufacturers will also be required to verify that purchasers of the manufacturers&#146; products are appropriately licensed. Further, under
	this new legislation, covered manufacturers will have drug product investigation, quarantine, disposition, and notification responsibilities related to counterfeit, diverted, stolen, and intentionally adulterated products, as well as products that
	are the subject of fraudulent transactions or which are otherwise unfit for distribution such that they would be reasonably likely to result in serious health consequences or death.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Additionally, there has been increasing legislative and enforcement interest in the United States with respect
	to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed bills designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under
	Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We cannot predict what healthcare reform initiatives may be adopted in the future. However, we anticipate that Congress, state
	legislatures, and third-party payors may continue to review and assess alternative healthcare delivery and payment systems and may in the future propose and adopt legislation or policy changes or implementations effecting additional fundamental
	changes in the healthcare delivery system. We also expect ongoing initiatives to increase pressure on drug pricing. We cannot assure you as to the ultimate content, timing, or effect of changes, nor is it possible at this time to estimate the impact
	of any such potential legislation; however, such changes or the ultimate impact of changes could negatively affect our revenue or sales of ADCETRIS or any future approved products.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Competition
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The biotechnology and biopharmaceutical industries are characterized by rapidly advancing technologies, intense
	competition and a strong emphasis on proprietary products. Many third parties compete with us in developing various approaches to treating cancer. They include pharmaceutical companies, biotechnology companies, academic institutions and other
	research organizations.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Many of our competitors
	have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approval and marketing than we do. In addition, many of these competitors
	are active in seeking patent protection and licensing arrangements in anticipation of collecting royalties for use of technology that they have developed. Smaller or early-stage companies may also prove to be significant competitors, particularly
	through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, as well as in acquiring technologies complementary to our
	programs.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	With respect to ADCETRIS, there are
	several other FDA-approved drugs for the treatment of relapsed or refractory Hodgkin lymphoma or sALCL, including Bristol-Myers Squibb&#146;s Opdivo for Hodgkin lymphoma after failure of auto-HSCT and ADCETRIS and Celgene&#146;s Istodax and Spectrum
	Pharmaceuticals&#146; Folotyn for relapsed or refractory peripheral T-cell lymphoma. Merck is also developing a PD-1 inhibitor, pembrolizumab,
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	30
</FONT>
</P>
<A NAME="eolPage33"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	and is conducting a clinical trial in relapsed or refractory classical Hodgkin lymphoma comparing pembrolizumab with ADCETRIS. In addition, we are aware of multiple investigational agents that
	are currently being studied, including Pfizer&#146;s crizotinib, AbbVie&#146;s ibrutinib, Kyowa&#146;s mogamulizumab, and Gilead&#146;s idelalisib, which, if successful, may compete with ADCETRIS in the future. Data have also been presented on
	several developing technologies, including bispecific antibodies and CAR modified T-cell therapies that may compete with ADCETRIS in the future. Further, there are many competing approaches used in the treatment of patients in ADCETRIS&#146; three
	approved indications, including auto-HSCT, conventional therapies, combination chemotherapy, clinical trials with experimental agents and single-agent regimens.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	With respect to SGN-CD33A, there are several investigational agents that, if approved, could be competitive with our product candidate,
	including AbbVie&#146;s venetoclax, which received breakthrough therapy designation from the FDA in January 2016 for use in combination with HMAs in treatment-na&iuml;ve patients with AML who are not eligible for standard high-dose induction
	treatment, Jazz&#146;s Vyxeos, Pfizer&#146;s Mylotarg, Astex&#146;s guadecitabine (SGI-110), and agents targeting biomarkers such as FLT3 and IDH1/2.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Many other pharmaceutical and biotechnology companies are developing and/or marketing therapies for the same types of cancer that our
	product candidates are designed and being developed to treat. For example, we believe that companies including AbbVie, ADC Therapeutics, Affimed, Agios, Amgen, Astellas, Bayer, Biogen, Bristol-Myers Squibb, Celgene, Eisai, Genentech, GSK, Gilead,
	ImmunoGen, Immunomedics, Infinity, Karyopharm, MedImmune, MEI Pharma, Merck, Novartis, Pfizer, Sanofi-Aventis, Spectrum Pharmaceuticals, Takeda, Teva, and Xencor are developing and/or marketing products or technologies that may compete with ours. In
	addition, our ADC collaborators may develop compounds utilizing our technology that may compete with product candidates that we are developing.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We are aware of other companies that have technologies that may be competitive with ours, including Astellas, AstraZeneca, Bristol-Myers
	Squibb, ImmunoGen, Immunomedics, MedImmune, Mersana, and Pfizer, all of which have ADC technology. ImmunoGen has several ADCs in development that may compete with our product candidates. ImmunoGen has also established partnerships with other
	pharmaceutical and biotechnology companies to allow those other companies to utilize ImmunoGen&#146;s technology, including Sanofi-Aventis, Genentech, Novartis, Takeda and Lilly. We are also aware of a number of companies developing monoclonal
	antibodies directed at the same antigen targets or for the treatment of the same diseases as our product candidates. For example, we believe Bristol-Myers Squibb has an anti-CD30 antibody program that may be competitive with ADCETRIS, and Amgen and
	Xencor have anti-CD19 programs that may be competitive with our product candidates.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In addition, in the United States, the Biologics Price Competition and Innovation Act of 2009 created an abbreviated approval pathway for biological products that are demonstrated to be &#147;highly
	similar&#148; or &#147;biosimilar&#148; to or &#147;interchangeable&#148; with an FDA-approved biological product. This pathway allows competitors to reference the FDA&#146;s prior approvals regarding innovative biological products and data
	submitted with a BLA to obtain approval of a biosimilar application 12&nbsp;years after the time of approval of the innovative biological product. The 12-year exclusivity period runs from the initial approval of the innovator product and not from
	approval of a new indication. In addition, the 12-year exclusivity period does not prevent another company from independently developing a product that is highly similar to the innovative product, generating all the data necessary for a full BLA and
	seeking approval. Exclusivity only assures that another company cannot rely on the FDA&#146;s prior approvals in approving a BLA for an innovator&#146;s biological product to support the biosimilar product&#146;s approval. Further, under the
	FDA&#146;s current interpretation, it is possible that a biosimilar applicant could obtain approval for one or more of the indications approved for the innovator product by extrapolating clinical data from one indication to support approval for
	other indications. The FDA approved the first biosimilar product in the United States in May 2015. In the European Union, the European Commission has granted marketing authorizations for several biosimilars pursuant to a set of general and product
	class-specific guidelines for biosimilar approvals issued since 2005. We are aware of many pharmaceutical and biotechnology and other companies that are actively engaged in research and development of biosimilars or interchangeable products.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	31
</FONT>
</P>
<A NAME="eolPage34"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	With respect to our current and potential future product candidates, we believe that our
	ability to compete effectively and develop products that can be manufactured cost-effectively and marketed successfully will depend on our ability to:
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	advance our technology platforms;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	license additional technology;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	complete clinical trials which position our products for regulatory and commercial success;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	maintain a proprietary position in our technologies and products;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	obtain required government and other public and private approvals on a timely basis;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	attract and retain key personnel;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	commercialize effectively;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	obtain reimbursement for our products in approved indications;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	comply with applicable laws, regulations and regulatory requirements and restrictions with respect to the commercialization of our products, including
	with respect to any changed or increased regulatory restrictions; and
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	enter into additional collaborations to advance the development and commercialization of our product candidates.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Manufacturing
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We do not currently have the internal ability to manufacture
	the drug products that we sell or need to conduct our clinical trials, and we therefore rely on corporate collaborators and contract manufacturing organizations to supply drug product for commercial supply and our IND-enabling studies and clinical
	trials. For the monoclonal antibody used in ADCETRIS, we have contracted with AbbVie for clinical and commercial supplies. For the drug linker used in ADCETRIS, we have contracted with Sigma Aldrich Fine Chemicals, or SAFC, for clinical and
	commercial supplies. We have multiple contract manufacturers for conjugating the drug linker to the antibody and producing the ADCETRIS product. For our ADC product candidates, multiple contract manufacturers, including AbbVie and SAFC, perform
	antibody and drug-linker manufacturing and several other contract manufacturers perform conjugation of the drug-linker to the antibody and fill/finish of the drug product. In addition, we rely on other third parties to perform additional steps in
	the manufacturing process, including shipping and storage of ADCETRIS and our product candidates.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We established our commercial scale supply chain for ADCETRIS prior to commercial launch. For the foreseeable future, we expect to continue to rely on contract manufacturers and other third parties to
	produce, vial and store sufficient quantities of ADCETRIS for use in our clinical trials and for commercial sale. In addition, we depend on outside vendors for the supply of raw materials used to produce ADCETRIS. For our pipeline programs, we
	believe that our existing supplies of drug product and our contract manufacturing relationships will be sufficient to accommodate clinical trials through phase 3. However, we may need to obtain additional manufacturing arrangements or increase our
	own manufacturing capability to meet our future commercial needs, both of which could require significant capital investment. In addition, we have committed to provide Takeda with their needs of certain parts of the ADCETRIS supply chain for a
	limited period of time, which may require us to arrange for additional manufacturing supply. We may also enter into collaborations with pharmaceutical or larger biotechnology companies to enhance the manufacturing capabilities for our product
	candidates.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	AbbVie
	Biotechnology
</I>
	.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In February 2004, we entered into a development and supply agreement with AbbVie (formerly a part of Abbott Laboratories) to manufacture developmental, clinical and commercial quantities of anti-CD30
	monoclonal antibody, which is a component of ADCETRIS. The agreement generally
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	32
</FONT>
</P>
<A NAME="eolPage35"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	provides for the supply by AbbVie and the purchase by us of such anti-CD30 monoclonal antibody. Under terms of the supply agreement, we may purchase a portion of our required anti-CD30 monoclonal
	antibody from a second source third-party supplier. We are required to make a minimum annual purchase. The anti-CD30 monoclonal antibody is purchased by us based upon a rolling forecast. The supply agreement will continue until 2025 with an
	automatic one-year term extension unless either party provides written termination notice to the other party. Either party has the right to terminate the supply agreement if the other party materially breaches its obligations thereunder.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	SAFC
</I>
	.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In December 2010,
	we entered into a commercial supply agreement with SAFC to manufacture commercial quantities of drug linker that is a component of ADCETRIS. The agreement generally provides for the supply by SAFC and the purchase by us of drug linker. Under terms
	of the supply agreement, we may purchase a portion of our required drug linker from a second source third-party supplier. We are required to make a minimum annual purchase. The drug linker is purchased by us based upon a rolling forecast. The supply
	agreement was made effective as of December&nbsp;1, 2010 and will continue until the completion of the tenth contract year following the initial commercial order with automatic term extension unless either party provides written termination notice
	to the other party. Either party has the right to terminate the supply agreement if the other party materially breaches its obligations thereunder.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Commercial Operations and Information About Geographic Areas
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We have allocated commercial resources, including sales,
	marketing, supply chain management and reimbursement capabilities, to commercialize ADCETRIS in the United States and Canada. We believe the U.S. and Canadian markets for ADCETRIS in the approved indications are addressable with a targeted sales and
	marketing organization, and we intend to continue promoting ADCETRIS ourselves in the United States and Canada for these and any additional indications we may obtain in the future. Takeda has commercial rights in the rest of the world. ADCETRIS was
	granted conditional marketing authorization in the European Union in October 2012 for patients with relapsed Hodgkin lymphoma or relapsed sALCL. As of January&nbsp;31, 2017, we and Takeda had received marketing authorizations by regulatory
	authorities in 66 countries, and Takeda continues to pursue marketing authorizations in multiple other countries.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We sell ADCETRIS through a limited number of pharmaceutical distributors. Health care providers order ADCETRIS through these distributors.
	We receive orders from distributors and generally ship product directly to the health care provider. Three of our major distributors, together with entities under their common control&#151;AmerisourceBergen Corporation, Cardinal Health, Inc., and
	McKesson Corporation&#151;each accounted for 10% or more of our total revenue in 2016 and 2015, respectively. Our net product sales of ADCETRIS for the years ended December&nbsp;31, 2016, 2015, and 2014, were $265.8 million, $226.1 million, and
	$178.2 million, respectively. Revenues generated outside the United States as determined by customer location were less than 10% of total revenues for the years ended December&nbsp;31, 2016, 2015, and 2014. Substantially all of our long-lived assets
	are located in the United States.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Employees
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	As of December&nbsp;31, 2016, we had 890 employees. Of these
	employees, 634 were engaged in or support research, development and clinical activities, 140 were in administrative and business related positions, and 116 were in sales and marketing. Each of our employees has signed confidentiality and inventions
	assignment agreements and none are covered by a collective bargaining agreement. We have never experienced employment-related work stoppages and consider our employee relations to be good.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Corporate Information
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%;PADDING-BOTTOM:0PX; ">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We were incorporated in Delaware on July&nbsp;15, 1997. Our principal executive offices are located at 21823
	30
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	th
</SUP>
</FONT>
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Drive SE, Bothell, Washington 98021. Our telephone
	number is (425)&nbsp;527-4000. Seattle Genetics
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	&reg;
</SUP>
</FONT>
	and
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2017/02/21/0001193125-17-050543_G481013G29S61.JPG" ALT="LOGO">
	are our registered trademarks in the United States. All other trademarks, tradenames and service marks included in this Annual Report on Form 10-K are the property of their respective owners.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	33
</FONT>
</P>
<A NAME="eolPage36"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We file electronically with the Securities and Exchange Commission our Annual Reports on
	Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934. We make available on our website at
	www.seattlegenetics.com, free of charge, through a hyperlink on our website, copies of these reports, as soon as reasonably practicable after electronically filing such reports with, or furnishing them to, the Securities and Exchange Commission. The
	information contained in, or that can be accessed through, our website is not part of, and is not incorporated into, this Annual Report on Form 10-K.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	34
</FONT>
</P>
<A NAME="eolPage37"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
</EFX_BUSINESS>
<EFX_RISK_FACTORS>
<A NAME="FIS_RISK_FACTORS"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D481013D10K_HTM_TOC481013_2">
</A>
	Item&nbsp;1A. Risk Factors
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	You should carefully consider the following risk factors, in
	addition to the other information contained in this Annual Report on Form&nbsp;10-K, including our condensed consolidated financial statements and related notes. If any of the events described in the following risk factors occurs, our business,
	operating results and financial condition could be seriously harmed. This Annual Report on Form 10-K also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in
	the forward-looking statements as a result of factors that are described below and elsewhere in this Annual Report on Form 10-K.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Risks Related to Our Business
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Our near-term prospects are substantially dependent on ADCETRIS. If we and/or Takeda are unable to effectively commercialize ADCETRIS for the
	treatment of patients in its approved indications and to continue to expand its labeled indications of use, our ability to generate significant revenue or potentially achieve profitability will be adversely affected.
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%;PADDING-BOTTOM:0PX; ">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	ADCETRIS
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	&reg;
</SUP>
</FONT>
	, or brentuximab vedotin, is now approved by the United States Food and Drug Administration, or FDA, and the European
	Commission for three indications, encompassing several settings for the treatment of relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma, or sALCL. ADCETRIS is our only product approved for marketing and our ability to
	generate revenue from product sales and potentially achieve profitability is substantially dependent on our continued ability to effectively commercialize ADCETRIS for the treatment of patients in its approved indications and our ability to continue
	to expand its labeled indications of use. We may not be able to fully realize the commercial potential of ADCETRIS for a number of reasons, including:
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	we may not be able to obtain and maintain regulatory approvals to market ADCETRIS for any additional indications, including for relapsed cutaneous
	T-cell lymphoma, or CTCL, frontline Hodgkin lymphoma or frontline mature T-cell lymphoma, or MTCL, or to otherwise continue to expand its labeled indications of use;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	negative or inconclusive results in our ECHELON-1 and ECHELON-2 phase 3 trials would negatively impact, or preclude altogether, our ability to obtain
	regulatory approval and commercialize ADCETRIS in the frontline Hodgkin lymphoma and frontline MTCL indications, respectively, either of which could limit our sales of, and the commercial potential of, ADCETRIS;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	we may fail to obtain regulatory approval and commercialize ADCETRIS in the ALCANZA treatment setting notwithstanding the positive data we reported
	from our ALCANZA trial, which would also limit our sales of, and the commercial potential of, ADCETRIS;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	results from our required post-approval study, the ECHELON-2 trial, may fail to verify the clinical benefit of ADCETRIS in relapsed sALCL, which could
	result in the withdrawal of approval of ADCETRIS in the relapsed sALCL indication and which could negatively impact our potential future product sales for the relapsed sALCL indication;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	new competitive therapies, including immuno-oncology agents such as PD-1 inhibitors (e.g., nivolumab and pembrolizumab), have been approved by
	regulatory authorities (as in the case of nivolumab) or may be submitted in the near term to regulatory authorities for approval in ADCETRIS&#146; labeled indications in relapsed Hodgkin lymphoma, and these competitive products could negatively
	impact our commercial sales of ADCETRIS;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	our commercial sales of ADCETRIS could be lower than our projections due to a lower market penetration rate, increased competition by alternative
	products or biosimilars, or a shorter duration of therapy in patients in ADCETRIS&#146; approved indications;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	we may be unable to effectively commercialize ADCETRIS in any new indications for which we receive marketing approval;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	35
</FONT>
</P>
<A NAME="eolPage38"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	there may be additional changes to the label for ADCETRIS, including ADCETRIS&#146; boxed warning, that further restrict how we market and sell
	ADCETRIS, including as a result of data collected from our required post-approval study, or as the result of adverse events observed in that study or in other studies, including in the post-approval confirmatory studies that Takeda is required to
	conduct as a condition to the conditional marketing authorization of ADCETRIS by the European Commission or in investigator-sponsored studies;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	we may not be able to establish or demonstrate in the medical community the safety and efficacy of ADCETRIS and its potential advantages over and side
	effects compared to existing and future therapeutics;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	physicians may be reluctant to prescribe ADCETRIS until results from our required post-approval study are available or other long term efficacy and
	safety data exist;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	the estimated incidence rate of new patients in ADCETRIS&#146; approved indications may be lower than our projections;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	there may be adverse results or events reported in any of the clinical trials that we and/or Takeda are conducting or may in the future conduct for
	ADCETRIS;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	we may be unable to continue to effectively market, sell and distribute ADCETRIS;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	ADCETRIS may be impacted by adverse reimbursement and coverage policies from government and private payers such as Medicare, Medicaid, insurance
	companies, health maintenance organizations and other plan administrators, or may be subject to pricing pressures enacted by industry organizations or state and federal governments, including as a result of increased scrutiny over drug-pricing
	strategies by pharmaceutical companies or otherwise;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	the relative price of ADCETRIS may be higher than alternative treatment options;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	there may be changed or increased regulatory restrictions;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	we may not have adequate financial or other resources to effectively commercialize ADCETRIS; and
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	we may not be able to obtain adequate commercial supplies of ADCETRIS to meet demand or at an acceptable cost.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In December 2009, we entered into an agreement with Takeda to
	develop and commercialize ADCETRIS, under which we have commercial rights in the United States and its territories and Canada, and Takeda has commercial rights in the rest of the world. The success of this collaboration and the activities of Takeda
	will significantly impact the commercialization of ADCETRIS in countries other than the United States and in Canada. In October 2012, Takeda announced that it had received conditional marketing authorization for ADCETRIS from the European Commission
	for patients with relapsed Hodgkin lymphoma or relapsed sALCL, and has since obtained marketing approvals for ADCETRIS in many other countries. Conditional marketing authorization by the European Commission includes obligations to provide additional
	clinical data at a later stage to confirm the positive benefit-risk balance. In July 2016, Takeda announced that it had received marketing authorization for ADCETRIS from the European Commission for the treatment of adult patients with CD30-positive
	Hodgkin lymphoma at increased risk of relapse or progression following autologous stem cell transplant. We cannot control the amount and timing of resources that Takeda dedicates to the commercialization of ADCETRIS, or to its marketing and
	distribution, and our ability to generate revenues from ADCETRIS product sales by Takeda depends on Takeda&#146;s ability to achieve market acceptance of, and to otherwise effectively market, ADCETRIS for its approved indications in Takeda&#146;s
	territory.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We believe that the level of our
	ongoing ADCETRIS sales in the United States is largely attributable to the incidence flow of patients eligible for treatment with ADCETRIS. We also believe that the incidence rate of new patients in ADCETRIS&#146; approved indications is relatively
	low, particularly when compared to many other oncology indications. For these and other reasons, we expect that our ability to accelerate ADCETRIS sales
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	36
</FONT>
</P>
<A NAME="eolPage39"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	growth, if at all, will depend primarily on our ability to continue to expand ADCETRIS&#146; labeled indications of use. Accordingly, we are exploring the use of ADCETRIS as a single agent and in
	combination therapy regimens earlier in the treatment of Hodgkin lymphoma and MTCL, including sALCL, and in a range of CD30-expressing hematologic malignancies, including CD30-expressing relapsed CTCL. This will continue to require additional time
	and investment in clinical trials and there can be no assurance that we and/or Takeda will obtain and maintain the necessary regulatory approvals to market ADCETRIS for any additional indications. In particular, negative or inconclusive results in
	our ECHELON-1 and ECHELON-2 trials would negatively impact, or preclude altogether, our ability to obtain regulatory approval in the frontline Hodgkin lymphoma and frontline MTCL, indications, respectively, either of which could limit our sales of,
	and the commercial potential of, ADCETRIS. For example, in accordance with the terms of their respective SPA, the ECHELON-1 and ECHELON-2 trials are designed to continue until a specified number of events designated for each trial have occurred
	(i.e. progressions or deaths). If events do not occur at the rate which was anticipated in one or both of these trials, the final data analysis for the applicable trial could be delayed beyond the predicted ranges. In addition, we may choose for a
	variety of reasons to complete the applicable trial with fewer events than planned. If we choose to complete a trial with fewer events than planned, the FDA may treat the applicable SPA as rescinded and the statistical power of that trial based on
	the original statistical analysis plan could be negatively impacted, making it more difficult for us to demonstrate that ADCETRIS is safe and effective and to successfully obtain regulatory approval for the specific indication studied in that trial.
	We may also undertake additional discussions with regulatory authorities or amend the protocol for one or both of these trials, and we cannot predict the outcome of those discussions or whether we would be able to reach agreement with the regulatory
	authorities. Should this situation occur, there could be a delay in our ability to obtain data from the applicable trial or impact the ability of the applicable trial to support approval of ADCETRIS for the specific indication studied in that trial.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In addition, although we reported in August 2016
	that the ALCANZA trial evaluating ADCETRIS in patients with relapsed CTCL met its primary endpoint demonstrating a statistically significant improvement in the rate of objective response lasting at least four months and we plan to submit a
	supplemental Biologics License Application, or sBLA, to the FDA to seek approval for a new indication in CD30-expressing relapsed CTCL, there can be no assurance that the FDA will accept our planned sBLA for filing or that we will ultimately obtain
	approval of our planned sBLA in a timely manner or at all. Our failure to obtain regulatory approval and commercialize ADCETRIS in the ALCANZA treatment setting would also limit our sales of, and the commercial potential of, ADCETRIS. In addition,
	while ADCETRIS product sales grew from 2014 to 2015 and from 2015 to 2016, and our future plans assume that sales of ADCETRIS will increase, we cannot assure you that ADCETRIS sales will continue to grow or that we can maintain sales of ADCETRIS at
	or near current levels.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We and Takeda have formed
	a collaboration with Ventana Medical Systems, Inc., or Ventana, under which Ventana is working to develop, manufacture and commercialize a molecular companion diagnostic test with the goal of identifying patients who might respond to treatment with
	ADCETRIS based on CD30 expression levels in their tissue specimens. However, Ventana may not be able to successfully develop and obtain regulatory approval for a molecular companion diagnostic that may be required by regulatory authorities to
	support regulatory approval of ADCETRIS in other CD30-expressing malignancies in a timely manner or at all.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Even if we and Takeda receive the required regulatory approvals to market ADCETRIS for any additional indications or in additional
	jurisdictions, we and Takeda may not be able to effectively commercialize ADCETRIS, including for the reasons set forth above. Our ability to grow ADCETRIS product sales in future periods is also dependent on price increases and we periodically
	increase the price of ADCETRIS. Price increases on ADCETRIS and negative publicity regarding drug pricing and price increases generally, whether on ADCETRIS or products distributed by other pharmaceutical companies, could negatively affect market
	acceptance of, and sales of, ADCETRIS. In any event, we cannot assure you that price increases we have taken or may take in the future will not in the future negatively affect ADCETRIS sales.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	37
</FONT>
</P>
<A NAME="eolPage40"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Reports of adverse events or safety concerns involving ADCETRIS or our product candidates could delay
	or prevent us from obtaining or maintaining regulatory approvals, or could negatively impact sales of ADCETRIS or the prospects for our product candidates.
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Reports of adverse events or safety concerns involving
	ADCETRIS could interrupt, delay or halt clinical trials of ADCETRIS, including the ongoing FDA-required ADCETRIS post-approval confirmatory study as well as the post-approval confirmatory studies that Takeda is required to conduct as a condition to
	the conditional marketing authorization of ADCETRIS by the European Commission. For example, during 2013 concerns regarding pancreatitis caused an investigator conducting an independent study involving ADCETRIS to temporarily halt enrollment in the
	trial and to amend the eligibility criteria and monitoring for the trial. Subsequently, we have revised our prescribing information to add pancreatitis as a known adverse event. In addition, reports of adverse events or safety concerns involving
	ADCETRIS could result in regulatory authorities denying or withdrawing approval of ADCETRIS for any or all indications, including the use of ADCETRIS for the treatment of patients in its approved indications. There are no assurances that patients
	receiving ADCETRIS will not experience serious adverse events in the future. Further, there are no assurances that patients receiving ADCETRIS with co-morbid diseases not previously studied, such as autoimmune diseases, will not experience new or
	different serious adverse events in the future.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Adverse events may negatively impact the sales of ADCETRIS. We may be required to further update the ADCETRIS prescribing information,
	including boxed warnings, based on reports of adverse events or safety concerns or implement a Risk Evaluation and Mitigation Strategy, or REMS, which could adversely affect ADCETRIS&#146; acceptance in the market, make competition easier or make it
	more difficult or expensive for us to distribute ADCETRIS. For example, the prescribing information for ADCETRIS includes pancreatitis, impaired hepatic function, impaired renal function, pulmonary toxicity, and gastrointestinal complications as
	known adverse events as well as a boxed warning related to the risk that JC virus infection resulting in progressive multifocal leukoencephalopathy, or PML, and death can occur in patients receiving ADCETRIS. Further, based on the identification of
	future adverse events, we may be required to further revise the prescribing information, including ADCETRIS&#146; boxed warning, which could negatively impact sales of ADCETRIS or adversely affect ADCETRIS&#146; acceptance in the market.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Likewise, reports of adverse events or safety concerns
	involving ADCETRIS or our product candidates could interrupt, delay or halt clinical trials of such product candidates, or could result in our inability to obtain regulatory approvals for any of our product candidates. For example, on December 27,
	2016, we announced that we had received notice from the FDA that a full clinical hold or partial clinical hold had been placed on several early stage trials of SGN-CD33A in AML to evaluate the potential risk of hepatotoxicity following adverse
	medical events, including fatal events. We may be unable to submit to the FDA all required clinical follow-up information to respond to the clinical holds. Even if we are able to provide such information, the FDA may not deem the information to be
	sufficient to lift any or all of the clinical holds. In addition, we may encounter delays in reaching an agreement with the FDA regarding the terms under which these trials may be resumed, or we may elect to discontinue one or more of these trials
	for safety or any other reasons. Furthermore, the FDA may require us to implement additional, potentially burdensome pharmacovigilance procedures or conduct additional pre-clinical studies before it will consider lifting the clinical holds, if at
	all. In addition, although the FDA has not placed a clinical hold on the CASCADE trial or our phase 1/2 trial in MDS and we continue to enroll patients in these trials, we cannot assure you that the FDA or another regulatory authority will not place
	a clinical hold on one or both of these trials. If we are unable to submit required information to the FDA in a timely manner, or at all; if the FDA does not lift the clinical holds in a timely manner, or at all; if the FDA does not permit us to
	initiate additional trials of SGN-CD33A and/or the FDA imposes clinical holds on the CASCADE trial or our phase 1/2 trial in MDS; or if there are additional safety results, including from our ongoing trials of SGN-CD33A, that alter the benefit-risk
	profile of SGN-CD33A or cause it to become unacceptable, we would be further delayed or prevented from advancing the clinical development of SGN-CD33A, which would adversely affect our business, results of operations and prospects.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	38
</FONT>
</P>
<A NAME="eolPage41"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Concerns regarding the safety of ADCETRIS or our product candidates as a result of
	undesirable side effects identified during clinical testing or otherwise could cause the FDA to order us to cease further development or commercialization of ADCETRIS or the applicable product candidate. Undesirable side effects caused by ADCETRIS
	or our product candidates could also result in denial of regulatory approval by the FDA or other regulatory authorities for any or all targeted indications, the requirement of additional trials or the inclusion of unfavorable information in our
	product labeling, and in turn delay or prevent us from commercializing ADCETRIS or the applicable product candidate. In addition, actual or potential drug-related side effects could affect patient recruitment or the ability of enrolled patients to
	complete a trial for ADCETRIS or our product candidates or result in potential product liability claims. Any of these events could prevent us from developing or commercializing ADCETRIS or the particular product candidate, and could significantly
	harm our business, results of operations and prospects.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Even though we have obtained approval to market ADCETRIS in three indications, we are subject to extensive ongoing regulatory obligations and
	review, including post-approval requirements that could result in the withdrawal of ADCETRIS from the market for certain indications if such requirements are not met.
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	ADCETRIS is approved for treating patients in one
	indication, the relapsed sALCL indication, under accelerated approval regulations in the U.S. and approval with conditions in two indications in Canada, which allow for approval of products for cancer or other serious or life threatening illnesses
	based on a surrogate endpoint or on a clinical endpoint other than survival or irreversible morbidity. Under these types of approvals, we are subject to certain post-approval requirements pursuant to which we are conducting an additional
	confirmatory phase 3 trial to verify and describe the clinical benefit of ADCETRIS. Our failure to complete this required post-approval study, or to confirm a clinical benefit during this post-approval study, could result in the withdrawal of
	approval of ADCETRIS in the relapsed sALCL indication in the U.S. and both indications in Canada, which would seriously harm our business. In addition, under the FDA&#146;s accelerated approval regulations, the labeling, packaging, adverse event
	reporting, storage, advertising and promotion of ADCETRIS for the treatment of patients with relapsed sALCL is subject to extensive regulatory requirements all of which entails significant expense and may limit our ability to commercialize ADCETRIS
	for the relapsed sALCL indication. Similarly, the conditional marketing authorization of ADCETRIS for two indications by the European Commission includes obligations to provide additional clinical data at a later time to confirm the results of the
	two pivotal studies. Takeda&#146;s failure to provide these additional clinical data or to confirm the results of the pivotal studies, could result in the European Commission withdrawing approval of ADCETRIS in the European Union, which would
	negatively impact anticipated royalty revenue from ADCETRIS sales by Takeda in the European Union and could adversely affect our results of operations. In addition, we are subject to extensive ongoing obligations and continued regulatory review from
	applicable regulatory agencies with respect to any product for which we have obtained regulatory approval, including ADCETRIS in each of its approved indications, such as continued adverse event reporting requirements and the requirement to have
	some of our promotional materials pre-cleared by the FDA. There may also be additional post-marketing obligations, all of which may result in significant expense and limit our ability to commercialize ADCETRIS in the United States, Canada or
	potentially other jurisdictions.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We and the
	manufacturers of ADCETRIS are also required to comply with current Good Manufacturing Practices, or cGMP, regulations, which include requirements relating to quality control and quality assurance as well as the corresponding maintenance of records
	and documentation. Further, regulatory agencies must approve these manufacturing facilities before they can be used to manufacture ADCETRIS, and these facilities are subject to ongoing regulatory inspections. In addition, regulatory agencies subject
	an approved product, its manufacturer and the manufacturer&#146;s facilities to continual review and inspections, including periodic unannounced inspections. The subsequent discovery of previously unknown problems with ADCETRIS, including adverse
	events of unanticipated severity or frequency, or problems with the facilities where ADCETRIS is manufactured, may result in restrictions on the marketing of ADCETRIS, up to and including withdrawal of ADCETRIS from the market. If our manufacturing
	facilities or those of our suppliers fail to comply with applicable regulatory requirements, such noncompliance could result in regulatory action and additional costs to us.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	39
</FONT>
</P>
<A NAME="eolPage42"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Failure to comply with applicable FDA and other regulatory requirements may subject us to
	administrative or judicially imposed sanctions, including:
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	issuance of Form FDA 483 notices or Warning Letters by the FDA or other regulatory agencies;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	imposition of fines and other civil penalties;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	criminal prosecutions;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	injunctions, suspensions or revocations of regulatory approvals;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	suspension of any ongoing clinical trials;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	total or partial suspension of manufacturing;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	delays in commercialization;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	refusal by the FDA to approve pending applications or supplements to approved applications submitted by us;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	refusals to permit drugs to be imported into or exported from the United States;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	restrictions on operations, including costly new manufacturing requirements; and
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	product recalls or seizures.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The policies of the FDA and other regulatory agencies may change and additional government regulations may be enacted that could prevent
	or delay regulatory approval of ADCETRIS in any additional indications or further restrict or regulate post-approval activities. We cannot predict the likelihood, nature or extent of adverse government regulation that may arise from future
	legislation or administrative action, either in the United States or abroad. If we are not able to maintain regulatory compliance, we or Takeda might not be permitted to market ADCETRIS and our business would suffer.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	If we or our collaborators are not able to obtain or maintain required
	regulatory approvals, we or our collaborators will not be able to successfully commercialize ADCETRIS or our product candidates.
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The research, testing, manufacturing, labeling, approval, selling, marketing and distribution of drug products are subject to extensive
	regulation by the FDA and other regulatory authorities in the United States and other countries, which regulations differ from country to country. Neither we nor our collaborators are permitted to market our product candidates in the United States
	or foreign countries until we obtain marketing approval from the FDA or other foreign regulatory authorities, and we or our collaborators may never receive regulatory approval for the commercial sale of any of our product candidates. In addition,
	part of our strategy is to continue to explore the use of ADCETRIS earlier in the treatment of Hodgkin lymphoma and MTCL and in other CD30-expressing malignancies, including CTCL, and we are currently conducting multiple clinical trials for
	ADCETRIS. However, we and/or Takeda may be unable to obtain or maintain any regulatory approvals for the commercial sale of ADCETRIS for any additional indications. Obtaining marketing approval is a lengthy, expensive and uncertain process and
	approval is never assured, and we have only limited experience in preparing and submitting the applications necessary to gain regulatory approvals. Further, the FDA and other foreign regulatory agencies have substantial discretion in the approval
	process, and determining when or whether regulatory approval will be obtained for any product candidate we develop, including any regulatory approvals for the potential commercial sale of ADCETRIS in additional indications or in any additional
	territories. In this regard, even if we believe the data collected from clinical trials of ADCETRIS and our product candidates are promising, such data may not be sufficient to support approval by the FDA or any other foreign regulatory authority.
	In addition, the FDA or their advisors may disagree with our interpretations of data from preclinical studies and clinical trials. In this regard, based on the positive data we reported from the ALCANZA trial, we plan to submit an sBLA to the FDA to
	seek approval for a new indication in CD30-expressing relapsed CTCL. Even if the FDA accepts our planned sBLA for filing, the FDA may disagree with our interpretations of the data from the ALCANZA trial and/or may otherwise determine not to approve
	our planned sBLA in a timely manner
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	40
</FONT>
</P>
<A NAME="eolPage43"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	or at all. Moreover, even though our ALCANZA, ECHELON-1 and ECHELON-2 trials are being conducted under SPA agreements with the FDA, this is not a guarantee or indication of approval, and we
	cannot be certain that the design of, or data collected from, any of our current or potential future clinical trials that were or are being conducted under SPAs with the FDA will be sufficient to support FDA approval. Further, an SPA agreement is
	not binding on the FDA if public health concerns unrecognized at the time the SPA agreement is entered into become evident, other new scientific concerns regarding product safety or efficacy arise, new drugs are approved in the same indication, or
	if we have failed to comply with the agreed upon trial protocols. In addition, an SPA agreement may be changed by us or the FDA on written agreement of both parties, and the FDA retains significant latitude and discretion in interpreting the terms
	of an SPA agreement and the data and results from the applicable clinical trial. For example, even though we believe that the data from the ALCANZA trial are supportive of approval of ADCETRIS in the ALCANZA treatment setting, our SPA with the FDA
	covering the ALCANZA trial is not a guarantee or indication of approval of ADCETRIS in the ALCANZA treatment setting (or in any other indication). Regulatory agencies also may approve a product candidate for fewer indications than requested or may
	grant approval subject to the performance of post-approval studies or REMS for a product candidate. Similarly, regulatory agencies may not approve the labeling claims that are necessary or desirable for the successful commercialization of ADCETRIS
	in additional indications, including any indications in the ALCANZA treatment setting.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In addition, changes in regulatory requirements and guidance may occur and we may need to amend clinical trial protocols and/or related SPA agreements to reflect these changes. Amendments may require us
	to resubmit our clinical trial protocols to institutional review boards, or IRBs, for reexamination, which may impact the costs, timing or successful completion of a clinical trial. In addition, as part of the U.S. Prescription Drug User Fee Act, or
	PDUFA, the FDA has a goal to review and act on a percentage of all regulatory submissions in a given time frame. However, the FDA does not always meet its PDUFA targeted action dates and if the FDA were to fail to meet a PDUFA targeted action date
	in the future for ADCETRIS or any of our product candidates, including in connection with our planned sBLA submission to seek approval to market ADCETRIS in the ALCANZA treatment setting, the commercialization of the affected product candidate or of
	ADCETRIS in any additional indications could be delayed or impaired. Due to these and other factors, ADCETRIS and our product candidates could take a significantly longer time to gain regulatory approvals than we expect or may never gain new
	regulatory approvals, which could delay or eliminate any potential product revenue from sales of our product candidates or of ADCETRIS in any additional indications, which could significantly delay or prevent us from achieving profitability.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	The successful commercialization of ADCETRIS and product
	candidates will depend in part on the extent to which governmental authorities and health insurers establish adequate coverage and reimbursement levels and pricing policies.
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Successful sales of ADCETRIS and any future products will depend, in part, on the extent to which coverage and
	reimbursement for our products will be available from government and health administration authorities, private health insurers and other third-party payors. To manage healthcare costs, many governments and third-party payors increasingly scrutinize
	the pricing of new products and require greater levels of evidence of favorable clinical outcomes and cost-effectiveness before extending coverage. In light of such challenges to prices, we cannot be sure that we will achieve and continue to have
	coverage available for ADCETRIS and any other product candidate that we commercialize and, if available, that the reimbursement rates will be adequate. If we are unable to obtain adequate levels of coverage and reimbursement for our product
	candidates, their marketability will be negatively and materially impacted.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Moreover, eligibility for coverage and reimbursement does not imply that a drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and
	distribution. In addition, obtaining and maintaining adequate coverage and reimbursement status is time-consuming and costly. Third-party payors may deny coverage and reimbursement status altogether of a given drug product, or cover the product but
	may also establish prices at levels that are too low to enable us to realize an appropriate return on our investment in product development. Further, one payor&#146;s determination to provide coverage for a product does
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	41
</FONT>
</P>
<A NAME="eolPage44"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	not assure that other payors will also provide coverage for the product. Because the rules and regulations regarding coverage and reimbursement change frequently, in some cases at short notice,
	even when there is favorable coverage and reimbursement, future changes may occur that adversely impact the favorable status.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The unavailability or inadequacy of third-party coverage and reimbursement could have a material adverse effect on the market acceptance
	of ADCETRIS and any of our future products and the future revenues we may expect to receive from those products. In addition, we are unable to predict what additional legislation or regulation relating to the healthcare industry or third-party
	coverage and reimbursement may be enacted in the future, or what effect such legislation or regulation would have on our business. Recent negative publicity regarding pharmaceutical prices and the results of the 2016 United States presidential and
	congressional elections create significant uncertainty regarding regulation of the healthcare industry and third party coverage and reimbursement.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Healthcare law and policy changes may have a material adverse effect on us.
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In March 2010, the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and
	Education Reconciliation Act of 2010, or collectively PPACA, became law in the United States. PPACA substantially changed the way healthcare is financed by both governmental and private insurers and significantly affects the pharmaceutical industry.
	The provisions of PPACA of greatest importance to the pharmaceutical industry include increased Medicaid rebates, expanded Medicaid eligibility, extension of Public Health Service eligibility, annual fees payable by manufacturers and importers of
	branded prescription drugs, annual reporting of financial relationships with physicians and teaching hospitals, and a new Patient-Centered Outcomes Research Institute. Many of these provisions have had the effect of reducing the revenue generated by
	our sales of ADCETRIS and will have the effect of reducing any revenue generated by sales of any future commercial products we may have. Further, there have been judicial and Congressional challenges to certain aspects of PPACA In January 2017,
	Congress voted to adopt a budget resolution for fiscal year 2017, or the Budget Resolution, that authorizes the implementation of legislation that would repeal portions of PPACA. The Budget Resolution is not a law; however, it is widely viewed as
	the first step toward the passage of legislation that would repeal certain aspects of PPACA. Further, on January&nbsp;20, 2017, President Trump signed an Executive Order directing federal agencies with authorities and responsibilities under PPACA to
	waive, defer, grant exemptions from, or delay the implementation of any provision of PPACA that would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical
	devices. Congress also could consider subsequent legislation to replace elements of PPACA that are repealed. Because of the continued uncertainty about the implementation of PPACA, including the potential for further legal challenges or repeal of
	PPACA, we cannot quantify or predict with any certainty the likely impact of the PPACA or its repeal on our business, prospects, financial condition or results of operations.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In addition, we anticipate that PPACA, as well as other
	healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and an additional downward pressure on the price that we receive for ADCETRIS or any future approved product, which may harm our business.
	For example, increased discounts, rebates or chargebacks may be mandated by governmental or private insurers or fee caps and pricing pressures could be enacted by industry organizations or state and federal governments, any of which could
	significantly affect the revenue generated by sales of our products, including ADCETRIS. In addition, drug- pricing strategies by pharmaceutical companies have recently come under increased scrutiny. Specifically, there have been several recent U.S.
	Congressional inquiries and proposed bills designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs and
	reform government program reimbursement methodologies for drugs. We expect further federal and state proposals and healthcare reforms to continue to be proposed to control increasing healthcare costs and to control the rising cost of prescription
	drugs. These proposals, if implemented, could limit the price for ADCETRIS or any future approved products. Commercial opportunity could be negatively impacted by legislative action that controls pricing, mandates price negotiations, or increases
	government discounts and rebates. For example, in March 2016, the Centers for Medicare and Medicaid Services, or CMS, proposed to conduct a demonstration project that would reduce the Medicare
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	42
</FONT>
</P>
<A NAME="eolPage45"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	payment rates for most Part B drugs for approximately half of all providers. If implemented, this project could potentially limit our ability to change pricing for ADCETRIS and all drugs
	reimbursed under Medicare Part B. Implementation could negatively impact future revenue from sales of ADCETRIS. We cannot predict how this initiative will be affected by the change in U.S. presidential administrations.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Also, price increases on ADCETRIS and negative publicity
	regarding drug pricing and price increases generally, whether on ADCETRIS or products distributed by other pharmaceutical companies, could negatively affect market acceptance of, and sales of, ADCETRIS. In addition, although ADCETRIS is approved in
	the European Union, Japan and other countries outside of the United States, government austerity measures or further healthcare reform measures and pricing pressures in other countries could adversely affect demand and pricing for ADCETRIS, which
	would negatively impact anticipated royalty revenue from ADCETRIS sales by Takeda.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Other legislative changes have also been proposed and adopted since PPACA was enacted. The Budget Control Act of 2011, among other things, created the Joint Select Committee on Deficit Reduction to
	recommend to Congress proposals in spending reductions. The Joint Select Committee did not achieve a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, triggering the legislation&#146;s automatic reduction to
	several government programs. This includes a 2% reduction in Medicare provider payments paid under Medicare Part B to physicians for physician-administered drugs, such as certain oral oncology drugs, which went into effect in April 2013 and,
	following passage of the Bipartisan Budget Act of 2015, will remain in effect through 2025 unless additional congressional action is taken. The American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several providers
	and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. In addition, legislation has been proposed to shorten the period of biologic data and market exclusivity granted by the
	FDA. If such legislation is enacted, we may face competition from biosimilars of ADCETRIS or any future approved products earlier than otherwise would have occurred.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We cannot predict what healthcare reform initiatives may be
	adopted in the future. However, we anticipate that Congress, state legislatures, and third-party payors may continue to review and assess alternative healthcare delivery and payment systems and may in the future propose and adopt legislation or
	policy changes or implementations effecting additional fundamental changes in the healthcare delivery system. We also expect ongoing initiatives to increase pressure on drug pricing. We cannot assure you as to the ultimate content, timing, or effect
	of changes, nor is it possible at this time to estimate the impact of any such potential legislation; however, such changes or the ultimate impact of changes could negatively affect our revenue or sales of ADCETRIS or any future approved products.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Clinical trials are expensive and time consuming, may take
	longer than we expect or may not be completed at all, and their outcome is uncertain.
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We are currently conducting multiple clinical trials for ADCETRIS and our product candidates and we plan to commence additional trials of ADCETRIS and our product candidates in the future. We are also
	conducting a phase 3 clinical trial for our product candidate SGN-CD33A, or the CASCADE trial, designed to evaluate SGN-CD33A in combination with hypomethylating agents, or HMAs, in previously untreated older AML patients. We initiated the CASCADE
	trial based on interim data presented at the December 2015 American Society of Hematology annual meeting from a cohort of a phase 1 trial that evaluated SGN-CD33A in combination with HMAs. While the interim phase 1 data may be promising, SGN-CD33A
	has not previously been evaluated in a randomized trial with other active agents and we cannot be certain that the design of, or data collected from, the CASCADE trial will be adequate to demonstrate the safety and efficacy of SGN-CD33A for the
	treatment of patients with AML, or will otherwise be sufficient to support FDA or any foreign regulatory approvals. In this regard, on December 27, 2016, we announced that we had received notice from the FDA that a full clinical hold or partial
	clinical hold had been placed on several early stage trials of SGN-CD33A in AML to evaluate the potential risk of hepatotoxicity following adverse medical events, including fatal events. We may be unable to submit to the FDA all required clinical
	follow-up information to respond to the clinical holds. Even if we are able
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	43
</FONT>
</P>
<A NAME="eolPage46"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	to provide such information, the FDA may not deem the information to be sufficient to lift any or all of the clinical holds. In addition, we may encounter delays in reaching an agreement with the
	FDA regarding the terms under which these trials may be resumed, or we may elect to discontinue one or more of these trials for safety or any other reasons. Furthermore, the FDA may require us to implement additional, potentially burdensome
	pharmacovigilance procedures or conduct additional pre-clinical studies before it will consider lifting the clinical holds, if at all. In addition, although the FDA has not placed a clinical hold on the CASCADE trial or our phase 1/2 trial in MDS
	and we continue to enroll patients in these trials, we cannot assure you that the FDA or another regulatory authority will not place a clinical hold on one or both of these trials. If we are unable to submit required information to the FDA in a
	timely manner, or at all; if the FDA does not lift the clinical holds in a timely manner, or at all; if the FDA does not permit us to initiate additional trials of SGN-CD33A and/or the FDA imposes clinical holds on the CASCADE trial or our phase 1/2
	trial in MDS; or if there are additional safety results, including from our ongoing trials of SGN-CD33A, that alter the benefit-risk profile of SGN-CD33A or cause it to become unacceptable, we would be further delayed or prevented from advancing the
	clinical development of SGN-CD33A, which would adversely affect our business, results of operations and prospects.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Each of our clinical trials requires the investment of substantial expense and time and the timing of the commencement, continuation and
	completion of these clinical trials may be subject to significant delays relating to various causes, including scheduling conflicts with participating clinicians and clinical institutions, difficulties in identifying and enrolling patients who meet
	trial eligibility criteria, failure of patients to complete the clinical trial, delays in accumulating the required number of clinical events for data analyses, delay or failure to obtain IRB approval to conduct a clinical trial at a prospective
	site, and shortages of available drug supply. For example, in accordance with the terms of their respective SPA, the ECHELON-1 and ECHELON-2 trials are designed to continue until a specified number of events designated for each trial have occurred
	(i.e. progressions or deaths). If events do not occur at the rate which was anticipated in one or both of these trials, the final data analysis for the applicable trial could be delayed beyond the predicted ranges. In addition, we may choose for a
	variety of reasons to complete the applicable trial with fewer events than planned. If we choose to complete a trial with fewer events than planned, the FDA may treat the applicable SPA as rescinded and/or the statistical power of that trial based
	on the original statistical analysis plan could be negatively impacted, making it more difficult for us to demonstrate that ADCETRIS is safe and effective and to successfully obtain regulatory approval for the specific indication studied in that
	trial. We may also undertake additional discussions with regulatory authorities or amend the protocol for one or both of these trials, and we cannot predict the outcome of those discussions or whether we would be able to reach agreement with the
	regulatory authorities. Should this situation occur, there could be a delay in our ability to obtain data from the applicable trial or impact the ability of the applicable trial to support approval of ADCETRIS for the specific indication studied in
	that trial.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Additionally, patient enrollment is a
	function of many factors, including the size of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial, the existence of competing clinical trials, perceived side effects and the availability of
	alternative or new treatments. Many of our future and ongoing ADCETRIS clinical trials are being or will be coordinated with Takeda, which may delay the commencement or affect the continuation or completion of these trials. From time to time, we
	have experienced enrollment-related delays in clinical trials and we will likely continue to experience similar delays in our current and future trials. We depend on medical institutions and clinical research organizations, or CROs, to conduct some
	of our clinical trials in compliance with Good Clinical Practice, or GCP, and to the extent they fail to enroll patients for our clinical trials, fail to conduct our trials in accordance with GCP, or are delayed for a significant time in achieving
	full enrollment, we may be affected by increased costs, program delays or both, which may harm our business. In addition, we conduct clinical trials in foreign countries which may subject us to further delays and expenses as a result of increased
	drug shipment costs, additional regulatory requirements and the engagement of foreign CROs, as well as expose us to risks associated with less experienced clinical investigators who are unknown to the FDA, different standards of medical care, and
	foreign currency transactions insofar as changes in the relative value of the U.S. dollar to the foreign currency where the trial is being conducted may impact our actual costs.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	44
</FONT>
</P>
<A NAME="eolPage47"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Clinical trials must be conducted in accordance with FDA or other applicable foreign
	government guidelines and are subject to oversight by the FDA, other foreign governmental agencies, the data safety monitoring boards for such trials and the IRBs for the institutions in which such trials are being conducted. In addition, clinical
	trials must be conducted with supplies of ADCETRIS or our product candidates produced under cGMP and other requirements in foreign countries, and may require large numbers of test patients. We, the FDA, other foreign governmental agencies or the
	applicable data safety monitoring boards and IRBs could delay, suspend, halt or modify our clinical trials of ADCETRIS or any of our product candidates, and we and/or the FDA could terminate or modify any related special protocol assessment, or SPA,
	agreements, for numerous reasons, including:
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	ADCETRIS or the applicable product candidate may have unforeseen safety issues or adverse side effects, including fatalities, or a determination may be
	made that a clinical trial presents unacceptable health risks;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	deficiencies in the conduct of the clinical trial, including failure to conduct the clinical trial in accordance with regulatory requirements, GCP or
	clinical protocols;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	deficiencies in the clinical trial operations or trial sites resulting in the imposition of a clinical hold;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	the time required to determine whether ADCETRIS or the applicable product candidate is effective may be longer than expected;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	fatalities or other adverse events arising during a clinical trial due to medical problems that may not be related to clinical trial treatments;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	ADCETRIS or the applicable product candidate may not appear to be more effective than current therapies;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	the quality or stability of ADCETRIS or the applicable product candidate may fall below acceptable standards;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	our inability to produce or obtain sufficient quantities of ADCETRIS or the applicable product candidate to complete the trials;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	our inability to reach agreement on acceptable terms with prospective CROs and trial sites, the terms of which can be subject to extensive negotiation
	and may vary significantly among different CROs and trial sites;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	our inability to obtain IRB approval to conduct a clinical trial at a prospective site;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	changes in governmental regulations or administrative actions that adversely affect our ability to continue to conduct or to complete clinical trials;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	lack of adequate funding to continue the clinical trial, including the incurrence of unforeseen costs due to enrollment delays, requirements to conduct
	additional trials and studies and increased expenses associated with the services of our CROs and other third parties;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	our inability to recruit and enroll patients to participate in clinical trials for reasons including competition from other clinical trial programs for
	the same or similar indications;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	our inability to retain patients who have initiated a clinical trial but may be prone to withdraw due to side effects from the therapy, lack of
	efficacy or personal issues, or who are lost to further follow-up; or
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	our inability to ensure adequate statistical power to detect statistically significant treatment effects, whether through our inability to enroll or
	retain patients in trials or as a result of our determination to choose to complete trials with fewer events than planned.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In addition, we may experience significant setbacks in advanced clinical trials, even after promising results in earlier trials, including
	unexpected adverse events that may occur when our product candidates are combined with other therapies. For example, on December&nbsp;27, 2016, we announced that we had received notice from the
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	45
</FONT>
</P>
<A NAME="eolPage48"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	FDA that a full clinical hold or partial clinical hold had been placed on several early stage trials of SGN-CD33A in AML to evaluate the potential risk of hepatotoxicity following adverse medical
	events, including fatal events. We may be unable to submit to the FDA all required clinical follow-up information to respond to the clinical holds, or even if we are able to provide such information, the FDA may not deem the information to be
	sufficient to lift any or all of the clinical holds. In addition, we may encounter delays in reaching an agreement with the FDA regarding the terms under which these trials may be resumed, or we may elect to discontinue one or more of these trials
	for safety or any other reasons. Furthermore, the FDA may require us to implement additional, potentially burdensome pharmacovigilance procedures or conduct additional pre-clinical studies before it will consider lifting the clinical holds, if at
	all. In addition, although the FDA has not placed a clinical hold on the CASCADE trial or our phase 1/2 trial in MDS and we continue to enroll patients in these trials, we cannot assure you that the FDA or another regulatory authority will not place
	a clinical hold on one or both of these trials. If we are unable to submit required information to the FDA in a timely manner, or at all; if the FDA does not lift the clinical holds in a timely manner, or at all; if the FDA does not permit us to
	initiate additional trials of
<FONT STYLE="WHITE-SPACE:NOWRAP">
	SGN-CD33A
</FONT>
	and/or the FDA imposes clinical holds on the CASCADE trial or our phase 1/2 trial in MDS; or if there are additional safety results, including from our ongoing trials of
	SGN-CD33A, that alter the benefit-risk profile of SGN-CD33A or cause it to become unacceptable, we would be further delayed or prevented from advancing the clinical development of SGN-CD33A, which would adversely affect our business, results of
	operations and prospects.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Negative or
	inconclusive clinical trial results could adversely affect our ability to obtain regulatory approvals of our product candidates or to market ADCETRIS and/or expand ADCETRIS into other indications. In particular, negative or inconclusive results in
	our ECHELON-1 and ECHELON-2 trials would negatively impact or preclude altogether, our ability to obtain regulatory approval in the frontline Hodgkin lymphoma and frontline MTCL indications, respectively, either of which could limit our sales of,
	and the commercial potential of, ADCETRIS. Likewise, the imposition of a clinical hold on, or the termination of, or otherwise negative or inconclusive results in our CASCADE trial, would negatively impact or preclude altogether, our ability to
	obtain regulatory approval of SGN-CD33A. In addition, clinical trial results are frequently susceptible to varying interpretations that may delay, limit or prevent regulatory approvals. For example, although we reported that our ALCANZA trial met
	its primary endpoint and we plan to submit an sBLA to the FDA to seek approval for a new indication in CD30-expressing relapsed CTCL, regulatory agencies, including the FDA, or their advisors, may disagree with our interpretations of data from the
	ALCANZA trial and may not approve the expansion of ADCETRIS&#146; labeled indications of use based on the results of the ALCANZA trial or any other of our clinical trials.&nbsp;Adverse medical events during a clinical trial, including patient
	fatalities, such as those hepatotoxicity events and patient fatalities observed in certain of our early stage trials of SGN-CD33A resulting in the imposition by the FDA of clinical holds on those trials, could cause a trial to be redone or
	terminated, curtail or end the development of a product candidate, and may result in other negative consequences to us. Further, some of our clinical trials, including the CASCADE trial, are overseen by an independent data monitoring committee, or
	IDMC, and an IDMC may determine to delay or suspend one or more of these trials due to safety or futility findings based on events occurring during a clinical trial.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	We face intense competition and rapid technological change, which may
	result in others discovering, developing or commercializing competing products before or more successfully than we do.
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The biotechnology and biopharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong
	emphasis on proprietary products. Many third parties compete with us in developing various approaches to treating cancer. They include pharmaceutical companies, biotechnology companies, academic institutions and other research organizations.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Many of our competitors have significantly
	greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approval and marketing than we do. In addition, many of these competitors are active in
	seeking patent protection and licensing arrangements in anticipation of collecting royalties for use of technology that they have developed. Smaller or early-stage companies may also prove to be significant competitors, particularly through
	collaborative
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	46
</FONT>
</P>
<A NAME="eolPage49"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, as well as in acquiring
	technologies complementary to our programs.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	With
	respect to ADCETRIS, there are several other FDA-approved drugs for the treatment of relapsed or refractory Hodgkin lymphoma or sALCL, including Bristol-Myers Squibb&#146;s Opdivo for Hodgkin lymphoma after failure of auto-HSCT and ADCETRIS and
	Celgene&#146;s Istodax and Spectrum Pharmaceuticals&#146; Folotyn for relapsed or refractory peripheral T-cell lymphoma. Merck is also developing a PD-1 inhibitor, pembrolizumab, and is conducting a clinical trial in relapsed or refractory classical
	Hodgkin lymphoma comparing pembrolizumab with ADCETRIS. In addition, we are aware of multiple investigational agents that are currently being studied, including Pfizer&#146;s crizotinib, AbbVie&#146;s ibrutinib, Kyowa&#146;s mogamulizumab, and
	Gilead&#146;s idelalisib, which, if successful, may compete with ADCETRIS in the future. Data have also been presented on several developing technologies, including bispecific antibodies and CAR modified T-cell therapies that may compete with
	ADCETRIS in the future. Further, there are many competing approaches used in the treatment of patients in ADCETRIS&#146; three approved indications, including auto-HSCT, conventional therapies, combination chemotherapy, clinical trials with
	experimental agents and single-agent regimens.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	With respect to SGN-CD33A, there are several investigational agents that, if approved, could be competitive with our product candidate,
	including AbbVie&#146;s venetoclax, which received breakthrough therapy designation from the FDA in January 2016 for use in combination with HMAs in treatment-na&iuml;ve patients with AML who are not eligible for standard high-dose induction
	treatment, Jazz&#146;s Vyxeos, Pfizer&#146;s Mylotarg, Astex&#146;s guadecitabine (SGI-110), and agents targeting biomarkers such as FLT3 and IDH1/2.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Many other pharmaceutical and biotechnology companies are developing and/or marketing therapies for the same types of cancer that our
	product candidates are designed and being developed to treat. For example, we believe that companies including AbbVie, ADC Therapeutics, Affimed, Agios, Amgen, Astellas, Bayer, Biogen, Bristol-Myers Squibb, Celgene, Eisai, Genentech, GSK, Gilead,
	ImmunoGen, Immunomedics, Infinity, Karyopharm, MedImmune, MEI Pharma, Merck, Novartis, Pfizer, Sanofi-Aventis, Spectrum Pharmaceuticals, Takeda, Teva, and Xencor are developing and/or marketing products or technologies that may compete with ours. In
	addition, our ADC collaborators may develop compounds utilizing our technology that may compete with product candidates that we are developing.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We are aware of other companies that have technologies that may be competitive with ours, including Astellas, AstraZeneca, Bristol-Myers
	Squibb, ImmunoGen, Immunomedics, MedImmune, Mersana and Pfizer, all of which have ADC technology. ImmunoGen has several ADCs in development that may compete with our product candidates. ImmunoGen has also established partnerships with other
	pharmaceutical and biotechnology companies to allow those other companies to utilize ImmunoGen&#146;s technology, including Sanofi-Aventis, Genentech, Novartis, Takeda and Lilly. We are also aware of a number of companies developing monoclonal
	antibodies directed at the same antigen targets or for the treatment of the same diseases as our product candidates. For example, we believe Bristol-Myers Squibb has an anti-CD30 antibody program that may be competitive with ADCETRIS, and Amgen and
	Xencor have anti-CD19 programs that may be competitive with our product candidates.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In addition, in the United States, the Biologics Price Competition and Innovation Act of 2009 created an abbreviated approval pathway for biological products that are demonstrated to be &#147;highly
	similar&#148; or &#147;biosimilar&#148; to or &#147;interchangeable&#148; with an FDA-approved biological product. This pathway allows competitors to reference the FDA&#146;s prior approvals regarding innovative biological products and data
	submitted with a BLA to obtain approval of a biosimilar application 12&nbsp;years after the time of approval of the innovative biological product. The 12-year exclusivity period runs from the initial approval of the innovator product and not from
	approval of a new indication. In addition, the 12-year exclusivity period does not prevent another company from independently developing a product that is highly similar to the innovative product, generating all the data necessary for a full BLA and
	seeking approval. Exclusivity only assures that another company cannot rely on the FDA&#146;s prior
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	47
</FONT>
</P>
<A NAME="eolPage50"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	approvals in approving a BLA for an innovator&#146;s biological product to support the biosimilar product&#146;s approval. Further, under the FDA&#146;s current interpretation, it is possible
	that a biosimilar applicant could obtain approval for one or more of the indications approved for the innovator product by extrapolating clinical data from one indication to support approval for other indications. The FDA approved the first
	biosimilar product in the United States in May 2015. In the European Union, the European Commission has granted marketing authorizations for several biosimilars pursuant to a set of general and product class-specific guidelines for biosimilar
	approvals issued since 2005. We are aware of many pharmaceutical and biotechnology and other companies that are actively engaged in research and development of biosimilars or interchangeable products.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	It is possible that our competitors will succeed in
	developing technologies that are more effective than ADCETRIS, SGN-CD33A or our other product candidates or that would render our technology obsolete or noncompetitive, or will succeed in developing biosimilar or interchangeable products for
	ADCETRIS, SGN-CD33A or our other product candidates. We anticipate that we will face increased competition in the future as new companies enter our market and scientific developments surrounding biosimilars and other cancer therapies continue to
	accelerate. We cannot predict to what extent the entry of biosimilars or other competing products will impact potential future sales of ADCETRIS, SGN-CD33A or our other product candidates.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Our operating results are difficult to predict and may fluctuate. If our operating results are below the expectations of
	securities analysts or investors, the trading price of our stock could decline.
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our operating results are difficult to predict and may fluctuate significantly from quarter to quarter and year to year. In addition, although we provide sales guidance for ADCETRIS from time to time, you
	should not rely on ADCETRIS sales results in any period as being indicative of future performance. Such guidance is based on assumptions that may be incorrect or that may change from quarter to quarter. Sales of ADCETRIS have, on occasion, been
	below the expectations of securities analysts and investors and have been below prior period sales, and sales of ADCETRIS in the future may also be below prior period sales, our own guidance and/or the expectations of securities analysts and
	investors. To the extent that we do not meet our guidance or the expectations of analysts or investors, our stock price may be adversely impacted, perhaps significantly. We believe that our quarterly and annual results of operations may be affected
	by a variety of factors, including:
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	customer ordering patterns for ADCETRIS, which may vary significantly from period to period;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	the overall level of demand for ADCETRIS including the impact of any competitive or biosimilar products and the duration of therapy for patients
	receiving ADCETRIS;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	the extent to which coverage and reimbursement for ADCETRIS is available from government and health administration authorities, private health
	insurers, managed care programs and other third-party payers;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	changes in the amount of deductions from gross sales, including government-mandated rebates, chargebacks and discounts that can vary because of changes
	to the government discount percentage, including increases in the government discount percentage resulting from price increases we have taken or may take in the future, or due to different levels of utilization by entities entitled to government
	rebates and discounts and changes in patient demographics;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	increases in the scope of eligibility for customers to purchase ADCETRIS at the discounted government price or to obtain government-mandated rebates on
	purchases of ADCETRIS;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	changes in our cost of sales;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	the incidence rate of new patients in ADCETRIS&#146; approved indications;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	the timing, cost and level of investment in our sales and marketing efforts to support ADCETRIS sales;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	the timing, cost and level of investment in our research and development and other activities involving ADCETRIS, SGN-CD33A and our other product
	candidates by us or our collaborators;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	expenditures we will or may incur to develop and/or commercialize any additional products, product candidates, or technologies that we may develop,
	in-license, or acquire.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	48
</FONT>
</P>
<A NAME="eolPage51"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In addition, we have entered into licensing and collaboration agreements with other
	companies that include development funding and milestone payments to us, and we expect that amounts earned from our collaboration agreements will continue to be an important source of our revenues. Accordingly, our revenues will also depend on
	development funding and the achievement of development and clinical milestones under our existing collaboration and license agreements, including, in particular, our ADCETRIS collaboration with Takeda, as well as entering into potential new
	collaboration and license agreements. These upfront and milestone payments may vary significantly from quarter to quarter and any such variance could cause a significant fluctuation in our operating results from one quarter to the next.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Further, changes in our operations, such as increased
	development, manufacturing and clinical trial expenses in connection with our expanding pipeline programs, including several phase 3 trials, or our undertaking of additional programs, business activities or entry into strategic transactions,
	including potential additional acquisitions of products, technologies or businesses, such as our anticipated in-licensing of IMMU-132, may also cause significant fluctuations in our expenses. In addition, we measure compensation cost for stock-based
	awards made to employees at the grant date of the award, based on the fair value of the award, and recognize the cost as an expense over the employee&#146;s requisite service period. As the variables that we use as a basis for valuing these awards
	change over time, including our underlying stock price, the magnitude of the expense that we must recognize may vary significantly. Additionally, we have implemented long-term incentive plans for our employees, and the incentives provided under
	these plans are contingent upon the achievement of certain regulatory milestones. Costs of performance-based compensation under our long-term incentive plans are not recorded as an expense until the achievement of the applicable milestones is deemed
	probable of being met, which may result in large fluctuations to the expense we must recognize in any particular period.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	For these and other reasons, it is difficult for us to accurately forecast future sales of ADCETRIS, collaboration and license agreement
	revenues, royalty revenues, operating expenses or future profits or losses. As a result, our operating results in future periods could be below our guidance or the expectations of securities analysts or investors, which could cause the trading price
	of our common stock to decline, perhaps substantially.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	We
	have a history of net losses. We expect to continue to incur net losses and may not achieve profitability for some time, if at all.
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We have incurred substantial net losses in each of our years of operation. We have incurred these losses principally from costs incurred
	in our research and development programs and from our selling, general and administrative expenses. We expect to continue to spend substantial amounts on research and development, including amounts for conducting required post-approval and other
	clinical trials of, and seeking additional regulatory approvals for, ADCETRIS as well as commercializing ADCETRIS for the treatment of patients in its three approved indications. In addition, we expect to make substantial expenditures to further
	develop and potentially commercialize SGN-CD33A and our other product candidates. Likewise, in connection with our anticipated in-licensing of IMMU-132, we expect to incur substantial upfront and milestone payment obligations and to make to make
	substantial expenditures to potentially further develop and potentially commercialize IMMU-132. Accordingly, we expect to continue to incur net losses and may not achieve profitability for some time, if at all. Although we recognize revenue from
	ADCETRIS product sales and we continue to earn amounts under our collaboration agreements, our revenue and profit potential is unproven and our limited commercialization history makes our future operating results difficult to predict. Even if we do
	achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. If we are unable to achieve and sustain profitability, the market value of our common stock will likely decline.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	49
</FONT>
</P>
<A NAME="eolPage52"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	We depend on collaborative relationships with other companies to assist in the research and
	development of ADCETRIS and for the development and commercialization of product candidates utilizing or incorporating our technologies. If we are not able to locate suitable collaborators or if our collaborators do not perform as expected, this may
	negatively affect our ability to commercialize ADCETRIS, develop other product candidates and/or generate revenues through technology licensing, or may otherwise negatively affect our business.
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We have established collaborations with third parties to
	develop and market ADCETRIS and some of our current and future product candidates. For example, we entered into a collaboration agreement with Takeda in December 2009 that granted Takeda rights to develop and commercialize ADCETRIS outside of the
	United States and Canada. In addition, we have entered into a 50/50 co-development agreement with Astellas for the development of ADCs, including ASG-22ME. We also have ADC collaborations with AbbVie, Bayer, Celldex, Genentech, GSK, Pfizer and
	Progenics, and an ADC co-development agreement with Genmab. In addition, we have entered into a collaboration agreement with Unum to develop and commercialize novel antibody-coupled
<FONT STYLE="WHITE-SPACE:NOWRAP">
	T-cell
</FONT>
	receptor, or ACTR,
	therapies incorporating our antibodies for cancer. Our dependence on collaborative arrangements to assist in the development and commercialization of ADCETRIS and for the development and commercialization of product candidates utilizing or
	incorporating our technologies subjects us to a number of risks, including:
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	we are not able to control the amount and timing of resources that our collaborators or co-development partners devote to the development or
	commercialization of products and product candidates utilizing or incorporating our technologies, or to their marketing and distribution;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	disputes may arise between us and our collaborators or co-development partners that result in the delay or termination of the research, development or
	commercialization of the applicable products and product candidates or that result in costly litigation or arbitration that diverts management&#146;s attention and resources;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	with respect to collaboration and co-development arrangements under which we have an active role, such as our ADCETRIS collaboration and our 50/50
	co-development agreement with Astellas, we may have differing opinions or priorities than our collaborators or co-development partners, or we may encounter challenges in joint decision making, which may result in the delay or termination of the
	research, development or commercialization of the applicable products and product candidates, including ADCETRIS and ASG-22ME;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	our current and potential future collaborators and co-development partners may delay clinical trials, provide insufficient funding for a clinical trial
	program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	significant delays in the development of product candidates by current and potential collaborators and co-development partners could allow competitors
	to bring products to market before product candidates utilizing or incorporating our technologies are approved and impair the ability of current and potential future collaborators and co-development partners to effectively commercialize these
	product candidates;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	our relationships with our collaborators and co-development partners may divert significant time and effort of our scientific staff and management team
	and require the effective allocation of our resources to multiple internal, collaborative and co-development projects;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	our current and potential future collaborators and co-development partners may not be successful in their efforts to obtain regulatory approvals in a
	timely manner, or at all;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	our current and potential future collaborators and co-development partners may receive regulatory sanctions relating to other aspects of their business
	that could adversely affect the development, approval or commercialization of the applicable products or product candidates;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	our current and potential future collaborators and co-development partners may not properly maintain or defend our intellectual property rights or may
	use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our proprietary information or expose us to potential litigation;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	50
</FONT>
</P>
<A NAME="eolPage53"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	business combinations or significant changes in a collaborator&#146;s or co-development partner&#146;s business strategy may adversely affect such
	party&#146;s willingness or ability to complete its obligations under any arrangement;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	a collaborator or co-development partner could independently move forward with competing products, therapeutic approaches or technologies to develop
	treatments for the diseases targeted by us or our collaborators or co-development partners that are developed by such collaborator or co-development partner either independently or in collaboration with others, including our competitors;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	our current and potential collaborators and co-development partners may experience financial difficulties; and
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	our collaborations and co-development agreements may be terminated, breached or allowed to expire, or our collaborators or co-development partners may
	reduce the scope of our agreements with them, which could have a material adverse effect on our financial position by reducing or eliminating the potential for us to receive technology access and license fees, milestones and royalties, and/or
	reimbursement of development costs, and which could require us to devote additional efforts and to incur the additional costs associated with pursuing internal development and commercialization of the applicable products and product candidates.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	If our collaborative or
	co-development arrangements are not successful as a result of any of the above factors, or any other factors, then our ability to advance the development and commercialization of the applicable products and product candidates and to otherwise
	generate revenue from these arrangements and to become profitable will be adversely affected, and our business and business prospects may be materially harmed. In particular, if Takeda were to terminate the ADCETRIS collaboration, we would not
	receive milestone payments, co-funded development payments or royalties for the sale of ADCETRIS outside the United States and Canada. As a result of such termination, we may have to engage another collaborator to complete the ADCETRIS development
	process and to commercialize ADCETRIS outside the United States and Canada, or to complete the development process and undertake commercializing ADCETRIS outside the United States and Canada ourselves, either of which could significantly delay the
	continued development and commercialization of ADCETRIS and increase our costs. In turn, this could significantly harm our financial position, adversely affect our stock price and require us to incur all the costs of developing and commercializing
	ADCETRIS, which are now being co-funded by Takeda.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In the future, we may not be able to locate third-party collaborators or co-development partners to develop and market products and
	product candidates utilizing or incorporating our technologies, and we may lack the capital and resources necessary to develop and market these products and product candidates alone.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	We have engaged in, and may in the future engage in strategic transactions that increase our capital requirements, dilute
	our stockholders, cause us to incur debt or assume contingent liabilities and subject us to other risks.
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We actively evaluate various strategic transactions on an ongoing basis, including licensing or otherwise acquiring complementary
	products, technologies or businesses, and we recently announced our entry into the Immunomedics License pursuant to which, if consummated, we would be granted an exclusive worldwide license to IMMU-132. Any potential acquisitions or in-licensing
	transactions, such as our anticipated in-licensing of IMMU-132, may entail numerous risks, including but not limited to:
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	risks associated with satisfying the closing conditions relating to such transactions and realizing their anticipated benefits;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	increased operating expenses and cash requirements;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	difficulty integrating acquired technologies, products, operations, and personnel with our existing business;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	51
</FONT>
</P>
<A NAME="eolPage54"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	diversion of management&#146;s attention in connection with both negotiating the acquisition or license and integrating the business, technology or
	product;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	retention of key employees;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	uncertainties in our ability to maintain key business relationships of any acquired entities;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	strain on managerial and operational resources;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	difficulty implementing and maintaining effective internal control over financial reporting at businesses that we acquire, particularly if they are not
	located near our existing operations;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	exposure to unforeseen liabilities of acquired companies or companies in which we invest; and
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	potential costly and time-consuming litigation, including stockholder lawsuits.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	As a result of these or other problems and risks, businesses,
	technologies or products we acquire or invest in or obtain licenses to may not produce the revenues, earnings or business synergies that we anticipated, acquired or licensed technologies may not result in regulatory approvals, and acquired or
	licensed products may not perform as expected. As a result, we may incur higher costs and realize lower revenues than we had anticipated. We cannot assure you that any acquisitions or investments we have made or may make in the future, including our
	anticipated in-licensing of IMMU-132, will be completed or that, if completed, the acquired business, licenses, investments, products, or technologies will generate sufficient revenue to offset the negative costs or other negative effects on our
	business. Failure to manage effectively our growth through acquisition or in-licensing transactions could adversely affect our growth prospects, business, results of operations, financial condition, and cash flow.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In addition, we may spend significant amounts, issue dilutive
	securities, assume or incur significant debt obligations, incur large one-time expenses and acquire intangible assets in connection with acquisitions and in-licensing transactions that could result in significant future amortization expense and
	write-offs. Moreover, we may not be able to locate suitable acquisition opportunities and this inability could impair our ability to grow or obtain access to technology or products that may be important to the development of our business. Even if
	appropriate opportunities are available, we may not be able to successfully identify them or we may not have the financial resources necessary to pursue them, and if pursued, we may be unable to structure and execute transactions in the anticipated
	timeframe, or at all. Other pharmaceutical companies, many of which may have substantially greater financial, marketing and sales resources, compete with us for these opportunities.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Even if we are able to successfully identify and acquire complementary products, technologies or businesses, we
	cannot assure you that we will be able to successfully manage the risks associated with integrating acquired products, technologies or businesses or the risks arising from anticipated and unanticipated problems in connection with an acquisition or
	in-licensing transaction. Further, while we seek to mitigate risks and liabilities of potential acquisitions and in-licensing transactions through, among other things, due diligence, there may be risks and liabilities that such due diligence efforts
	fail to discover, that are not disclosed to us, or that we inadequately assess. Any failure in identifying and managing these risks and uncertainties effectively, including in connection with the anticipated in-licensing of IMMU-132, would have a
	material adverse effect on our business. Additionally, we may not realize the anticipated benefits of such transactions, including the possibility that expected synergies and accretion will not be realized or will not be realized within the expected
	time frame.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Our current product candidates are in various
	stages of clinical development, and it is possible that none of these product candidates will ever become commercial products.
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our current product candidates are in various stages of clinical development, and other than SGN-CD33A, our product candidates are in
	relatively early stages of development. Our product candidates will require significant further development, financial resources and personnel to obtain regulatory approval and develop into commercially viable products, if at all. In 2016, we
	initiated the CASCADE trial, which is designed to evaluate SGN-CD33A in combination with HMAs in previously untreated older AML patients. SGN-CD33A has not
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	52
</FONT>
</P>
<A NAME="eolPage55"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	previously been evaluated in a randomized trial with other active agents and we cannot be certain that the design of, or data collected from, the CASCADE trial will be adequate to demonstrate the
	safety and efficacy of SGN-CD33A for the treatment of patients with AML, or will otherwise be sufficient to support FDA or any foreign regulatory approvals. In addition, certain early stage trials of SGN-CD33A are currently under clinical holds to
	evaluate the potential risk of hepatotoxicity following adverse medical events, including fatal events. We may be unable to submit to the FDA all required clinical follow-up information to respond to the clinical holds. Even if we are able to
	provide such information, the FDA may not deem the information to be sufficient to lift any or all of the clinical holds. In addition, we may encounter delays in reaching an agreement with the FDA regarding the terms under which these trials may be
	resumed, or we may elect to discontinue one or more of these trials for safety or any other reasons. Furthermore, the FDA may require us to implement additional, potentially burdensome pharmacovigilance procedures or conduct additional pre-clinical
	studies before it will consider lifting the clinical holds, if at all. In addition, although the FDA has not placed a clinical hold on the CASCADE trial or our phase 1/2 trial in MDS and we continue to enroll patients in these trials, we cannot
	assure you that the FDA or another regulatory authority will not place a clinical hold on one or both of these trials. If we are unable to submit required information to the FDA in a timely manner, or at all; if the FDA does not lift the clinical
	holds in a timely manner, or at all; if the FDA does not permit us to initiate additional trials of SGN-CD33A and/or the FDA imposes clinical holds on the CASCADE trial or our phase 1/2 trial in MDS, or if there are additional safety results,
	including from our ongoing trials of SGN-CD33A that alter the benefit-risk profile of SGN-CD33A or cause it to become unacceptable, we would be further delayed or prevented from advancing the clinical development of SGN-CD33A, which would adversely
	affect our business, results of operations and prospects.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Currently, our other clinical-stage product candidates include seven ADC programs, which consist of ASG-22ME, SGN-LIV1A, SGN-CD19A, SGN-CD19B, SGN-CD123A, SGN-352A, and ASG-15ME, as well as two
	immuno-oncology agents, SEA-CD40, which is based on our sugar-engineered antibody, or SEA, technology, and SGN-2FF, which is a novel small molecule. If a product candidate fails at any stage of development or we otherwise determine to discontinue
	development of that product candidate, we will not have the anticipated revenues from that product candidate to fund our operations, and we may not receive any return on our investment in that product candidate. Moreover, we still have only limited
	data from our phase 1 trials of our product candidates. In this regard, preclinical studies and any encouraging or positive preliminary and interim data from our clinical trials of our product candidates may not necessarily be predictive of the
	results of ongoing or later clinical trials. Even if we are able to complete our planned clinical trials of our product candidates according to our current development timeline, the encouraging or positive results from clinical trials of our product
	candidates in earlier stage trials may not be replicated in subsequent clinical trial results. As a result, we may conduct lengthy and expensive clinical trials of our product candidates only to learn that a product candidate is not an effective
	treatment or is not superior to existing approved therapies, or has an unacceptable safety profile, which could prevent or significantly delay regulatory approval for such product candidate. Also, our later-stage clinical trials could differ in
	significant ways from earlier stage clinical trials, which could cause the outcome of the later-stage trials to differ from our earlier stage clinical trials. For instance, though we reported phase 1 interim efficacy data that supported our decision
	to initiate the CASCADE trial, we may not receive positive results for SGN-CD33A even if we complete the CASCADE trial. Differences in earlier and later stage clinical trials may include changes to inclusion and exclusion criteria, efficacy
	endpoints and statistical design. Many companies in the pharmaceutical and biotechnology industries, including us, have suffered significant setbacks in late-stage clinical trials after achieving encouraging or positive results in early-stage
	development. We cannot be certain that we will not face similar setbacks in our ongoing clinical trials, for instance, in the CASCADE trial. We have not yet completed any late-stage clinical trials for our current product candidates, and if we fail
	to produce positive results in our ongoing or planned clinical trials of any of our product candidates, the development timeline and regulatory approval and commercialization prospects for our product candidates, and, correspondingly, our business
	and financial prospects, would be materially adversely affected.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Due to the uncertain and time-consuming clinical development and regulatory approval process, we may not successfully develop any of our product candidates and it is possible that none of our current
	product candidates will ever become commercial products. In addition, we expect that much of our effort and many of our
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	53
</FONT>
</P>
<A NAME="eolPage56"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	expenditures over the next few years will be devoted to the additional clinical development of and commercialization activities associated with ADCETRIS, which may restrict or delay our ability
	to develop our clinical and preclinical product candidates.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	To date, we have depended on a small number of collaborators for a substantial portion of our revenue. The loss of any one of these collaborators or
	changes in their product development or business strategy could result in a material decline in our revenue.
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We have collaborations with a limited number of companies. To date, a substantial portion of our revenue has resulted from payments made
	under agreements with our corporate collaborators, and although ADCETRIS sales currently comprise a greater proportion of our revenue, we expect that a portion of our revenue will continue to come from corporate collaborations. Even though we market
	ADCETRIS in the United States and Canada, our revenues still depend in part on Takeda&#146;s ability and willingness to market ADCETRIS outside of the United States and Canada. The loss of our collaborators, especially Takeda, changes in product
	development or business strategies of our collaborators, or the failure of our collaborators to perform their obligations under their agreements with us for any reason, including paying license or technology fees, milestone payments, royalties or
	reimbursements, could have a material adverse effect on our financial performance. Payments under our existing and potential future collaboration agreements are also subject to significant fluctuations in both timing and amount, which could cause
	our revenue to fall below the expectations of securities analysts and investors and cause a decrease in our stock price.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	We are dependent upon a small number of distributors for a significant portion of our net sales, and the loss of, or significant reduction or
	cancellation in sales to, any one of these distributors could adversely affect our operations and financial condition.
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In the United States and Canada, we sell ADCETRIS through a limited number of pharmaceutical distributors. Customers order ADCETRIS
	through these distributors. We generally receive orders from distributors and ship product directly to the customer. We do not promote ADCETRIS to these distributors and they do not set or determine demand for ADCETRIS; however, our ability to
	effectively commercialize ADCETRIS will depend, in part, on the performance of these distributors. Although we believe we can find alternative distributors on relatively short notice, the loss of a major distributor could materially and adversely
	affect our results of operations and financial condition.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	We currently rely on third-party manufacturers and other third parties for production of our drug products and our dependence on these manufacturers
	may impair the continued development and commercialization of ADCETRIS.
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We do not currently have the internal ability to manufacture the drug products that we sell or need to conduct our clinical trials, and we therefore rely on corporate collaborators and contract
	manufacturing organizations to supply drug product for commercial supply and our IND-enabling studies and clinical trials. For the monoclonal antibody used in ADCETRIS, we have contracted with AbbVie for clinical and commercial supplies. For the
	drug linker used in ADCETRIS, we have contracted with Sigma Aldrich Fine Chemicals, or SAFC, for clinical and commercial supplies. We have multiple contract manufacturers for conjugating the drug linker to the antibody and producing the ADCETRIS
	product. For our ADC product candidates, multiple contract manufacturers, including AbbVie and SAFC, perform antibody and drug-linker manufacturing and several other contract manufacturers perform conjugation of the drug-linker to the antibody and
	fill/finish of the drug product. In addition, we rely on other third parties to perform additional steps in the manufacturing process, including shipping and storage of ADCETRIS and our product candidates. For the foreseeable future, we expect to
	continue to rely on contract manufacturers and other third parties to produce, vial and store sufficient quantities of ADCETRIS for use in our clinical trials and for commercial sale. If our contract manufacturers or other third parties fail to
	deliver ADCETRIS for clinical use or sale on a timely basis, with sufficient quality, and at commercially reasonable prices, and we fail to find replacement manufacturers or to develop our own manufacturing capabilities, we may be required to delay
	or suspend clinical trials or otherwise discontinue development, production and sale of ADCETRIS. Moreover, contract manufacturers have a limited number of
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	54
</FONT>
</P>
<A NAME="eolPage57"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	facilities in which ADCETRIS can be produced and any interruption of the operation of those facilities due to events such as equipment malfunction or failure or damage to the facility by natural
	disasters or as the result of regulatory actions could result in the cancellation of shipments, loss of product in the manufacturing process, a shortfall in ADCETRIS supply, or the inability to sell our products in the U.S. or abroad. In addition,
	we have committed to provide Takeda with their needs of certain parts of the ADCETRIS supply chain for a limited period of time, which may require us to arrange for additional manufacturing supply. Moreover, we depend on outside vendors for the
	supply of raw materials used to produce ADCETRIS. If the third-party suppliers were to cease production or otherwise fail to supply us with quality raw materials and we were unable to contract on acceptable terms for these raw materials with
	alternative suppliers, our ability to have ADCETRIS manufactured to meet commercial and clinical requirements would be adversely affected.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	We are subject to various state and federal laws and regulations, including healthcare laws and regulations, that may impact our business and could
	subject us to significant fines and penalties or other negative consequences.
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our operations may be directly or indirectly subject to various state and federal healthcare laws, including, without limitation, the federal Anti-Kickback Statute, federal civil and criminal false claims
	laws, HIPAA/HITECH, the federal civil monetary penalties statute, and the federal transparency requirements under the PPACA. These laws may impact, among other things, the sales, marketing and education programs for ADCETRIS.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The federal Anti-Kickback Statute prohibits persons and
	entities from knowingly and willingly soliciting, offering, receiving or providing remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual, or the furnishing or arranging for a good or service, for
	which payment may be made under a federal healthcare program such as the Medicare and Medicaid programs. Several courts have interpreted the statute&#146;s intent requirement to mean that if any one purpose of an arrangement involving remuneration
	is to induce referrals of federal healthcare covered business, the statute has been violated. Additionally, PPACA amended the intent requirement of the federal Anti-Kickback Statute such that a person or entity no longer needs to have actual
	knowledge of the statute or specific intent to violate it. The Anti-Kickback Statute is broad and prohibits many arrangements and practices that are lawful in businesses outside of the healthcare industry. Penalties for violations of the federal
	Anti-Kickback Statute include criminal penalties and civil sanctions such as fines, imprisonment and possible exclusion from Medicare, Medicaid and other federal healthcare programs.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The federal civil and criminal false claims laws, including the civil False Claims Act, prohibit, among other
	things, persons or entities from knowingly presenting, or causing to be presented, a false claim to, or the knowing use of false statements to obtain payment from or approval by the federal government, including the Medicare and Medicaid programs,
	or knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim or to avoid, decrease, or conceal an obligation to pay money to the federal government. PPACA provides that the government
	may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act. Suits filed under the civil False Claims Act,
	known as &#147;qui tam&#148; actions, can be brought by any individual on behalf of the government and such individuals, commonly known as &#147;whistleblowers,&#148; may share in any amounts paid by the entity to the government in fines or
	settlement. Many pharmaceutical and other healthcare companies have recently been investigated or subject to lawsuits by whistleblowers and have reached substantial financial settlements with the federal government under the False Claims Act for a
	variety of alleged improper marketing or other activities, including providing free product to customers with the expectation that the customers would bill federal programs for the product; providing consulting fees, grants, free travel, and other
	benefits to physicians to induce them to prescribe the company&#146;s products; and inflating prices reported to private price publication services, which are used to set drug reimbursement rates under government healthcare programs.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The federal Health Insurance Portability and Accountability
	Act of 1996, or HIPAA, created additional federal criminal statutes that prohibit, among other things, knowingly and willfully executing, or attempting to
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	55
</FONT>
</P>
<A NAME="eolPage58"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	execute, a scheme to defraud any healthcare benefit program, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a
	healthcare offense, and knowingly and willfully falsifying, concealing, or covering up a material fact or making any materially false, fictitious, or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items,
	or services. Similar to the Anti-Kickback Statute, PPACA amended the intent requirement of the criminal healthcare fraud statutes such that a person or entity no longer needs to have actual knowledge of the statute or intent to violate it.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	HIPAA, as amended by the Health Information
	Technology for Economic and Clinical Health Act, or HITECH, and its implementing regulations, governs certain types of individuals and entities with respect to the conduct of certain electronic healthcare transactions and imposes certain obligations
	with respect to the security and privacy of protected health information.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The federal civil monetary penalties statute imposes penalties against any person or entity that, among other things, is determined to have presented or caused to be presented a claim to a federal health
	program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The federal transparency requirements under PPACA, the Physician Payments Sunshine Act, require certain manufacturers of drugs, devices,
	biologics and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#146;s Health Insurance Program to annually report to the U.S. Department of Health and Human Services&#146; Centers for Medicare&nbsp;&amp;
	Medicaid Services information related to payments and other transfers of value to physicians and teaching hospitals, and physician ownership and investment interests.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	There are foreign and state law equivalents of these laws and
	regulations, such as anti-kickback, false claims, and data privacy and security laws, to which we are currently and/or may in the future, be subject. We may also be subject to state laws that require manufacturers to report information related to
	payments and other transfers of value to physicians and other healthcare providers or marketing expenditures. Many of these state laws differ from each other in significant ways, thus complicating compliance efforts.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The FDA and other governmental authorities also actively
	investigate allegations of off-label promotion activities in order to enforce regulations prohibiting these types of activities. In recent years, private whistleblowers have also pursued False Claims Act cases against a number of pharmaceutical
	companies for causing false claims to be submitted as a result of off-label promotion. If we are found to have promoted an approved product, including ADCETRIS, for off-label uses we may be subject to significant liability, including civil and
	administrative financial penalties and other remedies as well as criminal financial penalties and other sanctions. Even when a company is not determined to have engaged in off-label promotion, the allegation from government authorities or market
	participants that a company has engaged in such activities could have a significant impact on the company&#146;s sales, business and financial condition. The U.S. government has also required companies to enter into complex corporate integrity
	agreements and/or non-prosecution agreements that impose significant reporting and other burdens on the affected companies.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We are also subject to numerous other laws and regulations that are not specific to the healthcare industry. For instance, the U.S.
	Foreign Corrupt Practices Act, or FCPA, prohibits companies and individuals from engaging in specified activities to obtain or retain business or to influence a person working in an official capacity. Under the FCPA, it is illegal to pay, offer to
	pay, or authorize the payment of anything of value to any foreign government official, governmental staff members, political party or political candidate in an attempt to obtain or retain business or to otherwise influence a person working in an
	official capacity. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The number and complexity of both U.S. federal
	and state laws continue to increase. In addition to enforcement by governmental agencies, we also expect a continuation of the trend of private plaintiff lawsuits
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	56
</FONT>
</P>
<A NAME="eolPage59"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	against pharmaceutical manufacturers under the whistleblower provisions of the False Claims Act and state equivalents or other laws and regulations such as securities rules and the evolution of
	new theories of liability under those statutes. Government agencies will likely continue to intervene in such private whistleblower lawsuits and such intervention typically raises the company&#146;s cost significantly. For example, federal
	enforcement agencies have recently scrutinized product and patient assistance programs, including manufacturer reimbursement support services as well as relationships with specialty pharmacies. Several investigations have resulted in government
	enforcement authorities intervening in related whistleblower lawsuits and obtaining significant civil and criminal settlements.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In order to comply with these laws, we have implemented a comprehensive compliance program to actively identify, prevent and mitigate risk
	through the implementation of compliance policies and systems and by promoting a culture of compliance. Although we take our obligation to maintain our compliance with these various laws and regulations seriously and our compliance program is
	designed to prevent the violation of these laws and regulations, we cannot guarantee that our compliance program will be sufficient or effective, that our employees will comply with our policies and that our employees will notify us of any violation
	of our policies, that we will have the ability to take appropriate and timely corrective action in response to any such violation, or that we will make decisions and take actions that will necessarily limit or avoid liability for whistleblower
	claims that individuals, such as employees or former employees, may bring against us or that governmental authorities may prosecute against us based on information provided by individuals. If we are found to be in violation of any of the laws and
	regulations described above or other applicable state and federal healthcare laws, we may be subject to penalties, including civil and criminal penalties, damages, fines, disgorgement, contractual damages, reputational harm, imprisonment, diminished
	profits and future earnings, exclusion from government healthcare reimbursement programs, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of
	non-compliance with these laws, and/or the curtailment or restructuring of our operations, any of which could have a material adverse effect on our business, results of operations and growth prospects. Any action against us for violation of these
	laws or regulations, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#146;s attention from the operation of our business. Moreover, achieving and sustaining compliance with
	applicable federal, state and foreign healthcare laws is costly and time-consuming for our management.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	As we expand our operations internationally, we are subject to an increased risk of conducting activities in a manner that violates applicable anti-bribery or anti-corruption laws. We are also
	subject to foreign laws and regulations covering data privacy and the protection of health-related and other personal information. These laws and regulations could create liability for us or increase our cost of doing business, any of which could
	have a material adverse effect on our business, results of operations and growth prospects.
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We are expanding our operations internationally, and we currently have subsidiaries in the U.K., Switzerland and Canada. Though we are at
	an early stage with our international expansion, our business activities outside of the United States are subject to the FCPA, which is described above, and similar anti-bribery or anti-corruption laws, regulations or rules of other countries in
	which we currently and may in the future operate, including the U.K. Bribery Act. The U.K. Bribery Act prohibits giving, offering, or promising bribes to any person, including non-U.K. government officials and private persons, as well as requesting,
	agreeing to receive, or accepting bribes from any person. In addition, under the U.K. Bribery Act, companies which carry on a business or part of a business in the U.K. may be held liable for bribes given, offered or promised to any person,
	including non-U.K. government officials and private persons, by employees and persons associated with such company in order to obtain or retain business or a business advantage for such company. In the course of expanding our operations
	internationally, we will need to establish and expand business relationships with various third parties, such as independent contractors, distributors, vendors, advocacy groups and physicians, and we will interact more frequently with foreign
	officials, including regulatory authorities and physicians employed by state-run healthcare institutions who may be deemed to be foreign officials under the FCPA, U.K. Bribery Act or similar laws of other countries that may govern our activities.
	Any interactions with any such parties or individuals where compensation is provided that are found to be in violation of such laws could result in substantial fines and penalties and could materially harm our business. Furthermore, any finding of a
	violation
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	57
</FONT>
</P>
<A NAME="eolPage60"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	under one country&#146;s laws may increase the likelihood that we will be prosecuted and be found to have violated another country&#146;s laws. If our business practices outside the United States
	are found to be in violation of the FCPA, U.K. Bribery Act or other similar laws, we may be subject to significant civil and criminal penalties which could have a material adverse effect on our business, results of operations and growth prospects.
	We are also subject to foreign laws and regulations covering data privacy and the protection of health-related and other personal information. In this regard, European Union member states and other foreign jurisdictions, including Switzerland, have
	adopted data protection laws and regulations which impose significant compliance obligations. Failure to comply with these laws could lead to government enforcement actions and significant penalties against us, which could have a material adverse
	effect on our business, results of operations and growth prospects.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Any failures or further setbacks in our ADC development program would negatively affect our business and financial position.
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	ADCETRIS and our SGN-CD33A, ASG-22ME, SGN-LIV1A, SGN-CD19A,
	SGN-CD19B, SGN-CD123A, SGN-CD352A, and ASG-15ME product candidates are all based on our ADC technology, which utilizes proprietary stable linkers and potent cell-killing synthetic agents. Our ADC technology is also the basis of our collaborations
	with AbbVie, Astellas, Bayer, Celldex, Genentech, GSK, Pfizer, and Progenics, and our co-development agreements with Takeda, Astellas, and Genmab. Although ADCETRIS has received marketing approval in the United States, Canada, the European Union,
	Japan and other countries, ADCETRIS is our first and only ADC product that has been approved for commercial sale in any jurisdiction. Any failures or further setbacks in our ADC development program, including adverse effects resulting from the use
	of this technology in human clinical trials and/or the imposition of additional clinical holds on our trials of SGN-CD33A or any of our other product candidates, could have a detrimental impact on the continued commercialization of ADCETRIS in its
	current or any potential future approved indications and on our internal product candidate pipeline, as well as our ability to maintain and/or enter into new corporate collaborations regarding our ADC technology, which would negatively affect our
	business and financial position.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	We have been named a
	defendant in a purported securities class action lawsuit and a lawsuit in connection with the Immunomedics License. This, and potential similar or related litigation, could result in substantial damages and may divert management&#146;s time and
	attention from our business.
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On
	January&nbsp;10, 2017, a purported securities class action lawsuit was commenced in the United States District Court for the Western District of Washington, naming as defendants us and certain of our officers. The lawsuit alleges material
	misrepresentations and omissions in public statements regarding our business, operational and compliance policies, violations by all named defendants of Section&nbsp;10(b) of the Exchange Act, and Rule 10b-5 thereunder, as well as violations of
	Section&nbsp;20(a) of the Exchange Act. The complaint seeks compensatory damages of an undisclosed amount. The plaintiff alleges, among other things, that we made false and/or misleading statements and/or failed to disclose that SGN-CD33A presents a
	significant risk of fatal hepatotoxicity and that we had therefore overstated the viability of SGN-CD33A as a treatment for AML. It is possible that additional suits will be filed, or allegations received from stockholders, with respect to these
	same matters and also naming us and/or our officers and directors as defendants.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In addition, on February 13, 2017, we were named a co-defendant in a lawsuit filed by venBio in the Delaware Chancery Court against the members of the board of directors of Immunomedics. The lawsuit, or
	the venBio lawsuit, alleges that the members of the Immunomedics board breached their fiduciary duties toward their stockholders by hastily licensing
<FONT STYLE="WHITE-SPACE:NOWRAP">
	IMMU-132
</FONT>
	to us. We are alleged to have aided and abetted
	the breach of fiduciary duties. Among other things, venBio seeks to enjoin the closing of the transactions contemplated by the Immunomedics License. As a result of the pending litigation challenging the transactions contemplated by the Immunomedics
	License, Immunomedics and we have committed to the Court not to close the transactions contemplated by the Immunomedics License prior to March 10, 2017. We cannot predict the timing or outcome of the venBio lawsuit or the impact it may have on the
	Immunomedics License or the closing of the transactions contemplated by the Immunomedics License. However, it is possible that, in connection with the venBio lawsuit, the Immunomedics License could be rescinded or reformed in a way that is
	disadvantageous to us, including by
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	58
</FONT>
</P>
<A NAME="eolPage61"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	requiring us to increase the transaction consideration payable to Immunomedics under the Immunomedics License, or that otherwise adversely affects the anticipated benefits to us of the
	Immunomedics License.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We believe that we have
	meritorious defenses and intend to defend these lawsuits vigorously. These lawsuits and any other related lawsuits are subject to inherent uncertainties, and the actual costs to be incurred relating to the lawsuits will depend upon many unknown
	factors. The outcome of the litigation is necessarily uncertain, and we could be forced to expend significant resources in the defense of these suits, and we may not prevail. Monitoring and defending against legal actions is time-consuming for our
	management and detracts from our ability to fully focus our internal resources on our business activities, which could result in delays of our clinical trials or our development and commercialization efforts. In addition, we may incur substantial
	legal fees and costs in connection with the litigation. We are also generally obligated, to the extent permitted by law, to indemnify our current and former directors and officers who are named as defendants in these and similar lawsuits. We are not
	currently able to estimate the possible cost to us from this matter, as these lawsuits are currently at an early stage and we cannot be certain how long it may take to resolve these matters or the possible amount of any damages that we may be
	required to pay. We have not established any reserves for any potential liability relating to these lawsuits. It is possible that we could, in the future, incur judgments or enter into settlements of claims for monetary damages. Decisions adverse to
	our interests in these lawsuits could result in the payment of substantial damages, or possibly fines, and could have a material adverse effect on our cash flow, results of operations and financial position. Decisions adverse to our interests in the
	venBio lawsuit could also result in the termination of the Immunomedics License or otherwise frustrate our ability to, or increase our costs to, consummate the transactions contemplated by the Immunomedics License. In addition, the uncertainty of
	the currently pending litigation could lead to increased volatility in our stock price.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	We may need to raise significant amounts of additional capital that may not be available to us.
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We expect to make additional capital outlays and to increase operating expenditures over the next several years as we hire additional
	employees, support our preclinical development, manufacturing and clinical trial activities for ADCETRIS and our other pipeline programs, and expand internationally, as well as commercialize ADCETRIS and position ADCETRIS for potential additional
	regulatory approvals. In addition, we anticipate committing substantial capital resources to the transactions contemplated by the Immunomedics License and the anticipated transfer, integration and development activities related to IMMU-132,
	including with respect to our upfront and milestone payment obligations to Immunomedics. Our commitment of resources to the continuing development, regulatory and commercialization activities for ADCETRIS, the transactions contemplated by the
	Immunomedics License and the anticipated transfer, integration and development activities related to IMMU-132, and the research, continued development and manufacturing of our product candidates will likely require us to raise substantial amounts of
	additional capital. In addition, we actively evaluate various strategic transactions on an ongoing basis, including licensing or otherwise acquiring complementary products, technologies or businesses, such as our anticipated in-licensing of
	IMMU-132, and we may require significant additional capital in order to complete or otherwise provide funding for any additional acquisitions. We may seek additional funding through some or all of the following methods: corporate collaborations,
	licensing arrangements, and public or private debt or equity financings. We do not know whether additional capital will be available when needed, or that, if available, we will obtain financing on terms favorable to us or our stockholders. If we are
	unable to raise additional funds when we need them, we may be required to delay, reduce the scope of, or eliminate one or more of our development programs, which may adversely affect our business and operations. Our future capital requirements will
	depend upon a number of factors, including:
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	the level of sales and market acceptance of ADCETRIS;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	the rate of progress and cost of the confirmatory post-approval study that we are required to conduct as a condition to the FDA&#146;s accelerated
	approval of ADCETRIS in the relapsed sALCL indication;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	the time and costs involved in obtaining regulatory approvals of ADCETRIS in additional indications, if any;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	the size, complexity, timing, progress and number of our clinical programs;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	59
</FONT>
</P>
<A NAME="eolPage62"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	the timing, receipt and amount of milestone-based payments or other revenue from our collaborations or license arrangements, including royalty revenue
	generated from commercial sales of ADCETRIS by Takeda;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	the cost of establishing and maintaining clinical and commercial supplies of ADCETRIS;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	the costs associated with acquisitions or licenses of additional technologies, products, or companies, as well as licenses we may need to commercialize
	our products, including the actual costs to us of our anticipated in-licensing of IMMU-132;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	the terms and timing of any future collaborative, licensing and other arrangements that we may establish;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	expenses associated with the pending and potential additional related purported securities class action lawsuits, as well as any other potential
	litigation;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	the potential costs associated with international, state and federal taxes; and
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	competing technological and market developments.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In addition, changes in our spending rate may occur that
	would consume available capital resources sooner, such as increased development, manufacturing and clinical trial expenses in connection with our expanding pipeline programs, including several phase 3 trials, or our undertaking of additional
	programs, business activities or entry into strategic transactions, including potential additional acquisitions of products, technologies or businesses such as our anticipated in-licensing of IMMU-132. To the extent that we raise additional capital
	by issuing equity securities, our stockholders may experience substantial dilution. To the extent that we raise additional funds through collaboration and licensing arrangements, we may be required to relinquish some rights to our technologies or
	product candidates, or grant licenses on terms that are not favorable to us.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	During the past several years, domestic and international financial markets have experienced extreme disruption from time to time, including, among other things, high volatility and significant declines
	in stock prices and severely diminished liquidity and credit availability for both borrowers and investors. For example, in June&nbsp;2016, the electorate in the U.K. voted in favor of leaving the European Union (commonly referred to as
	&#147;Brexit&#148;). The withdrawal of the U.K. from the European Union will take effect either on the effective date of the withdrawal agreement or, in the absence of agreement, two years after the United Kingdom provides a notice of withdrawal
	pursuant to the EU Treaty. The U.K. government has announced that it intends to deliver a notice of withdrawal by the end of March 2017. It is likely that the withdrawal of the U.K. from the European Union will involve a process of lengthy
	negotiations between the U.K and European Union member states to determine the future terms of the U.K.&#146;s relationship with the European Union. This could lead to a period of considerable uncertainty, particularly in relation to global
	financial markets which in turn could adversely affect our ability to raise additional capital. Such adverse capital and credit market conditions could make it more difficult to obtain additional capital on favorable terms, or at all, which could
	have a material adverse effect on our business and growth prospects.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	We rely on license agreements for certain aspects of ADCETRIS and our ADC technology. Failure to maintain these license agreements or to secure any required new licenses could prevent us from
	continuing to develop and commercialize ADCETRIS and our product candidates.
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We have entered into agreements with third-party commercial and academic institutions to license technology for use in ADCETRIS and our ADC technology. Currently, we have license agreements with
	Bristol-Myers Squibb and the University of Miami, among others. In addition to royalty provisions, some of these license agreements contain diligence and milestone-based termination provisions, in which case our failure to meet any agreed upon
	royalty or diligence requirements or milestones may allow the licensor to terminate the agreement. Many of our license agreements grant us exclusive licenses to the underlying technologies. If our licensors terminate our license agreements or if we
	are unable to maintain the exclusivity of our exclusive license agreements, we may be unable to continue to develop and commercialize ADCETRIS or our product candidates.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	60
</FONT>
</P>
<A NAME="eolPage63"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Further, we have had in the past, and may in the future have, disputes with our licensors, which may impact our ability to develop and commercialize ADCETRIS or our product candidates or require
	us to enter into additional licenses. An adverse result in potential future disputes with our licensors may impact our ability to develop and commercialize ADCETRIS and our product candidates, or may require us to enter into additional licenses or
	to incur additional costs in litigation or settlement. In addition, continued development and commercialization of ADCETRIS and our product candidates will likely require us to secure licenses to additional technologies. We may not be able to secure
	these licenses on commercially reasonable terms, if at all.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	If we are unable to enforce our intellectual property rights or if we fail to sustain and further build our intellectual property rights, we may not
	be able to successfully commercialize ADCETRIS or future products and competitors may be able to develop competing therapies.
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our success depends, in part, on obtaining and maintaining patent protection and successfully enforcing these patents and defending them
	against third-party challenges in the United States and other countries. We own multiple U.S. and foreign patents and pending patent applications for our technologies. We also have rights to issued U.S. patents, patent applications, and their
	foreign counterparts, relating to our monoclonal antibody, linker and drug-based technologies. Our rights to these patents and patent applications are derived in part from worldwide licenses from third parties. In addition, we have licensed certain
	of our U.S. and foreign patents and patent applications to third parties.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The standards that the U.S. Patent and Trademark Office and foreign patent offices use to grant patents are not always applied predictably or uniformly and can change. Consequently, our pending patent
	applications may not be allowed and, if allowed, may not contain the type and extent of patent claims that will be adequate to conduct our business as planned. Additionally, any issued patents we currently own or obtain in the future may have a
	shorter patent term than expected or may not contain claims that will permit us to stop competitors from using our technology or similar technology or from copying our products. Similarly, the standards that courts use to interpret patents are not
	always applied predictably or uniformly and may evolve, particularly as new technologies develop. In addition, changes to patent laws in the United States or other countries may be applied retroactively to affect the validation enforceability, or
	term of our patent. For example, the U.S. Supreme Court has recently modified some legal standards applied by the U.S. Patent and Trademark Office in examination of U.S. patent applications, which may decrease the likelihood that we will be able to
	obtain patents and may increase the likelihood of challenges to patents we obtain or license. In addition, changes to the U.S. patent system have come into force under the Leahy-Smith America Invents Act, or the America Invents Act, including
	changes from a &#147;first-to-invent&#148; system to a &#147;first to file&#148; system, changes to examination of U.S. patent applications and changes to the processes for challenging issued patents. These changes include provisions that affect the
	way patent applications are being filed, prosecuted and litigated. For example, the America Invents Act enacted proceedings involving post-issuance patent review procedures, such as inter partes review, or IPR, and post-grant review and covered
	business methods. These proceedings are conducted before the Patent Trial and Appeal Board, or PTAB, of the U.S. Patent and Trademark Office, or USPTO. Each proceeding has different eligibility criteria and different patentability challenges that
	can be raised. In this regard, the IPR process permits any person (except a party who has been litigating the patent for more than a year) to challenge the validity of some patents on the grounds that it was anticipated or made obvious by prior art.
	As a result, non-practicing entities associated with hedge funds, pharmaceutical companies who may be our competitors and others have challenged certain valuable pharmaceutical U.S. patents based on prior art through the IPR process. A decision in
	such a proceeding adverse to our interests could result in the loss of valuable patent rights which would have a material adverse effect on our business, financial condition, results of operations and growth prospects. In any event, the America
	Invents Act and any other potential future changes to the U.S. patent system could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could
	have a material adverse effect on our business, financial condition, results of operations and growth prospects.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We rely on trade secrets and other proprietary information where we believe patent protection is not appropriate or obtainable. However,
	trade secrets and other proprietary information are difficult to protect. We
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	61
</FONT>
</P>
<A NAME="eolPage64"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	have taken measures to protect our unpatented trade secrets and know-how, including the use of confidentiality and assignment of inventions agreements with our employees, consultants and certain
	contractors. It is possible, however, that these persons may breach the agreements or that our competitors may independently develop or otherwise discover our trade secrets or other proprietary information. Our research collaborators may publish
	confidential data or other restricted information to which we have rights. If we cannot maintain the confidentiality of our technology and other confidential information in connection with our collaborations, then our ability to receive patent
	protection or protect our proprietary information may be impaired.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	We may incur substantial costs and lose important rights or may not be able to continue to commercialize ADCETRIS or to commercialize any of our
	product candidates that may be approved for commercial sale as a result of litigation or other proceedings relating to patent and other intellectual property rights, and we may be required to obtain patent and other intellectual property rights from
	others.
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We may face potential lawsuits
	by companies, academic institutions or others alleging infringement of their intellectual property. Because patent applications can take a few years to publish, there may be currently pending applications of which we are unaware that may later
	result in issued patents that adversely affect the continued commercialization of ADCETRIS or future commercialization of our product candidates in development. In addition, we are monitoring the progress of multiple pending patent applications of
	other organizations that, if granted, may require us to license or challenge their enforceability in order to continue commercializing ADCETRIS or to commercialize our product candidates that may be approved for commercial sale. Our challenges to
	patents of other organizations may not be successful, which may affect our ability to commercialize ADCETRIS or our product candidates. As a result of the patent infringement lawsuits that have been filed or may be filed against us in the future by
	third parties alleging infringement by us of patent or other intellectual property rights, we may be required to pay substantial damages, including lost profits, royalties, treble damages, attorneys&#146; fees and costs, for past infringement if it
	is ultimately determined that our products infringe a third party&#146;s intellectual property rights. Even if infringement claims against us are without merit, the results may be unpredictable. In addition, defending lawsuits takes significant
	time, may be expensive and may divert management&#146;s attention from other business concerns. Further, we may be stopped from developing, manufacturing or selling our products until we obtain a license from the owner of the relevant technology or
	other intellectual property rights, or be forced to undertake costly design-arounds, if feasible. If such a license is available at all, it may require us to pay substantial royalties or other fees.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We are or may be from time to time involved in the defense
	and enforcement of our patent or other intellectual property rights in a court of law, USPTO interference, IPR, post-grant review or reexamination proceeding, foreign opposition proceeding or related legal and administrative proceeding in the United
	States and elsewhere. In addition, if we choose to go to court to stop a third party from infringing our patents, that third party has the right to ask the court to rule that these patents are invalid, not infringed and/or should not be enforced.
	Under the America Invents Act, a third party may also have the option to challenge the validity of certain patents at the PTAB, whether they are accused of infringing our patents or not, and certain entities associated with hedge funds,
	pharmaceutical companies and other entities have challenged valuable pharmaceutical patents through the IPR process. These lawsuits and administrative proceedings are expensive and consume time and other resources, and we may not be successful in
	these proceedings or in stopping infringement. In addition, there is a risk that a court will decide that these patents are not valid or not infringed or otherwise not enforceable, or that the PTAB will decide that certain patents are not valid or
	should have a shorter term, and that we do not have the right to stop a third party from using the patented subject matter. Successful challenges to our patent or other intellectual property rights through these proceedings could result in a loss of
	rights in the relevant jurisdiction and may allow third parties to use our proprietary technologies without a license from us or our collaborators, which may also result in loss of future royalty payments. Furthermore, if such challenges to our
	rights are not resolved promptly in our favor, our existing business relationships may be jeopardized and we could be delayed or prevented from entering into new collaborations or from commercializing potential products, which could adversely affect
	our business and results of operations. In addition, we may challenge the patent or other intellectual property rights of third parties and if we are unsuccessful in actions we bring against the rights of such parties, through litigation or
	otherwise, and it is
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	62
</FONT>
</P>
<A NAME="eolPage65"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	determined that we infringe the intellectual property rights of such parties, we may be prevented from commercializing potential products in the relevant jurisdiction, or may be required to
	obtain licenses to those rights or develop or obtain alternative technologies, any of which could harm our business.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	If we lose our key personnel or are unable to attract and retain additional qualified personnel, our future growth and ability to compete would
	suffer.
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We are highly dependent on the
	efforts and abilities of the principal members of our senior management. Additionally, we have scientific personnel with significant and unique expertise in monoclonal antibodies, ADCs and related technologies. The loss of the services of any one of
	the principal members of our managerial or scientific staff may prevent us from achieving our business objectives.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In addition, the competition for qualified personnel in the biotechnology field is intense, and our future success depends upon our
	ability to attract, retain and motivate highly skilled scientific, technical and managerial employees. In order to commercialize ADCETRIS, we have been required to expand our workforce, particularly in the areas of manufacturing, clinical trials
	management, regulatory affairs, business development, sales and marketing. These activities required the addition of new personnel, including sales and marketing management, and the development of additional expertise by existing management
	personnel. We continue to face intense competition for qualified individuals from numerous pharmaceutical and biotechnology companies, as well as academic and other research institutions. To the extent we are not able to retain these individuals on
	favorable terms or attract any additional personnel that may be required, our business may be harmed.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	If we are unable to manage our growth, our business, financial condition, results of operations and prospects may be adversely affected.
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We have experienced and expect to continue to experience
	significant growth in the number of our employees and in the scope of our operations. This growth places significant demands on our management, operational and financial resources, and our current and planned personnel, systems, procedures and
	controls may not be adequate to support our growth. To effectively manage our growth, we must continue to improve existing, and implement new, operational and financial systems, procedures and controls and must expand, train and manage our growing
	employee base, and there can be no assurance that we will effectively manage our growth without experiencing operating inefficiencies or control deficiencies. We expect that we may need to increase our management personnel to oversee our expanding
	operations, and recruiting and retaining qualified individuals is difficult. In addition, the physical expansion of our operations may lead to significant costs and may divert our management and capital resources. If we are unable to manage our
	growth effectively, or are unsuccessful in recruiting qualified management personnel, our business, financial condition, results of operations and prospects may be adversely affected.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Product liability and product recalls could harm our business, and we may not be able to obtain adequate insurance to
	protect us against product liability losses.
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The current and future use of ADCETRIS by us and our corporate collaborators in clinical trials and the sale of ADCETRIS, expose us to product liability claims. These claims have and may in the future be
	made directly by consumers or healthcare providers or indirectly by pharmaceutical companies, our corporate collaborators or others selling such products. We may experience substantial financial losses in the future due to product liability claims.
	We have obtained product liability coverage, including coverage for human clinical trials and product sold commercially. However, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against
	all losses. If a successful product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured amounts, our assets may not be sufficient to cover such claims and our business operations could be
	impaired.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Product recalls may be issued at our
	discretion, or at the discretion of government agencies and other entities that have regulatory authority for pharmaceutical sales. Any recall of ADCETRIS could materially adversely affect our business by rendering us unable to sell ADCETRIS for
	some time and by adversely affecting our reputation.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	63
</FONT>
</P>
<A NAME="eolPage66"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Risks associated with operating in foreign countries could materially adversely affect our business.
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We are expanding our operations
	internationally, and we currently have subsidiaries in the U.K., Switzerland and Canada. Consequently, we are, and will continue to be, subject to risks related to operating in foreign countries. Risks associated with conducting operations in
	foreign countries include:
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	diverse regulatory, financial and legal requirements, and any future changes to such requirements, in one or more countries where we are located or do
	business;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	adverse tax consequences, including changes in applicable tax laws and regulations;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	applicable trade laws, tariffs, export quotas, custom duties or other trade restrictions and any changes to them;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	economic weakness, including inflation, or political or economic instability in particular foreign economies and markets;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	foreign currency fluctuations, which could result in increased operating expenses or reduced revenues, and other obligations incident to doing business
	or operating in another country;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	liabilities for activities of, or related to, our international operations;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	workforce uncertainty in countries where labor unrest is more common than in the United States; and
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	laws and regulations relating to data security and the unauthorized use of, or access to, commercial and personal information.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	For example, since a
	significant proportion of the regulatory framework in the U.K. is derived from European Union directives and regulations, Brexit could materially change the regulatory regime applicable to our operations and those of our collaborators, including
	with respect to marketing authorizations for ADCETRIS and our product candidates. We may also face new regulatory costs and challenges as result of Brexit that could have a material adverse effect on our operations. Depending on the terms of Brexit,
	the U.K. could lose the benefits of global trade agreements negotiated by the European Union on behalf of its members, which may result in increased trade barriers which could make our doing business in Europe more difficult. In addition, currency
	exchange rates for the British Pound and the Euro with respect to each other and the U.S. dollar have already been affected by Brexit. Should this foreign exchange volatility continue, it could cause volatility in our quarterly financial results. In
	any event, we cannot predict to what extent these changes will impact our business or results of operations, or our ability to conduct operations in Europe.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	These and other risks described elsewhere in these risk factors associated with expanding our international operations could materially
	adversely affect our business.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Our operations involve
	hazardous materials and are subject to environmental, health and safety controls and regulations.
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We are subject to environmental, health and safety laws and regulations, including those governing the use of hazardous materials, and we
	spend considerable time complying with such laws and regulations. Our business activities involve the controlled use of hazardous materials and although we take precautions to prevent accidental contamination or injury from these materials, we
	cannot completely eliminate the risk of using these materials. In the event of an accident or environmental discharge, we may be held liable for any resulting damages, which may materially harm our business, financial condition and results of
	operations.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	If any of our facilities are damaged or our
	clinical, research and development or other business processes are interrupted, our business could be seriously harmed.
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We conduct most of our business in a limited number of facilities in a single geographical location in Bothell, Washington. Damage or
	extended periods of interruption to our corporate, development or research
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	64
</FONT>
</P>
<A NAME="eolPage67"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	facilities due to fire, natural disaster, power loss, communications failure, unauthorized entry or other events could cause us to cease or delay development of some or all of our product
	candidates or interrupt the sales process for ADCETRIS. Although we maintain property damage and business interruption insurance coverage on these facilities, our insurance might not cover all losses under such circumstances and our business may be
	seriously harmed by such delays and interruption.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	If we
	experience a significant disruption in our information technology systems or breaches of data security, our business could be adversely affected.
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We rely on information technology systems to keep financial records, capture laboratory data, maintain clinical trial data and corporate
	records, communicate with staff and external parties and operate other critical functions. Our information technology systems are potentially vulnerable to disruption due to breakdown, malicious intrusion and computer viruses or other disruptive
	events including but not limited to natural disaster. If we were to experience a prolonged system disruption in our information technology systems or those of certain of our vendors, it could delay or negatively impact the development and
	commercialization of ADCETRIS and our product candidates, which could adversely impact our business. Although we maintain offsite back-ups of our data, if operations at our facilities were disrupted, it may cause a material disruption in our
	business if we are not capable of restoring function on an acceptable timeframe. In addition, our information technology systems are potentially vulnerable to data security breaches&#151;whether by employees or others&#151;which may expose sensitive
	data to unauthorized persons. Such data security breaches could lead to the loss of trade secrets or other intellectual property, or could lead to the public exposure of personal information (including sensitive personal information) of our
	employees, customers and others, any of which could have a material adverse effect on our business, financial condition and results of operations. Moreover, a security breach or privacy violation that leads to disclosure or modification of,
	personally identifiable information, could harm our reputation, compel us to comply with federal and/or state breach notification laws, subject us to mandatory corrective action, require us to verify the correctness of database contents and
	otherwise subject us to liability under laws and regulations that protect personal data, resulting in increased costs or loss of revenue. In addition, a data security breach could result in loss of clinical trial data or damage to the integrity of
	that data. If we are unable to prevent such security breaches or privacy violations or implement satisfactory remedial measures, our operations could be disrupted, and we may suffer loss of reputation, financial loss and other negative consequences
	because of lost or misappropriated information. In addition, these breaches and other inappropriate access can be difficult to detect, and any delay in identifying them may lead to increased harm of the type described above.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Increasing use of social media could give rise to liability.
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We are increasingly relying on social
	media tools as a means of communications. To the extent that we continue to use these tools as a means to communicate about ADCETRIS and our product candidates or about the diseases that ADCETRIS and our product candidates are intended to treat,
	there are significant uncertainties as to either the rules that apply to such communications, or as to the interpretations that health authorities will apply to the rules that exist. As a result, despite our efforts to comply with applicable rules,
	there is a significant risk that our use of social media for such purposes may cause us to nonetheless be found in violation of them. Such uses of social media could have a material adverse effect on our business, financial condition and results of
	operations.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Legislative actions and new accounting
	pronouncements are likely to impact our future financial position or results of operations.
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Future changes in financial accounting standards may cause adverse, unexpected revenue fluctuations and affect our financial position or
	results of operations. New pronouncements and varying interpretations of pronouncements have occurred with frequency in the past and are expected to occur again in the future and as a result we may be required to make changes in our accounting
	policies. Those changes could adversely affect our reported revenues and expenses, future profitability or financial position. Compliance with new regulations regarding corporate governance and public disclosure may result in additional expenses.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	65
</FONT>
</P>
<A NAME="eolPage68"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	For example, in May 2014, the Financial Accounting Standards Board, or FASB, issued an
	Accounting Standards Update entitled &#147;ASU 2014-09, Revenue from Contracts with Customers&#148; which will replace the existing revenue recognition guidance in U.S. GAAP when it becomes effective for us on January&nbsp;1, 2018. Our preliminary
	assessment of this new standard is that it will generally not change the way in which we recognize product revenue from sales of ADCETRIS. However, we expect that sales-based royalties will be recorded in the period of the related sale based on
	estimates, rather than recording them as reported by the customer. In addition, the achievement of development milestones under our collaborations will be recorded in the period their achievement becomes probable, which may result in their
	recognition earlier than under current accounting principles. We are continuing to evaluate the impact of the new standard on all of our revenues, including those mentioned above, and our assessments may change in the future based on our continuing
	evaluation. In any event, the application of existing or future financial accounting standards, particularly those relating to the way we account for revenues and costs, could have a significant impact on our reported results. In addition,
	compliance with new regulations regarding corporate governance and public disclosure may result in additional expenses. As a result, we intend to invest all reasonably necessary resources to comply with evolving standards, and this investment may
	result in increased general and administrative expenses and a diversion of management time and attention from science and business activities to compliance activities.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Risks Related to the Immunomedics License
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Failure to consummate the transactions contemplated by the
	Immunomedics License could negatively impact our stock price and our future business and financial results.
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We announced on February 10, 2017 that we had entered into the Immunomedics License pursuant to which, upon the terms and subject to the
	conditions set forth in the Immunomedics License, we would receive exclusive worldwide rights to develop and commercialize IMMU-132. The closing of the transactions contemplated by the Immunomedics License, which has not yet occurred, is subject to
	customary closing conditions, including expiration of the applicable waiting period under the HSR Act, there being no pending court or administrative challenges to the Immunomedics License and there being no court or administrative orders blocking
	the closing. On February&nbsp;20, 2017, Immunomedics and we entered into a letter agreement pursuant to which Immunomedics irrevocably waived to the extent applicable to Immunomedics the condition precedent to the closing and effectiveness of the
	Immunomedics License that there be no pending court or administrative challenges to the transaction. Additionally, under the terms of the Immunomedics License, Immunomedics had the right to continue discussions with a small number of parties that
	previously expressed interest in licensing IMMU-132 until 11:59 p.m. New York City time on February&nbsp;19, 2017. If a third party had provided Immunomedics with a financially superior licensing offer, we would have had the right to match any such
	offer, and if we had decided not to match, Immunomedics would have had the right to accept the superior offer and terminate the Immunomedics License upon payment of a termination fee to us. We have not received notice from Immunomedics of any such
	third party offers during this limited time period, and on February&nbsp;21, 2017, Immunomedics announced that it is subject to customary &#147;no-shop&#148; restrictions on its and its representatives&#146; ability to solicit, discuss or negotiate
	alternative licensing agreement proposals from third parties with regard to IMMU-132. On February&nbsp;13, 2017, we were named a co-defendant in a lawsuit filed by venBio in the Delaware Chancery Court against the members of the board of directors
	of Immunomedics, pursuant to which, among other things, venBio seeks to enjoin the closing of the transactions contemplated by the Immunomedics License. venBio has also initiated a proxy contest with respect the Immunomedics annual meeting to be
	held on March&nbsp;3, 2017, seeking to have its nominees elected to the Immunomedics board of directors in lieu of Immunomedics&#146; management nominees. As a result of the pending litigation challenging the transactions contemplated by the
	Immunomedics License, Immunomedics and we have committed to the Court not to close the transactions contemplated by the Immunomedics License prior to March&nbsp;10, 2017. We cannot predict the timing or outcome of the venBio lawsuit or the impact it
	may have on the Immunomedics License or the closing of the transactions contemplated by the Immunomedics License. Likewise, we cannot predict the effect a potential change in the board of directors of Immunomedics could have on our ability to
	consummate the transactions contemplated by the Immunomedics License. However, it is possible that, in connection with the venBio lawsuit and/or the proxy contest, the Immunomedics License could be rescinded or reformed in a way
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	66
</FONT>
</P>
<A NAME="eolPage69"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	that is disadvantageous to us, including by requiring us to increase the transaction consideration payable to Immunomedics under the Immunomedics License, or that otherwise adversely affects the
	anticipated benefits to us of the Immunomedics License. If the transactions contemplated by the Immunomedics License are not consummated, our ongoing business may be adversely affected and, without realizing any of the benefits of having consummated
	the transactions contemplated by the Immunomedics License, we will be subject to a number of risks, including the following:
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	the current price of our common stock may reflect a market assumption that the closing of the transactions contemplated by the Immunomedics License
	will occur, such that a failure to complete such transactions could result in a decline in our stock price;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	we have made an equity investment of approximately $14.7 million in Immunomedics (which investment may never result in a financial return to us) in
	contemplation of securing exclusive development and commercialization rights to IMMU-132 without realizing any of the benefits of securing such rights;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	matters relating to the Immunomedics License have required and will continue to require substantial commitments of time and resources by our management
	and other employees, which could otherwise have been devoted to other opportunities that may have been beneficial to us;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	we may be required to reimburse Immunomedics for certain expenses incurred by Immunomedics in connection with the Immunomedics License if it is not
	consummated; and
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	we may incur significant costs and potential additional harms in connection with the lawsuit brought by venBio.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We also could be subject to additional litigation related to
	any failure to consummate the transactions contemplated by the Immunomedics License or to perform our obligations under the Immunomedics License. If the transactions contemplated by the Immunomedics License are not consummated, these risks may
	materialize and may adversely affect our business, financial results and stock price.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Obtaining required approvals necessary to satisfy the conditions to the closing of the transactions contemplated by the Immunomedics License and the effect of the venBio lawsuit and the outcome of
	the Immunomedics proxy contest may delay or prevent completion of the closing of the transactions contemplated by the Immunomedics License, result in additional expenditures of money and resources and/or reduce or eliminate the anticipated benefits
	to us of the Immunomedics License.
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The
	closing of the transactions contemplated by the Immunomedics License is subject to customary closing conditions. These closing conditions include, among others, the expiration of the applicable waiting period under the HSR Act, compliance with
	antitrust-related filing requirements in certain other countries, there being no pending court or administrative challenges to the Immunomedics License and there being no court or administrative orders blocking the closing. On February 20, 2017,
	Immunomedics and we entered into a letter agreement pursuant to which Immunomedics irrevocably waived to the extent applicable to Immunomedics the condition precedent to the closing and effectiveness of the Immunomedics License that there be no
	pending court or administrative challenges to the transaction. Additionally, under the terms of the Immunomedics License, Immunomedics had the right to continue discussions with a small number of parties that previously expressed interest in
	licensing IMMU-132 until 11:59 p.m. New York City time on February&nbsp;19, 2017. If a third party had provided Immunomedics with a financially superior licensing offer, we would have had the right to match any such offer, and if we had decided not
	to match, Immunomedics would have had the right to accept the superior offer and terminate the Immunomedics License upon payment of a termination fee to us. We have not received notice from Immunomedics of any such third party offers during this
	limited time period, and on February 21, 2017, Immunomedics announced that it is subject to customary &#147;no-shop&#148; restrictions on its and its representatives&#146; ability to solicit, discuss or negotiate alternative licensing agreement
	proposals from third parties with regard to IMMU-132. The governmental agencies from which the parties will seek approvals have broad discretion in administering the governing regulations. As a condition to their approval, agencies may impose
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	67
</FONT>
</P>
<A NAME="eolPage70"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	requirements, limitations or costs or require divestitures or place restrictions on the conduct of our IMMU-132 activities after the closing. These requirements, limitations, costs, divestitures
	or restrictions could jeopardize or delay the closing of the transactions contemplated by the Immunomedics License or may reduce the anticipated benefits to us of the Immunomedics License. If we and Immunomedics agree to any material requirements,
	limitations, costs or restrictions in order to obtain any approvals required to consummate the transactions contemplated by the Immunomedics License, these requirements, limitations, costs or restrictions could adversely affect the anticipated
	benefits of the Immunomedics License. In addition, it is possible that, in connection with the venBio lawsuit and/or the proxy contest, the Immunomedics License could be rescinded or reformed in a way that is disadvantageous to us, including by
	requiring us to increase the transaction consideration payable to Immunomedics under the Immunomedics License, or that otherwise adversely affects the anticipated benefits to us of the Immunomedics License. Any of these factors could result in a
	failure to consummate these transactions or have a material adverse effect on our business and results of operations.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	We may not be able to successfully integrate IMMU-132 or any other potential future product candidates we may acquire or license rights to, or we
	may otherwise fail to realize their full potential.
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We actively evaluate various strategic transactions on an ongoing basis, including licensing or otherwise acquiring complementary products, technologies or businesses, and we recently announced our entry
	into the Immunomedics License with Immunomedics pursuant to which, if consummated, we would be granted an exclusive worldwide license to IMMU-132. However, we cannot ensure that we would be able to manage the risks associated with the transfer of
	development, regulatory and manufacturing activities for IMMU-132 from Immunomedics to us or manage the risks associated with integrating IMMU-132 into our existing business and infrastructure. We may encounter unexpected difficulties during the
	transfer, integration or further development of IMMU-132, any of which may cause us to expend greater funds and efforts or may slow, delay or limit the progress of IMMU-132&#146;s development. Unexpected difficulties may further be disruptive to our
	ongoing development and commercialization efforts, put a strain on our existing personnel, infrastructure and business and divert management&#146;s time and attention. As a result of these or other problems and risks, even if the transactions
	contemplated by the Immunomedics License are consummated, we may never receive regulatory approval for IMMU-132, we may not realize the full potential of IMMU-132 or we may never generate significant value or revenues from IMMU-132.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In addition, the market price of our common stock may decline
	if the integration or further development of IMMU-132 is unsuccessful, takes longer than expected or fails to result in benefits to the extent anticipated by financial analysts or investors, or the effect of our license of IMMU-132 on our financial
	position and results of operations is otherwise not consistent with the expectations of financial analysts or investors.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Risks Related to Our Common Stock
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Our stock price is volatile and our shares may suffer a decline in value.
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The market price of our stock has in the past been, and is likely to continue in the future to be, very
	volatile. During the year ended December&nbsp;31, 2016, our closing stock price fluctuated between $26.87 and $73.71 per share. As a result of fluctuations in the price of our common stock, you may be unable to sell your shares at or above the price
	you paid for them. The market price of our common stock may be subject to substantial volatility in response to many risk factors listed in this section, and others beyond our control, including:
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	the level of ADCETRIS sales in the United States, Canada, the European Union, Japan and other countries in which Takeda has received approval by
	relevant regulatory authorities;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	announcements regarding the results of discovery efforts and preclinical, clinical and commercial activities by us, or those of our competitors;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	announcements of FDA or foreign regulatory approval or non-approval of ADCETRIS, or specific label indications for or restrictions, warnings or
	limitations in its use, or delays in the regulatory review or approval process, including in connection with our planned sBLA submission to the FDA to seek approval of ADCETRIS in the ALCANZA treatment setting;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	68
</FONT>
</P>
<A NAME="eolPage71"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	announcements regarding the results of the clinical trials we and/or Takeda are conducting or may in the future conduct for ADCETRIS, including our
	ECHELON-1 and ECHELON-2 phase 3 trials;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	announcements regarding, or negative publicity concerning, adverse events associated with the use of ADCETRIS or our product candidates, including
	announcements similar to our December 2016 announcement that the FDA had placed a clinical hold or a partial clinical hold on several early stage trials of SGN-CD33A in AML to evaluate the potential risk of hepatotoxicity following adverse medical
	events, including fatal events;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	issuance of new or changed analysts&#146; reports and recommendations regarding us or our competitors;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	termination of or changes in our existing collaborations or licensing arrangements, especially our ADCETRIS collaboration with Takeda or establishment
	of new collaborations or licensing arrangements;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	announcements regarding the Immunomedics License, or the termination of or other changes to the Immunomedics License and the related lawsuit brought by
	venBio;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	our entry into additional material strategic transactions including licensing or acquisition of products, businesses or technologies;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	actions taken by regulatory authorities with respect to our product candidates, our clinical trials or our regulatory filings, including the imposition
	or lifting of clinical trial holds on trials of SGN-CD33A and our product candidates;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	our raising of additional capital and the terms upon which we may raise any additional capital;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	market conditions for equity investments in general, or the biotechnology or pharmaceutical industries in particular;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	developments or disputes concerning our proprietary rights;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	developments regarding the pending and potential additional related purported securities class action lawsuits, as well as any other potential
	litigation;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	share price and volume fluctuations attributable to inconsistent trading volume levels of our shares;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	changes in government regulations; and
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	economic or other external factors.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The stock markets in general, and the markets for biotechnology and pharmaceutical stocks in particular, have historically experienced
	significant volatility that has often been unrelated or disproportionate to the operating performance of particular companies. For example, negative publicity regarding drug pricing and price increases by pharmaceutical companies has negatively
	impacted, and may continue to negatively impact, the markets for biotechnology and pharmaceutical stocks. Likewise, as a result of Brexit and/or significant changes in U.S. social, political, regulatory and economic conditions or in laws and
	policies governing foreign trade and health care spending and delivery, including the potential repeal and/or replacement of all or portions of PPACA or greater restrictions on free trade stemming from Trump Administration policies, the financial
	markets could experience significant volatility that could also negatively impact the markets for biotechnology and pharmaceutical stocks. These broad market fluctuations have adversely affected and may in the future adversely affect the trading
	price of our common stock.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In the past, class
	action or derivative litigation has often been instituted against companies whose securities have experienced periods of volatility in market price. In this regard, we have become, and may in the future again become, subject to claims and litigation
	alleging violations of the securities laws or other related claims, which could harm our business and require us to incur significant costs. The pending purported securities class action lawsuit and any additional lawsuits brought against us could
	result in substantial costs, which would hurt our financial condition and results of operations and divert management&#146;s attention and resources, which could result in delays of our clinical trials or our development and commercialization
	efforts.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	69
</FONT>
</P>
<A NAME="eolPage72"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Substantial future sales of shares of our common stock or equity-related securities could cause the
	market price of our common stock to decline.
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Sales of a substantial number of shares of our common stock into the public market, including sales by members of our management or board of directors or entities affiliated with such members, could occur
	at any time. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock and could impair our ability to raise capital through the sale of
	additional equity or equity-related securities. We are unable to predict the effect that such sales may have on the prevailing market price of our common stock. As of February&nbsp;16, 2017, we had 142,493,676 shares of common stock outstanding, all
	of which shares are eligible for sale in the public market, subject in some cases to the volume limitations and manner of sale and other requirements under Rule 144. In addition, we may issue a substantial number of shares of our common stock or
	equity- related securities, including convertible debt, to meet our capital needs, including in connection with funding acquisition or licensing opportunities, capital expenditures or product development costs, which issuances could be substantially
	dilutive and could adversely affect the market price of our common stock. Likewise, future issuances by us of our common stock upon the exercise, conversion or settlement of equity-based awards or other equity-related securities would dilute
	existing stockholders&#146; ownership interest in our company and any sales in the public market of these shares, or the perception that these sales might occur, could also adversely affect the market price of our common stock.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Moreover, we have in the past and may in the future grant
	rights to some of our stockholders that require us to register the resale of our common stock or other securities on behalf of these stockholders and/or facilitate public offerings of our securities held by these stockholders, including in
	connection with potential future acquisition or capital-raising transactions. For example, in connection with our September 2015 public offering of common stock, we entered into a registration rights agreement with entities affiliated with Baker
	Bros. Advisors LP, or the Baker Entities, that together, based on information available to us, collectively beneficially owned approximately 32.1% of our common stock as of February&nbsp;16, 2017. Under the registration rights agreement, if at any
	time and from time to time the Baker Entities demand that we register their shares of our common stock for resale under the Securities Act of 1933, we would be obligated to effect such registration. On October&nbsp;12, 2016, pursuant to the
	registration rights agreement, we registered for resale, from time to time, up to 44,059,594 shares of our common stock held by the Baker Entities. Our registration obligations under the registration rights agreement cover all shares now held or
	hereafter acquired by the Baker Entities, will continue in effect for up to ten years, and include our obligation to facilitate certain underwritten public offerings of our common stock by the Baker Entities in the future. If the Baker Entities, by
	its exercise of these registration and/or underwriting rights in the future, or otherwise, sell a large number of our shares, or the market perceives that the Baker Entities intend to sell a large number of our shares, including in connection with
	our October 2016 registration of shares held by the Baker Entities for resale, this could adversely affect the market price of our common stock. We have also filed registration statements to register the sale of our common stock reserved for
	issuance under our equity incentive and employee stock purchase plans. Accordingly, these shares will be able to be freely sold in the public market upon issuance as permitted by any applicable vesting requirements.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Our existing stockholders have significant control of our management
	and affairs.
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our executive officers and
	directors and holders of greater than five percent of our outstanding voting stock, together with entities that may be deemed affiliates of, or related to, such persons or entities, beneficially owned approximately 68.1% of our voting power as of
	February16, 2017. As a result, these stockholders, acting together, are able to control our management and affairs and matters requiring stockholder approval, including the election of directors and approval of significant corporate transactions,
	such as mergers, consolidations or the sale of substantially all of our assets. Consequently, this concentration of ownership may have the effect of delaying, deferring or preventing a change in control, including a merger, consolidation, takeover
	or other business combination involving us or discourage a potential acquirer from making a tender offer or otherwise attempting to obtain control, which might affect the market price of our common stock.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	70
</FONT>
</P>
<A NAME="eolPage73"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Anti-takeover provisions could make it more difficult for a third party to acquire us.
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our Board of Directors has the authority
	to issue up to 5,000,000 shares of preferred stock and to determine the price, rights, preferences, privileges and restrictions, including voting rights, of those shares without any further vote or action by the stockholders, which authority could
	be used to adopt a &#147;poison pill&#148; that could act to prevent a change of control of Seattle Genetics that has not been approved by our Board of Directors. The rights of the holders of common stock may be subject to, and may be adversely
	affected by, the rights of the holders of any preferred stock that may be issued in the future. The issuance of preferred stock may have the effect of delaying, deferring or preventing a change of control of Seattle Genetics without further action
	by the stockholders and may adversely affect the voting and other rights of the holders of common stock. Further, certain provisions of our charter documents, including provisions eliminating the ability of stockholders to take action by written
	consent and limiting the ability of stockholders to raise matters at a meeting of stockholders without giving advance notice, may have the effect of delaying or preventing changes in control or management of Seattle Genetics, which could have an
	adverse effect on the market price of our stock. In addition, our charter documents provide for a classified board, which may make it more difficult for a third party to gain control of our Board of Directors. Similarly, state anti-takeover laws in
	Delaware and Washington related to corporate takeovers may prevent or delay a change of control of Seattle Genetics.
</FONT>
</P>
</EFX_RISK_FACTORS>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<EFX_UNRESOLVED_STAFF_COMMENTS>
<A NAME="FIS_UNRESOLVED_STAFF_COMMENTS"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D481013D10K_HTM_TOC481013_3">
</A>
	Item&nbsp;1B. Unresolved Staff Comments
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	None.
</FONT>
</P>
</EFX_UNRESOLVED_STAFF_COMMENTS>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<EFX_PROPERTIES>
<A NAME="FIS_PROPERTIES"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D481013D10K_HTM_TOC481013_4">
</A>
	Item&nbsp;2. Properties
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our headquarters are in Bothell, Washington, where we lease
	six buildings totaling approximately 355,000 square feet of office space that we use for laboratory, discovery, research and development and general and administrative purposes. All of our leases include renewal options.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We believe that our facilities are currently adequate to meet
	our needs.
</FONT>
</P>
</EFX_PROPERTIES>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<EFX_LEGAL_PROCEEDINGS>
<A NAME="FIS_LEGAL_PROCEEDINGS"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D481013D10K_HTM_TOC481013_5">
</A>
	Item&nbsp;3. Legal
	Proceedings
</B>
<B>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On January&nbsp;10,
	2017, a putative securities class action complaint was filed against Seattle Genetics, Inc., our chief executive officer, Clay Siegall, and our chief financial officer, Todd Simpson, in the United States District Court for the Western District of
	Washington under the following captions: Samit Patel, etc., v. Seattle Genetics, Inc., et al., No. C17-41. The putative class is composed of all purchasers of our securities between October&nbsp;27, 2016 and December&nbsp;26, 2016, inclusive. The
	complaint alleges material misrepresentations and omissions in public statements regarding our business, operational and compliance policies, violations by all named defendants of Section&nbsp;10(b) of the Exchange Act, and Rule 10b-5 thereunder, as
	well as violations of Section&nbsp;20(a) of the Exchange Act. The plaintiff alleges, among other things, that we made false and/or misleading statements and/or failed to disclose that SGN-CD33A presents a significant risk of fatal hepatotoxicity and
	that we had therefore overstated the viability of SGN-CD33A as a treatment for AML. The complaint seeks compensatory damages of an undisclosed amount. We believe that we have meritorious defenses and intend to defend this lawsuit vigorously.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On February&nbsp;13, 2017, we were named a
	co-defendant in a lawsuit filed by venBio against the members of the board of directors of Immunomedics, or the venBio lawsuit.&nbsp;The venBio lawsuit was filed in the Court of Chancery of the State of Delaware under the caption venBio v.
	Goldenberg et. al. and alleges that the members of the Immunomedics board breached their fiduciary duties toward their stockholders by hastily licensing IMMU-132 to us. We are alleged to have aided and abetted the breach of fiduciary duties. Among
	other things, venBio seeks to enjoin the closing of the transactions contemplated by the Immunomedics License. As a result of the pending litigation challenging the transactions contemplated by the Immunomedics License, Immunomedics and we have
	committed to the Court not to close the transactions contemplated by the Immunomedics License prior to March 10, 2017.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	71
</FONT>
</P>
<A NAME="eolPage74"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We do not believe it is feasible to predict or determine the outcome or resolution of these
	lawsuits, or to estimate the amount of, or potential range of, loss with respect to these lawsuits. In addition, the timing of the final resolution of these lawsuits is uncertain. As a result of these lawsuits, we will incur litigation expenses and
	may incur indemnification expenses, and potential resolutions of these lawsuits could include a settlement requiring payments by us.&nbsp;Those expenses could have a material impact on our financial position, results of operations, and cash flows.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In addition, from time to time in the ordinary
	course of business we become involved in various lawsuits, claims and proceedings relating to the conduct of our business, including those pertaining to the defense and enforcement of our patent or other intellectual property rights. These
	proceedings are costly and time consuming. Successful challenges to our patent or other intellectual property rights through these proceedings could result in a loss of rights in the relevant jurisdiction and may allow third parties to use our
	proprietary technologies without a license from us or our collaborators.
</FONT>
</P>
</EFX_LEGAL_PROCEEDINGS>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<EFX_MINE_SAFETY_DISCLOSURE>
<A NAME="FIS_MINE_SAFETY_DISCLOSURE"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D481013D10K_HTM_TOC481013_6">
</A>
	Item&nbsp;4. Mine Safety Disclosures
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Not applicable.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	72
</FONT>
</P>
<A NAME="eolPage75"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
</EFX_MINE_SAFETY_DISCLOSURE>
</EFX_PART_I>
<EFX_PART_II>
<A NAME="FIS_PART_II"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	PART II
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<EFX_MARKET>
<A NAME="FIS_MARKET"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D481013D10K_HTM_TOC481013_7">
</A>
	Item&nbsp;5. Market for Registrant&#146;s Common
	Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Price Range of Our Common Stock
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our common stock is traded on the NASDAQ Global Select Market under the symbol &#147;SGEN.&#148; As of February&nbsp;16, 2017, there were 142,493,676 shares of our common stock outstanding, which were
	held by approximately 70 holders of record of our common stock. On February&nbsp;16, 2017, the closing price of our common stock as reported on the NASDAQ Global Select Market was $65.30 per share.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The following table sets forth, for the periods indicated,
	the reported high and low sales prices per share of our common stock as reported on the NASDAQ Global Select Market, as applicable:
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_5"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="80%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	High
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Low
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	2015
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	First Quarter
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	39.98
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	30.05
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Second Quarter
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	49.84
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	32.68
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Third Quarter
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	52.33
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	35.94
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Fourth Quarter
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	46.74
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	36.85
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	2016
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	First Quarter
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	44.45
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	26.02
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Second Quarter
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	44.07
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	32.40
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Third Quarter
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	57.23
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	39.38
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Fourth Quarter
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	75.36
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	47.29
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	2017
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	First Quarter (through February 16, 2017)
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	66.64
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	50.65
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Dividend Policy
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We have not paid any cash dividends on our common stock
	since our inception. We do not intend to pay any cash dividends in the foreseeable future, but intend to retain all earnings, if any, for use in our business operations.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Sales of Unregistered Securities and Issuer Repurchases of Securities
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	There were no unregistered sales of
	equity securities by us during the year ended December&nbsp;31, 2016. In addition, we did not repurchase any of our equity securities during the fourth quarter of 2016.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	73
</FONT>
</P>
<A NAME="eolPage76"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Stock Performance Graph
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We show below the cumulative total return to our
	stockholders during the period from December&nbsp;31, 2011 through December&nbsp;31, 2016 in comparison to the cumulative return on the NASDAQ Pharmaceutical Index, the NASDAQ Composite Index and the NASDAQ Biotechnology Index during that same
	period. The results assume that $100 was invested on December&nbsp;31, 2011 in our common stock and each of the indexes listed above, including reinvestment of dividends, if any.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2017/02/21/0001193125-17-050543_G481013G26O50.JPG" ALT="LOGO">
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_6"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="58%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD ROWSPAN="2" VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="22" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Years ended
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	12/11
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	12/12
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	12/13
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	12/14
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	12/15
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	12/16
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Seattle Genetics, Inc.
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	100.00
</B>
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	138.62
</B>
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	238.65
</B>
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	192.22
</B>
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	268.50
</B>
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	315.70
</B>
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	&nbsp;
</B>
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	NASDAQ Composite
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	100.00
</B>
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	116.41
</B>
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	165.47
</B>
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	188.69
</B>
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	200.32
</B>
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	216.54
</B>
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	&nbsp;
</B>
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	NASDAQ Pharmaceutical
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	100.00
</B>
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	136.13
</B>
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	229.92
</B>
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	296.47
</B>
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	308.15
</B>
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	243.63
</B>
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	&nbsp;
</B>
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	NASDAQ Biotechnology
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	100.00
</B>
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	134.68
</B>
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	232.37
</B>
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	307.67
</B>
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	328.76
</B>
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	262.08
</B>
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	&nbsp;
</B>
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	This information under
	&#147;Stock Performance Graph&#148; is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference in any filing of Seattle Genetics, Inc. under the Securities Act of 1933, as amended, or the Securities
	Exchange Act of 1934, as amended, whether made before or after the date of this Annual Report on Form 10-K and irrespective of any general incorporation language in those filings.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	74
</FONT>
</P>
<A NAME="eolPage77"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
</EFX_MARKET>
<EFX_FINANCIAL_DATA>
<A NAME="FIS_FINANCIAL_DATA"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D481013D10K_HTM_TOC481013_8">
</A>
	Item&nbsp;6. Selected Financial Data
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The following selected financial data should be read in
	conjunction with our consolidated financial statements and notes to our consolidated financial statements and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; contained elsewhere in this Annual
	Report on Form 10-K. The selected Consolidated Statements of Comprehensive Loss data for the years ended December&nbsp;31, 2016, 2015, and 2014, and Consolidated Balance Sheet data as of December&nbsp;31, 2016 and 2015 have been derived from our
	audited financial statements appearing elsewhere in this Annual Report on Form 10-K. The selected Consolidated Statements of Comprehensive Loss data for the years ended December&nbsp;31, 2013 and 2012 and Consolidated Balance Sheet data as of
	December&nbsp;31, 2014, 2013, and 2012 have been derived from our audited financial statements that are not included in this Annual Report on Form 10-K. Historical results are not necessarily indicative of future results.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_7"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="53%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="18" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Years ended December&nbsp;31,
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2016
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2015
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2014
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2013
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2012
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="18" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	(in thousands, except for per share amounts)
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Consolidated Statements of Comprehensive Loss Data:
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD COLSPAN="5" VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD COLSPAN="5" VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Revenues:
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD COLSPAN="5" VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD COLSPAN="5" VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Net product sales
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	265,766
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	226,052
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	178,198
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	144,665
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	138,200
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Collaboration and license agreement revenues
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	84,926
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	69,770
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	68,556
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	106,781
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	67,547
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Royalty revenues
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	67,455
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	40,980
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	40,004
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	17,818
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	5,065
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Total revenues
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	418,147
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	336,802
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	286,758
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	269,264
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	210,812
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Costs and expenses:
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD COLSPAN="5" VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD COLSPAN="5" VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Cost of sales
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	28,168
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	24,476
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	17,513
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	13,759
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	11,546
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Cost of royalty revenues
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	14,149
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	12,964
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	11,545
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	7,385
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,923
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Research and development
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	379,308
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	294,529
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	230,743
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	218,627
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	170,297
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Selling, general and administrative
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	139,247
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	125,783
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	104,320
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	92,354
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	84,300
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Loss from operations
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(142,725
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(120,950
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(77,363
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(62,861
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(57,254
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Investment and other income, net
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2,614
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	464
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,222
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	341
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	3,472
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Net loss
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(140,111
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(120,486
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(76,141
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(62,520
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(53,782
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Net loss per share&#151;basic and diluted
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(1.00
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(0.93
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(0.62
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(0.51
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(0.46
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Shares used in computation of net loss per share&#151;basic and diluted
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	140,746
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	129,184
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	123,408
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	121,575
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	117,851
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_8"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="50%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="18" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	December&nbsp;31,
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2016
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2015
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2014
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2013
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2012
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="18" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	(in thousands)
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Consolidated Balance Sheet Data:
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Cash, cash equivalents and investment securities
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	618,974
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	712,711
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	313,413
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	374,267
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	364,258
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Working capital
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	586,132
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	636,793
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	282,093
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	338,058
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	340,283
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Total assets
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	838,396
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	895,095
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	458,965
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	483,898
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	471,422
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Stockholders&#146; equity
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	634,087
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	685,911
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	210,834
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	230,185
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	226,148
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	75
</FONT>
</P>
<A NAME="eolPage78"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
</EFX_FINANCIAL_DATA>
<EFX_MANAGEMENTS_DISCUSSION>
<A NAME="FIS_MANAGEMENTS_DISCUSSION"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D481013D10K_HTM_TOC481013_9">
</A>
	Item&nbsp;7. Management&#146;s Discussion and Analysis of Financial Condition
	and Results of Operations
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Forward-Looking Statements
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	The following discussion of our financial
	condition and results of operations contains forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act of 1933 and Section&nbsp;21E of the Securities Exchange Act of 1934. Forward-looking statements are based on our
	management&#146;s beliefs and assumptions and on information currently available to our management. All statements other than statements of historical facts are &#147;forward-looking statements&#148; for purposes of these provisions, including those
	relating to future events or our future financial performance and financial guidance. In some cases, you can identify forward-looking statements by terminology such as &#147;may,&#148; &#147;might,&#148; &#147;will,&#148; &#147;should,&#148;
	&#147;expect,&#148; &#147;plan,&#148; &#147;anticipate,&#148; &#147;project,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;predict,&#148; &#147;potential,&#148; &#147;intend&#148; or &#147;continue,&#148; the negative of terms like these or
	other comparable terminology, and other words or terms of similar meaning in connection with any discussion of future operating or financial performance. These statements are only predictions. All forward-looking statements included in this Annual
	Report on Form 10-K are based on information available to us on the date hereof, and we assume no obligation to update any such forward-looking statements. Any or all of our forward-looking statements in this document may turn out to be wrong.
	Actual events or results may differ materially. Our forward-looking statements can be affected by inaccurate assumptions we might make or by known or unknown risks, uncertainties and other factors. We discuss many of these risks, uncertainties and
	other factors in this Annual Report on Form 10-K in greater detail under the heading &#147;Item 1A&#151;Risk Factors.&#148; We caution investors that our business and financial performance are subject to substantial risks and uncertainties.
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Overview
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%;PADDING-BOTTOM:0PX; ">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Seattle Genetics is a biotechnology
	company focused on the development and commercialization of targeted therapies for the treatment of cancer. Our marketed product ADCETRIS
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	&reg;
</SUP>
</FONT>
	, or brentuximab vedotin, is now approved by the United States Food and Drug Administration, or FDA, and the European Commission for three indications, encompassing
	several settings for the treatment of relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma, or sALCL. ADCETRIS is commercially available in 66 countries around the world, including in the United States, Canada, members of
	the European Union and Japan. We are collaborating with Takeda Pharmaceutical Company Limited, or Takeda, to develop and commercialize ADCETRIS on a global basis. Under this collaboration, Seattle Genetics retains commercial rights for ADCETRIS in
	the United States and its territories and in Canada, and Takeda has commercial rights in the rest of the world.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Beyond our current labeled indications, we and Takeda have a broad development strategy for ADCETRIS evaluating its therapeutic potential
	in earlier lines of therapy for patients with Hodgkin lymphoma or mature T-cell lymphoma, or MTCL, also known as peripheral T-Cell lymphoma, or PTCL, including sALCL, and in other CD30-expressing malignancies. We and Takeda are currently conducting
	three phase 3 clinical trials of ADCETRIS: ALCANZA, ECHELON-1 and ECHELON-2. All of these trials are being conducted under Special Protocol Assessment, or SPA, agreements with the FDA and pursuant to scientific advice from the European Medicines
	Agency, or EMA. An SPA is an agreement with the FDA regarding the design of the clinical trial, including size and clinical endpoints, to support an efficacy claim in a new drug application or a Biologics License Application, or BLA, submission to
	the FDA if the trial achieves its primary endpoints. We plan to submit a supplemental Biologics License Application, or sBLA, to the FDA in mid-2017 to seek approval for a new indication in CD30-expressing relapsed CTCL. We have also completed
	enrollment of 1,334 patients in our ECHELON-1 trial and expect to report data in 2017. In November 2016, we completed enrollment of 452 patients in our ECHELON-2 trial, and expect to report data in 2018.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We are also advancing the development of SGN-CD33A, or
	vadastuximab talirine. A phase 3 clinical trial, called the CASCADE trial, was initiated in the second quarter of 2016 based on data from our phase 1 clinical trial for patients with acute myeloid leukemia, or AML. The CASCADE trial is evaluating
	SGN-CD33A in combination with hypomethylating agents, or HMAs, in previously untreated older patients with AML who are
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	76
</FONT>
</P>
<A NAME="eolPage79"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	not candidates for intensive induction chemotherapy. We also have been evaluating SGN-CD33A in additional treatment settings, and overall, more than 300 patients have been treated with SGN-CD33A
	to date in clinical trials across these multiple treatment settings. On December 27, 2016, we announced that we had received notice from the FDA that a full clinical hold or partial clinical hold had been placed on several early stage trials of
	SGN-CD33A in AML to evaluate the potential risk of hepatotoxicity following adverse medical events, including fatal events. We are working diligently with the FDA to determine whether there is any association between hepatotoxicity and treatment
	with SGN-CD33A and to promptly identify appropriate measures for patient safety with the goal of addressing the FDA&#146;s concerns.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In addition, in collaboration with Astellas Pharma, Inc., or Astellas, we are developing ASG-22ME, or enfortumab vedotin. We and Astellas
	are planning discussions with regulatory agencies during 2017 to advance the program into potential registrational trials in urothelial cancer patients, including patients who have been previously treated with a checkpoint inhibitor therapy.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our clinical-stage pipeline also includes six
	other antibody-drug conjugate, or ADC, programs consisting of SGN-LIV1A, SGN-CD19A, or denintuzumab mafodotin, SGN-CD19B, SGN-CD123A, SGN-CD352A, and ASG-15ME, as well as two immuno-oncology agents, SEA-CD40, which is based on our sugar-engineered
	antibody, or SEA, technology, and SGN-2FF, which is a novel small molecule. In addition, we have multiple preclinical and research-stage programs that employ our proprietary technologies, including SGN-CD48A, a preclinical ADC that is a candidate
	for investigational new drug, or IND, submission in 2017.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We announced on February&nbsp;10, 2017 that we had entered into a development and license agreement, or the Immunomedics License, with Immunomedics, Inc., or Immunomedics, pursuant to which, upon the
	terms and subject to the conditions set forth in the Immunomedics License, we would receive exclusive worldwide rights to develop, manufacture and commercialize sacituzumab govitecan (IMMU-132). IMMU-132 is an ADC targeted to TROP-2, which is
	expressed in several solid tumors, and is in a pivotal phase 1/2 trial for patients with triple negative breast cancer, or TNBC, and is being investigated in other solid tumors. IMMU-132 received Breakthrough Therapy Designation, or BTD, from the
	FDA for the treatment of patients with TNBC who have failed prior therapies for metastatic disease. In connection with the closing of the transactions contemplated by the Immunomedics License, Immunomedics would receive an upfront payment of $250
	million. In addition, Immunomedics would also be eligible to receive development, regulatory and sales-dependent milestone payments across multiple indications and geographical regions of up to a total maximum of approximately $1.7&nbsp;billion, as
	well as royalties which are based on a percentage of annual net sales of the licensed products, if any, beginning in the teens and rising to twenty percent based on sales volume. The closing of the transactions contemplated by the Immunomedics
	License is subject to customary closing conditions, including the expiration of the applicable waiting period under the
<FONT STYLE="WHITE-SPACE:NOWRAP">
<FONT STYLE="WHITE-SPACE:NOWRAP">
	Hart-Scott-Rodino
</FONT>
</FONT>
	Antitrust Improvements Act of
	1976, as amended, or the HSR Act, there being no pending court or administrative challenges to the Immunomedics License and there being no court or administrative order blocking the closing. On February 20, 2017, Immunomedics and we entered into a
	letter agreement pursuant to which Immunomedics irrevocably waived to the extent applicable to Immunomedics the condition precedent to the closing and effectiveness of the Immunomedics License that there be no pending court or administrative
	challenges to the transaction. Additionally, under the terms of the Immunomedics License, Immunomedics had the right to continue discussions with a small number of parties that previously expressed interest in licensing IMMU-132 until 11:59 p.m. New
	York City time on February&nbsp;19, 2017. If a third party had provided Immunomedics with a financially superior licensing offer, we would have had the right to match any such offer, and if we had decided not to match, Immunomedics would have had
	the right to accept the superior offer and terminate the Immunomedics License upon payment of a termination fee to us. We have not received notice from Immunomedics of any such third party offers during this limited time period, and on February 21,
	2017, Immunomedics announced that it is subject to customary &#147;no-shop&#148; restrictions on its and its representatives&#146; ability to solicit, discuss or negotiate alternative licensing agreement proposals from third parties with regard to
	IMMU-132. On February&nbsp;13, 2017, we were named a co-defendant in a lawsuit filed by venBio Select Advisors LLC, or venBio, in the Delaware Chancery Court against the members of the board of directors of Immunomedics pursuant to which, among
	other things, venBio seeks to enjoin the closing of the
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	77
</FONT>
</P>
<A NAME="eolPage80"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	transactions contemplated by the Immunomedics License. As a result of the pending litigation challenging the transactions contemplated by the Immunomedics License, Immunomedics and we have
	committed to the Court not to close the transactions contemplated by the Immunomedics License prior to March 10, 2017. We cannot predict the timing or outcome of this legal proceeding or the impact it may have on the Immunomedics License or the
	closing of the transactions contemplated by the Immunomedics License. However, it is possible that, in connection with the venBio lawsuit, the Immunomedics License could be rescinded or reformed in a way that is disadvantageous to us, including by
	requiring us to increase the transaction consideration payable to Immunomedics under the Immunomedics License, or that otherwise adversely affects the anticipated benefits to us of the Immunomedics License. See &#147;License
	Agreements&#151;Immunomedics License&#148; in Item 1&#151;Business for more information.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We have collaborations for our ADC technology with a number of biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd., or AbbVie; Bayer Pharma AG, or Bayer; Celldex Therapeutics,
	Inc., or Celldex; Genentech, Inc., a member of the Roche Group, or Genentech; GlaxoSmithKline LLC, or GSK; Pfizer, Inc., or Pfizer; and PSMA Development Company LLC, a subsidiary of Progenics Pharmaceuticals Inc., or Progenics. In addition, we have
	entered into a 50/50 co-development agreement with Agensys, Inc., an affiliate of Astellas, for the development of ADCs, including ASG-22ME. We also have an option for an ADC co-development agreement with Genmab A/S, or Genmab, and a collaboration
	with Unum Therapeutics, Inc., or Unum, to develop and commercialize novel antibody-coupled T-cell receptor, or ACTR, therapies incorporating our antibodies for the treatment of cancer.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our ongoing research, development and commercial activities, together with our anticipated transfer,
	integration and development activities related to IMMU-132, will require substantial amounts of capital and may not ultimately be successful. In addition, we may encounter unexpected difficulties during our anticipated transfer, integration and
	development activities related to IMMU-132, any of which may cause us to expend greater funds and efforts or may slow, delay or limit the progress of IMMU-132&#146;s development. Over the next several years, we expect that we will incur substantial
	expenses, primarily as a result of activities related to the commercialization of ADCETRIS, the continued development of ADCETRIS and SGN-CD33A and the anticipated development of IMMU-132 under the Immunomedics License. Our other product candidates
	are in relatively early stages of development; SGN-CD33A, our other product candidates and IMMU-132 will require significant further development, financial resources and personnel to pursue and obtain regulatory approval and develop into
	commercially viable products, if at all. In addition, SGN-CD33A is our only product candidate in late stage clinical development and if we are unable to resolve the clinical holds on our SGN-CD33A trials or to otherwise advance the development of
	SGN-CD33A, or if we fail to produce positive results in the CASCADE trial, the commercialization prospects for SGN-CD33A, as well as our business and financial prospects, would be materially adversely affected. In addition, despite the substantial
	commitments of time and resources by our management and other employees already incurred in connection with the Immunomedics License as well as our equity investment of approximately $14.7 million in Immunomedics, we may be unable to consummate the
	transactions contemplated the Immunomedics License, whether as a result of the venBio lawsuit or otherwise, in which case we will not realize any of the benefits of the licensing of IMMU-132. Likewise, it is possible that, in connection with the
	venBio lawsuit and/or the proxy contest that venBio has initiated with respect to the election of directors at the Immunomedics annual meeting, the Immunomedics License could be reformed in a way that is disadvantageous to us, including by requiring
	us to increase the transaction consideration payable to Immunomedics under the Immunomedics License, or that otherwise adversely affects the anticipated benefits to us of the Immunomedics License. Our commitment of resources to the continuing
	development, regulatory and commercialization activities for ADCETRIS, the research, continued development and manufacturing of our product candidates, the transactions contemplated by the Immunomedics License, including the related upfront and
	milestone payments provided for under the Immunomedics License, and the anticipated transfer, integration and development activities related to IMMU-132, will likely require us to raise substantial amounts of additional capital and our operating
	expenses will fluctuate as a result of such activities. In addition, we may incur significant milestone payment obligations to certain of our licensors, including to Immunomedics if the
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	78
</FONT>
</P>
<A NAME="eolPage81"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	transactions contemplated by the Immunomedics License are comsummated, as our product candidates progress through clinical trials towards potential commercialization.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We recognize revenue from ADCETRIS product sales in the
	United States and Canada. Our future ADCETRIS product sales are difficult to accurately predict from period to period. In this regard, our product sales have varied, and may continue to vary, significantly from period to period and may be affected
	by a variety of factors. Such factors include the incidence rate of new patients in ADCETRIS&#146; approved indications, customer ordering patterns, the overall level of demand for ADCETRIS, the duration of therapy for patients receiving ADCETRIS,
	and the extent to which coverage and reimbursement for ADCETRIS is available from government and other third-party payers. Obtaining and maintaining appropriate coverage and reimbursement for ADCETRIS is increasingly challenging due to, among other
	things, the attention being paid to healthcare cost containment and other austerity measures in the U.S. and worldwide, as well as increasing legislative and enforcement interest in the United States with respect to pharmaceutical drug pricing
	practices. We anticipate that healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria and an additional downward pressure on the price that we receive for ADCETRIS. We also anticipate that Congress,
	state legislatures, and third-party payors may continue to review and assess alternative healthcare delivery and payment systems and may in the future propose and adopt legislation or policy changes or implementations effecting additional
	fundamental changes in the healthcare delivery system, any of which could negatively affect our revenue or sales of ADCETRIS (or any future approved products). We also believe that the level of our current ADCETRIS sales in the United States has
	been attributable to the incidence flow of patients eligible for treatment with ADCETRIS, which can vary significantly from period to period. Moreover, we believe that the incidence rate in ADCETRIS&#146; approved indications is relatively low,
	particularly when compared to many other oncology indications. For these and other reasons, we expect that our ability to accelerate ADCETRIS sales growth, if at all, will depend primarily on our ability to continue to expand ADCETRIS&#146; labeled
	indications of use, particularly with respect to the frontline Hodgkin lymphoma and frontline MTCL indications. Our efforts to continue to expand ADCETRIS&#146; labeled indications of use will continue to require additional time and investment in
	clinical trials to complete and may not be successful. Our ability to successfully commercialize ADCETRIS and to continue to expand its labeled indications of use are subject to a number of risks and uncertainties, including those discussed in Part
	I, Item&nbsp;1A of this Annual Report on Form 10-K. In particular, negative or inconclusive results in our ECHELON-1 and ECHELON-2 trials would negatively impact, or preclude altogether, our ability to obtain regulatory approval in the frontline
	Hodgkin lymphoma and frontline MTCL indications, respectively, either of which could limit our sales of, and the commercial potential of, ADCETRIS. In addition, although we reported in August 2016 that the ALCANZA trial evaluating ADCETRIS in
	patients with relapsed CTCL met its primary endpoint demonstrating a statistically significant improvement in the rate of objective response lasting at least four months and we plan to submit an sBLA to the FDA to seek approval for a new indication
	in CD30-expressing relapsed CTCL, there can be no assurance that the FDA will accept our planned sBLA for filing or that we will ultimately obtain approval of our planned sBLA in a timely manner or at all. Our failure to obtain regulatory approval
	and commercialize ADCETRIS in the ALCANZA treatment setting would also limit our sales of, and the commercial potential of, ADCETRIS. We also expect that amounts earned from our collaboration agreements, including royalties, will continue to be an
	important source of our revenues and cash flows. These revenues will be impacted by future development funding and the achievement of development, clinical and commercial success by our collaborators under our existing collaboration and license
	agreements, including our ADCETRIS collaboration with Takeda, as well as by entering into potential new collaboration and license agreements. Our results of operations may vary substantially from year to year and from quarter to quarter and, as a
	result, we believe that period to period comparisons of our operating results may not be meaningful and should not be relied upon as being indicative of our future performance.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:2%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Financial summary
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Total revenues increased to $418.1 million in 2016, compared
	to $336.8 million in 2015. This increase was primarily driven by ADCETRIS net product sales that increased 18% to $265.8 million in 2016 as compared to
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	79
</FONT>
</P>
<A NAME="eolPage82"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$226.1 million in 2015, and by royalty revenues that increased 65% to $67.5 million in 2016 as compared to $41.0 million in 2015. During 2016, royalty revenues included a one-time $20.0 million
	milestone payment triggered by Takeda exceeding $200 million in annual net sales of ADCETRIS in its territory during 2015. Total costs and expenses increased 23% to $560.9 million in 2016, compared to $457.8 million in 2015. This primarily reflects
	increases in our investment in SGN-CD33A and increased ADCETRIS collaboration activities for product supply to Takeda, as well as investment in our growing pipeline of preclinical and clinical-stage programs. As of December&nbsp;31, 2016, we had
	$619.0 million in cash, cash equivalents and investments, and $634.1 million in total stockholders&#146; equity.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Critical Accounting Policies
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The preparation of financial statements in accordance with generally accepted accounting principles, or GAAP, requires us to make estimates, assumptions and judgments that affect the reported amounts of
	assets, liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. We believe the following critical accounting policies describe the more significant judgments and estimates used in the preparation of our
	financial statements.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Revenue
	Recognition
</B>
	.&nbsp;&nbsp;&nbsp;&nbsp;Our revenues are comprised of ADCETRIS net product sales, amounts earned under our collaboration and licensing agreements and royalties. Revenue recognition is predicated upon persuasive evidence of an
	agreement existing, delivery of products or services being rendered, amounts payable being fixed or determinable, and collectibility being reasonably assured.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Net product sales
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We sell ADCETRIS through a limited number of pharmaceutical distributors. Customers order ADCETRIS through these distributors and we
	typically ship product directly to the customer. We record product sales when title and risk of loss pass, which generally occurs upon delivery of the product to the customer. Product sales are recorded net of estimated government-mandated rebates
	and chargebacks, distribution fees, estimated product returns and other deductions. These are generally referred to as gross-to-net deductions. Accruals are established for these deductions and actual amounts incurred are offset against applicable
	accruals. We reflect these accruals as either a reduction in the related account receivable from the distributor, or as an accrued liability depending on the nature of the sales deduction. Sales deductions are based on our estimates that consider
	payer mix in target markets and our experience to date. These estimates involve a substantial degree of judgment.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Government-mandated rebates and chargebacks:&nbsp;&nbsp;&nbsp;&nbsp;
</I>
	We have entered into a Medicaid Drug Rebate Agreement with the
	Centers for Medicare&nbsp;&amp; Medicaid Services. This agreement provides for a rebate to participating states based on covered purchases of ADCETRIS. Medicaid rebates are invoiced to us by the various state Medicaid programs. We estimate Medicaid
	rebates based on a variety of factors, including our experience to date. We also have completed our Federal Supply Schedule, or FSS, agreement under which certain U.S. government purchasers receive a discount on eligible purchases of ADCETRIS. We
	have entered into a Pharmaceutical Pricing Agreement with the Secretary of Health and Human Services which enables certain entities that qualify for government pricing under the Public Health Services Act, or PHS, to receive discounts on their
	qualified purchases of ADCETRIS. Under these agreements, distributors process a chargeback to us for the difference between wholesale acquisition cost and the applicable discounted price. As a result of our direct-ship distribution model, we can
	identify the entities purchasing ADCETRIS and this information enables us to estimate expected chargebacks for FSS and PHS purchases based on each entity&#146;s eligibility for the FSS and PHS programs. We also review actual rebate and chargeback
	information to further refine these estimates.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Distribution fees, product returns and other deductions:&nbsp;&nbsp;&nbsp;&nbsp;
</I>
	Our distributors charge a volume-based fee for
	distribution services that they perform for us. We allow for the return of product that is within 30 days of its expiration date or that is damaged. We estimate product returns based on our experience to date. In addition, we consider our
	direct-ship distribution model, our belief that product is not typically held in the distribution channel, and the expected rapid use of the product by healthcare providers. We provide financial assistance to
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	80
</FONT>
</P>
<A NAME="eolPage83"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	qualifying patients that are underinsured or cannot cover the cost of commercial coinsurance amounts through SeaGen Secure. SeaGen Secure is available to patients in the U.S. and its territories
	who meet various financial and treatment need criteria. Estimated contributions for commercial coinsurance under SeaGen Secure are deducted from gross sales and are based on an analysis of expected plan utilization. These estimates are adjusted as
	necessary to reflect our actual experience.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Collaboration and
	license agreement revenues
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our proprietary
	ADC technologies are the basis of our ADC collaborations that we have entered into in the ordinary course of business with a number of biotechnology and pharmaceutical companies. Under these ADC collaboration agreements, we grant our collaborators
	research and commercial licenses to our technology and typically provide technology transfer services, technical advice, supplies and services for a period of time.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	If there are continuing performance obligations, we use a
	time-based proportional performance model to recognize revenue over our performance period for the related agreement. Collaboration and license agreements are evaluated to determine whether the multiple elements and associated deliverables can be
	considered separate units of accounting. To date, the pre-commercial deliverables under our collaboration and license agreements have not qualified as separate units of accounting. The assessment of multiple element arrangements requires judgment in
	order to determine the appropriate point in time, or period of time, that revenue should be recognized. We believe that the development period in each agreement is a reasonable estimate of the performance obligation period of such agreement.
	Accordingly, all amounts received or due, including any upfront payments, maintenance fees, development and regulatory milestone payments and reimbursement payments, are recognized as revenue over the performance obligation periods of each
	agreement. These performance obligation periods typically range from one to three years. The agreements with Takeda Pharmaceutical Company Limited, or Takeda, and Genentech, Inc., a member of the Roche Group, or Genentech, have performance
	obligation periods of ten and seventeen years, respectively. All of the remaining performance obligation periods for our active collaborations are currently expected to be completed in three years or less. When no performance obligations are
	required of us, or following the completion of the performance obligation period, such amounts are recognized as revenue when collectibility is reasonably assured. Generally, all amounts received or due other than sales-based milestones and
	royalties are classified as collaboration and license agreement revenues as they are earned. Sales-based milestones and royalties are recognized as royalty revenue as they are reported to us.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our collaboration and license agreements include contractual milestones. Generally, the milestone events
	contained in our collaboration and license agreements coincide with the progression of the collaborators&#146; product candidates from development to regulatory approval and then to commercialization.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Development milestones in our collaborations may include the
	following types of events:
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Designation of a product candidate or initiation of pre-clinical studies. Our collaborators must undertake significant pre-clinical research and
	studies to make a determination of the suitability of a product candidate and the time from those studies or designation to initiation of a clinical trial may take several years.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Initiation of a phase 1 clinical trial. Generally, phase 1 clinical trials may take one to two years to complete.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Initiation of a phase 2 clinical trial. Generally, phase 2 clinical trials may take one to three years to complete.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Initiation of a phase 3 clinical trial. Generally, phase 3 clinical trials may take two to six years to complete.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	81
</FONT>
</P>
<A NAME="eolPage84"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Regulatory milestones in our collaborations may include the following types of events:
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Filing of regulatory applications for marketing approval such as a BLA in the United States or a Marketing Authorization Application in Europe.
	Generally, it may take up to twelve months to prepare and submit regulatory filings.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Receiving marketing approval in a major market, such as in the United States, Europe, Japan or other significant countries. Generally it may take up to
	three years after a marketing application is submitted to obtain approval for marketing and pricing from the applicable regulatory agency.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Commercialization milestones in our collaborations may include the following types of events:
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	First commercial sale in a particular market, such as in the United States, Europe, Japan or other significant countries.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Product sales in excess of a pre-specified threshold. The amount of time to achieve this type of milestone depends on several factors, including, but
	not limited to, the dollar amount of the threshold, the pricing of the product, market penetration of the product and the rate at which customers begin using the product.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our ADC collaborators are solely responsible for the development of their product candidates and the
	achievement of milestones in any of the categories identified above is based solely on the collaborators&#146; efforts.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In the case of our ADCETRIS collaboration with Takeda, we may be involved in certain development activities; however, the achievement of
	development, regulatory and commercial milestone events under the agreement is primarily based on activities undertaken by Takeda.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The process of successfully developing a product candidate, obtaining regulatory approval and ultimately commercializing a product
	candidate is highly uncertain and the attainment of any milestones is therefore uncertain and difficult to predict. In addition, since we do not take a substantive role or control the research, development or commercialization of any products
	generated by our ADC collaborators, we are not able to reasonably estimate when, if at all, any milestone payments or royalties may be payable to us by our ADC collaborators. As such, the milestone payments associated with our ADC collaborations
	involve a substantial degree of uncertainty and risk that they may never be received. Similarly, even in those collaborations where we may have an active role in the development of the product candidate, such as our ADCETRIS collaboration with
	Takeda, the attainment of a milestone is based on the collaborator&#146;s activities and is generally outside our direction and control.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We generally invoice our collaborators and licensees on a monthly or quarterly basis, or upon the completion of the effort or achievement
	of a milestone, based on the terms of each agreement. Any deferred revenue arising from amounts received in advance of the culmination of the earnings process is recognized as revenue in future periods when the applicable revenue recognition
	criteria have been met. Deferred revenue expected to be recognized within the next twelve months is classified as a current liability.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Royalty revenues and cost of royalty revenues
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Royalty revenues primarily reflect royalties paid to us by Takeda under the ADCETRIS collaboration. These royalties include commercial
	sales-based milestones and sales royalties. The royalty rate paid by Takeda is calculated as a percentage of Takeda&#146;s net sales of ADCETRIS, ranges from the mid-teens to the mid-twenties depending on sales volumes, and resets annually. Takeda
	bears a portion of third-party royalty costs owed on sales of ADCETRIS in its territory. This amount is also included in our royalty revenues. Cost of royalty revenues reflect amounts owed to our third-party licensors related to the sale of ADCETRIS
	in Takeda&#146;s territory. These amounts are recognized in the quarter in which Takeda reports its sales activity to us, which is the quarter following the related sales. Royalty revenues also include certain amounts earned in connection with our
	ADC collaborations.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	82
</FONT>
</P>
<A NAME="eolPage85"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Investments.
</B>
	&nbsp;&nbsp;&nbsp;&nbsp;We have investments in debt securities in
	accordance with our investment policy. We classify our investments as available-for-sale, which are reported at estimated fair value with the related unrealized gains and losses included in accumulated other comprehensive loss in stockholders&#146;
	equity. Realized gains and losses and declines in value of investments judged to be other-than-temporary are included in investment and other income, net. The fair value of our investments is subject to volatility. Declines in the fair value of our
	investments judged to be other-than-temporary could adversely affect our future operating results. We estimate fair values in accordance with a hierarchy prescribed by GAAP. This hierarchy prioritizes the inputs and assumptions used, and the
	valuation techniques used to measure fair value.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Accrued Liabilities.
</B>
	&nbsp;&nbsp;&nbsp;&nbsp;As part of the process of preparing financial statements, we are required to estimate
	accrued liabilities. This process involves identifying services that have been performed on our behalf and estimating the level of services performed and the associated costs incurred for such services where we have not yet been invoiced or
	otherwise notified of actual cost. We record these estimates in our consolidated financial statements as of each balance sheet date. Examples of estimated accrued liabilities include fees due to contract research organizations and other costs in
	conjunction with clinical trials, fees due in conjunction with manufacturing ADCETRIS and our product candidates, third-party royalties that accrue on our sales of ADCETRIS and professional service fees, among other items.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In accruing service fees, we estimate the time period over
	which services will be provided and the level of effort in each period. If the actual timing of the provision of services or the level of effort varies from the estimate, we will adjust the accrual accordingly. In the event that we do not identify
	costs that have been incurred or we under or overestimate the level of services performed or the costs of such services, our actual liabilities would differ from such estimates. The date on which some services commence, the level of services
	performed on or before a given date and the cost of such services are often subjective determinations. We make judgments based upon the facts and circumstances known to us at the time and in accordance with GAAP.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Research and
	Development.
</B>
	&nbsp;&nbsp;&nbsp;&nbsp;Research and development expenses consist of salaries, benefits and other headcount related costs of our research and development staff, preclinical activities, clinical trials, lab supplies, drug
	manufacturing costs for our product candidates and for ADCETRIS when used in research and clinical trials, contract and outside service fees, and facilities and overhead expenses. Clinical trial expenses are a significant component of research and
	development expenses, and we outsource a significant portion of these costs to third parties. Our third-party clinical trial expenses include investigator fees, site costs, clinical research organization costs, the cost for other comparative or
	companion drugs used in the conduct of clinical trials, and costs for central laboratory testing and data management. Research and development activities are expensed as incurred. Costs associated with activities performed under research and
	development co-development collaborations are reflected in research and development expense. Non-refundable advance payments for goods or services that will be used or rendered for future research and development activities are capitalized and
	recognized as expense as the related goods are delivered or the related services are performed. Technology in-licensing fees, including milestones and maintenance fees, and other costs to acquire technologies for product candidates that have not yet
	received regulatory approval that are utilized in research and development and that are not expected to have alternative future use are expensed when incurred.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Share-based Compensation.
</B>
	&nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation cost is based on the fair value of the award on the date
	of grant. We use the Black-Scholes option pricing model to determine the fair value of options on the date of grant which requires certain estimates to be made by management, including the expected forfeiture rate and expected term of the options.
	We also make decisions regarding the method of calculating the expected stock price volatility and the risk free interest rate used in the model. Fluctuations that affect these estimates could have an impact on the resulting compensation cost. We
	recognize this estimated fair value over the vesting period of the arrangement using the graded-vesting attribution method for stock options which vest ratably over the vesting period. For performance-based stock options, we recognized this
	estimated fair value over the service period of the award when we believe vesting of the performance-based stock options is considered probable. Once vesting of performance-based stock options is considered probable, we record compensation expense
	based on the
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	83
</FONT>
</P>
<A NAME="eolPage86"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	portion of the service period elapsed to date, with a cumulative catch-up, net of estimated forfeitures, and recognize remaining compensation expense, if any, over the remaining estimated service
	period.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The fair value of each restricted stock
	unit, or RSU, equals the closing price of our common stock on the date of grant. RSUs granted to date vest 100% at a single point in time. We therefore amortize the value of RSUs, net of estimated forfeitures, to expense on a straight-line basis
	over the vesting period of the award.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Long-term Incentive Plans.
</B>
	&nbsp;&nbsp;&nbsp;&nbsp;We have long term incentive plans which provide eligible employees with the
	opportunity to receive performance-based incentive compensation comprised of cash and stock options or restricted stock units. The payment of cash and the grant or vesting of equity are contingent upon the achievement of pre-determined regulatory
	milestones. We record compensation expense over the estimated service period for a milestone when we believe the milestone is considered probable, which we assess at each reporting date. Once a milestone is considered probable, we record
	compensation expense based on the portion of the service period elapsed to date with respect to that milestone, with a cumulative catch-up, net of estimated forfeitures, and recognize any remaining compensation expense, if any, over the remaining
	estimated service period.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Income
	Taxes.
</B>
	&nbsp;&nbsp;&nbsp;&nbsp;We have net deferred tax assets which are fully offset by a valuation allowance due to our determination that it is more likely than not that the deferred assets will not be realized. We believe that a full
	valuation allowance is appropriate as we have a history of net operating losses. In the event we were to determine that we would be able to realize our net deferred tax assets in the future, an adjustment to the valuation allowance would be made, a
	portion of which would increase income (or decrease losses) in the period in which such a determination was made. We follow the guidance related to accounting for uncertainty in income taxes, which requires the recognition of an uncertain tax
	position when it is more likely than not to be sustainable upon audit by the applicable taxing authority.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Inventories.
</B>
	&nbsp;&nbsp;&nbsp;&nbsp;We consider regulatory approval of product candidates to be uncertain. Accordingly, we charge
	manufacturing costs to research and development expense until such time as a product has received regulatory approval for commercial sale. We began capitalizing ADCETRIS production costs into inventory following its accelerated approval by the FDA
	in 2011. ADCETRIS inventory that is deployed into clinical, research or development use is removed from inventory and charged to research and development expense when it is no longer available for use in commercial sales. Production costs for our
	other product candidates continue to be charged to research and development expense.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We value our inventories at the lower of cost or market value. Cost is determined on a specific identification basis. Inventory includes the cost of materials, third-party contract manufacturing and
	overhead associated with the production of ADCETRIS. We would write-down inventory cost to net realizable value if we were to determine that we had any excess, obsolete or unsalable inventory.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Loss Contingencies.
</B>
	&nbsp;&nbsp;&nbsp;&nbsp;We are involved in various legal proceedings in the normal
	course of our business. A loss contingency is recorded if it is probable that an asset has been impaired or a liability has been incurred and the amount of the loss can be reasonably estimated. We evaluate, among other factors, the probability of an
	unfavorable outcome and our ability to make a reasonable estimate of the amount of the ultimate loss. Loss contingencies that we determine to be reasonably possible, but not probable, are disclosed but not recorded. Changes in these estimates could
	materially affect our financial position and results of operations. Legal fees incurred as a result of our involvement in legal proceedings are expensed as incurred.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On January&nbsp;10, 2017, a putative securities class action
	complaint was filed against Seattle Genetics, Inc., our chief executive officer, Clay Siegall, and our chief financial officer, Todd Simpson, in the United States District Court for the Western District of Washington under the following captions:
	Samit Patel, etc., v. Seattle Genetics, Inc., et al., No. C17-41. The putative class is composed of all purchasers of our securities between October&nbsp;27, 2016 and December&nbsp;26, 2016, inclusive. The complaint alleges material
	misrepresentations and omissions in
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	84
</FONT>
</P>
<A NAME="eolPage87"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	public statements regarding our business, operational and compliance policies, violations by all named defendants of Section&nbsp;10(b) of the Exchange Act, and Rule 10b-5 thereunder, as well as
	violations of Section&nbsp;20(a) of the Exchange Act. The complaint seeks compensatory damages of an undisclosed amount.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On February&nbsp;13, 2017, we were named a co-defendant in a lawsuit filed by venBio against the members of the board of directors of
	Immunomedics, or the venBio lawsuit.&nbsp;The venBio lawsuit was filed in the Court of Chancery of the State of Delaware under the caption venBio v. Goldenberg et. al. and alleges that the members of the Immunomedics board breached their fiduciary
	duties toward their stockholders by hastily licensing IMMU-132 to us. We are alleged to have aided and abetted the breach of fiduciary duties. Among other things, venBio seeks to enjoin the closing of the transactions contemplated by the
	Immunomedics License. As a result of the pending litigation challenging the transactions contemplated by the Immunomedics License, Immunomedics and we have committed to the Court not to close the transactions contemplated by the Immunomedics License
	prior to March 10, 2017.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We do not believe it is
	feasible to predict or determine the outcome or resolution of these lawsuits, or to estimate the amount of, or potential range of, loss with respect to these lawsuits. In addition, the timing of the final resolution of these lawsuits uncertain. As a
	result of these lawsuits, we will incur litigation expenses and may incur indemnification expenses, and potential resolutions of these lawsuits could include settlements requiring payments by us.&nbsp;Those expenses could have a material impact on
	our financial position, results of operations, and cash flows.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On an ongoing basis, we evaluate our estimates, including those related to revenue recognition, investments, accrued expenses, research and development, share-based compensation, income taxes, inventories
	and loss contingencies. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form our basis for making judgments about the carrying values of
	assets and liabilities and the reported amounts of revenues and expenses that are not readily apparent from other sources. Actual results may differ from those estimates under different assumptions and conditions.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<EFX_RESULTS_OF_OPERATIONS>
<A NAME="FIS_RESULTS_OF_OPERATIONS"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Results of Operations
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Years Ended December&nbsp;31, 2016, 2015, and 2014
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Net product sales
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We sell ADCETRIS in the U.S. and Canada. Our net product
	sales were as follows ($ in thousands):
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="52%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ROWSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2016
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM" ROWSPAN="2">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ROWSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2015
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM" ROWSPAN="2">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ROWSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2014
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM" ROWSPAN="2">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Annual percentage
<BR>
	change
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2016/2015
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2015/2014
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Net product sales
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	265,766
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	226,052
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	178,198
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	18
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	27
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Net product sales increased
	in 2016 and 2015 as compared to prior years due to an increase in sales volume and, to a lesser extent, from the effect of price increases. The increases in sales volume in 2016 and 2015 were primarily driven by increased use of ADCETRIS across
	multiple lines of therapy for the treatment of Hodgkin lymphoma, sALCL and for the treatment of other CD30 expressing malignancies. Additionally, our 2016 sales volume includes a full year of ADCETRIS sales for the post-autologous hematopoietic stem
	cell transplantation, or auto-HSCT, consolidation indication for which we received FDA approval in the third quarter of 2015.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	ADCETRIS received approval from the FDA in 2011 for the treatment of patients with classical Hodgkin lymphoma after failure of auto-HSCT
	or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates, and for the treatment of patients with sALCL, after failure of at least one prior multi-agent chemotherapy regimen. In August
	2015, ADCETRIS was approved by the FDA for the treatment of patients with classical Hodgkin lymphoma at high risk of relapse or progression as post-auto-HSCT consolidation.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	85
</FONT>
</P>
<A NAME="eolPage88"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We expect continued growth in ADCETRIS sales in 2017 as compared to 2016. Our ability to
	accelerate the rate of ADCETRIS sales growth in future periods, if at all, will be primarily dependent on our ability to continue to expand ADCETRIS&#146; labeled indications of use. Our efforts to expand ADCETRIS&#146; labeled indications of use
	will continue to require additional time and investment in clinical trials to complete and may not be successful.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We record product sales net of estimated government-mandated rebates and chargebacks, distribution fees, product returns and other
	deductions. These are generally referred to as gross-to-net deductions. Gross-to-net deductions, net of related payments and credits, are summarized as follows:
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_9"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="36%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="10" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	December&nbsp;31, 2016
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="10" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	December&nbsp;31, 2015
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="10" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	December&nbsp;31, 2014
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Rebates &amp;
<BR>
	chargebacks
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Distribution&nbsp;fees,
<BR>
	product returns
<BR>
	and other
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Total
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Rebates &amp;
<BR>
	chargebacks
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Distribution&nbsp;fees,
<BR>
	product returns
<BR>
	and other
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Total
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Rebates &amp;
<BR>
	chargebacks
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Distribution&nbsp;fees,
<BR>
	product returns
<BR>
	and other
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Total
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	Balance, beginning of year
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	7,111
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	2,359
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	9,470
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	5,268
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	1,618
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	6,886
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	4,525
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	1,523
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	6,048
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	Provision related to current year sales
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	74,075
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	6,522
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	80,597
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	48,214
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	5,391
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	53,605
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	31,541
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	4,370
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	35,911
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	Adjustments for prior period sales
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	(1,043
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	(141
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	(1,184
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	(1,065
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	34
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	(1,031
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	(913
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	(62
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	(975
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	Payments/credits for current year sales
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	(65,598
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	(4,733
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	(70,331
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	(42,656
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	(4,070)
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	(46,726
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	(28,038
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	(3,753
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	(31,791
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	Payments/credits for prior year sales
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	(5,045
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	(809
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	(5,854
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	(2,650
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	(614)
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	(3,264
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	(1,847
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	(460
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	(2,307
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	Balance, end of year
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	9,500
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	3,198
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	12,698
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	7,111
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	2,359
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	9,470
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	5,268
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	1,618
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	6,886
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Mandatory government
	discounts are the most significant component of our total gross to net deductions and the discount percentage has been increasing. These discount percentages increased during 2016 and 2015 as a result of price increases we instituted that exceeded
	the rate of inflation, and to a lesser extent in 2016, as a result of an increase in the proportion of our sales eligible for government mandated rebates or chargebacks. Generally, the change in government prices is limited to the rate of inflation.
	Distribution fees, product returns and other gross to net deductions were virtually unchanged as a percentage of our gross sales among the three years presented above. We expect future gross-to-net deductions to fluctuate based on the volume of
	purchases eligible for government mandated discounts and rebates, as well as changes in the discount percentage which is impacted by potential future price increases, the rate of inflation, and other factors. We implemented a price increase at the
	beginning of 2017 and, as a result of this price increase, and a recent increase in the percentage of our gross sales that are eligible for government mandated rebates and chargebacks we expect gross-to-net deductions to increase in 2017. In recent
	months there has been extensive discussion in the United States about expanding government discount programs, including allowing Medicare to negotiate drug prices, and pressure on pharmaceutical drug pricing is expected to increase. If government
	discounted programs are expanded or discounts increased as a result of changes in regulations in the United States, our gross to net deductions will increase and our net sales will be negatively impacted.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	86
</FONT>
</P>
<A NAME="eolPage89"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Collaboration and license agreement revenues
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Collaboration and license agreement revenues reflect amounts
	earned under product collaborations and ADC collaboration and co-development agreements. These revenues reflect the earned portion of payments received by us for technology access and maintenance fees, milestone payments and reimbursement payments
	for research and development support that we provide to our collaborators. Collaboration and license agreement revenues are summarized by collaborator as follows:
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_10"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="50%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="6%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="6%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="6%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="6%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="6%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM" NOWRAP>
<P STYLE="BORDER-BOTTOM:1PX SOLID #000000;WIDTH:167PT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Collaboration and license agreement revenues by
<BR>
	collaborator ($ in thousands)
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Annual percentage
<BR>
	change
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2016
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2015
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2014
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2016/2015
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2015/2014
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Takeda
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	44,384
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	17,234
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	31,787
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	158
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(46
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	AbbVie
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	25,676
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	31,055
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	14,851
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(17
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	109
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Genentech
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	4,324
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	9,110
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	7,791
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(53
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	17
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Other
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10,542
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	12,371
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	14,127
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(15
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(12
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Total
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	84,926
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	69,770
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	68,556
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	22
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Collaboration revenues from
	Takeda fluctuate based on changes in the earned portion of reimbursement funding under the ADCETRIS collaboration, which are influenced by the activities each party is performing under the collaboration agreement at a given time. For example, when
	Takeda&#146;s level of spending on clinical collaboration activities increases above our own, our earned portion of reimbursement funding generally decreases. Additionally, we receive reimbursement for the cost of drug product supplied to Takeda for
	its use, the timing of which fluctuates based on Takeda&#146;s product supply needs. The earned portion of reimbursement funding fluctuates based upon how much drug product Takeda has purchased from us in a given period.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The increase in the earned portion of reimbursement funding
	in 2016 primarily reflects a decrease in clinical trial costs related to activity performed by Takeda as the ALCANZA and ECHELON-1 studies advanced, and an increase in drug product supply activities to Takeda. The reduction in the earned portion of
	reimbursement funding in 2015 occurred as clinical trial activity performed by Takeda for the ALCANZA and ECHELON-1 studies increased significantly, resulting in net reimbursement payments by us to Takeda in 2015.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Revenues from AbbVie decreased during 2016 as compared to
	2015 primarily as a result of a decrease in the earned portion of milestone payments achieved in 2015. Revenues from AbbVie increased during 2015 as compared to 2014 primarily as a result of the earned portion of milestone payments achieved upon
	AbbVie&#146;s commencement of clinical trials for multiple product targets, the completion of a contract amendment in 2015 that expanded the scope of our ADC collaboration with AbbVie, and increased reimbursements for support activities provided by
	us to AbbVie in 2015.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Changes in revenues
	recognized from our Genentech and other collaboration agreements, which include our ADC collaborations and our co-development collaborations, reflect the timing of development milestones and licensing fees.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our collaboration and license agreement revenues are impacted
	by the term and duration of our collaboration agreements and by progress-dependent milestones, annual maintenance fees and reimbursement of materials and support services. Collaboration and license agreement revenues may vary substantially from year
	to year and quarter to quarter depending on the progress made by our collaborators with their product candidates, the level of support we provide to our collaborators, specifically to Takeda under our ADCETRIS collaboration, the timing of milestones
	achieved and our ability to enter into additional collaboration and co-development agreements. We expect our collaboration and license agreement revenues in 2017 to be consistent with 2016. We have a significant balance of deferred revenue,
	representing prior payments from our collaborators that have not yet been recognized as revenue. This deferred revenue will be recognized as revenue in future periods using a time-based approach as we fulfill our performance obligations.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	87
</FONT>
</P>
<A NAME="eolPage90"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Collaboration Agreements
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Takeda
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our ADCETRIS collaboration with Takeda provides for the global co-development of ADCETRIS by the companies and
	the commercialization of ADCETRIS by Takeda in its territory. We received an upfront payment and have received and are entitled to receive progress-dependent milestone payments based on Takeda&#146;s achievement of certain events related to ADCETRIS
	development. Additionally, the companies equally co-fund the cost of selected development activities conducted under the collaboration. We recognize as collaboration revenue the upfront payment, progress-dependent development and regulatory
	milestone payments, and net development cost reimbursement payments from Takeda over the ten-year development period of the collaboration, which began in December 2009. When the performance of development activities under the collaboration results
	in us making a reimbursement payment to Takeda, the effect is to reduce the amount of collaboration revenue that we record. We also receive reimbursement for the cost of drug product supplied to Takeda for its use and, in some cases, pay Takeda for
	drug product they supply to us. The earned portion of net collaboration payments is reflected as a component of collaboration and license agreement revenues.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	As of December&nbsp;31, 2016, total future potential milestone payments to us under the ADCETRIS collaboration could total approximately
	$165 million. Of the remaining amount, up to approximately $7 million relates to the achievement of development milestones, up to approximately $118 million relates to the achievement of regulatory milestones and up to approximately $40 million
	relates to the achievement of commercial milestones. As of December&nbsp;31, 2016, $70 million in milestones had been achieved as a result of regulatory and commercial progress by Takeda.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Astellas
</I>
	&nbsp;
<I>
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We entered into an agreement with Agensys, subsequently acquired by Astellas, to jointly research, develop and commercialize ADCs for the
	treatment of several types of cancer. The collaboration encompasses combinations of our ADC technology with fully-human antibodies developed by Astellas to proprietary cancer targets.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Under the collaboration agreement, we and Astellas are co-funding all development and commercialization costs
	for ASG-22ME and ASG-15ME, and will share in any profits that may come from these product candidates if successfully commercialized on a 50/50 basis. Costs associated with co-development activities are included in research and development expense.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Astellas is developing another ADC product
	candidate on its own, subject to paying us annual maintenance fees, milestones, royalties and support fees for research and development services and material provided under the collaboration agreement. Amounts received for this product candidate
	being developed solely by Astellas are recognized as revenue.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Unum Therapeutics
</I>
	&nbsp;
<I>
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We have a strategic collaboration and license agreement with Unum to develop and commercialize novel ACTR therapies incorporating our
	antibodies for cancer. We and Unum will initially develop two ACTR product candidates that combine Unum&#146;s ACTR technology with our antibodies, and we have an option to expand the collaboration to include a third ACTR product candidate upon
	payment of an additional fee. Unum is obligated to conduct preclinical research and clinical development activities through phase 1 clinical trials and we are obligated to provide funding for these activities. The agreement calls for us to work
	together to co-develop and jointly fund programs after phase 1 clinical trials unless either company opts out. Costs associated with co-development activities are included in research and development expense.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We and Unum would co-commercialize any successfully developed
	product candidates and share any profits 50/50 on any co- developed programs in the United States. We retain exclusive commercial rights outside
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	88
</FONT>
</P>
<A NAME="eolPage91"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	of the United States, paying Unum a royalty that is a high single digit to mid-teens percentage of ex-U.S. sales, if any. The potential future licensing and progress-dependent milestone payments
	to Unum under the collaboration may total up to $615 million across all three ACTR programs, payment of which is triggered by the achievement of development, regulatory and commercial milestones.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	ADC Collaboration Agreements
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We have other active collaborations with a number of
	companies to allow them to use our proprietary ADC technology. Under our ADC collaborations, which we have entered into in the ordinary course of business, we typically receive or are entitled to receive upfront cash payments, progress-dependent
	milestones and royalties on net sales of products incorporating our ADC technology, as well as annual maintenance fees and support fees for research and development services and materials provided under the agreements. These amounts are recognized
	as revenue as they are realized, or over the performance obligation period of the agreements during which we provide limited support to the collaborator. Our ADC collaborators are responsible for development, manufacturing and commercialization of
	any ADC product candidates that result from the collaborations and are solely responsible for the achievement of the potential milestones under these collaborations.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	As of December&nbsp;31, 2016, our ADC collaborations and
	co-development agreements had generated more than $350 million, primarily in the form of upfront payments. Total milestone payments to us under our current ADC collaboration and co-development agreements could total up to approximately $3.3 billion
	if all potential product candidates achieved all of their milestone events. Of this amount, approximately $0.5 billion relates to the achievement of development milestones, approximately $1.3 billion relates to the achievement of regulatory
	milestones and approximately $1.5 billion relates to the achievement of commercial milestones. Since we do not control the research, development or commercialization of any of the products that would generate these milestones, we are not able to
	reasonably estimate when, if at all, any milestone payments or royalties may be payable by our collaborators. Successfully developing a product candidate, obtaining regulatory approval and ultimately commercializing it is a significantly lengthy and
	highly uncertain process which entails a significant risk of failure. In addition, business combinations, changes in a collaborator&#146;s business strategy and financial difficulties or other factors could result and have resulted in a collaborator
	abandoning or delaying development of its product candidates. As such, the milestone payments associated with our ADC collaborations and co-development agreements involve a substantial degree of risk and may never be received. Accordingly, we do not
	expect, and investors should not assume, that we will receive all of the potential milestone payments described above and it is possible that we may never receive any significant milestone payments under these agreements.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Royalty Revenues and Cost of Royalty Revenues
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Royalty revenues primarily reflect royalties
	paid to us by Takeda under the ADCETRIS collaboration. These royalties include commercial sales-based milestones and sales royalties, which are based on a percentage of Takeda&#146;s net sales at rates that range from the mid-teens to the
	mid-twenties based on sales volume. Takeda bears a portion of third-party royalty costs owed on sales of ADCETRIS in its territory. This amount is included in our royalty revenues. Cost of royalty revenues reflect amounts owed to our third-party
	licensors related to the sale of ADCETRIS in Takeda&#146;s territory.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our royalty revenues and cost of royalty revenues were as follows ($ in thousands):
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_11"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="50%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="6%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="6%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="6%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="6%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="6%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Annual percentage
<BR>
	change
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2016
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2015
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2014
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2016/2015
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2015/2014
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Royalty revenues
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	67,455
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	40,980
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	40,004
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	65
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Cost of royalty revenues
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	14,149
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	12,964
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	11,545
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	9
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	12
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Royalty revenues increased in
	2016 and 2015 as compared to the prior year amounts primarily as a result of an increase in sales volumes of ADCETRIS by Takeda in its territory. Royalty revenues in 2016 and 2014
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	89
</FONT>
</P>
<A NAME="eolPage92"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	included a $20 million and a $5 million milestone payment, respectively, related to Takeda achieving one-time sales-based milestone targets. Royalty revenues also increased in both periods as a
	result of regulatory approvals of ADCETRIS in additional countries, as well as increases in the royalty rate based on sales volumes. Takeda&#146;s international sales of ADCETRIS are converted to U.S. dollars for purposes of determining the amount
	of royalties payable to us and therefore, our royalty revenues are subject to foreign exchange rate volatility. The U.S. dollar strengthened during 2016 and 2015, which limited to some extent the rate of royalty growth year over year.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Cost of royalty revenues fluctuates based on the amount of
	net sales of ADCETRIS by Takeda in its territories.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We expect that royalty revenues will decrease in 2017 as compared to 2016 primarily as a result of the 2016 royalty revenues including a
	$20 million one-time sales milestone triggered by Takeda&#146;s exceeding $200 million in annual sales for the first time. We expect cost of royalty revenues to increase in 2017 primarily due to anticipated increases in sales volumes in
	Takeda&#146;s territory.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Cost of Sales
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	ADCETRIS cost of sales includes
	manufacturing costs of product sold, third-party royalty costs, amortization of technology license costs, and distribution and other costs.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="50%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="6%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="6%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="6%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="6%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="6%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ROWSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2016
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM" ROWSPAN="2">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ROWSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2015
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM" ROWSPAN="2">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ROWSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2014
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM" ROWSPAN="2">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Annual percentage
<BR>
	change
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2016/2015
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2015/2014
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Cost of sales
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	28,168
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	24,476
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	17,513
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	15
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	40
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Cost of sales increased
	during 2016 as compared to 2015 primarily due to increased sales volumes. Cost of sales increased in 2015 as compared to 2014 primarily due to increased sales volumes and, to a lesser extent, due to a higher average cost of product sold as remaining
	pre-commercial ADCETRIS inventory was fully depleted in the fourth quarter of 2015.We began capitalizing ADCETRIS manufacturing costs as inventory following the accelerated approval of ADCETRIS by the FDA in 2011. The cost of product manufactured
	prior to FDA approval was expensed as research and development expense as incurred and was combined with other research and development expenses. Certain components manufactured prior to FDA approval, and therefore expensed, continued to provide
	some cost benefit through the end of 2015. We expect cost of sales to increase in 2017, primarily due to anticipated increases in sales volumes.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Research and development
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our research and development expenses are summarized as follows:
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_12"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="52%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM" NOWRAP>
<P STYLE="BORDER-BOTTOM:1PX SOLID #000000;WIDTH:148PT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Research and development ($ in thousands)
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Annual percentage
<BR>
	change
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2016
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2015
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2014
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2016/2015
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2015/2014
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Research (1)
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	62,071
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	77,215
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	41,190
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(20
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	87
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Development and contract manufacturing
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	143,920
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	93,734
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	83,326
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	54
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	12
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Clinical (1)
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	173,317
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	123,580
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	106,227
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	40
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	16
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Total research and development expenses
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	379,308
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	294,529
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	230,743
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	29
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	28
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="LINE-HEIGHT:8PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:2PX;BORDER-BOTTOM:0.5PT SOLID #000000;WIDTH:26%">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(1)
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The cost of pharmacology and toxicology studies from the 2015 and 2014 periods have been reclassified from Clinical to Research to conform to our fiscal 2016
	classification in the above table.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Research expenses include personnel, occupancy and laboratory expenses, technology access fees associated with the discovery and
	identification of new monoclonal antibodies and related technologies, and the
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	90
</FONT>
</P>
<A NAME="eolPage93"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	development of novel classes of stable linkers and cell-killing agents for our ADC technology. Research expenses also include research activities associated with our product candidates, such as
	preclinical translational biology and
<I>
	in vitro
</I>
	and
<I>
	in vivo
</I>
	studies, and investigational new drug, or IND-enabling pharmacology and toxicology studies. The decrease in research expenses in 2016 as compared to 2015 is primarily the
	result of a $25.0 million technology access fee related to the initiation of our collaboration agreement with Unum in June of 2015, offset partially by increased staffing, facilities and other costs to support our growing pipeline of product
	candidates, as well as increases in technology access fees paid and cost reimbursements to Unum under our collaboration agreement. The increase in research expenses in 2015 as compared to 2014 reflects increases in staffing costs and discovery
	activities in support of our growing pipeline of product candidates, and a $25.0 million technology access fee related to our collaboration agreement with Unum.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Development and contract manufacturing expenses include personnel and occupancy expenses, external contract manufacturing costs for the
	scale up and pre-approval manufacturing of drug product used in research and our clinical trials, and costs for drug product supplied to our collaborators. Development and contract manufacturing expenses also include quality control and assurance
	activities, and storage and shipment of our product candidates. The increase in development and contract manufacturing expenses in 2016 as compared to 2015 resulted primarily from an increase in drug product supplied to Takeda under the ADCETRIS
	collaboration, and to a lesser extent, increases in staffing and other costs to support our growing pipeline of product candidates and cost reimbursements to Astellas under our collaboration. The increase in development and contract manufacturing
	expenses in 2015 as compared to 2014 was primarily the result of increased staffing, facilities and other costs to support our growing pipeline of product candidates.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Clinical expenses include personnel, travel, occupancy costs,
	and external clinical trial costs including costs for clinical sites, clinical research organizations, central laboratories, data management, contractors and regulatory activities associated with conducting human clinical trials. The increases in
	clinical expenses in both 2016 and 2015 as compared to prior years reflect increased clinical trial activity for our product candidates, primarily SGN-CD33A, and to a lesser extent, increases in compensation, facilities and other employee related
	costs as a result of increased staffing levels to support the clinical development of our product candidates.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We utilize our employee and infrastructure resources across multiple development projects as well as our discovery and research programs
	directed towards identifying monoclonal antibodies and new classes of stable linkers and cell-killing agents for our ADC program. We track human resource efforts expended on many of our programs for purposes of billing our collaborators for time
	incurred at agreed upon rates and for resource planning. We do not account for actual costs on a project-by-project basis as it relates to our infrastructure, facility, employee and other indirect costs. We do, however, separately track significant
	third-party costs including clinical trial costs, manufacturing costs and other contracted service costs on a project-by-project basis.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	91
</FONT>
</P>
<A NAME="eolPage94"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The following table shows expenses incurred for research, contract manufacturing of our
	product candidates and clinical and regulatory services provided by third parties as well as pre-commercial milestone payments for in-licensed technology for ADCETRIS and certain of our clinical-stage product candidates. The table also presents
	other third-party costs and overhead consisting of personnel, facilities and other indirect costs not directly charged to these development programs.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_13"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="38%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM" ROWSPAN="2" NOWRAP>
<P STYLE="BORDER-BOTTOM:1PX SOLID #000000;WIDTH:122PT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Product candidates ($ in thousands)
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Annual percentage
<BR>
	change
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ROWSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	(5
	years)
<BR>
	January&nbsp;1,&nbsp;2012&nbsp;to
<BR>
	December&nbsp;31,&nbsp;2016
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM" ROWSPAN="2">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2016
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2015
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2014
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2016/2015
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2015/2014
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	ADCETRIS (brentuximab vedotin)
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	73,623
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	50,965
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	53,473
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	44
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(5
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	290,620
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	SGN-CD33A (vadastuximab talirine)
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	49,387
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	15,769
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	7,371
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	213
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	114
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	87,811
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	SGN-CD19A (denintuzumab mafodotin)
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	7,696
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	5,356
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	7,276
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	44
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(26
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	30,154
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	ASG-22ME (enfortumab vedotin)
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	5,607
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2,618
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2,100
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	114
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	25
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	18,751
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Other clinical stage programs
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	19,437
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	17,875
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	13,490
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	9
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	33
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	65,858
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Total third-party costs
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	155,750
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	92,583
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	83,710
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	68
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	11
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	493,194
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Other costs and overhead
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	223,558
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	201,946
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	147,033
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	11
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	37
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	800,310
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Total research and development
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	379,308
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	294,529
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	230,743
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	29
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	28
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,293,504
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Third-party costs for
	ADCETRIS increased during 2016 as compared to 2015 primarily as a result of an increase in drug product supplied to Takeda, and to a lesser extent, third-party clinical trial costs as we evaluated the use of ADCETRIS in other lines of therapy.
	Third-party costs for ADCETRIS decreased during 2015 as compared to 2014 primarily due to a decrease in drug product supplied to Takeda. The cost of drug product supplied to Takeda is charged to research and development expense. We are reimbursed
	for the drug product, which is included as a component of collaboration revenue.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Third-party costs for SGN-CD33A increased during 2016 and 2015 as compared to prior years due to increases in clinical trial costs and drug supply activities for both ongoing and potential additional
	clinical trials. In 2016, we initiated a phase 3 clinical trial of SGN-CD33A called the CASCADE trial, and continued planning for potential additional phase 1 and 2 trials.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Third-party costs for SGN-19A increased during 2016 as
	compared to 2015 due to an increase in clinical trial costs as we continued to make progress in our clinical trials in DLBCL. Third party costs decreased in 2015 as compared to 2014 due to the timing of drug supply activities.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Third-party costs for ASG-22ME increased during 2016 as
	compared to 2015 due to an increase in drug supply activities as we prepare to initiate additional clinical trials in 2017. The modest change in third party costs between 2014 and 2015 reflects increasing activity on this project.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The increase in third-party costs of our other clinical stage
	programs during 2016 and 2015 reflects the continued investment in our other pipeline products, which are primarily in phase 1 clinical trials. The development costs for our product candidates typically accelerate in preparation for an IND
	submission to the FDA and then decrease until the subsequent clinical trials commence. During 2016, we advanced SGN-CD19B, SGN-CD123A, and SGN-CD352A into phase 1 clinical trials. During 2015, we advanced SEA-CD40 into phase 1 clinical trials.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Other costs and overhead include third-party
	costs of our other preclinical programs, including our strategic collaboration with Unum, and costs associated with personnel and facilities. The increases in 2016 and 2015
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	92
</FONT>
</P>
<A NAME="eolPage95"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	primarily reflect increases in staffing levels and the expansion of our facilities to accommodate our growth. Additionally, these costs increased during 2015 due to a $25.0 million technology
	access fee related to our collaboration agreement with Unum.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our expenditures on our ADCETRIS clinical development program and on our current and future preclinical and clinical development programs are subject to numerous uncertainties in timing and cost to
	completion. In order to advance our product candidates toward commercialization, the product candidates are tested in numerous preclinical safety, toxicology and efficacy studies. We then conduct clinical trials for those product candidates that
	take several years or more to complete. The length of time varies substantially based upon the type, complexity, novelty and intended use of a product candidate. Likewise, in order to expand ADCETRIS&#146; labeled indications of use, we are required
	to conduct additional extensive clinical studies. The cost of clinical trials may vary significantly over the life of a project as a result of a variety of factors, including:
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="3%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	the number of patients required in our clinical trials;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="3%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	the length of time required to enroll trial participants;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="3%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	the number and location of sites included in the trials;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="3%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	the costs of producing supplies of the product candidates needed for clinical trials and regulatory submissions;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="3%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	the safety and efficacy profile of the product candidate;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="3%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	the use of clinical research organizations to assist with the management of the trials; and
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="3%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	the costs and timing of, and the ability to secure, regulatory approvals.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Reports of adverse events or safety concerns involving ADCETRIS and our product candidates can interrupt, delay
	or halt clinical trials of ADCETRIS, including the ADCETRIS post-approval confirmatory study that is required as a condition to our relapsed sALCL approval in the United States, or clinical trials of our other product candidates. In this regard, in
	December 2016, several trials of SGN-CD33A in AML patients were placed on full or partial clinical holds. No new studies of SGN-CD33A will be initiated unless and until the clinical holds are lifted, and these delays could increase the cost of
	conducting clinical trials. Our other ongoing trials of SGN-CD33A, the phase 3 CASCADE trial in older AML patients and phase 1/2 trial in myelodysplastic syndrome, are proceeding with enrollment.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our strategy has included entering into collaborations with
	third parties. In these situations, the preclinical development or clinical trial process for a product candidate and the estimated completion date are largely under the control of that third party and not under our control. We cannot forecast with
	any degree of certainty which of our product candidates will be subject to future collaborations or how such arrangements would affect our development plans or capital requirements.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We anticipate that our total research and development expenses in 2017 will increase compared to 2016 due to
	increased costs for the development of our product candidates, primarily SGN-CD33A, ASG-22ME,
<FONT STYLE="WHITE-SPACE:NOWRAP">
	SGN-CD19A,
</FONT>
	and SGN-LIV1A. If the transactions contemplated by the Immunomedics License are consummated as
	anticipated, we expect total research and development expenses to potentially increase significantly as a result of the upfront and other milestone payments and development costs that we would undertake as part of the Immunomedics License. Certain
	ADCETRIS development activities, including some clinical studies, will be conducted by Takeda, the costs of which are not reflected in our research and development expenses. Because of these and other factors, expenses will fluctuate based upon many
	factors, including the degree of collaborative activities, timing of manufacturing campaigns, numbers of patients enrolled in our clinical trials and the outcome of each clinical trial event.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The risks and uncertainties associated with our research and development projects are discussed more fully in
	Item&nbsp;1A&#151;Risk Factors. As a result of the uncertainties discussed above, we are unable to determine, with any
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	93
</FONT>
</P>
<A NAME="eolPage96"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	degree of certainty, the duration and completion costs of our research and development projects, anticipated completion dates or when and to what extent we will receive cash inflows from the
	commercialization and sale of ADCETRIS in any additional approved indications or of any of our product candidates.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Selling, general and administrative
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="52%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM" NOWRAP>
<P STYLE="BORDER-BOTTOM:1PX SOLID #000000;WIDTH:175PT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Selling, general and administrative ($ in thousands)
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Annual percentage
<BR>
	change
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2016
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2015
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2014
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2016/2015
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2015/2014
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Selling, general and administrative
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	139,247
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	125,783
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	104,320
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	11
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	21
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Selling, general and
	administrative expenses in 2016 primarily reflect increases in costs for staffing to support our continued growth. Selling, general and administrative expenses in 2015 primarily reflect increases in commercial activities in support of ADCETRIS, and
	to a lesser extent, increases in costs for staffing and legal matters.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We anticipate that selling, general and administrative expenses will increase in 2017 compared to 2016 as we continue our commercial activities in support of the commercialization of ADCETRIS, as well as
	our support of general operations. If the transactions contemplated by the Immunomedics License are consummated as anticipated, we expect selling, general and administrative expenses to increase further.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Investment and other income, net
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="78%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM" NOWRAP>
<P STYLE="BORDER-BOTTOM:1PX SOLID #000000;WIDTH:170PT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Investment and other income, net ($ in thousands)
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2016
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2015
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2014
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Total
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2,614
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	464
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,222
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Investment and other income,
	net reflects amounts earned on our investments in U.S. Treasury securities. Investment income increased during 2016 as compared to 2015 due to higher average investment balances following our public offering in September 2015, which resulted in net
	proceeds to us of approximately $526.6 million. Investment income in 2014 was higher than in 2015. This reflects a gain on the sale of a security sold in 2014.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Liquidity and capital resources
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_14"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="66%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="10" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	December&nbsp;31,
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM" NOWRAP>
<P STYLE="BORDER-BOTTOM:1PX SOLID #000000;WIDTH:197PT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Selected balance sheet and cash flow data ($ in thousands)
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2016
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2015
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2014
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Cash, cash equivalents and investments
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	618,974
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	712,711
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	313,413
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Working capital
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	586,132
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	636,793
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	282,093
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Stockholders&#146; equity
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	634,087
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	685,911
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	210,834
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="12">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="10" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Years ended December 31,
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2016
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2015
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2014
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Cash provided by (used in):
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Operating activities
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(96,971
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(133,203
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(59,999
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Investing activities
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	68,193
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(375,850
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	36,622
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Financing activities
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	35,196
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	554,381
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	16,188
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The changes in net cash used
	in operating activities are primarily related to our net loss, working capital fluctuations and changes in our non-cash expenses, all of which are highly variable. The changes in cash provided by (used in) investing activities reflect differences
	between the proceeds received from sale and
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	94
</FONT>
</P>
<A NAME="eolPage97"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	maturity of our investments and amounts reinvested. Cash provided by financing activities includes proceeds from stock option exercises and our employee stock purchase plan for all years
	presented, and for 2015 includes $526.6 million in net proceeds from our underwritten public offering in September 2015.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We have primarily financed the majority of our operations through the issuance of equity securities, by amounts received pursuant to
	product collaborations, our ADC collaborations and through collections from commercial sales of ADCETRIS. To a lesser degree, we have also financed our operations through royalty revenues and interest earned on cash, cash equivalents and investment
	securities. These financing and revenue sources have historically allowed us to maintain adequate levels of cash and investments.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our cash, cash equivalents, and investments are held in a variety of non-interest bearing bank accounts and interest-bearing instruments
	subject to investment guidelines allowing for holdings in U.S. government and agency securities, corporate securities, taxable municipal bonds, commercial paper and money market accounts. Our investment portfolio is structured to provide for
	investment maturities and access to cash to fund our anticipated working capital needs. However, if our liquidity needs should be accelerated for any reason in the near term, or investments do not pay at maturity, we may be required to sell
	investment securities in our portfolio prior to their scheduled maturities, which may result in a loss. As of December&nbsp;31, 2016, we had $589.0 million held in cash or investments scheduled to mature within the next twelve months.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	At our currently planned spending rates we believe that our
	financial resources, together with product and royalty revenues from sales of ADCETRIS and the fees, milestone payments and reimbursements we expect to receive under our existing collaboration and license agreements, will be sufficient to fund our
	operations for at least the next twelve months, including with respect to the upfront payment we would be required to make to Immunomedics if the transactions contemplated by the Immunomedics License are consummated on the currently-agreed upon
	terms. Changes in our spending rate may occur that would consume available capital resources sooner, such as increased development, manufacturing and clinical trial expenses in connection with our expanding pipeline programs, including several phase
	3 trials, or our undertaking of additional programs, business activities, or entry into strategic transactions, including potential additional acquisitions of products, technologies or businesses such as our anticipated in-licensing of IMMU-132. In
	addition, we do not currently have sufficient capital to fund all of the potential milestone payments to Immunomedics and to Unum under our agreements with those companies. Accordingly, we may be required to, or may otherwise determine to, raise
	additional capital to fund those obligations or otherwise in connection with our entry into the Immunomedics License and/or our collaboration agreement with Unum. Further, in the event of a termination of the ADCETRIS collaboration agreement with
	Takeda, we would not receive development cost sharing payments or milestone payments or royalties for the development or sale of ADCETRIS in Takeda&#146;s territory, and we would be required to fund all ADCETRIS development and commercial
	activities. Any of these factors could lead to a need for us to raise additional capital.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We expect to make additional capital outlays and to increase operating expenditures over the next several years as we hire additional employees, support our preclinical development, manufacturing and
	clinical trial activities for ADCETRIS and our other pipeline programs, and expand internationally, as well as commercialize ADCETRIS and position ADCETRIS for potential additional regulatory approvals. In addition, we anticipate committing
	substantial capital resources to the transactions contemplated by the Immunomedics License and the anticipated transfer, integration and development activities related to IMMU-132, including with respect to our potential upfront and milestone
	payment obligations to Immunomedics. Our commitment of resources to the continuing development, regulatory and commercialization activities for ADCETRIS, the transactions contemplated by the Immunomedics License and the anticipated transfer,
	integration and development activities related to IMMU-132, and the research, continued development and manufacturing of our product candidates will likely require us to raise substantial amounts of additional capital. In addition, we actively
	evaluate various strategic transactions on an ongoing basis, including licensing or otherwise acquiring complementary products, technologies or businesses, such as our anticipated in-licensing of IMMU-132, and we may require significant additional
	capital in order to complete or otherwise provide funding for any additional acquisitions. We may seek
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	95
</FONT>
</P>
<A NAME="eolPage98"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	additional funding through some or all of the following methods: corporate collaborations, licensing arrangements and public or private debt or equity financings. We do not know whether
	additional capital will be available when needed, or that, if available, we will obtain financing on terms favorable to us or our stockholders. If we are unable to raise additional funds when we need them, we may be required to delay, reduce the
	scope of, or eliminate one or more of our development programs, which may adversely affect our business and operations.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_15"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Commitments
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The following table reflects our future minimum contractual commitments as of December&nbsp;31, 2016 (in thousands):
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="42%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Total
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2017
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2018
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2019
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2020
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2021
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Thereafter
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Operating leases
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	26,189
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	6,995
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	4,706
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2,500
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2,575
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2,653
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	6,760
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Tenant improvements
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	11,477
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	11,477
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Manufacturing, license&nbsp;&amp; collaboration agreements
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	266,939
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	71,318
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	29,644
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	26,554
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	25,165
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	25,988
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	88,270
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Total
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	304,605
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	89,790
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	34,350
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	29,054
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	27,740
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	28,641
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	95,030
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We have entered into leases
	for our office and laboratory facilities expiring in 2018 through 2024 that contain rate escalations and options for us to extend the leases. Operating lease obligations in the table above do not assume the exercise by us of any extension options.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Manufacturing, license and collaboration
	agreement commitments include non-cancellable obligations under our manufacturing, license and collaboration agreements. A substantial portion of the minimum payments under manufacturing, license and collaboration agreements represents contractual
	obligations related to manufacturing our product candidates for use in our clinical trials and for commercial operations in the case of ADCETRIS.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Some of our manufacturing, license and collaboration agreements provide for periodic maintenance fees over specified time periods, as well
	as payments by us upon the achievement of development and regulatory milestones. Some of our licensing agreements obligate us to pay royalties from the low single digit to mid-teens based on net sales of products utilizing licensed technology. Such
	royalties are dependent on future product sales and are not provided for in the table above as they are dependent on events that have not yet occurred. Future milestone payments for research and pre-clinical stage development programs have not been
	included in the above table as the event triggering such payment or obligation has not yet occurred. The above table also excludes up to $1.9 billion in upfront and potential future milestone payments currently provided for under the Immunomedics
	License, up to $615.0 million in potential future milestone payments to Unum under our collaboration agreement with Unum and up to approximately $96.8 million in potential future milestone payments to other third parties under license agreements for
	our clinical-stage development programs. These milestone payments generally become due and payable only upon the achievement of certain developmental, clinical, regulatory and/or commercial milestones. These contingent payments have not been
	included in the above table as the event triggering such payment or obligation has not yet occurred. No milestones were paid to Unum during 2016 or 2015; however, we made an upfront payment of $25.0 million to Unum and a $5.0 million equity
	investment in Unum in connection with our entering into the Unum collaboration in June 2015. Milestone payments under license agreements for clinical-stage development programs through December&nbsp;31, 2016 have totaled $14.6 million.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Recent accounting pronouncements
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In May 2014, the Financial Accounting Standards Board, or
	FASB, issued an Accounting Standards Update entitled &#147;ASU 2014-09, Revenue from Contracts with Customers.&#148; The standard requires entities to recognize
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	96
</FONT>
</P>
<A NAME="eolPage99"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	revenue through an evaluation that includes identification of the contract, identification of the performance obligations, determination of the transaction price, allocation of the transaction
	price to the performance obligations, and recognition of revenue as the entity satisfies the performance obligations. In August 2015, FASB issued an Accounting Standards Update entitled &#147;ASU 2015-14, Revenue from Contracts with Customers:
	Deferral of the Effective Date&#148;, which defers the effective date of ASU 2014-09 to our fiscal year beginning January&nbsp;1, 2018. The FASB has continued to issue accounting standards updates to clarify and provide implementation guidance
	related to Revenue from Contracts with Customers, including &#147;ASU 2016-08, Revenue from Contract with Customers: Principal versus Agent Considerations&#148;, &#147;ASU 2016-10, Revenue from Contracts with Customers: Identifying Performance
	Obligations and Licensing&#148;, &#147;ASU 2016-12, Revenue from Contracts with Customers: Narrow-Scope Improvements and Practical Expedients&#148; and &#147;ASU 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts
	with Customers.&#148; Our preliminary assessment of this new standard is that it will generally not change the way in which we recognize product revenue from sales of ADCETRIS. However, we expect that sales-based royalties will be recorded in the
	period of the related sale based on estimates, rather than as reported by the customer. In addition, the achievement of development milestones under our collaborations will be recorded in the period their achievement becomes probable, which may
	result in their recognition earlier than under current accounting principles. The new standard also requires more extensive disclosures related to revenue recognition, particularly in quarterly financial statements. We will adopt the standard on
	January&nbsp;1, 2018 and intend to use the modified retrospective method of adoption. We are continuing to evaluate the impact of the standard on all of our revenues, including those mentioned above, and our assessments may change in the future
	based on our ongoing evaluation.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In January 2016,
	FASB issued an Accounting Standards Update entitled &#147;ASU 2016-01, Financial Instruments: Overall.&#148; The standard addresses certain aspects of recognition, measurement, presentation and disclosure of financial instruments. The standard will
	become effective for us beginning January&nbsp;1, 2018. We are currently evaluating the guidance to determine the potential impact on our financial condition, results of operations and cash flows, and financial statement disclosures.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In February 2016, FASB issued an Accounting Standards Update
	entitled &#147;ASU 2016-02, Leases.&#148; The standard requires entities to recognize in the consolidated balance sheet a liability to make lease payments and a right-of-use asset representing its right to use the underlying asset for the lease
	term. The standard will become effective for us beginning January&nbsp;1, 2019, with early adoption permitted. We are currently evaluating the guidance to determine the potential impact on our financial condition, results of operations and cash
	flows, and financial statement disclosures.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In
	March 2016, FASB issued an Accounting Standard Update entitled &#147;ASU 2016-09, Compensation &#150; Stock Compensation.&#148; The standard is intended to simplify certain elements of accounting for share-based payment transactions, including the
	income tax impact, classification of awards as either equity or liabilities, and classification on the statement of cash flows. In addition, the standard allows an entity-wide accounting policy election to either estimate the number of awards that
	are expected to vest, as currently required, or account for forfeitures when they occur. We have elected to continue estimating the number of awards that are expected to vest. We will adopt the standard as of January&nbsp;1, 2017. Since we have
	incurred net losses since our inception and maintain a full valuation allowance on our net deferred tax assets, the adoption is not expected to have a material impact on our financial condition, results of operations and cash flows. Upon
	implementing the new standard, the amount of deferred tax assets disclosed, prior to any related valuation allowance, will increase due to the change in the manner of accounting for the income tax benefit of the excess tax deduction over financial
	statement expense for share-based compensation. Currently, we maintain a valuation allowance that fully offsets our deferred tax assets.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In October 2016, FASB issued an Accounting Standard Update entitled &#147;ASU 2016-16, Accounting for Income Taxes: Intra-Entity Asset
	Transfers of Assets Other than Inventory&#148;. The standard is intended to simplify the accounting for intercompany sales of assets other than inventory. Under current GAAP, the tax effects of intra-entity asset transfers are deferred until the
	transferred asset is sold to a third party or otherwise recovered
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	97
</FONT>
</P>
<A NAME="eolPage100"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	through use. Under the new guidance, a reporting entity would recognized the tax expense from the sale of the asset in the seller&#146;s jurisdiction when the transfer occurs, even though the
	pre-tax effects of that transaction are eliminated in consolidation. Any deferred tax asset that arises in the buyer&#146;s jurisdiction would also be recognized at the time of the transfer. The standard will become effective for us beginning on
	January&nbsp;1, 2018. We are currently evaluating the new standard; however, since we have incurred net losses since our inception and maintain a full valuation allowance on our net deferred tax assets, the adoption is not expected to have a
	material impact on our financial condition, results of operations and cash flows, or financial statement disclosures.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In June 2016, FASB issued an Accounting Standard Update entitled &#147;ASU 2016-13, Financial Instruments: Credit Losses&#148;. The
	objective of the standard is to provide information about expected credit losses on financial instruments at each reporting date, and to change how other than temporary impairments on investments securities are recorded. The standard will become
	effective for us beginning on January&nbsp;1, 2020 with early adoption permitted. We are currently evaluating the guidance to determine the potential impact on our financial condition, results of operations and cash flows, and financial statement
	disclosures.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In January 2017, FASB issued an
	Accounting Standard Update entitled, &#147;ASU 2017-01, Business Combinations: Clarifying the Definition of a Business.&#148; The objective of the standard is to clarify the definition of a business with the objective of adding guidance to assist
	entities with evaluating whether transactions should be accounted for as acquisitions of assets or businesses. We have elected to early adopt this standard on a prospective basis as of January&nbsp;1, 2017. The adoption of this standard did not have
	a material impact on our financial condition, results of operations and cash flows, or financial statement disclosures.
</FONT>
</P>
</EFX_RESULTS_OF_OPERATIONS>
</EFX_MANAGEMENTS_DISCUSSION>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<EFX_MARKET_RISK>
<A NAME="FIS_MARKET_RISK"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D481013D10K_HTM_TOC481013_10">
</A>
	Item&nbsp;7A. Quantitative and Qualitative Disclosures about Market Risk
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Interest Rate Risk
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Our exposure to market risk for changes in interest rates
	relates primarily to our investment portfolio. We do not have any derivative financial instruments in our investment portfolio. We currently have holdings in U.S. Treasury securities. A summary of our investment securities follows (in thousands):
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_16"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="78%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD ROWSPAN="2" VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	December&nbsp;31,
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2016
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2015
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Short-term investments
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	480,313
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	547,396
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Long-term investments
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	29,988
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	63,060
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Total
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	510,301
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	610,456
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	We have estimated the effect
	on our investment portfolio of a hypothetical increase in interest rates by one percent to be a reduction of $2.4 million in the fair value of our investments as of December&nbsp;31, 2016. In addition, a hypothetical decrease of 10% in the effective
	yield of our investments would reduce our expected investment income by less than $0.4 million over the next twelve months based on our investment balance at December&nbsp;31, 2016.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<I>
	Foreign Currency Risk
</I>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Most of our revenues and expenses are denominated in U.S.
	dollars and as a result, we have not experienced significant foreign currency transaction gains and losses to date. Our commercial sales in Canada are denominated in Canadian Dollars. We also had other transactions denominated in foreign currencies
	during the year ended December&nbsp;31, 2016, primarily related to contract manufacturing and ex-U.S. clinical trial activities, and we expect to continue to do so. Our primary exposure is to fluctuations in the Euro, British Pound, Canadian Dollar
	and Swiss Franc. We do not anticipate that foreign currency transaction gains or losses will be significant at our current level of operations. However, transaction gains or losses may become significant in the future as we continue to expand our
	operations internationally. We have not engaged in foreign currency hedging to date; however, we may do so in the future.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	98
</FONT>
</P>
<A NAME="eolPage101"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
</EFX_MARKET_RISK>
<EFX_FINANCIAL_STATEMENTS>
<A NAME="FIS_FINANCIAL_STATEMENTS"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D481013D10K_HTM_TOC481013_11">
</A>
	Item&nbsp;8. Financial Statements and Supplementary Data
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D481013D10K_HTM_TOC">
</A>
	Seattle Genetics, Inc.
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Index to Financial Statements
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="94%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Page
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D481013D10K_HTM_TX481013_23">
	Report of Independent Registered Public Accounting Firm
</A>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	100
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D481013D10K_HTM_TX481013_24">
	Consolidated Balance Sheets
</A>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	101
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D481013D10K_HTM_TX481013_25">
	Consolidated Statements of Comprehensive Loss
</A>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	102
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D481013D10K_HTM_TX481013_26">
	Consolidated Statements of Stockholders&#146; Equity
</A>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	103
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D481013D10K_HTM_TX481013_27">
	Consolidated Statements of Cash Flows
</A>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	104
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<A HREF="#D481013D10K_HTM_TX481013_28">
	Notes to Consolidated Financial Statements
</A>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	105
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	99
</FONT>
</P>
<A NAME="eolPage102"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<EFX_AUDITORS_OPINION>
<A NAME="FIS_AUDITORS_OPINION"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D481013D10K_HTM_TX481013_23">
</A>
	Report of Independent Registered Public Accounting Firm
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:2%; TEXT-INDENT:-2%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	To the Board of Directors
	and Stockholders of
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:2%; TEXT-INDENT:-2%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Seattle Genetics, Inc.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In our opinion, the accompanying consolidated balance sheets and the related consolidated statements of
	comprehensive loss, stockholders&#146; equity and cash flows present fairly, in all material respects, the financial position of Seattle Genetics, Inc. and its subsidiaries at December&nbsp;31, 2016 and 2015 and the results of their operations and
	their cash flows for each of the three years in the period ended December&nbsp;31, 2016 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material
	respects, effective internal control over financial reporting as of December&nbsp;31, 2016, based on criteria established in
<I>
	Internal Control&#151;Integrated Framework (2013)
</I>
	&nbsp;issued by the Committee of Sponsoring Organizations of the
	Treadway Commission, or COSO. The Company&#146;s management is responsible for these financial statements, for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over
	financial reporting, included in Management&#146;s Annual Report on Internal Control over Financial Reporting appearing under Item&nbsp;9A. Our responsibility is to express opinions on these financial statements and on the Company&#146;s internal
	control over financial reporting based on our integrated audits. We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audits
	to obtain reasonable assurance about whether the financial statements are free of material misstatement and whether effective internal control over financial reporting was maintained in all material respects. Our audits of the financial statements
	included examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement
	presentation. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and
	operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our
	opinions.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	A company&#146;s internal control over
	financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.
	A company&#146;s internal control over financial reporting includes those policies and procedures that (i)&nbsp;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the
	assets of the company; (ii)&nbsp;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures
	of the company are being made only in accordance with authorizations of management and directors of the company; and (iii)&nbsp;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of
	the company&#146;s assets that could have a material effect on the financial statements.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject
	to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	/s/ PricewaterhouseCoopers LLP
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:2%; TEXT-INDENT:-2%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Seattle, Washington
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:2%; TEXT-INDENT:-2%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	February&nbsp;21, 2017
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	100
</FONT>
</P>
<A NAME="eolPage103"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
</EFX_AUDITORS_OPINION>
<EFX_BALANCE_SHEET>
<A NAME="FIS_BALANCE_SHEET"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D481013D10K_HTM_TX481013_24">
</A>
	Seattle Genetics, Inc.
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Consolidated Balance Sheets
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	(In thousands, except par value)
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="76%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	December&nbsp;31,
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2016
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2015
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Assets
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Current assets
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:2.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Cash and cash equivalents
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	108,673
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	102,255
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:2.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Short-term investments
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	480,313
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	547,396
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:2.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Accounts receivable, net
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	61,928
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	52,930
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:2.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Inventories
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	68,124
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	56,963
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:2.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Prepaid expenses and other current assets
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	15,610
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	11,515
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Total current assets
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	734,648
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	771,059
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Property and equipment, net
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	62,870
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	49,598
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Long-term investments
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	29,988
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	63,060
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Other non-current assets
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10,890
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	11,378
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Total assets
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	838,396
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	895,095
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Liabilities and Stockholders&#146; Equity
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Current liabilities
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:2.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Accounts payable and accrued liabilities
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	120,669
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	88,031
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:2.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Current portion of deferred revenue
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	27,847
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	46,235
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Total current liabilities
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	148,516
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	134,266
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Long-term liabilities
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:2.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Deferred revenue, less current portion
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	53,006
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	71,249
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:2.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Deferred rent and other long-term liabilities
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2,787
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	3,669
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Total long-term liabilities
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	55,793
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	74,918
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Commitments and contingencies
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Stockholders&#146; equity
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:2.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Preferred stock, $0.001 par value, 5,000 shares authorized; none issued
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:2.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Common stock, $0.001 par value, 250,000 shares authorized; 142,193 shares issued and outstanding at December&nbsp;31, 2016 and
	139,674 shares issued and outstanding at December&nbsp;31, 2015
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	142
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	140
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:2.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Additional paid-in capital
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,701,048
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,613,383
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:2.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Accumulated other comprehensive loss
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(63
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(683
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:2.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Accumulated deficit
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(1,067,040
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(926,929
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Total stockholders&#146; equity
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	634,087
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	685,911
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Total liabilities and stockholders&#146; equity
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	838,396
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	895,095
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_BALANCE_SHEET>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The accompanying notes are an
	integral part of these consolidated financial statements.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	101
</FONT>
</P>
<A NAME="eolPage104"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_17"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D481013D10K_HTM_TX481013_25">
</A>
	Seattle Genetics, Inc.
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Consolidated Statements of Comprehensive Loss
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	(In thousands, except per share amounts)
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="68%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="10" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Years ended December&nbsp;31,
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2016
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2015
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2014
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Revenues
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:2.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Net product sales
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	265,766
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	226,052
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	178,198
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:2.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Collaboration and license agreement revenues
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	84,926
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	69,770
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	68,556
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:2.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Royalty revenues
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	67,455
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	40,980
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	40,004
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Total revenues
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	418,147
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	336,802
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	286,758
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Costs and expenses
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:2.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Cost of sales
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	28,168
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	24,476
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	17,513
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:2.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Cost of royalty revenues
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	14,149
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	12,964
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	11,545
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:2.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Research and development
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	379,308
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	294,529
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	230,743
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:2.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Selling, general and administrative
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	139,247
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	125,783
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	104,320
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Total costs and expenses
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	560,872
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	457,752
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	364,121
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Loss from operations
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(142,725
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(120,950
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(77,363
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Investment and other income, net
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2,614
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	464
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,222
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Net loss
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(140,111
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(120,486
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(76,141
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Net loss per share&#151;basic and diluted
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(1.00
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(0.93
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(0.62
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Shares used in computation of net loss per share&#151;basic and diluted
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	140,746
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	129,184
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	123,408
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Comprehensive income (loss):
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Net loss
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(140,111
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(120,486
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(76,141
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Other comprehensive income (loss):
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:2.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Foreign currency translation gain (loss)
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	4
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(12
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:2.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Unrealized gain (loss) on securities available for sale
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	616
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(642
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(18
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Total other comprehensive income (loss)
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	620
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(654
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(18
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Comprehensive loss
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(139,491
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(121,140
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(76,159
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The accompanying notes are an
	integral part of these consolidated financial statements.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	102
</FONT>
</P>
<A NAME="eolPage105"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<EFX_STOCKHOLDERS_EQUITY>
<A NAME="FIS_STOCKHOLDERS_EQUITY"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D481013D10K_HTM_TX481013_26">
</A>
	Seattle Genetics, Inc.
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Consolidated Statements of Stockholders&#146; Equity
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	(In thousands)
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="39%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Common stock
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ROWSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Additional
<BR>
	paid-in
<BR>
	capital
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM" ROWSPAN="2">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ROWSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Accumulated
<BR>
	other
<BR>
	comprehensive
<BR>
	income (loss)
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM" ROWSPAN="2">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ROWSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Accumulated
<BR>
	deficit
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM" ROWSPAN="2">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ROWSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Total
<BR>
	stockholders&#146;
<BR>
	equity
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM" ROWSPAN="2">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Shares
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Amount
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Balances at December&nbsp;31, 2013
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	122,615
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	123
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	960,375
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(11
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(730,302
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	230,185
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Net loss
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(76,141
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(76,141
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Other comprehensive loss
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(18
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(18
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Issuance of common stock for employee stock purchase plan
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	150
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	4,939
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	4,939
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Stock option exercises
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	886
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	11,249
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	11,250
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Restricted stock vested during the period, net
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	322
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Share-based compensation
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	40,619
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	40,619
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Balances at December&nbsp;31, 2014
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	123,973
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	124
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,017,182
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(29
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(806,443
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	210,834
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Net loss
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(120,486
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(120,486
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Other comprehensive loss
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(654
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(654
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Issuance of common stock for employee stock purchase plan
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	201
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	5,317
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	5,317
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Stock option exercises
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,502
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	22,444
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	22,446
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Restricted stock vested during the period, net
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	535
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(1
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Issuance of common stock
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	13,463
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	13
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	526,605
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	526,618
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Share-based compensation
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	41,836
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	41,836
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Balances at December&nbsp;31, 2015
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	139,674
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	140
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,613,383
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(683
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(926,929
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	685,911
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Net loss
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(140,111
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(140,111
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Other comprehensive income
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	620
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	620
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Issuance of common stock for employee stock purchase plan
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	203
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	5,686
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	5,686
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Stock option exercises
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,778
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	29,509
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	29,510
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Restricted stock vested during the period, net
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	538
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(1
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Share-based compensation
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	52,471
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	52,471
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Balances at December&nbsp;31, 2016
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	142,193
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	142
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,701,048
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(63
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(1,067,040
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	634,087
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_STOCKHOLDERS_EQUITY>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The accompanying notes are an
	integral part of these consolidated financial statements.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	103
</FONT>
</P>
<A NAME="eolPage106"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<EFX_CASH_FLOW>
<A NAME="FIS_CASH_FLOW"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D481013D10K_HTM_TX481013_27">
</A>
	Seattle Genetics, Inc.
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Consolidated Statements of Cash Flows
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	(In thousands)
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="69%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="10" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Years ended December&nbsp;31,
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2016
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2015
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2014
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Operating activities
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:2.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Net loss
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(140,111
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(120,486
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(76,141
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:2.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Adjustments to reconcile net loss to net cash used in operating activities
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Share-based compensation
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	52,471
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	41,836
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	40,619
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Depreciation and amortization
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	18,034
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	14,505
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	12,490
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Amortization of premiums, accretion of discounts and gain (loss) on investments
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	4,746
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2,846
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(150
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Deferred rent and other long-term liabilities
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(882
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(921
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(734
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Changes in operating assets and liabilities
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:4.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Accounts receivable, net
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(8,998
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(13,682
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(9,740
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:4.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Inventories
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(11,161
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(13,512
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(16,378
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:4.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Prepaid expenses and other assets
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(4,378
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(1,952
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(5,232
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:4.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Accounts payable and accrued liabilities
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	29,939
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	6,539
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	18,448
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:4.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Deferred revenue
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(36,631
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(48,376
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(23,181
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Net cash used in operating activities
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(96,971
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(133,203
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(59,999
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Investing activities
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:2.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Purchases of securities available for sale
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(603,772
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(754,663
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(451,274
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:2.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Proceeds from maturities of securities available for sale
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	699,800
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	367,200
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	504,100
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:2.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Proceeds from sales of securities available for sale
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	30,005
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	972
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:2.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Purchases of property and equipment
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(27,835
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(13,392
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(17,176
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:2.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Purchase of cost-method investment
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(5,000
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Net cash provided by (used in) investing activities
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	68,193
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(375,850
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	36,622
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Financing activities
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:2.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Net proceeds from issuance of common stock
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	526,618
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:2.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Proceeds from exercise of stock options and employee stock purchase plan
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	35,196
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	27,763
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	16,188
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Net cash provided by financing activities
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	35,196
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	554,381
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	16,188
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Net increase (decrease) in cash and cash equivalents
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	6,418
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	45,328
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(7,189
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Cash and cash equivalents at beginning of year
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	102,255
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	56,927
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	64,116
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Cash and cash equivalents at end of year
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	108,673
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	102,255
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	56,927
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_CASH_FLOW>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The accompanying notes are an
	integral part of these consolidated financial statements.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	104
</FONT>
</P>
<A NAME="eolPage107"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D481013D10K_HTM_TX481013_28">
</A>
	Seattle Genetics, Inc.
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<EFX_NOTES_TO_FINANCIAL_STATEMENT>
<A NAME="FIS_NOTES_TO_FINANCIAL_STATEMENT"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Notes to Consolidated Financial Statements
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	1. Organization and Business
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:2%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Organization
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%;PADDING-BOTTOM:0PX; ">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The Company is a biotechnology company
	focused on the development and commercialization of targeted therapies for the treatment of cancer. The Company&#146;s marketed product ADCETRIS
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<SUP STYLE="VERTICAL-ALIGN:BASELINE; POSITION:RELATIVE; BOTTOM:.8EX">
	&reg;
</SUP>
</FONT>
	, or brentuximab vedotin, is now approved for three indications, encompassing several settings for the treatment of relapsed Hodgkin lymphoma and relapsed systemic
	anaplastic large cell lymphoma, or sALCL, in 66 countries around the world, including the United States, Canada, members of the European Union and Japan. The Company also has multiple clinical and pre-clinical product candidates in development
	utilizing the Company&#146;s proprietary antibody drug conjugate, or ADC, technology as well as other technologies.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:2%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Capital Requirements
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	To execute the Company&#146;s growth plans, it may need to seek additional funding through public or private financings, including debt or
	equity financings, and through other means, including collaborations and license agreements. If the Company cannot maintain adequate funds, it may be required to delay, reduce the scope of or eliminate one or more of its development programs.
	Additional financing may not be available when needed, or if available, the Company may not be able to obtain financing on favorable terms.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	2. Summary of Significant Accounting Policies
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:2%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Basis of presentation
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The accompanying consolidated financial statements reflect the accounts of Seattle Genetics, Inc. and its wholly-owned subsidiaries
	(collectively &#147;Seattle Genetics&#148; or the &#147;Company&#148;). The consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP. All significant intercompany transactions and
	balances have been eliminated. Management has determined that the Company operates in one segment: the development and sale of pharmaceutical products on its own behalf or in collaboration with others. Substantially all of the Company&#146;s assets
	and revenues are related to operations in the United States; however, the Company also has subsidiaries in the United Kingdom, Switzerland and Canada.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:2%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Use of estimates
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the
	reported amounts in the financial statements and accompanying notes. Actual results could differ from those estimates.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:2%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Cash and cash equivalents
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The Company considers all highly liquid investments with maturities of three months or less at the date of acquisition to be cash
	equivalents.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:2%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Non-cash investing activities
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The Company had $8.1 million and $5.4
	million of accrued capital expenditures as of December&nbsp;31, 2016 and December&nbsp;31, 2015, respectively. Accrued capital expenditures have been treated as a non-cash investing activity and, accordingly, have not been included in the statement
	of cash flows until such amounts have been paid in cash.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:2%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Investments
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The Company classifies its securities as available-for-sale, which are reported at estimated fair value with unrealized gains and losses included in accumulated other comprehensive loss in
	stockholders&#146; equity. Realized
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	105
</FONT>
</P>
<A NAME="eolPage108"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Seattle Genetics, Inc.
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Notes to Consolidated Financial Statements&nbsp;(Continued)
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	gains, realized losses and declines in the value of securities judged to be other-than-temporary, are included in investment and other income, net. The cost of investments for purposes of
	computing realized and unrealized gains and losses is based on the specific identification method. Amortization of premiums and accretion of discounts are included in investment and other income, net. Interest and dividends earned on all securities
	are included in investment and other income, net. The Company classifies investments maturing within one year of the reporting date, or where management&#146;s intent is to use the investments to fund current operations or to make them available for
	current operations as short-term investments.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	If
	the estimated fair value of a security is below its carrying value, the Company evaluates whether it is more likely than not that it will sell the security before its anticipated recovery in market value and whether evidence indicating that the cost
	of the investment is recoverable within a reasonable period of time outweighs evidence to the contrary. The Company also evaluates whether or not it intends to sell the investment. If the impairment is considered to be other-than-temporary, the
	security is written down to its estimated fair value. In addition, the Company considers whether credit losses exist for any securities. A credit loss exists if the present value of cash flows expected to be collected is less than the amortized cost
	basis of the security. Other-than-temporary declines in estimated fair value and credit losses are charged against investment and other income, net.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:2%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Fair value of financial instruments
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The recorded amounts of certain financial instruments, including cash and cash equivalents, interest receivable, accounts receivable,
	accounts payable and accrued liabilities approximate fair value due to their relatively short maturities. Investments that are classified as available-for-sale are recorded at fair value. The fair value for securities held is determined using quoted
	market prices, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:2%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Inventories
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The Company considers regulatory approval of product candidates to be uncertain. Accordingly, it charges manufacturing costs to research
	and development expense until such time as a product has received regulatory approval for commercial sale. Production costs for the Company&#146;s marketed product, ADCETRIS, are capitalized into inventory. ADCETRIS inventory that is deployed for
	clinical, research or development use is charged to research and development expense when it is no longer available for commercial sales. Production costs for the Company&#146;s other product candidates continue to be charged to research and
	development expense.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The Company values its
	inventories at the lower of cost or market value. Cost is determined on a specific identification basis. Inventory includes the cost of materials, third-party contract manufacturing and overhead associated with the production of ADCETRIS. In the
	event that the Company identifies excess, obsolete or unsalable inventory, its value is written down to net realizable value.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:2%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Property and equipment
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Property and equipment are stated at cost and are depreciated using the straight-line method over the estimated useful lives of the
	assets, which are generally as follows:
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_18"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="92%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="7%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Years
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Laboratory equipment
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	5
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Furniture and fixtures
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	5
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Computers, software and office equipment
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	3
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Leasehold improvements are
	amortized over the shorter of the remaining term of the applicable lease or the useful life of the asset. Gains and losses from the disposal of property and equipment are reflected in the
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	106
</FONT>
</P>
<A NAME="eolPage109"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Seattle Genetics, Inc.
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Notes to Consolidated Financial Statements&nbsp;(Continued)
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	consolidated statement of comprehensive loss at the time of disposition and have not been significant. Expenditures for additions and improvements to the Company&#146;s facilities are capitalized
	and expenditures for maintenance and repairs are charged to expense as incurred. Concessions received by the Company in connection with leases, including tenant improvement allowances and prorated rent, are included in deferred rent and other
	long-term liabilities and recognized as a reduction in rent expense over the term of the applicable lease.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:2%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Other non-current assets
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Included in other non-current assets are intangible assets resulting from milestone payments that became due upon the approval of ADCETRIS
	related to certain in-licensed technology. Intangible assets are amortized to cost of sales over the estimated life of the related licenses which range from six to ten years.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_19"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="80%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	December&nbsp;31,
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2016
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2015
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Intangible assets
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	5,650
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	5,650
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Less: accumulated amortization
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(4,115
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(3,343
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Total
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,535
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2,307
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Amortization expenses on
	intangible assets was $0.8 million for each of the years ended December&nbsp;31, 2016, 2015, and 2014, respectively. Assuming no changes in the cost basis of intangible assets, the estimated aggregate amortization for the next five years will total
	$1.5 million.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Other non-current assets also
	include a $5.0 million non-controlling investment in a privately-held company that is accounted for under the cost method of accounting. The Company periodically evaluates the carrying value of the investment if significant adverse events or
	circumstances indicate an impairment in value.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:2%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Impairment of long-lived assets
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The Company assesses the impairment of long-lived assets, primarily property and equipment and intangible assets, included in other
	non-current assets, whenever events or changes in business circumstances indicate that the carrying amounts of the assets may not be fully recoverable. When such events occur, management determines whether there has been an impairment in value by
	comparing the asset&#146;s carrying value with its fair value, as measured by the anticipated undiscounted net cash flows of the asset. If an impairment in value exists, the asset is written down to its estimated fair value. The Company has not
	recognized any impairment losses through December&nbsp;31, 2016 as there have been no events warranting an impairment analysis. The Company&#146;s long-lived assets are primarily located in the United States.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:2%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Revenue Recognition
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The Company&#146;s revenues are comprised of ADCETRIS net
	product sales, amounts earned under its collaboration and licensing agreements and royalties. Revenue recognition is predicated upon persuasive evidence of an agreement existing, delivery of products or services being rendered, amounts payable being
	fixed or determinable, and collectibility being reasonably assured.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:2%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Net product sales
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The Company sells ADCETRIS through a limited number of pharmaceutical distributors in the U.S. and Canada. Customers order ADCETRIS through these distributors and the Company typically ships product
	directly to the customer. The Company records product sales when title and risk of loss pass, which generally occurs upon delivery of the product to the customer. Product sales are recorded net of estimated
	government-
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	107
</FONT>
</P>
<A NAME="eolPage110"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Seattle Genetics, Inc.
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Notes to Consolidated Financial Statements&nbsp;(Continued)
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	mandated rebates and chargebacks, distribution fees, estimated product returns and other deductions. Accruals are established for these deductions and actual amounts incurred are offset against
	applicable accruals. The Company reflects these accruals as either a reduction in the related account receivable from the distributor, or as an accrued liability depending on the nature of the sales deduction. Sales deductions are based on
	management&#146;s estimates that consider payer mix in target markets and experience to date. These estimates involve a substantial degree of judgment.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Government-mandated rebates and chargebacks
</B>
	:&nbsp;&nbsp;&nbsp;&nbsp;The Company has entered into a Medicaid Drug Rebate Agreement,
	or MDRA, with the Centers for Medicare&nbsp;&amp; Medicaid Services. This agreement provides for a rebate based on covered purchases of ADCETRIS. Medicaid rebates are invoiced to the Company by the various state Medicaid programs. The Company
	estimates Medicaid rebates based on a variety of factors, including its experience to date. The Company has also completed a Federal Supply Schedule, or FSS, agreement under which certain U.S. government purchasers receive a discount on eligible
	purchases of ADCETRIS. The Company has entered into a Pharmaceutical Pricing Agreement with the Secretary of Health and Human Services, which enables certain entities that qualify for government pricing under the Public Health Services Act, or PHS,
	to receive discounts on their qualified purchases of ADCETRIS. Under these agreements, distributors process a chargeback to the Company for the difference between wholesale acquisition cost and the applicable discounted price. As a result of the
	Company&#146;s direct-ship distribution model, it can determine the entities purchasing ADCETRIS and this information enables the Company to estimate expected chargebacks for FSS and PHS purchases based on each entity&#146;s eligibility for the FSS
	and PHS programs. The Company also reviews historical rebate and chargeback information to further refine these estimates.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Distribution fees, product returns and other deductions
</B>
	:&nbsp;&nbsp;&nbsp;&nbsp;The Company&#146;s distributors charge a
	volume-based fee for distribution services that they perform for the Company. The Company allows for the return of product that is within 30 days of its expiration date or that is damaged. The Company estimates product returns based on its
	experience to date. In addition, the Company considers its direct-ship distribution model, its belief that product is not typically held in the distribution channel, and the expected rapid use of the product by healthcare providers. The Company
	provides financial assistance to qualifying patients that are underinsured or cannot cover the cost of commercial coinsurance amounts through SeaGen Secure. SeaGen Secure is available to patients in the U.S. and its territories who meet various
	financial and treatment need criteria. Estimated contributions for commercial coinsurance under SeaGen Secure are deducted from gross sales and are based on an analysis of expected plan utilization. These estimates are adjusted as necessary to
	reflect the Company&#146;s actual experience.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The
	Company has developed a proprietary technology for linking cytotoxic agents to monoclonal antibodies called antibody-drug conjugates, or ADCs. This proprietary technology is the basis of ADC collaborations that the Company has entered into in the
	ordinary course of its business with a number of biotechnology and pharmaceutical companies. Under these ADC collaboration agreements, the Company grants its collaborators research and commercial licenses to the Company&#146;s technology and
	provides technology transfer services, technical advice, supplies and services for a period of time.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	If there are continuing performance obligations, the Company uses a time-based proportional performance model to recognize revenue over
	the Company&#146;s performance period for the related agreement. Collaboration and license agreements are evaluated to determine whether the multiple elements and associated deliverables can be considered separate units of accounting. To date, the
	pre-commercial deliverables under the Company&#146;s collaboration and license agreements have not qualified as separate units of accounting. The assessment of multiple element arrangements requires judgment in order to determine the appropriate
	point in time, or period of time, that revenue should be recognized. The Company believes that the development period in each agreement
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	108
</FONT>
</P>
<A NAME="eolPage111"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Seattle Genetics, Inc.
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Notes to Consolidated Financial Statements&nbsp;(Continued)
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	is a reasonable estimate of the performance obligation period of such agreement. Accordingly, all amounts received or due, including any upfront payments, maintenance fees, development and
	regulatory milestone payments and reimbursement payments, are recognized as revenue over the performance obligation periods of each agreement. These performance obligation periods typically range from one to three years. The agreements with Takeda
	Pharmaceutical Company Limited, or Takeda, and Genentech, Inc., a member of the Roche Group, or Genentech, have performance obligation periods of ten and seventeen years, respectively. All of the remaining performance obligation periods for our
	active collaborations are currently expected to be completed in three years or less. When no performance obligations are required of the Company, or following the completion of the performance obligation period, such amounts are recognized as
	revenue when collectibility is reasonably assured. Generally, all amounts received or due other than sales-based milestones and royalties are classified as collaboration and license agreement revenues as they are earned. Sales-based milestones and
	royalties are recognized as royalty revenue as they are reported to the Company.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The Company&#146;s collaboration and license agreements include contractual milestones. Generally, the milestone events contained in the Company&#146;s collaboration and license agreements coincide with
	the progression of the collaborators&#146; product candidates from development, to regulatory approval and then to commercialization and fall into the following categories.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Development milestones in the Company&#146;s collaborations
	may include the following types of events:
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Designation of a product candidate or initiation of preclinical studies. The Company&#146;s collaborators must undertake significant preclinical
	research and studies to make a determination of the suitability of a product candidate and the time from those studies or designation to initiation of a clinical trial may take several years.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Initiation of a phase 1 clinical trial. Generally, phase 1 clinical trials may take one to two years to complete.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Initiation of a phase 2 clinical trial. Generally, phase 2 clinical trials may take one to three years to complete.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Initiation of a phase 3 clinical trial. Generally, phase 3 clinical trials may take two to six years to complete.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Regulatory milestones in the Company&#146;s collaborations
	may include the following types of events:
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Filing of regulatory applications for marketing approval such as a Biologics License Application in the United States or a Marketing Authorization
	Application in Europe. Generally, it may take up to twelve months to prepare and submit regulatory filings.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Receiving marketing approval in a major market, such as in the United States, Europe, Japan or other significant countries. Generally it may take up to
	three years after a marketing application is submitted to obtain approval for marketing and pricing from the applicable regulatory agency.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Commercialization milestones in the Company&#146;s collaborations may include the following types of events:
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	First commercial sale in a particular market, such as in the United States, Europe, Japan or other significant countries.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#149;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Product sales in excess of a pre-specified threshold. The amount of time to achieve this type of milestone depends on several factors, including, but
	not limited to, the dollar amount of the threshold, the pricing of the product, market penetration of the product and the rate at which customers begin using the product.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	109
</FONT>
</P>
<A NAME="eolPage112"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Seattle Genetics, Inc.
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Notes to Consolidated Financial Statements&nbsp;(Continued)
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The Company&#146;s ADC collaborators are solely responsible for the development of their
	product candidates and the achievement of milestones in any of the categories identified above is based solely on the collaborators&#146; efforts.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In the case of the Company&#146;s ADCETRIS collaboration with Takeda, the Company may be involved in certain development activities;
	however, the achievement of milestone events under the agreement is primarily based on activities undertaken by Takeda.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The process of successfully developing a product candidate, obtaining regulatory approval and ultimately commercializing a product
	candidate is highly uncertain and the attainment of any milestones is therefore uncertain and difficult to predict. In addition, since the Company does not take a substantive role or control the research, development or commercialization of any
	products generated by its ADC collaborators, the Company is not able to reasonably estimate when, if at all, any milestone payments or royalties may be payable to the Company by its ADC collaborators. As such, the milestone payments associated with
	its ADC collaborations involve a substantial degree of uncertainty and risk that they may never be received. Similarly, even in those collaborations where the Company may have an active role in the development of the product candidate, such as the
	Company&#146;s ADCETRIS collaboration with Takeda, the attainment of a milestone is based on the collaborator&#146;s activities and is generally outside the direction and control of the Company.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The Company generally invoices its collaborators and
	licensees on a monthly or quarterly basis, or upon the completion of the effort or achievement of a milestone, based on the terms of each agreement. Deferred revenue arises from amounts received in advance of the culmination of the earnings process
	and is recognized as revenue in future periods when the applicable revenue recognition criteria have been met. Deferred revenue expected to be recognized within the next twelve months is classified as a current liability.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:2%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Royalty revenues and cost of royalty revenues
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Royalty revenues primarily reflect amounts
	earned under the ADCETRIS collaboration with Takeda. These royalties include sales royalties, which are based on a percentage of Takeda&#146;s net sales at rates that range from the mid-teens to the mid-twenties based on sales volume, and commercial
	sales-based milestones. Takeda bears a portion of third-party royalty costs owed on its sales of ADCETRIS. This amount is included in royalty revenue in the Company&#146;s consolidated financial statements. Cost of royalty revenues reflects amounts
	owed to the Company&#146;s third party licensors related to Takeda&#146;s sales of ADCETRIS. These amounts are recognized in the quarter in which Takeda reports its sales activity to the Company, which is the quarter following the related sales.
	Royalty revenues also include amounts earned in connection with the Company&#146;s ADC collaborations.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:2%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Research and development expenses
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Research and development, or R&amp;D, expenses consist of salaries, benefits and other headcount related costs of the Company&#146;s
	R&amp;D staff, preclinical activities, clinical trials and related manufacturing costs, lab supplies, contract and outside service fees and facilities and overhead expenses for research, development and preclinical studies focused on drug discovery,
	development and testing. Clinical trial expenses are a significant component of research and development expenses, and the Company outsources a significant portion of these costs to third parties. Third party clinical trial expenses include
	investigator fees, site costs, clinical research organization costs, and costs for central laboratory testing and data management. R&amp;D activities are expensed as incurred. In-licensing fees, milestones, maintenance fees and other costs to
	acquire technologies that are utilized in R&amp;D for product candidates that have not yet received regulatory approval, and that are not expected to have alternative future use are expensed when incurred. Costs associated with activities performed
	under co-development collaborations are reflected in R&amp;D expense. Non-refundable advance payments for goods or services that will
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	110
</FONT>
</P>
<A NAME="eolPage113"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Seattle Genetics, Inc.
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Notes to Consolidated Financial Statements&nbsp;(Continued)
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	be used or rendered for future R&amp;D activities are capitalized and recognized as expense as the related goods are delivered or the related services are performed. This results in the temporary
	deferral of recording expense for amounts incurred for research and development activities from the time payments are made until the time goods or services are provided.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:2%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Advertising
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Advertising costs are expensed as incurred. The Company
	incurred $12.9 million, $16.4 million, and $10.1&nbsp;million in advertising expense during 2016, 2015, and 2014, respectively.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:2%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Concentration of credit risk
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Cash, cash equivalents and investments are invested in accordance with the Company&#146;s investment policy. The policy includes
	guidelines for the investment of cash reserves and is reviewed periodically to minimize credit risk. Most of the Company&#146;s investments are not federally insured. The Company has accounts receivable from the sale of ADCETRIS from a small number
	of distributors. The Company does not require collateral on amounts due from its distributors or its collaborators and is therefore subject to credit risk. The Company has not experienced any significant credit losses to date as a result of credit
	risk concentration and does not consider an allowance for doubtful accounts to be necessary.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:2%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Major customers
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The Company sells ADCETRIS through a limited number of distributors. Certain of these distributors, together with entities under their common control, each individually accounted for greater than 10% of
	total revenues and greater than 10% of accounts receivable as noted below. In addition, one of the Company&#146;s collaborators accounted for greater than 10% of total revenues as noted below. Revenues generated outside the United States, as
	determined by customer location, were less than 10% of total revenues for all years presented.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The following table presents each major distributor or collaborator that comprised more than 10% of total revenue in the periods presented:
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_20"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="79%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="6%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="6%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="6%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="10" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Percent&nbsp;of&nbsp;total&nbsp;revenues
<BR>
	for the years ended
<BR>
	December 31,
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2016
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2015
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2014
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Distributor A
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	22
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	24
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	22
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Distributor B
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	19
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	21
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	20
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Distributor C
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	17
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	18
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	16
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Collaborator A
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	27
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	17
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	25
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The following table presents
	each major distributor that accounted for more than 10% of accounts receivable as of the dates presented:
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_21"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="76%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="11%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="11%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Percent&nbsp;of&nbsp;total&nbsp;accounts
<BR>
	receivable at
<BR>
	December 31,
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2016
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2015
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Distributor A
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	34
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	34
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Distributor B
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	26
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	29
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Distributor C
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	26
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	27
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	111
</FONT>
</P>
<A NAME="eolPage114"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Seattle Genetics, Inc.
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Notes to Consolidated Financial Statements&nbsp;(Continued)
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:2%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Major suppliers
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The use of a relatively small number of contract manufacturers to supply drug product necessary for the
	Company&#146;s commercial operations and clinical trials creates a concentration of risk for the Company. While primarily one source of supply is utilized for certain components of ADCETRIS and each of the Company&#146;s product candidates, other
	sources are available should the Company need to change suppliers. The Company also endeavors to maintain reasonable levels of drug supply for its use. A change in suppliers, however, could cause a delay in delivery of drug product which could
	result in the interruption of commercial operations or clinical trials. Such an event would adversely affect the Company&#146;s business.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:2%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Income taxes
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in
	the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the differences between the financial statement and tax bases of assets and liabilities using tax rates in effect for the year in which the
	differences are expected to reverse. The Company has provided a full valuation allowance against its deferred tax assets for all periods presented. A valuation allowance is recorded when it is more likely than not that the net deferred tax asset
	will not be realized. The Company follows the guidance related to accounting for uncertainty in income taxes, which requires the recognition of an uncertain tax position when it is more likely than not to be sustainable upon audit by the applicable
	taxing authority.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:2%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Share-based compensation
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The Company uses the graded-vesting
	attribution method for recognizing compensation expense for its stock options and the straight-line method for recognizing compensation expense for its restricted stock units (&#147;RSUs&#148;). Compensation expense is recognized on awards
	ultimately expected to vest and reduced for forfeitures that are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. For performance-based stock options, the Company will
	record compensation expense over the estimated service period once the achievement of the performance-based milestone is considered probable. At each reporting date, the Company assesses whether achievement of a milestone is considered probable, and
	if so, records compensation expense based on the portion of the service period elapsed to date with respect to that milestone, with a cumulative catch-up, net of estimated forfeitures. The Company will recognize remaining compensation expense with
	respect to a milestone, if any, over the remaining estimated service period.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:2%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Long-term incentive plans
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In May and July of 2016, the Company established two Long-Term Incentive Plans, or the First LTIP and the Second LTIP, respectively. The First LTIP provides eligible employees with the opportunity to
	receive a performance-based incentive comprised of a cash payment and a stock option. The Second LTIP provides eligible employees with the opportunity to receive a performance-based incentive comprised of a cash payment and a restricted stock unit
	award. The payment of the cash, commencement of the vesting of the stock options, and grant and commencement of vesting of the restricted stock units under the LTIPs are contingent upon the achievement of pre-determined regulatory milestones. The
	Company will record compensation expense for the LTIPs over the estimated service period for each milestone once the achievement of the milestone is considered probable in accordance with the provisions of ASC 450, Contingencies. At each reporting
	date, the Company assesses whether achievement of a milestone is considered probable, and if so, records compensation expense based on the portion of the service period elapsed to date with respect to that milestone, with a cumulative catch-up, net
	of estimated forfeitures. The Company will recognize remaining compensation expense with respect to a milestone, if any, over the remaining estimated service period. As of December&nbsp;31, 2016, the estimated value to be delivered in cash and stock
	options for employees currently eligible under the First LTIP was approximately
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	112
</FONT>
</P>
<A NAME="eolPage115"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Seattle Genetics, Inc.
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Notes to Consolidated Financial Statements&nbsp;(Continued)
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$20.8 million. As of December&nbsp;31, 2016, the estimated value to be delivered in cash and restricted stock units for employees currently eligible under the Second LTIP was approximately $20.6
	million. No compensation expense has been recorded to date under the LTIPs as the conditions for recognizing expense have not yet been met. The total potential value to be delivered under the LTIPs is expected to change in the future for several
	reasons, including the addition of more eligible employees to the LTIPs.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:2%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Comprehensive loss
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Comprehensive loss is the change in stockholders&#146; equity from transactions and other events and circumstances other than those resulting from investments by stockholders and distributions to
	stockholders. The Company&#146;s comprehensive loss is comprised of net loss, unrealized gains and losses on available-for-sale investments, and foreign currency translation adjustments.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:2%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Legal matters
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The Company is involved in various legal proceedings in the normal course of its business. Legal fees incurred as a result of the
	Company&#146;s involvement in legal procedures are expensed as incurred.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The Company is a named defendant in a securities class action complaint filed on January 10, 2017 seeking compensatory damages of an undisclosed amount. The lawsuit alleges material misrepresentations and
	omissions in public statements regarding the Company&#146;s business, operational and compliance policies, violations by all named defendants of Section 10(b) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and Rule 10b-5
	thereunder, as well as violations of Section 20(a) of the Exchange Act. The Company is also named as co-defendant in a lawsuit filed by venBio Select Advisors, LLC, or venBio, in the Delaware Chancery Court on February 13, 2017, against the members
	of the board of directors of Immunomedics, Inc., or Immunomedics. The lawsuit alleges that the members of the Immunomedics board have breached their fiduciary duties toward their stockholders by hastily licensing IMMU-132 to the Company. The Company
	is alleged to have aided and abetted the breach of fiduciary duties. Among other things, venBio seeks to enjoin closing of the transactions contemplated by the development and license agreement the Company entered into with Immunomedics with respect
	to the in-licensing of IMMU-132, or the Immunomedics License. As a result of the pending litigation challenging the transactions contemplated by the Immunomedics License, the Company and Immunomedics have committed to the court not to close the
	transactions contemplated by the Immunomedics License prior to March 10, 2017.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The Company does not believe it is feasible to predict or determine the outcome or resolution of these lawsuits, or to estimate the amount of, or potential range of, loss with respect to these lawsuits.
	In addition, the timing of the final resolution of these lawsuits is uncertain. As a result of these lawsuits, the Company will incur litigation expenses and may incur indemnification expenses, and potential resolutions of these lawsuits could
	include settlements requiring payments by the Company. Those expenses could have a material impact on the Company&#146;s financial position, results of operations, and cash flows.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Arizona State University and related entities filed patent
	infringement lawsuits in the United States and in Italy against the Company, and in Italy and France against Takeda, the Company&#146;s licensee of rights to ADCETRIS outside the U.S. and Canada, concerning certain patents owned by Arizona State
	University. In August 2015, the lawsuit in the United States against the Company was dismissed by the U.S. District Court of Arizona. In September 2015, the Company, Takeda and Arizona State University and their related entities entered into an
	agreement to fully and finally settle all remaining claims and disputes between the parties throughout the world, including proceedings asserting European patent rights owned by Arizona State University.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	113
</FONT>
</P>
<A NAME="eolPage116"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Seattle Genetics, Inc.
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Notes to Consolidated Financial Statements&nbsp;(Continued)
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:2%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Certain risks and uncertainties
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The Company&#146;s revenues are derived from ADCETRIS sales
	and royalties and from collaboration and license agreements. ADCETRIS is the Company&#146;s only product available for sale and is subject to regulation by the FDA in the United States and other regulatory agencies outside the United States as well
	as competition by other pharmaceutical companies. The Company&#146;s collaboration and license agreement revenues are derived from a relatively small number of agreements. Each of these agreements can be terminated by the Company&#146;s
	collaborators at their discretion. The Company is also subject to risks common to companies in the pharmaceutical industry, including risks and uncertainties related to commercial success and acceptance of ADCETRIS and the Company&#146;s potential
	future products by patients, physicians and payers, competition from other products, regulatory approvals, regulatory requirements and protection of intellectual property. Also, drug development is a lengthy process characterized by a relatively low
	rate of success. The Company may commit substantial resources toward developing product candidates that never result in further development, achieve regulatory approvals or achieve commercial success. Likewise, the Company has committed and expects
	to continue to commit substantial resources towards additional clinical development of ADCETRIS in an effort to continue to expand ADCETRIS&#146; labeled indications of use, and there can be no assurance that the Company and/or Takeda will obtain
	and maintain the necessary regulatory approvals to market ADCETRIS for any additional indications.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:2%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Guarantees
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In the normal course of business, the Company indemnifies its directors, certain employees and other parties, including distributors, collaboration partners, lessors and other parties that perform certain
	work on behalf of, or for the Company or take licenses to the Company&#146;s technologies. The Company has agreed to hold these parties harmless against losses arising from the Company&#146;s breach of representations or covenants, intellectual
	property infringement or other claims made against these parties in performance of their work with the Company. These agreements typically limit the time within which the party may seek indemnification by the Company and the amount of the claim. It
	is not possible to prospectively determine the maximum potential amount of liability under these indemnification agreements. Further, each potential claim would be based on the unique facts and circumstances of the claim and the particular
	provisions of each agreement.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:2%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Net loss per
	share
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Basic and diluted net loss per share
	is computed by dividing net loss by the weighted average number of common shares outstanding during the period. The Company excluded all RSUs and options to purchase common stock from the calculation of basic and diluted net loss per share as such
	securities are anti-dilutive for all periods presented.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The following table presents the weighted-average shares that have been excluded from the number of shares used to calculate basic and diluted net loss per share (in thousands):
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="73%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="10" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Years ended December&nbsp;31,
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2016
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2015
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2014
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Stock options and RSUs
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	12,987
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	11,953
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	11,868
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:2%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Recent accounting
	pronouncements
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In May 2014, the Financial
	Accounting Standards Board, or FASB, issued an Accounting Standards Update entitled &#147;ASU 2014-09, Revenue from Contracts with Customers.&#148; The standard requires entities to recognize revenue through an evaluation that includes
	identification of the contract, identification of the performance obligations, determination of the transaction price, allocation of the transaction price to the performance
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	114
</FONT>
</P>
<A NAME="eolPage117"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Seattle Genetics, Inc.
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Notes to Consolidated Financial Statements&nbsp;(Continued)
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	obligations, and recognition of revenue as the entity satisfies the performance obligations. In August 2015, FASB issued an Accounting Standards Update entitled &#147;ASU 2015-14, Revenue from
	Contracts with Customers: Deferral of the Effective Date&#148;, which defers the effective date of ASU 2014-09 to the Company&#146;s fiscal year beginning January&nbsp;1, 2018. The FASB has continued to issue accounting standards updates to clarify
	and provide implementation guidance related to Revenue from Contracts with Customers, including &#147;ASU 2016-08, Revenue from Contract with Customers: Principal versus Agent Considerations&#148;, &#147;ASU 2016-10, Revenue from Contracts with
	Customers: Identifying Performance Obligations and Licensing&#148;, &#147;ASU 2016-12, Revenue from Contracts with Customers: Narrow-Scope Improvements and Practical Expedients&#148; and &#147;ASU 2016-20, Technical Corrections and Improvements to
	Topic 606, Revenue from Contracts with Customers.&#148; The Company&#146;s preliminary assessment of this new standard is that it will generally not change the way in which the Company recognizes product revenue from sales of ADCETRIS. However, the
	Company expects that sales-based royalties will be recorded in the period of the related sale based on estimates, rather than recording them as reported by the customer. In addition, the achievement of development milestones under the Company&#146;s
	collaborations will be recorded in the period their achievement becomes probable, which may result in their recognition earlier than under current accounting principles. The new standard also requires more extensive disclosures related to revenue
	recognition, particularly in quarterly financial statements. The Company will adopt the standard on January&nbsp;1, 2018 and intends to use the modified retrospective method of adoption. The Company is continuing to evaluate the impact of the
	standard on all of its revenues, including those mentioned above, and its assessments may change in the future based on its ongoing evaluation.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In January 2016, FASB issued an Accounting Standards Update entitled &#147;ASU 2016-01, Financial Instruments: Overall.&#148; The standard
	addresses certain aspects of recognition, measurement, presentation and disclosure of financial instruments. The standard will become effective for the Company beginning January&nbsp;1, 2018. The Company is currently evaluating the guidance to
	determine the potential impact on its financial condition, results of operations and cash flows, and financial statement disclosures.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In February 2016, FASB issued an Accounting Standards Update entitled &#147;ASU 2016-02, Leases.&#148; The standard requires entities to
	recognize in the consolidated balance sheet a liability to make lease payments and a right-of-use asset representing its right to use the underlying asset for the lease term. The standard will become effective for the Company beginning
	January&nbsp;1, 2019, with early adoption permitted. The Company is currently evaluating the guidance to determine the potential impact on its financial condition, results of operations and cash flows, and financial statement disclosures.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In March 2016, FASB issued an Accounting Standard
	Update entitled &#147;ASU 2016-09, Compensation &#150; Stock Compensation.&#148; The standard is intended to simplify certain elements of accounting for share-based payment transactions, including the income tax impact, classification of awards as
	either equity or liabilities, and classification on the statement of cash flows. In addition, the standard allows an entity-wide accounting policy election to either estimate the number of awards that are expected to vest, as currently required, or
	account for forfeitures when they occur. The Company has elected to continue estimating the number of awards that are expected to vest. The Company will adopt the standard as of January&nbsp;1, 2017. Since the Company has incurred net losses since
	its inception and maintains a full valuation allowance on its net deferred tax assets, the adoption is not expected to have a material impact on the Company&#146;s financial condition, results of operations and cash flows. Upon implementing the new
	standard, the amount of deferred tax assets disclosed, prior to any related valuation allowance, will increase due to the change in the manner of accounting for the income tax benefit of the excess tax deduction over financial statement expense for
	share-based compensation. Currently, the Company maintains a valuation allowance that fully offsets its deferred tax assets.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In October 2016, FASB issued an Accounting Standard Update entitled &#147;ASU 2016-16, Accounting for Income Taxes: Intra-Entity Asset
	Transfers of Assets Other than Inventory&#148;. The standard is intended to simplify
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	115
</FONT>
</P>
<A NAME="eolPage118"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Seattle Genetics, Inc.
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Notes to Consolidated Financial Statements&nbsp;(Continued)
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	the accounting for intercompany sales of assets other than inventory. Under current GAAP, the tax effects of intra-entity asset transfers are deferred until the transferred asset is sold to a
	third party or otherwise recovered through use. Under the new guidance, a reporting entity would recognized the tax expense from the sale of the asset in the seller&#146;s jurisdiction when the transfer occurs, even though the pre-tax effects of
	that transaction are eliminated in consolidation. Any deferred tax asset that arises in the buyer&#146;s jurisdiction would also be recognized at the time of the transfer. The standard will become effective for the Company beginning on
	January&nbsp;1, 2018. The Company is currently evaluating the new standard; however, since the Company has incurred net losses since its inception and maintains a full valuation allowance on its net deferred tax assets, the adoption is not expected
	to have a material impact on the Company&#146;s financial condition, results of operations and cash flows, or financial statement disclosures.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In June 2016, FASB issued an Accounting Standard Update entitled &#147;ASU 2016-13, Financial Instruments: Credit Losses&#148;. The
	objective of the standard is to provide information about expected credit losses on financial instruments at each reporting date, and to change how other than temporary impairments on investments securities are recorded. The standard will become
	effective for the Company beginning on January&nbsp;1, 2020 with early adoption permitted. The Company is currently evaluating the guidance to determine the potential impact on its financial condition, results of operations and cash flows, and
	financial statement disclosures.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In January 2017,
	FASB issued an Accounting Standard Update entitled, &#147;ASU 2017-01, Business Combinations: Clarifying the Definition of a Business.&#148; The objective of the standard is to clarify the definition of a business with the objective of adding
	guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions of assets or businesses. The Company has elected to early adopt this standard on a prospective basis as of January&nbsp;1, 2017. The adoption of
	this standard did not have a material impact on the Company&#146;s financial condition, results of operations and cash flows, or financial statement disclosures.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	3. Investments
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Investments consisted of available-for-sale securities as
	follows (in thousands):
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_22"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="54%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="6%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="6%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="6%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="6%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Amortized
<BR>
	cost
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Gross
<BR>
	unrealized
<BR>
	gains
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Gross
<BR>
	unrealized
<BR>
	losses
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Fair
<BR>
	value
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	December&nbsp;31, 2016
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:2.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	U.S. Treasury securities
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	510,356
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	68
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(123
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	510,301
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Contractual Maturities
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:2.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Due in one year or less
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	229,856
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	229,864
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:2.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Due in one to two years
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	280,500
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	280,437
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Total
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	510,356
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	510,301
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="4">
</TD>
<TD HEIGHT="16" COLSPAN="4">
</TD>
<TD HEIGHT="16" COLSPAN="4">
</TD>
<TD HEIGHT="16" COLSPAN="4">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Amortized
<BR>
	cost
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Gross
<BR>
	unrealized
<BR>
	gains
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Gross
<BR>
	unrealized
<BR>
	losses
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Fair
<BR>
	value
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	December&nbsp;31, 2015
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:2.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	U.S. Treasury securities
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	611,128
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(673
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	610,456
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Contractual Maturities
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:2.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Due in one year or less
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	532,823
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	532,418
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:2.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Due in one to two years
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	78,305
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	78,038
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Total
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	611,128
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	610,456
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	116
</FONT>
</P>
<A NAME="eolPage119"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_23"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Seattle Genetics, Inc.
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Notes to Consolidated Financial Statements&nbsp;(Continued)
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Investments are presented in the accompanying consolidated balance sheets as follows (in
	thousands):
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="76%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD ROWSPAN="2" VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	December&nbsp;31,
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2016
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2015
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Short-term investments
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	480,313
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	547,396
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Long-term investments
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	29,988
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	63,060
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Total
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	510,301
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	610,456
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The aggregate estimated fair
	value of the Company&#146;s investments with unrealized losses was as follows (in thousands):
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_24"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="54%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="7%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="7%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="7%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="7%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="14" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Period of continuous unrealized loss
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	12 Months or less
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Greater&nbsp;than&nbsp;12&nbsp;months
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Fair
<BR>
	value
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Gross
<BR>
	unrealized
<BR>
	losses
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Fair
<BR>
	value
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Gross
<BR>
	unrealized
<BR>
	losses
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	December&nbsp;31, 2016
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	U.S. Treasury securities
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	200,327
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(123
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	NA
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	NA
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	December&nbsp;31, 2015
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	U.S. Treasury securities
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	605,457
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(673
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	NA
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	NA
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	4. Fair Value
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The Company holds short-term and long-term
	available-for-sale securities that are measured at fair value which is determined on a recurring basis according to a fair value hierarchy that prioritizes the inputs and assumptions used, and the valuation techniques used to measure fair value. The
	hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value
	hierarchy are described as follows:
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_25"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="7%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD WIDTH="90%">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Level&nbsp;1:
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Level 2:
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly.
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Level 3:
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The determination of a
	financial instrument&#146;s level within the fair value hierarchy is based on an assessment of the lowest level of any input that is significant to the fair value measurement. The Company considers observable data to be market data which is readily
	available, regularly distributed or updated, reliable and verifiable, not proprietary, and provided by independent sources that are actively involved in the relevant market.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	117
</FONT>
</P>
<A NAME="eolPage120"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Seattle Genetics, Inc.
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Notes to Consolidated Financial Statements&nbsp;(Continued)
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Level 1 investments, which include investments that are valued based on quoted market
	prices in active markets, consisted of U.S. Treasury securities. The Company did not hold any Level 2 or 3 investments as of December&nbsp;31, 2016 or 2015 and did not transfer any investments in or out of Levels 1, 2 and 3 during the years ended
	December&nbsp;31, 2016 or 2015.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The following
	table presents the Company&#146;s available-for-sale securities by level within the fair value hierarchy (in thousands):
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_26"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="56%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="7%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="7%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="7%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="7%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="14" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Fair value measurement using:
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Quoted&nbsp;prices
<BR>
	in active
<BR>
	markets for
<BR>
	identical
<BR>
	assets
<BR>
	(Level 1)
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Other
<BR>
	observable
<BR>
	inputs
<BR>
	(Level 2)
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Significant
<BR>
	unobservable
<BR>
	inputs
<BR>
	(Level 3)
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Total
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	As of December&nbsp;31, 2016
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Short-term investments&#151;U.S. Treasury securities
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	480,313
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	480,313
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Long-term investments&#151;U.S. Treasury securities
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	29,988
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	29,988
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Total
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	510,301
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	510,301
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_27"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="56%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="7%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="7%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="7%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="7%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="14" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Fair value measurement using:
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Quoted&nbsp;prices
<BR>
	in active
<BR>
	markets for
<BR>
	identical
<BR>
	assets
<BR>
	(Level 1)
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Other
<BR>
	observable
<BR>
	inputs
<BR>
	(Level 2)
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Significant
<BR>
	unobservable
<BR>
	inputs
<BR>
	(Level 3)
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Total
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	As of December&nbsp;31, 2015
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Short-term investments&#151;U.S. Treasury securities
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	547,396
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	547,396
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Long-term investments&#151;U.S. Treasury securities
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	63,060
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	63,060
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Total
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	610,456
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	610,456
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	5. Inventories
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The following table presents the Company&#146;s inventories
	of ADCETRIS (in thousands):
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_28"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="78%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	December&nbsp;31,
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2016
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2015
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Raw materials
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	62,516
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	50,501
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Work in process
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,693
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Finished goods
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	5,600
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	4,769
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Total
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	68,124
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	56,963
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	118
</FONT>
</P>
<A NAME="eolPage121"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Seattle Genetics, Inc.
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Notes to Consolidated Financial Statements&nbsp;(Continued)
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	6. Property and equipment
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Property and equipment consisted of the following (in
	thousands):
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_29"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="76%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	December&nbsp;31,
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2016
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2015
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Leasehold improvements
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	77,133
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	59,025
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Laboratory equipment
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	37,639
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	32,471
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Computers, software and office equipment
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	15,076
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10,700
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Furniture and fixtures
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	6,598
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	6,157
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	136,446
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	108,353
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Less: accumulated depreciation and amortization
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(73,576
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(58,755
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Total
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	62,870
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	49,598
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Depreciation and amortization
	expenses on property and equipment totaled $17.3 million, $13.7 million, and $11.7 million for the years ended December&nbsp;31, 2016, 2015, and 2014, respectively. Leasehold improvements included $17.8 million and $9.6 million of construction in
	process at December&nbsp;31, 2016 and December&nbsp;31, 2015, respectively, related to facility improvements.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	7. Accounts payable and accrued liabilities
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Accounts payable and accrued liabilities consisted of the following (in thousands):
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_30"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="78%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	December&nbsp;31,
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2016
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2015
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Employee compensation and benefits
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	29,670
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	24,829
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Trade accounts payable
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	29,005
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	20,786
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Clinical trial and related costs
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	21,006
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	17,142
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Contract manufacturing
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	22,008
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	12,780
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Third-party royalties and government rebates
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	12,351
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	9,678
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Other
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	6,629
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2,816
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Total
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	120,669
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	88,031
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	8. Income taxes
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The Company&#146;s deferred tax assets primarily consist of
	net operating loss, or NOL, carryforwards, deferred revenue, capitalized research and development expense and tax credit carryforwards. Realization of deferred tax assets is dependent upon a number of factors, including future earnings, the timing
	and amount of which is uncertain. Accordingly, the deferred tax assets have been fully offset by a valuation allowance. At December&nbsp;31, 2016, the Company has gross federal NOL carryforwards of $600.8 million expiring from 2021 to 2036 if not
	utilized, gross state NOL carryforwards of $199.3 million, gross foreign NOL carryforwards of $19.0 million and tax credit carryforwards of $140.4 million expiring from 2021 to 2036.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Utilization of the NOL and tax credit carryforwards may be subject to a substantial annual limitation in the
	event of a change in ownership as set forth in Section&nbsp;382 of the Internal Revenue Code of 1986, as amended. The Company has evaluated ownership changes through the year ended December&nbsp;31, 2014 and believes that it is likely that
	utilization of its NOLs should not be limited under Section&nbsp;382 as of December&nbsp;31, 2014. It is possible that there may be a change in ownership after this date, which would limit the Company&#146;s ability to utilize its NOL. Any
	limitation may result in the expiration of the NOL and tax credit carryforwards before utilization.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	119
</FONT>
</P>
<A NAME="eolPage122"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_31"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Seattle Genetics, Inc.
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Notes to Consolidated Financial Statements&nbsp;(Continued)
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The Company&#146;s book income (loss) by jurisdiction consisted of the following (in
	thousands):
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="74%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	December&nbsp;31,
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2016
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2015
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	US
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(66,215
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(95,860
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Foreign
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(73,896
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(24,626
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Total
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(140,111
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(120,486
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The Company&#146;s net
	deferred tax assets consisted of the following (in thousands):
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_32"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="74%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	December&nbsp;31,
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2016
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2015
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Deferred tax assets
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Net operating loss carryforwards
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	150,465
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	145,595
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Foreign net operating loss
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,702
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	145
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Tax credit carryforwards
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	124,396
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	75,270
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Deferred revenue
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	30,731
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	42,563
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Share-based compensation
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	33,041
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	29,310
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Capitalized research and development
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	12,578
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	6,806
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Depreciation and amortization
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8,970
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	6,103
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Other
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	19,468
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	16,375
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Total deferred tax assets
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	381,351
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	322,167
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Less: valuation allowance
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(381,351
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(322,167
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Net deferred tax assets
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The tax credit carry forward
	increase in 2016 is a result of the completion of a tax credit study during the year. Increases in the valuation allowance were $59.2 million in 2016 and $4.5 million in 2015.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	A reconciliation of the federal statutory income tax rate to
	the effective income tax rate is as follows:
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_33"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="76%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="7%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="7%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="7%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="10" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Years&nbsp;ended&nbsp;December&nbsp;31,
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2016
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2015
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2014
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Statutory federal income tax rate
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(35
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(35
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(35
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Tax credits
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(25
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(13
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(10
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Foreign rate differential
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	16
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	5
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	State income taxes and other
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	4
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(4
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Valuation allowance
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	40
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	41
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	49
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Effective tax rate
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The foreign rate differential
	in the table above reflects the effect of operations in jurisdictions with tax rates that differ from the rate in the United States. This primarily results from the Company&#146;s operations in Switzerland which began in 2015. At December&nbsp;31,
	2016, unremitted earnings of the Company&#146;s foreign subsidiaries, which were insignificant, will be retained indefinitely by the foreign subsidiaries for continuing investment. If foreign earnings were to be repatriated to the United States, the
	Company could be subject to additional U.S. federal income taxes.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	120
</FONT>
</P>
<A NAME="eolPage123"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Seattle Genetics, Inc.
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Notes to Consolidated Financial Statements&nbsp;(Continued)
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The financial statement recognition of the benefit for a tax position is dependent upon
	the benefit being more likely than not to be sustainable upon audit by the applicable taxing authority. If this threshold is met, the tax benefit is then measured and recognized at the largest amount that is greater than 50% likely of being realized
	upon ultimate settlement. A reconciliation of the beginning and ending amount of unrecognized tax benefits for the years ended December&nbsp;31, 2016, 2015 and 2014 is as follows (in thousands):
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_34"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="77%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="10" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Years&nbsp;ended&nbsp;December&nbsp;31,
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2016
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2015
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2014
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Balance as of January&nbsp;1
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Increase related to prior year tax positions
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	12,631
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Increase related to current year tax positions
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	3,392
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Lapses of statute of limitations
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Balance at December&nbsp;31
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	16,023
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The Company does not
	anticipate any significant changes to its unrecognized tax positions or benefits during the next twelve months. Interest and penalties related to the settlement of uncertain tax positions, if any, will be reflected in income tax expense. Tax years
	2001to 2016 remain subject to future examination for federal income taxes.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	9. Collaboration and license agreements
</B>
<B>
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The Company has entered into various product, collaboration and license agreements with pharmaceutical and biotechnology companies.
	Revenues recognized under these agreements were as follows (in thousands):
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_35"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="67%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="10" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Years ended December&nbsp;31,
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2016
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2015
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2014
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Takeda
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	44,384
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	17,234
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	31,787
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	AbbVie
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	25,676
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	31,055
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	14,851
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Genentech
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	4,324
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	9,110
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	7,791
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Other
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10,542
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	12,371
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	14,127
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Total
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	84,926
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	69,770
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	68,556
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Takeda ADCETRIS Collaboration
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The ADCETRIS collaboration provides for the
	global co-development of ADCETRIS and the commercialization of ADCETRIS by Takeda in its territory. Under this collaboration, the Company has retained commercial rights for ADCETRIS in the United States and its territories and in Canada, and Takeda
	has commercial rights in the rest of the world. Additionally, the companies equally co-fund the cost of development activities conducted under the collaboration. In Japan, Takeda is solely responsible for development costs. Costs incurred by the
	Company associated with co-development activities performed under this collaboration are included in research and development expense in the accompanying consolidated statements of comprehensive loss.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The Company recognizes as collaboration revenue the upfront
	payment, progress-dependent development and regulatory milestone payments, and net development cost reimbursement payments from Takeda over the ten-year development period of the collaboration which began in December 2009. When the performance of
	development activities under the collaboration results in the Company making a reimbursement payment to Takeda, the effect is to reduce the amount of collaboration revenue recorded by the Company. The Company also
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	121
</FONT>
</P>
<A NAME="eolPage124"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Seattle Genetics, Inc.
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Notes to Consolidated Financial Statements&nbsp;(Continued)
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	receives reimbursement for the cost of drug product supplied to Takeda for its use and, in some cases, pays Takeda for drug product they supply to the Company. The earned portion of net
	collaboration payments is reflected as a component of collaboration revenue.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The Company also receives royalties based on a percentage of Takeda&#146;s net sales of ADCETRIS in its territory ranging from the mid-teens to the mid-twenties based on sales volume and sales-based
	milestones. Takeda also bears a portion of third-party royalty costs owed on its sales of ADCETRIS which is included as a component of the Company&#146;s royalty revenue. Either party may terminate the collaboration agreement if the other party
	materially breaches the agreement and such breach remains uncured. Takeda may terminate the collaboration agreement for any reason upon prior written notice to the Company. The collaboration agreement can also be terminated by mutual written consent
	of the parties. If neither party terminates the collaboration agreement, then the agreement automatically terminates on the expiration of all payment obligations.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Astellas Co-Development Collaboration
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The Company has entered into an agreement with Astellas to
	jointly research, develop and commercialize ADCs for the treatment of certain types of cancer. The agreement encompasses combinations of the Company&#146;s ADC technology with fully-human antibodies developed by Astellas to proprietary cancer
	targets. Under this collaboration, Astellas conducted research and development aimed at identifying product candidates for multiple designated antigens and is now conducting clinical trials on various ADC product candidates.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The Company and Astellas are co-funding all development and
	commercialization costs for ASG-22ME and ASG-15ME, and will share in any profits that may come from these product candidates if successfully commercialized on a 50/50 basis. Either party may opt out of co-development and profit-sharing in return for
	receiving milestones and royalties from the continuing party.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Costs associated with co-development activities performed under this collaboration are included in research and development expense in the accompanying consolidated statements of comprehensive loss. The
	Astellas collaboration agreement defines a mechanism for calculating the costs of co-development activities and for reimbursing the other party in order to maintain an equal sharing of development costs. Third-party costs are billed at actual cost
	and internal labor and support costs are billed at a contractual rate. The following table summarizes research and development expenses incurred by the Company and funding provided to Astellas under the collaboration to achieve equal cost sharing.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_36"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="72%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="10" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Years ended December&nbsp;31,
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2016
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2015
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2014
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Research and development expense using contractual rates
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2,947
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	539
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	275
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Co-development funding paid to Astellas
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	12,043
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	5,545
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	3,785
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Total
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	14,990
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	6,084
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	4,060
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The agreement also allows
	Astellas to develop and commercialize another ADC product candidates on its own, subject to paying the Company annual maintenance fees, milestones, royalties and support fees for research and development services and material provided under the
	agreement. Amounts received for the product candidate being developed solely by Astellas are recognized in revenues as they become due.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Unum Therapeutics Collaboration
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In June 2015, the Company entered into a strategic collaboration and license agreement with Unum Therapeutics, Inc., or Unum, to develop
	and commercialize novel antibody-coupled T-cell receptor, or ACTR,
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	122
</FONT>
</P>
<A NAME="eolPage125"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Seattle Genetics, Inc.
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Notes to Consolidated Financial Statements&nbsp;(Continued)
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	therapies for cancer. Under the terms of the agreement, the Company made an upfront payment of $25.0 million and an equity investment of $5.0 million in Unum. The agreement provides for the
	Company and Unum to initially develop two ACTR products incorporating the Company&#146;s antibodies, and the Company has an option to expand the collaboration to include a third ACTR product upon payment of an additional fee. Unum is conducting
	preclinical research and clinical development activities through phase 1 clinical trials and the Company is providing funding for these activities. The agreement calls for the Company and Unum to work together to co-develop and jointly fund programs
	after phase 1 clinical trials unless either company opts out.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The Company and Unum would co-commercialize any successfully developed product candidates and share any profits 50/50 on any co-developed programs in the United States. The Company retains exclusive
	commercial rights outside of the United States, paying Unum a royalty that is a high single digit to mid-teens percentage of ex-U.S. sales. The potential future licensing and progress-dependent milestone payments to Unum under the collaboration may
	total up to $615 million across all three ACTR programs, payment of which is triggered by the achievement of development, regulatory and commercial milestones.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Costs associated with co-development activities performed under this collaboration are included in research and development expense in the
	accompanying consolidated statements of comprehensive loss. The following table summarizes third party research and development expenses incurred by the Company and funding provided to Unum under the collaboration.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_37"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="75%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="12%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Years&nbsp;ended&nbsp;December&nbsp;31,
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2016
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2015
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Co-development funding paid to Unum
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	3,243
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	569
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Third party research and development expenses incurred
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2,086
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Total
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	5,329
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	569
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	ADC collaboration agreements
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The Company has entered into collaborations
	for its ADC technology with a number of biotechnology and pharmaceutical companies. Under the ADC collaborations, which the Company has entered into in the ordinary course of business, the Company has granted research and commercial licenses to use
	its technology in conjunction with the collaborator&#146;s technology. The Company also has agreed to conduct limited development activities and to provide other materials, supplies and services to its ADC collaborators during the performance
	obligation period of the collaboration. The Company receives upfront cash payments, progress- and sales-dependent milestones for the achievement by its collaborators of certain events, annual maintenance fees and support fees for research and
	development services and materials provided under the agreements. The Company is also entitled to receive royalties on net sales of any resulting products incorporating its ADC technology. The Company&#146;s ADC collaborators are solely responsible
	for research, product development, manufacturing and commercialization of all products under these collaborations
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	10. License agreements
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The Company has in-licensed antibodies, targets and enabling technologies from pharmaceutical and biotechnology companies and academic institutions for use in ADCETRIS, its pipeline programs and ADC
	technology, including the following:
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Bristol-Myers Squibb.
</I>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has obtained rights to some of its technologies and product
	candidates, portions of which are exclusive, through a license agreement with Bristol-Myers Squibb. Through this license, the Company secured rights to monoclonal antibody-based cancer targeting technologies, including
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	123
</FONT>
</P>
<A NAME="eolPage126"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Seattle Genetics, Inc.
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Notes to Consolidated Financial Statements&nbsp;(Continued)
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	patents, monoclonal antibodies, chemical linkers, including the linker used in ADCETRIS and other product candidates, a ribosome-inactivating protein and enabling technologies. Under the terms of
	the license agreement, the Company is required to pay a low single-digit royalty on net sales of products, including ADCETRIS, that incorporate patented technology licensed from Bristol-Myers Squibb.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	University of Miami.
</I>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
	Company has entered into an exclusive license agreement with the University of Miami, Florida, covering an anti-CD30 monoclonal antibody that is the basis for the antibody component of ADCETRIS. Under the terms of this license, the Company made an
	upfront payment and progress-dependent milestone payments. The Company is obligated to pay annual maintenance fees and a low single-digit royalty on net sales of products, including ADCETRIS, incorporating technology licensed from the University of
	Miami.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Other
	Licenses
</I>
	.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has other non-exclusive licenses to other technology used in ADCETRIS that require the Company to pay a low single-digit royalty on net sales of ADCETRIS.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	11. Commitments and contingencies
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Commitments.
</I>
	&nbsp;&nbsp;&nbsp;&nbsp;The Company is
	obligated to make future minimum payments under five operating leases for approximately 355,000 square feet of space used for general office and research and development purposes. The leases expire between 2018 through 2024 and include options to
	renew at the then fair market rental for the facilities. The lease agreements typically contain scheduled rent increases and provide for tenant improvement allowances. Accordingly, the Company has recorded a deferred rent liability of $2.2 million
	at December&nbsp;31, 2016, and $3.2 million at December&nbsp;31, 2015. This deferred rent liability is amortized over the term of the related lease. Assuming the Company does not exercise any extensions, future minimum lease payments under all
	noncancelable operating leases are set forth below.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In addition, the Company has certain noncancelable obligations under other agreements, including supply agreements relating to the
	manufacture of ADCETRIS and the Company&#146;s product candidates which contain annual minimum purchase commitments and other firm commitments when a binding forecast is provided. As of December&nbsp;31, 2016, the Company&#146;s future obligations
	related to its supply and other agreements are as follows (in thousands):
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_38"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="76%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Leases
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Other
<BR>
	Agreements
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Years ending December 31,
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2017
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	6,995
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	82,795
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2018
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	4,706
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	29,644
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2019
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2,500
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	26,554
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2020
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2,575
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	25,165
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2021
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2,653
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	25,988
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Thereafter
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	6,760
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	88,270
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	26,189
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	278,416
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Rent expense attributable to
	noncancelable operating leases totaled approximately $5.6 million, $4.1 million, and $3.6 million for the years ended December&nbsp;31, 2016, 2015, and 2014, respectively.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Noncancelable obligations under other agreements do not
	include payments that are contingent upon achievement of certain progress-dependent milestones, as well as the payment of royalties based on net sales of commercial products. These amounts have been excluded from the table because the events
	triggering the obligations have not yet occurred.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	124
</FONT>
</P>
<A NAME="eolPage127"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Seattle Genetics, Inc.
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Notes to Consolidated Financial Statements&nbsp;(Continued)
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	12. Stockholders&#146; equity
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:2%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Common stock
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In September 2015, the Company completed an underwritten public offering of 13,463,415 shares of its common stock at a public offering
	price of $41.00 per share. The offering resulted in net proceeds to the Company of approximately $526.6 million, after deducting underwriting discounts and commissions and other offering expenses.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	At December&nbsp;31, 2016, shares of common stock reserved
	for future issuance are as follows (in thousands):
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_39"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="90%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Stock options and RSUs outstanding
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	13,480
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Shares available for future grant under the 2007 Equity Incentive Plan
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	5,513
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Employee stock purchase plan shares available for future issuance
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	761
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Total
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	19,754
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	13. Share-based compensation
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:2%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	2007 Equity Incentive Plan
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In 2007, the Company adopted the 2007 Equity
	Incentive Plan, or the 2007 Plan, that provides for the issuance of the Company&#146;s common stock to employees, including officers, directors and consultants of the Company and its affiliates. The 2007 Plan was amended and restated in May 2016 to
	reserve an additional 6,000,000 shares thereunder, such that an aggregate of 27,000,000 shares of the Company&#146;s common stock were authorized for issuance under the 2007 Plan at December&nbsp;31, 2016. Under the 2007 Plan, the Company may issue
	stock options (including incentive stock options and nonstatutory stock options), restricted stock, RSUs, stock appreciation rights and other similar types of awards (including awards, such as RSUs, that do not require the awardee to pay any amount
	in connection with receiving the shares or that have an exercise or purchase price that is less than the grant date fair market value of the Company&#146;s stock). No awardee may be granted, in any calendar year under the 2007 Plan, options or stock
	awards covering more than 1,000,000 shares. The 2007 Plan was also amended and restated in May 2014 to extend its term through May 2024 unless it is terminated earlier pursuant to its terms.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Restricted stock grants are awards of a specific number of shares of the Company&#146;s common stock. RSUs
	represent a promise to deliver shares of the Company&#146;s common stock, or an amount of cash or property equal to the value of the underlying shares, at a future date. Stock appreciation rights are rights to receive cash and/or shares of the
	Company&#146;s common stock based on the amount by which the exercise date fair market value of a specific number of shares exceeds the grant date fair market value of the exercised portion of the stock appreciation right. The Company has only
	issued options to purchase shares of common stock and RSUs under the 2007 Plan.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Incentive stock options under the 2007 Plan may be granted only to employees of the Company or its subsidiaries. The exercise price of an incentive stock option or a nonstatutory stock option may not be
	less than 100% of the fair market value of the common stock on the date the option is granted and the options have a maximum term of ten years from the date of grant. In the case of options granted to holders of more than 10% of the voting power of
	the Company, the exercise price may not be less than 110% of the fair market value of the common stock on the date the option is granted and the term of the option may not exceed five years. The Company may grant options with exercise prices lower
	than the fair market value of its common stock on the date of grant in connection with an acquisition by the Company of another company. Options become exercisable in whole or in part from time to time as determined by the Board of Directors, which
	administers the 2007 Plan.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	125
</FONT>
</P>
<A NAME="eolPage128"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Seattle Genetics, Inc.
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Notes to Consolidated Financial Statements&nbsp;(Continued)
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Generally, options granted to employees under the 2007 Plan vest 25% one year after the beginning of the vesting period and thereafter ratably each month over the following thirty-six months.
	RSUs granted to employees vest 100% on the third anniversary of the beginning of the vesting period. Option and RSU grants to independent members of the Company&#146;s board of directors vest over one year. Performance-based options granted under
	the 2007 Plan pursuant to the First LTIP commence vesting upon the achievement of a regulatory milestone, and vest 25% each year over four years beginning one year after the achievement of the milestone. The Equity Plan provides for (i)&nbsp;the
	full acceleration of vesting of equity awards, including stock options and RSUs, upon a change in control (as defined in the 2007 Plan) if the successor company does not assume, substitute or otherwise replace the stock awards upon the change in
	control; and (ii)&nbsp;the full acceleration of vesting of any equity awards, including stock options and RSUs, if at the time of, immediately prior to or within twelve months after a change in control of the Company, the holder of such equity
	awards is involuntarily terminated without cause or is constructively terminated by the successor company that assumed, substituted or otherwise replaced such stock awards in connection with the change in control.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Each equity award agreement under the 2007 Plan contains
	provisions regarding (i)&nbsp;the number of shares subject to the equity award, (ii)&nbsp;the purchase or exercise price of the shares, if any, and the means of payment for the shares, (iii)&nbsp;in the case of stock options, the type of option and
	term of the option; (iv)&nbsp;the performance criteria (including qualifying performance criteria), if any, and level of achievement versus these criteria that will determine the number of shares granted, issued, retainable and vested, as
	applicable, (v)&nbsp;such terms and conditions on the grant, issuance, vesting and forfeiture of the shares, as applicable, as may be determined from time to time by the plan administrator, (vi)&nbsp;restrictions on the transferability of the equity
	award or the shares, and (vii)&nbsp;such further terms and conditions, in each case not inconsistent with the 2007 Plan, as may be determined from time to time by the plan administrator; provided, however, that each stock award must have a minimum
	vesting period of one year from the date of grant.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:2%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Share-based compensation
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The Company recorded total share based compensation cost of $52.5 million, $41.8 million, and $40.6 million for the years ended
	December&nbsp;31, 2016, 2015, and 2014, respectively. No tax benefit was recognized related to share-based compensation cost since the Company has not reported taxable income to date and has established a full valuation allowance to offset all of
	the potential tax benefits associated with its deferred tax assets. During 2016, 2015, and 2014, $1.0 million, $1.4 million, and $1.4 million of share based compensation costs were included in production overhead used in the determination of
	inventory cost, respectively.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:2%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Valuation
	assumptions
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The Company calculates the fair
	value of each option award on the date of grant using the Black-Scholes option pricing model. The following weighted-average assumptions were used for the periods indicated:
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_40"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="51%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="10" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2007 Plan
<BR>
	Years&nbsp;ended&nbsp;December&nbsp;31,
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="10" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Employee&nbsp;Stock&nbsp;Purchase&nbsp;Plan
<BR>
	Years ended December&nbsp;31,
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2016
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2015
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2014
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2016
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2015
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	2014
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Risk-free interest rate
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1.3
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1.5
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1.7
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0.35
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0.1
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0.1
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Expected lives in years
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	6.5
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	5.5
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	5.5
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0.5
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0.5
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0.5
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Expected dividends
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Expected volatility
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	44
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	42
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	44
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	46
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	42
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	41
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	%&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The risk-free interest rate
	is based on the U.S. Treasury yield curve in effect at the time of grant for the expected life of the award. The Company&#146;s computation of expected life was determined based on its historical experience with similar awards, giving consideration
	to the contractual terms of the share-based awards, vesting
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	126
</FONT>
</P>
<A NAME="eolPage129"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Seattle Genetics, Inc.
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Notes to Consolidated Financial Statements&nbsp;(Continued)
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	schedules and expectations of future employee behavior. A forfeiture rate is estimated at the time of grant to reflect the amount of awards that are granted, but are expected to be forfeited by
	the award holder prior to vesting. The estimated forfeiture rate applied to these amounts is derived from historical stock award forfeiture behavior. The Company has never paid cash dividends and does not currently intend to pay cash dividends, thus
	has assumed a 0% dividend yield. The Company&#146;s computation of expected volatility is based on the historical volatility of the Company&#146;s stock price. Determination of all of these assumptions involves management&#146;s best estimates at
	the time, which impact the fair value of the awards calculated under the Black-Scholes methodology, and ultimately the expense that will be recognized over the life of the award.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:2%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Stock option activity
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	A summary of stock option activity, excluding
	performance-based stock options, is as follows:
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_41"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="41%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="8%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="8%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="8%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="8%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Shares
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Weighted-
<BR>
	average
<BR>
	exercise
<BR>
	price&nbsp;per&nbsp;share
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Weighted-average
<BR>
	remaining&nbsp;contractual
<BR>
	term
<BR>
	(in years)
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Aggregate
<BR>
	intrinsic value
<BR>
	(in&nbsp;thousands)
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Balances at December&nbsp;31, 2015
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10,572,663
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	25.28
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Granted
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,984,175
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	44.79
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Exercised
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(1,778,056
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	16.60
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Forfeited/expired
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(182,462
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	40.15
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Balances at December&nbsp;31, 2016
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10,596,320
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	30.14
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	6.23
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	240,143
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Expected to vest
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10,264,488
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	29.70
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	6.13
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	237,036
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Options exercisable
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	6,966,828
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	23.46
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	4.82
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	204,236
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The weighted average
	grant-date fair values of options granted with exercise prices equal to market were $18.20, $15.84, and $18.24, for the years ended December&nbsp;31, 2016, 2015, and 2014, respectively.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The aggregate intrinsic value in the table above is calculated as the difference between the exercise price of
	the underlying options and the quoted price of the Company&#146;s common stock for all options that were in-the-money at December&nbsp;31, 2016. The aggregate intrinsic value of options exercised was $61.4 million during 2016, $36.2 million during
	2015, and $27.7 million during 2014, determined as of the date of option exercise. As of December&nbsp;31, 2016, there was approximately $33.9 million of total unrecognized compensation cost related to unvested option arrangements, as adjusted for
	expected forfeitures, granted under the 2007 Plan. That cost is expected to be recognized over a weighted-average period of 1.43 years. The Company utilizes newly issued shares to satisfy option exercises.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	A summary of performance-based stock option activity for
	performance-based options granted under the 2007 Plan pursuant to the First LTIP plan is as follows:
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_42"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="45%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="8%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="8%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="8%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="8%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Shares
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Weighted-
<BR>
	average
<BR>
	exercise
<BR>
	price&nbsp;per&nbsp;share
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Weighted-average
<BR>
	remaining&nbsp;contractual
<BR>
	term
<BR>
	(in years)
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Aggregate
<BR>
	intrinsic value
<BR>
	(in&nbsp;thousands)
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Balances at December&nbsp;31, 2015
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Granted
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	834,211
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	34.20
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Exercised
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	0
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Forfeited/expired
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(29,810
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	34.20
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Balances at December&nbsp;31, 2016
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	804,401
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	34.20
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	9.34
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	14,938
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	127
</FONT>
</P>
<A NAME="eolPage130"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Seattle Genetics, Inc.
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Notes to Consolidated Financial Statements&nbsp;(Continued)
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The weighted average grant-date fair value of performance-based options granted with an
	exercise price equal to market was $18.54 for the year ended December&nbsp;31, 2016. No share based compensation expense has been recorded to date with respect to the First LTIP performance-based options as the conditions for recognizing expense
	have not yet been met.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:2%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	RSU activity
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The fair value of RSUs is determined based
	on the closing price of the Company&#146;s common stock on the date of grant.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	A summary of RSU activity under the 2007 Plan is as follows:
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_43"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="75%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM" NOWRAP>
<P STYLE="BORDER-BOTTOM:1PX SOLID #000000;WIDTH:59PT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Non-vested RSUs
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Share
<BR>
	equivalent
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Weighted-
<BR>
	average
<BR>
	grant&nbsp;date
<BR>
	fair value
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Non-vested at December&nbsp;31, 2015
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1,832,704
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	40.55
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Changes during the period:
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Granted
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	873,496
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	44.72
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Vested
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(537,545
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	39.46
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Forfeited
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(89,716
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	40.53
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Non-vested at December&nbsp;31, 2016
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2,078,939
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	42.58
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="BORDER-TOP:3PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The total value of RSUs that
	vested during 2016 (measured on the date of vesting) was $23.3 million. As of December&nbsp;31, 2016, there was approximately $45.3 million of total unrecognized compensation cost related to non-vested RSU awards that will be recognized as expense
	over a weighted-average period of 1.74 years. The Company recognizes compensation cost for RSUs on a straight-line basis over the requisite service period for the entire award, as adjusted for expected forfeitures. The Company will utilize newly
	issued shares for RSUs that vest.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:2%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Employee
	Stock Purchase Plan
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The Company has an
	Amended and Restated 2000 Employee Stock Purchase Plan, or the Stock Purchase Plan, with a total of 760,809 shares of common stock available for issuance as of December&nbsp;31, 2016. Activity under the Stock Purchase Plan for the years ended
	December&nbsp;31, was as follows:
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_44"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="73%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="7%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="7%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Shares
<BR>
	Purchased
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Weighted-
<BR>
	average
<BR>
	purchase&nbsp;price
<BR>
	per share
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2016
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	203,225
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	27.98
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2015
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	201,103
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	26.44
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2014
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	149,576
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	33.02
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Under the current terms of
	the Stock Purchase Plan, shares are purchased at the lower of 85 percent of the fair market value of the Company&#146;s common stock on either the first day or the last day of each six month offering period.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	14. Employee benefit plan
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The Company has a 401(k) Plan for all of its employees. The
	401(k) Plan allows eligible employees to defer, at the employee&#146;s discretion, up to 75% of their pretax compensation up to the IRS annual limit. The
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	128
</FONT>
</P>
<A NAME="eolPage131"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Seattle Genetics, Inc.
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Notes to Consolidated Financial Statements&nbsp;(Continued)
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Company has a 401(k) matching program whereby the Company may, at its discretion, match a portion of an employee&#146;s contributions, not to exceed a prescribed annual limit. The Company&#146;s
	matching contribution vests over four years from the start of employment. Under this matching program, the Company contributed a total of approximately $4.7 million in 2016, $2.6 million in 2015, and $2.2 million in 2014.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	15. Quarterly Financial Data (unaudited)
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The following table contains selected unaudited financial
	data for each quarter of 2016 and 2015. The unaudited information should be read in conjunction with the Company&#146;s financial statements and related notes included elsewhere in this report. The Company believes that the following unaudited
	information reflects all normal recurring adjustments necessary for a fair presentation of the information for the periods presented. The operating results for any quarter are not necessarily indicative of results for any future period.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_45"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Quarterly Financial Data (in thousands, except per share data):
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD WIDTH="52%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="14" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Three months ended
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	March&nbsp;31,
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	June&nbsp;30,
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	September&nbsp;30,
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	December&nbsp;31,
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	2016
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Total revenues
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	111,155
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	95,402
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	106,315
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	105,275
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Net loss
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(20,478
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(32,743
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(31,752
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(55,138
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Net loss per share&#151;basic and diluted
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(0.15
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(0.23
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(0.23
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(0.39
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	2015
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Total revenues
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	82,157
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	77,096
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	84,072
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	93,477
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Net loss
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(21,690
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(47,502
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(26,438
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(24,856
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Net loss per share&#151;basic and diluted
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(0.17
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(0.38
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(0.21
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	$
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(0.18
</FONT>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	)&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	16. Subsequent events
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On January&nbsp;10, 2017, the Company became a named
	defendant in a securities class action complaint seeking compensatory damages of an undisclosed amount. The Company does not believe it is feasible to predict or determine the outcome or resolution of this litigation, or to estimate the amount of,
	or potential range of, loss with respect to this proceeding. In addition, the timing of the final resolution of this proceeding is uncertain. As a result of the lawsuit, the Company will incur litigation expenses and may incur indemnification
	expenses, and potential resolutions of the lawsuit could include a settlement requiring payments.&nbsp;Those expenses could have a material impact on the Company&#146;s financial position, results of operations, and cash flows.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On February&nbsp;10, 2017, the Company entered into a
	development and license agreement with Immunomedics pursuant to which Immunomedics granted, subject to the terms and conditions of the agreement, the Company exclusive worldwide rights to develop, manufacture, and commercialize sacituzumab
	govitecan, or IMMU-132, for all human therapeutic uses in any and all indications. Sacituzumab govitecan is an antibody-drug conjugate targeted to TROP-2, which is expressed in several solid tumors including cancers of the breast, lung and bladder.
	Under the agreement, the Company would have primary responsibility for development, regulatory approval and commercialization of IMMU-132. Immunomedics will have the right to exercise a co-promotion option to provide up to 50% of the sales efforts
	for the commercialization of IMMU-132 in the United States, subject to certain parameters set forth in the agreement.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Under and subject to the agreement, the Company agreed to pay Immunomedics an upfront payment of $250 million following the closing of the
	agreement. In addition, the Company agreed to pay development, regulatory and sales-dependent milestone payments to Immunomedics across multiple indications and
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	129
</FONT>
</P>
<A NAME="eolPage132"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Seattle Genetics, Inc.
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Notes to Consolidated Financial Statements&nbsp;(Continued)
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	geographic regions of up to a total maximum of approximately $1.7 billion, as well as royalties which are based on a percentage of worldwide annual net sales of licensed products, if any,
	beginning in the teens and rising to twenty percent based on sales volume. The Company will bear the future costs of worldwide development and commercialization of licensed products. The closing of the agreement is subject to customary closing
	conditions, including the expiration of the applicable waiting period of the Hart-Scott-Rodino Antitrust Improvements Act of 1976, there being no pending court or administrative challenges to the Immunomedics License and there being no court or
	administrative orders blocking the closing. On February 20, 2017, the Company and Immunomedics entered into a letter agreement pursuant to which Immunomedics irrevocably waived to the extent applicable to Immunomedics the condition precedent to the
	closing and effectiveness of the Immunomedics License that there be no pending court or administrative challenges to the transaction. Additionally, under the terms of the Immunomedics License, Immunomedics had the right to continue discussions with
	a small number of parties that previously expressed interest in licensing IMMU-132 until 11:59 p.m. New York City time on February&nbsp;19, 2017. If a third party had provided Immunomedics with a financially superior licensing offer, the Company
	would have had the right to match any such offer, and if the Company had decided not to match, Immunomedics would have had the right to accept the superior offer and terminate the Immunomedics License upon payment of a termination fee to the
	Company. The Company has not received notice from Immunomedics of any such third party offers during this limited time period, and on February 21, 2017, Immunomedics announced that it is subject to customary &#147;no-shop&#148; restrictions on its
	and its representatives&#146; ability to solicit, discuss or negotiate alternative licensing agreement proposals from third parties with regard to IMMU-132.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On February&nbsp;10, 2017, the Company also entered into an agreement to purchase 3,000,000 shares of common stock of Immunomedics at an
	aggregate purchase price of $14.7 million, and on February&nbsp;16, 2017, Immunomedics issued the Company a warrant to purchase up to 8,655,804 additional shares of common stock of Immunomedics at an exercise price of $4.90 until February&nbsp;10,
	2020. The issuances of the purchased common shares and the shares underlying the warrants have not been registered under the Securities Act. The Company entered into a Registration Rights Agreement with Immunomedics under which Immunomedics agreed
	to file a registration statement to register the common shares and the shares underlying the warrant.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	On February&nbsp;13, 2017, the Company was named as co-defendant in a lawsuit filed by venBio in the Delaware Chancery Court against the
	members of the board of directors of Immunomedics.&nbsp;The lawsuit alleges that the members of the Immunomedics board have breached their fiduciary duties toward their stockholders by hastily licensing IMMU-132 to the Company. The Company is
	alleged to have aided and abetted the breach of fiduciary duties. Among other things, venBio seeks to enjoin the closing of the transactions contemplated by the Immunomedics License. As a result of the pending litigation challenging the transactions
	contemplated by the Immunomedics License, the Company and Immunomedics have committed to the court not to close the transactions contemplated by the Immunomedics License prior to March 10, 2017. The Company does not believe it is feasible to predict
	or determine the outcome or resolution of this lawsuit, or to estimate the amount of, or potential range of, loss with respect to this lawsuit. In addition, the timing of the final resolution of this lawsuit is uncertain. As a result of the lawsuit,
	the Company will incur litigation expenses, and potential resolution of the lawsuit could include a settlement requiring payments.&nbsp;Those expenses could have a material impact on the Company&#146;s financial position, results of operations, and
	cash flows.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	130
</FONT>
</P>
<A NAME="eolPage133"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
</EFX_NOTES_TO_FINANCIAL_STATEMENT>
</EFX_FINANCIAL_STATEMENTS>
<EFX_ACCOUNTING_CHANGES>
<A NAME="FIS_ACCOUNTING_CHANGES"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D481013D10K_HTM_TOC481013_12">
</A>
	Item&nbsp;9. Changes in and Disagreements with Accountants on Accounting and
	Financial Disclosure
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	None.
</FONT>
</P>
</EFX_ACCOUNTING_CHANGES>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<EFX_CONTROL_AND_PROCEDURES>
<A NAME="FIS_CONTROL_AND_PROCEDURES"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D481013D10K_HTM_TOC481013_13">
</A>
	Item&nbsp;9A. Controls and Procedures
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(a)
<I>
	Evaluation of disclosure controls and
	procedures.
</I>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Chief Executive Officer and our Chief Financial Officer have evaluated our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended) prior
	to the filing of this annual report. Based on that evaluation, they have concluded that, as of the end of the period covered by this annual report, our disclosure controls and procedures were, in design and operation, effective.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(b)
<I>
	Changes in internal control over financial
	reporting.
</I>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There have not been any changes in our internal control over financial reporting during the quarter ended December&nbsp;31, 2016 that have materially affected, or are reasonably likely to materially
	affect, our internal control over financial reporting.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(c)
<I>
	Management&#146;s Annual Report on Internal Control Over Financial Reporting.
</I>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our management is responsible for establishing and maintaining adequate internal
	control over financial reporting, as such term is defined in Rule 13a-15(f) under the Securities Exchange Act of 1934, as amended. Our management conducted an evaluation of the effectiveness of our internal control over financial reporting based on
	the 2013 framework in
<I>
	Internal Control&#151;Integrated Framework
</I>
	issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on its evaluation under the framework in
<I>
	Internal Control&#151;Integrated Framework,
</I>
	our management concluded that our internal control over financial reporting was effective as of December&nbsp;31, 2016.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The effectiveness of our internal control over financial reporting as of December&nbsp;31, 2016 has been audited by PricewaterhouseCoopers
	LLP, an independent registered public accounting firm, as stated in their report which is included in Item&nbsp;8 in this Annual Report on Form 10-K.
</FONT>
</P>
</EFX_CONTROL_AND_PROCEDURES>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<EFX_OTHER_INFORMATION>
<A NAME="FIS_OTHER_INFORMATION"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D481013D10K_HTM_TOC481013_14">
</A>
	Item&nbsp;&nbsp;9B. Other Information
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	None.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	131
</FONT>
</P>
<A NAME="eolPage134"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
</EFX_OTHER_INFORMATION>
</EFX_PART_II>
<EFX_PART_III>
<A NAME="FIS_PART_III"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	PART III
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The information required by Part III is omitted from this
	report because we will file a definitive proxy statement within 120 days after the end of our 2016 fiscal year pursuant to Regulation 14A for our 2017 Annual Meeting of Stockholders, or the 2017 Proxy Statement, and the information to be included in
	the 2017 Proxy Statement is incorporated herein by reference.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<EFX_DIRECTORS_AND_OFFICERS>
<A NAME="FIS_DIRECTORS_AND_OFFICERS"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D481013D10K_HTM_TOC481013_15">
</A>
	Item&nbsp;&nbsp;10. Directors, Executive Officers and Corporate Governance
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(1) The information required by this Item concerning our
	executive officers and our directors and nominees for director, including information with respect to our audit committee and audit committee financial expert, may be found under the section entitled &#147;Proposal No.&nbsp;1&#151;Election of
	Directors&#148; appearing in the 2017 Proxy Statement. Such information is incorporated herein by reference.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(2) The information required by this Item concerning our code of ethics may be found under the section entitled &#147;Proposal
	No.&nbsp;1&#151;Election of Directors&#151;Certain Other Corporate Governance Matters&#151;Code of Ethics&#148; appearing in the 2017 Proxy Statement. Such information is incorporated herein by reference.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(3) The information required by this Item concerning
	compliance with Section&nbsp;16(a) of the Securities Exchange Act of 1934 may be found in the section entitled &#147;Section 16(a) Beneficial Ownership Reporting Compliance&#148; appearing in the 2017 Proxy Statement. Such information is
	incorporated herein by reference.
</FONT>
</P>
</EFX_DIRECTORS_AND_OFFICERS>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<EFX_COMPENSATION>
<A NAME="FIS_COMPENSATION"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D481013D10K_HTM_TOC481013_16">
</A>
	Item&nbsp;&nbsp;11. Executive Compensation
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The information required by this Item may be found under the
	sections entitled &#147;Proposal No.&nbsp;1&#151;Election of Directors&#151;Director Compensation&#148; and &#147;Compensation of Executive Officers&#148; appearing in the 2017 Proxy Statement. Such information is incorporated herein by reference.
</FONT>
</P>
</EFX_COMPENSATION>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<EFX_SECURITY_OWNERS>
<A NAME="FIS_SECURITY_OWNERS"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D481013D10K_HTM_TOC481013_17">
</A>
	Item&nbsp;&nbsp;12. Security
	Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(1) The information required by this Item with respect to security ownership of certain beneficial owners and management may be found under the section entitled &#147;Security Ownership of Certain
	Beneficial Owners and Management&#148; appearing in the 2017 Proxy Statement. Such information is incorporated herein by reference.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(2) The information required by this Item with respect to securities authorized for issuance under our equity compensation plans may be
	found under the sections entitled &#147;Equity Compensation Plan Information&#148; appearing in the 2017 Proxy Statement. Such information is incorporated herein by reference.
</FONT>
</P>
</EFX_SECURITY_OWNERS>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<EFX_OFFICER_TRANSACTIONS>
<A NAME="FIS_OFFICER_TRANSACTIONS"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D481013D10K_HTM_TOC481013_18">
</A>
	Item&nbsp;&nbsp;13. Certain Relationships and
	Related Transactions, and Director Independence
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(1) The information required by this Item concerning related party transactions may be found under the section entitled &#147;Certain Relationships and Related Party Transactions&#148; appearing in the
	2017 Proxy Statement. Such information is incorporated herein by reference.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(2) The information required by this Item concerning director independence may be found under the section entitled &#147;Proposal No.&nbsp;1&#151;Election of Directors&#148; appearing in the 2017 Proxy
	Statement. Such information is incorporated herein by reference.
</FONT>
</P>
</EFX_OFFICER_TRANSACTIONS>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<EFX_ACCOUNTANT_FEES>
<A NAME="FIS_ACCOUNTANT_FEES"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D481013D10K_HTM_TOC481013_19">
</A>
	Item&nbsp;&nbsp;14. Principal Accounting Fees and Services
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The information required by this Item may be found under the section entitled &#147;Proposal
	No.&nbsp;2&#151;Ratification of Appointment of Independent Registered Public Accounting Firm&#148; appearing in the 2017 Proxy Statement. Such information is incorporated herein by reference.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	132
</FONT>
</P>
<A NAME="eolPage135"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
</EFX_ACCOUNTANT_FEES>
</EFX_PART_III>
<EFX_PART_IV>
<A NAME="FIS_PART_IV"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	PART IV
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<EFX_EXHIBITS>
<A NAME="FIS_EXHIBITS"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D481013D10K_HTM_TOC481013_20">
</A>
	Item&nbsp;15. Exhibits, Financial Statement
	Schedules
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	(a)
</B>
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	The following documents are filed as part of this report:
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="3%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(1)
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Financial Statements and Report of Independent Registered Public Accounting Firm
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="3%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(2)
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Financial Statement Schedules
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; MARGIN-LEFT:13%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Financial Statement Schedules have been omitted because the information required to be set forth therein is not applicable or is shown in
	the financial statements or notes thereto.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="3%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(3)
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Exhibits are incorporated herein by reference or are filed with this report as indicated below (numbered in accordance with Item&nbsp;601 of Regulation S-K).
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	(b)
</B>
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Exhibits
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_46"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD WIDTH="53%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM" COLSPAN="2" ROWSPAN="2" NOWRAP ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX;BORDER-BOTTOM:1PX SOLID #000000;WIDTH:28PT" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Exhibit
<BR>
	Number
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM" ROWSPAN="2">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="7" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Incorporation By Reference
</B>
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Exhibit Description
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Form
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	SEC&nbsp;File&nbsp;No.
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Exhibit
</B>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Filing&nbsp;Date
</B>
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	3.1
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Fourth Amended and Restated Certificate of Incorporation of Seattle Genetics, Inc.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10-Q
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-32405
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	3.1
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	11/7/2008
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	3.2
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Certificate of Amendment of Fourth Amended and Restated Certificate of Incorporation of Seattle Genetics, Inc.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8-K
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-32405
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	3.3
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	5/26/2011
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	3.3
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Amended and Restated Bylaws of Seattle Genetics,&nbsp;Inc.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8-K
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-32405
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	3.1
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	11/25/2015
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	4.1
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Specimen Stock Certificate.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<FONT STYLE="WHITE-SPACE:NOWRAP">
	S-1/A
</FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	333-50266
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	4.1
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2/8/2001
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	4.2
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Investor Rights Agreement dated July&nbsp;8, 2003 among Seattle Genetics, Inc. and certain of its
	stockholders.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10-Q
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-32405
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	4.3
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	11/7/2008
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	4.3
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Registration Rights Agreement, dated September 10, 2015, by and between Seattle Genetics, Inc. and the persons listed on
	Schedule A attached thereto.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8-K
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-32405
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.1
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	9/11/2015
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.1
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	License Agreement dated March&nbsp;30, 1998 between Seattle Genetics, Inc. and Bristol-Myers Squibb Company.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10-K/A
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-32405
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.1
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	11/26/2010
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.2
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Amendment Letter to the Bristol-Myers Squibb Company License Agreement dated July&nbsp;29, 1999 between Seattle Genetics, Inc.
	and Bristol-Myers Squibb Company.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10-K/A
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-32405
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.2
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	11/26/2010
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.3
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Amendment Agreement to the Bristol-Myers Squibb Company License Agreement dated July&nbsp;26, 2000 between Seattle Genetics,
	Inc. and Bristol-Myers Squibb Company.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	S-1/A
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	333-50266
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.7
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	12/5/2000
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.4&#134;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Amendment to License Agreement to the Bristol-Myers Squibb Company License Agreement dated December&nbsp;18, 2015 between
	Seattle Genetics, Inc. and Bristol-Myers Squibb Company.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10-K
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-32405
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.4
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2/19/2016
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.5
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	License Agreement dated September&nbsp;20, 1999 between Seattle Genetics, Inc. and the University of Miami.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10-K/A
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-32405
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.6
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	11/26/2010
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	133
</FONT>
</P>
<A NAME="eolPage136"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_47"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD WIDTH="55%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.6
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Amendment No. 1 to the University of Miami License Agreement dated August&nbsp;4, 2000 between Seattle Genetics, Inc. and the
	University of Miami.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10-K/A
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-32405
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.7
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	11/26/2010
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.7&#134;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Letter Agreement Regarding Royalty between the University of Miami and Seattle Genetics, Inc. dated April 11,
	2016
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10-Q
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-32405
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.1
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	7/26/2016
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.8
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Lease Agreement dated December&nbsp;1, 2000 between Seattle Genetics, Inc. and WCM132-302, LLC.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	S-1/A
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	333-50266
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.21
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1/4/2001
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.9
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	First Amendment to Lease dated May&nbsp;28, 2003 between Seattle Genetics, Inc. and B&amp;N&nbsp;141-302, LLC.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10-Q
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	333-50266
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.1
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8/12/2003
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.10&#134;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Second Amendment to Lease dated July&nbsp;1, 2008 between Seattle Genetics, Inc. and B&amp;N&nbsp;141-302,
	LLC.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10-Q
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-32405
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.1
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	11/7/2008
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.11&#134;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Third Amendment to Lease dated May&nbsp;9, 2011 between Seattle Genetics, Inc. and B&amp;N 141-302, LLC.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10-Q
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-32405
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.2
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8/5/2011
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.12&#134;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Office Lease dated May&nbsp;9, 2011 between Seattle Genetics, Inc. and WCM Highlands II, LLC.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10-Q
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-32405
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.1
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8/5/2011
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.13&#134;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Collaboration and License Agreement dated January&nbsp;7, 2007 between Seattle Genetics, Inc. and Agensys,
	Inc.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10-Q
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-32405
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.1
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	5/8/2007
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.14&#134;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Amendment to the Collaboration and License Agreement between Seattle Genetics, Inc. and Agensys, Inc. dated effective
	November&nbsp;20, 2009.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10-K
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-32405
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.49
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	3/12/2010
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.15&#134;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Collaboration Agreement between Seattle Genetics, Inc. and Millennium Pharmaceuticals, Inc. (a wholly-owned subsidiary of
	Takeda Pharmaceutical Company Limited) dated December&nbsp;14, 2009.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10-K
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-32405
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.50
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	3/12/2010
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.16&#134;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Commercial Supply Agreement dated December&nbsp;1, 2010 between Seattle Genetics, Inc. and SAFC, an operating division of
	Sigma-Aldrich, Inc.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10-Q
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-32405
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.1
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	11/4/2011
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.17+&#134;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	First Amendment to Commercial Supply Agreement effective as of January 20, 2014 between Seattle Genetics, Inc. and SAFC, an
	operating division of Sigma-Aldrich, Inc.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.18+&#134;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Second Amendment to Commercial Supply Agreement effective as of December 2, 2016 between Seattle Genetics, Inc. and SAFC, an
	operating division of Sigma-Aldrich, Inc.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.19
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Development and Supply Agreement dated February&nbsp;23, 2004 between Seattle Genetics, Inc. and Abbott
	Laboratories.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10-K
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-32405
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.15
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2/27/2015
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.20&#134;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	First Amendment to Development and Supply Agreement dated April&nbsp;17, 2008 between Seattle Genetics, Inc. and Abbott
	Laboratories, Inc.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10-Q
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-32405
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.1
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8/8/2008
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	134
</FONT>
</P>
<A NAME="eolPage137"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_48"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD WIDTH="54%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.21&#134;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Second Amendment to Development and Supply Agreement dated June&nbsp;15, 2009 between Seattle Genetics, Inc. and Abbott
	Laboratories, Inc.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10-Q
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-32405
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.4
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	11/4/2011
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.22&#134;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Third Amendment to Development and Supply Agreement dated November&nbsp;5, 2009 between Seattle Genetics, Inc. and Abbott
	Laboratories, Inc.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10-Q
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<FONT STYLE="WHITE-SPACE:NOWRAP">
	000-32405
</FONT>
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.5
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	11/4/2011
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.23&#134;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Fourth Amendment to Development and Supply Agreement dated April&nbsp;18, 2010 between Seattle Genetics, Inc. and Abbott
	Laboratories, Inc.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10-Q
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-32405
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.6
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	11/4/2011
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.24&#134;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Fifth Amendment to Development and Supply Agreement dated August&nbsp;24, 2010 between Seattle Genetics, Inc. and Abbott
	Laboratories, Inc.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10-Q
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-32405
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.7
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	11/4/2011
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.25&#134;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Sixth Amendment to Development and Supply Agreement dated November&nbsp;18, 2010 between Seattle Genetics, Inc. and Abbott
	Laboratories, Inc.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10-Q
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-32405
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.8
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	11/4/2011
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.26&#134;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Seventh Amendment to Development and Supply Agreement dated January&nbsp;2, 2013 between Seattle Genetics, Inc. and Abbott
	Laboratories, Inc.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10-K
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-32405
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.42
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2/27/2013
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.27&#134;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Eighth Amendment to Development and Supply Agreement dated July 7, 2015 between Seattle Genetics, Inc. and AbbVie Inc.
	(formerly part of Abbott Laboratories, Inc.).
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10-Q
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-32405
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.2
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	7/30/2015
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.28&#134;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Ninth Amendment to Development and Supply Agreement, effective as of August 23, 2016 between Seattle Genetics, Inc. and AbbVie
	Inc. (formerly part of Abbott Laboratories, Inc.).
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10-Q
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-32405
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.1
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10/27/2016
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.29+&#134;
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Tenth Amendment to Development and Supply Agreement, effective as of December 26, 2016 between Seattle Genetics, Inc. and
	AbbVie, Inc. (formerly part of Abbott Laboratories, Inc.).
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.30*
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Form of Indemnification Agreement between Seattle Genetics, Inc. and each of its officers and directors.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	S-1/A
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	333-50266
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.29
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1/4/2001
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.31*
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Amended and Restated 1998 Stock Option Plan, effective as of August&nbsp;5, 2009.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10-Q
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-32405
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.1
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8/10/2009
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.32*
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Form Notice of Grant and Stock Option Agreement under Seattle Genetics, Inc. Amended and Restated 1998 Stock Option
	Plan.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10-K
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-32405
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.11
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	3/15/2005
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.33*
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2000 Directors&#146; Stock Option Plan, as amended February&nbsp;5, 2010.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10-K
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-32405
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.13
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	3/12/2010
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.34*
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Form Notice of Grant and Stock Option Agreement under Seattle Genetics, Inc. 2000 Directors&#146; Stock Option
	Plan.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10-K
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-32405
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.12
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	3/15/2005
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.35+*
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Amended and Restated 2000 Employee Stock Purchase Plan, effective May&nbsp;20, 2011.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	135
</FONT>
</P>
<A NAME="eolPage138"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_49"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD WIDTH="52%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.36*
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Seattle Genetics, Inc. Amended and Restated 2007 Equity Incentive Plan, effective as of May&nbsp;18, 2012.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10-Q
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-32405
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.1
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8/8/2012
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.37*
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Seattle Genetics, Inc. Amended and Restated 2007 Equity Incentive Plan, effective as of May 16, 2014.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10-Q
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-32405
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.1
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8/8/2014
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.38*
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Seattle Genetics, Inc. Amended and Restated 2007 Equity Incentive Plan, effective as of May 20, 2016.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10-Q
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-32405
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.4
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	7/26/2016
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.39*
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Form Stock Option Agreement for employees under Seattle Genetics, Inc. 2007 Equity Incentive Plan.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10-K
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-32405
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.44
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	3/13/2009
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.40*
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Form of Stock Unit Grant Notice and Stock Unit Agreement for employees under Seattle Genetics, Inc. Amended and Restated 2007
	Equity Incentive Plan.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8-K
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-32405
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.1
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8/30/2011
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.41*
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Form of Notice of Stock Option Grant and Stock Option Agreement for non-employee directors under the Amended and Restated 2007
	Equity Incentive Plan.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10-Q
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-32405
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.4
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8/5/2011
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.42*
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Form of Stock Unit Grant Notice and Stock Unit Agreement for non-employee directors under the Amended and Restated 2007 Equity
	Incentive Plan.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10-K
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-32405
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.33
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2/28/2014
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.43*
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Amended and Restated Employment Agreement, dated October 26, 2016, between Seattle Genetics, Inc. and Clay&nbsp;B.
	Siegall.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10-Q
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-32405
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.4
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10/27/2016
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.44*
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Amended and Restated Employment Agreement, dated October 26, 2016, between Seattle Genetics, Inc. and Todd&nbsp;E.
	Simpson.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10-Q
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-32405
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.5
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10/27/2016
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.45*
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Amended and Restated Employment Agreement, dated October&nbsp;26, 2016, between Seattle Genetics, Inc. and Eric&nbsp;L.
	Dobmeier.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10-Q
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-32405
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.6
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10/27/2016
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.46*
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Amended and Restated Employment Agreement, dated October 26, 2016, between Seattle Genetics, Inc. and Jonathan
	Drachman.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10-Q
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-32405
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.7
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10/27/2016
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.47*
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Amended and Restated Employment Agreement, dated October 26, 2016, between Seattle Genetics, Inc. and
	Vaughn&nbsp;Himes.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10-Q
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-32405
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.8
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10/27/2016
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.48*
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Amended and Restated Employment Agreement, dated October 26, 2016, between Seattle Genetics, Inc. and Jean
	Liu.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10-Q
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-32405
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.9
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10/27/2016
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.49*
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Amended and Restated Employment Agreement, dated October 26, 2016, between Seattle Genetics, Inc. and Darren
	Cline.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10-Q
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-32405
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.10
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10/27/2016
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.50*
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Seattle Genetics, Inc. 2016 Senior Executive Annual Bonus Plan.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8-K
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-32405
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.1
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1/29/2016
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	136
</FONT>
</P>
<A NAME="eolPage139"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_50"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="CENTER">
<TR>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD WIDTH="55%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.51*
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Seattle Genetics, Inc. 2017 Senior Executive Annual Bonus Plan
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	8-K
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-32405
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.1
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2/1/2017
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.52*
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Seattle Genetics, Inc. Long Term Incentive Plan for ECHELON-1.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10-Q
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-32405
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.2
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	7/26/2016
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.53*
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Form of Stock Option Agreement for Long Term Incentive Plan for ECHELON-1 under the Seattle Genetics, Inc. Amended and
	Restated 2007 Equity Incentive Plan.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10-Q
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-32405
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.3
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	7/26/2016
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.54*
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Seattle Genetics, Inc. Long Term Incentive Plan for SGN-CD33A.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10-Q
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-32405
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.2
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10/27/2016
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.55*
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Form of Stock Option Agreement for Long Term Incentive Plan for SGN-CD33A under the Seattle Genetics, Inc. Amended and
	Restated 2007 Equity Incentive Plan.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10-Q
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	000-32405
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.3
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10/27/2016
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	10.56+*
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Compensation Information for Executive Officers and Directors.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	21.1+
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Subsidiaries of Seattle Genetics, Inc.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	23.1+
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Consent of Independent Registered Public Accounting Firm.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	31.1+
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Certification of Chief Executive Officer pursuant to Rule 13a-14(a).
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	31.2+
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Certification of Chief Financial Officer pursuant to Rule 13a-14(a).
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	32.1+
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	32.2+
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Certification of Chief Financial Officer pursuant to 18&nbsp;U.S.C. Section 1350.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	101.INS+
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	XBRL Instance Document
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	101.SCH+
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	XBRL Taxonomy Extension Schema Document.
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	101.CAL+
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	XBRL Taxonomy Extension Calculation Linkbase Document
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	101.DEF+
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	XBRL Taxonomy Extension Definition Linkbase Document
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	101.LAB+
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	XBRL Taxonomy Extension Labels Linkbase Document
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="5" COLSPAN="3">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
<TD HEIGHT="5" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	101.PRE+
</FONT>
</TD>
<TD NOWRAP VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	XBRL Taxonomy Extension Presentation Linkbase Document
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#151;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="LINE-HEIGHT:8PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:2PX;BORDER-BOTTOM:0.5PT SOLID #000000;WIDTH:26%">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="1%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	+
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Filed herewith.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="1%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	&#134;
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Pursuant to a request for confidential treatment, portions of this Exhibit have been redacted from the publicly filed document and have been furnished separately to the
	Securities and Exchange Commission as required by Rule 24b-2 under the Securities Exchange Act of 1934.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="1%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	*
</FONT>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Indicates a management contract or compensatory plan or arrangement.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D481013D10K_HTM_TOC481013_21">
</A>
	Item&nbsp;16. Form 10-K Summary
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:-6PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Not applicable.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	137
</FONT>
</P>
<A NAME="eolPage140"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D481013D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
</EFX_EXHIBITS>
</EFX_PART_IV>
<EFX_SIGNATURES>
<A NAME="FIS_SIGNATURES"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
<A NAME="D481013D10K_HTM_TOC481013_22">
</A>
	SIGNATURES
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Pursuant to the requirements of Section&nbsp;13 or 15(d) of
	the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">
<TR>
<TD WIDTH="47%">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD WIDTH="3%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="48%">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Date: February 21, 2017
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" COLSPAN="3">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	S
<SMALL>
	EATTLE
</SMALL>
	G
<SMALL>
	ENETICS
</SMALL>
	, I
<SMALL>
	NC
</SMALL>
	.
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	By:&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX;BORDER-BOTTOM:1PX SOLID #000000" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	/
<SMALL>
	S
</SMALL>
	/ &nbsp;&nbsp;&nbsp;&nbsp;C
<SMALL>
	LAY
</SMALL>
	B.
	S
<SMALL>
	IEGALL
</SMALL>
</FONT>
</P>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Clay B. Siegall
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	President &amp; Chief Executive Officer
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	(Principal Executive
	Officer)
</I>
</FONT>
</P>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Date: February 21, 2017
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	By:&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX;BORDER-BOTTOM:1PX SOLID #000000" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	/
<SMALL>
	S
</SMALL>
	/ &nbsp;&nbsp;&nbsp;&nbsp;T
<SMALL>
	ODD
</SMALL>
	E.
	S
<SMALL>
	IMPSON
</SMALL>
</FONT>
</P>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Todd E. Simpson
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Chief Financial Officer
</I>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	(Principal Financial and Accounting
	Officer)
</I>
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Pursuant to the requirements
	of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">
<TR>
<TD WIDTH="40%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="35%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD WIDTH="21%">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<P STYLE="BORDER-BOTTOM:1PX SOLID #000000;WIDTH:33PT" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Signature
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<P STYLE="BORDER-BOTTOM:1PX SOLID #000000;WIDTH:15PT" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Title
</B>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<P STYLE="BORDER-BOTTOM:1PX SOLID #000000;WIDTH:16PT" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="1">
<B>
	Date
</B>
</FONT>
</P>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX;BORDER-BOTTOM:1PX SOLID #000000; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	/
<SMALL>
	S
</SMALL>
	/&nbsp;&nbsp;&nbsp;&nbsp;C
<SMALL>
	LAY
</SMALL>
	B.
	S
<SMALL>
	IEGALL
</SMALL>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Clay B. Siegall
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Director, President &amp;&nbsp;CEO&nbsp;(Principal Executive Officer)
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	February&nbsp;21, 2017
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX;BORDER-BOTTOM:1PX SOLID #000000; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	/
<SMALL>
	S
</SMALL>
	/&nbsp;&nbsp;&nbsp;&nbsp;T
<SMALL>
	ODD
</SMALL>
	E.
	S
<SMALL>
	IMPSON
</SMALL>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Todd E. Simpson
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Chief&nbsp;Financial&nbsp;Officer (Principal Financial and Accounting Officer)
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	February&nbsp;21, 2017
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX;BORDER-BOTTOM:1PX SOLID #000000; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	/
<SMALL>
	S
</SMALL>
	/&nbsp;&nbsp;&nbsp;&nbsp;S
<SMALL>
	RINIVAS
</SMALL>
	A
<SMALL>
	KKARAJU
</SMALL>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Srinivas Akkaraju
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Director
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	February&nbsp;21, 2017
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX;BORDER-BOTTOM:1PX SOLID #000000; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	/
<SMALL>
	S
</SMALL>
	/&nbsp;&nbsp;&nbsp;&nbsp;F
<SMALL>
	ELIX
</SMALL>
	B
<SMALL>
	AKER
</SMALL>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Felix Baker
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Director
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	February&nbsp;21, 2017
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX;BORDER-BOTTOM:1PX SOLID #000000; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	/
<SMALL>
	S
</SMALL>
	/&nbsp;&nbsp;&nbsp;&nbsp;D
<SMALL>
	AVID
</SMALL>
	W.
	G
<SMALL>
	RYSKA
</SMALL>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	David W. Gryska
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Director
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	February&nbsp;21, 2017
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX;BORDER-BOTTOM:1PX SOLID #000000; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	/
<SMALL>
	S
</SMALL>
	/&nbsp;&nbsp;&nbsp;&nbsp;M
<SMALL>
	ARC
</SMALL>
	E.
	L
<SMALL>
	IPPMAN
</SMALL>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Marc E. Lippman
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Director
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	February&nbsp;21, 2017
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX;BORDER-BOTTOM:1PX SOLID #000000; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	/
<SMALL>
	S
</SMALL>
	/&nbsp;&nbsp;&nbsp;&nbsp;J
<SMALL>
	OHN
</SMALL>
	A.
	O
<SMALL>
	RWIN
</SMALL>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	John A. Orwin
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Director
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	February&nbsp;21, 2017
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX;BORDER-BOTTOM:1PX SOLID #000000; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	/
<SMALL>
	S
</SMALL>
	/&nbsp;&nbsp;&nbsp;&nbsp;N
<SMALL>
	ANCY
</SMALL>
	A.
	S
<SMALL>
	IMONIAN
</SMALL>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Nancy A. Simonian
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Director
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	February&nbsp;21, 2017
</FONT>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX;BORDER-BOTTOM:1PX SOLID #000000; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	/
<SMALL>
	S
</SMALL>
	/&nbsp;&nbsp;&nbsp;&nbsp;D
<SMALL>
	ANIEL
</SMALL>
	G.
	W
<SMALL>
	ELCH
</SMALL>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Daniel G. Welch
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Director
</FONT>
</TD>
<TD VALIGN="BOTTOM">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	February&nbsp;21, 2017
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT SIZE="1">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	138
</FONT>
</P>
</EFX_SIGNATURES>
</EFX_FORM>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage141"></A>
<A NAME="D481013DEX1017_HTM"></A>
<EFX_EXHIBIT_10>
<A NAME="FIS_EXHIBIT_10"></A>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="RIGHT">
<B>
	Exhibit 10.17
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
	Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2017/02/21/0001193125-17-050543_G481013EX10_117.JPG" ALT="LOGO">
	Inspiring Science
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	Amendment to SGD-1006
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	Commercial Supply Agreement executed on 1&nbsp;December 2010.
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	[*] Manufacturing Controls Price Increase
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	27&nbsp;August 2013
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Vaughn Himes
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	VP, Manufacturing
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	21823- 30th Drive S.E.
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Bothell, WA 98021
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Dear Vaughn:
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Based on the recent Safebridge assessment of SGD-1006 and SGD-1010 occupation exposure level (OEL), a [*]classification has been applied to these molecules.
	This change in classification will require additional manufacturing containment and precautions for these [*].
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	This letter serves to amend the SGD-1006
	pricing outlined in the supply agreement executed on 1&nbsp;December 2010. The purpose of this costing revision is to capture the additional time and materials required to manufacture SGD-1006 [*].
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	[*] implementation will require extended suite time, additional materials, and FTEs. It is estimated that the implementation will result in a cost increase of
<B>
	[*]
</B>
	. Based on this assessment Seattle Genetics have agreed to increase payment for the [*]. The revised price per gram is outlined in the table below:
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_51"></A>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Revised SGD-1006 Pricing Schedule:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT" ALIGN="CENTER">
<TR>
<TD WIDTH="24%">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD WIDTH="24%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="25%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="24%">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID ; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	SG6 Quantity (g)
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	Current Price ($)/g
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	Batch Cost Increase
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	Revised Cost/g
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID ; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:12PT">
<TD VALIGN="TOP" ALIGN="CENTER">
<B>
	[*]
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
<B>
	[*]
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
<B>
	[*]
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
<B>
	[*]
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	[*]
</B>
</P>
<A NAME="eolPage142"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2017/02/21/0001193125-17-050543_G481013EX10_117.JPG" ALT="LOGO">
	Inspiring Science
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	IN WITNESS WHEREOF, the parties have executed this Amendment, effective as of the Amendment Effective
	Date.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; TEXT-INDENT:-2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Agreed and Accepted:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TR>
<TD WIDTH="4%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="41%">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD WIDTH="5%">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD WIDTH="4%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="42%">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID ; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" COLSPAN="3">
	SAFC, Inc.
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="3">
	Seattle Genetics, Inc.
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID ; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	By:
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; BORDER-BOTTOM:1PX SOLID #000000; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	/s/ Gills Cotter
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	By:
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; BORDER-BOTTOM:1PX SOLID #000000; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	/s/ Clay B. Siegall
</P>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID ; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	Name:
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; BORDER-BOTTOM:1PX SOLID #000000; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Gills Cotter
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	Name:
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; BORDER-BOTTOM:1PX SOLID #000000; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Clay B. Siegall
</P>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID ; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	Title:
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; BORDER-BOTTOM:1PX SOLID #000000; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	President
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	Title:
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; BORDER-BOTTOM:1PX SOLID #000000; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	President and CEO
</P>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID ; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	Date:
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; BORDER-BOTTOM:1PX SOLID #000000; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	December 15, 2014
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	Date:
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; BORDER-BOTTOM:1PX SOLID #000000; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	January 20, 2014
</P>
</TD>
</TR>
</TABLE>
</EFX_EXHIBIT_10>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage143"></A>
<A NAME="D481013DEX1018_HTM"></A>
<EFX_EXHIBIT_10>
<A NAME="FIS_EXHIBIT_10_2"></A>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="RIGHT">
<B>
	Exhibit 10.18
</B>
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="83%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="12%">
</TD>
<TD>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID ; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="BOTTOM" ROWSPAN="5" NOWRAP>
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2017/02/21/0001193125-17-050543_G481013EX10_118.JPG" ALT="LOGO">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	3050 Spruce Street
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID ; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	St.&nbsp;Louis,&nbsp;MO&nbsp;63103
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID ; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	Tel (800) 448-0471
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID ; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	Fax (314) 286-7817
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID ; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<B>
	www.safcglobal.net
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately
	with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Second Amendment
	to SGD-1006
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Commercial Supply Agreement executed on 1&nbsp;December 2010 and
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	First Amendment to Commercial Supply Agreement executed on
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	20&nbsp;January 2014 (the &#147;First Amendment&#148;)(the Commercial Supply
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Agreement together with the First Amendment, the &#147;Supply Agreement&#148;)
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	19&nbsp;September 2016
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Vaughn Himes
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	21823 30
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	th
</SUP>
	Drive S.E.
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Bothell, WA 98021
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Dear Vaughn
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	This letter agreement (the &#147;Second Amendment&#148;) confirms the Parties&#146; agreement to amend the Supply Agreement to change the price per gram/per
	Batch (the &#147;Price&#148;) for SGD 1006 set forth in Appendix C to the Supply Agreement. The purpose of the pricing revision is to a) capture the cost of the [*] used in the manufacture of SGD-1006, b) capture the operational efficiencies gained
	during the manufacturing of the [*] c) capture the increased labor and overhead costs in the [*], and d) capture the [*] inventory remaining from production [*]. Beginning as of January&nbsp;1, 2017, certain [*], as listed in the second table below,
	that were previously provided [*] in accordance with cGMP, Applicable Laws and the Quality Agreement, and the [*]. Through 2016, these [*] had been provided by or purchased separately by [*]. In addition, effective as of January&nbsp;1, 2017, any
	[*] from each batch production will now be owned by [*].
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The table below compares the current price per gram under the First Amendment with the Price per
	gram effective as of the Effective Date of this Second Amendment.
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_52"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="86%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="11%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID ; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM" NOWRAP>
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:84.85PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN">
	SGD-1006 - 300 gm batch
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
	Price&nbsp;per&nbsp;gm
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID ; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	First Amendment to Commercial Supply Agreement executed on 20&nbsp;January 2014
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<B>
	[*]
</B>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID ; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Second Amendment to Commercial Supply Agreement
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
<B>
	[*]
</B>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<B>
	&nbsp;
</B>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="LINE-HEIGHT:3.0PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:2PT;BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="50%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="48%">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID ; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	CONFIDENTIAL
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
	Page1 of 3
</TD>
</TR>
</TABLE>
<A NAME="eolPage144"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2017/02/21/0001193125-17-050543_G481013EX10_118.JPG" ALT="LOGO">
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="LINE-HEIGHT:3.0PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:2PT;BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The table below itemizes the components of the amended Price.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	[*]
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="LINE-HEIGHT:3.0PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:2PT;BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In addition to the [*] in this Second Amendment, SAFC
	and Seattle Genetics agree to perform an analysis of the [*] prior to discussing any change to the Price for 2018 to further [*].
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Price as set forth
	in this Second Amendment shall be effective as of the first date of Manufacture of the [*].
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Terms capitalized, but not defined, herein shall have the
	meaning ascribed to them in the Supply Agreement. This Second Amendment shall be effective as of the date of the last signature below (the &#147;Effective Date&#148;). Except as set forth in this Second Amendment, all of the terms and conditions of
	the Supply Agreement remain in full force and effect.
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="50%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="48%">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID ; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	CONFIDENTIAL
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
	Page 2 of 3
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately
	with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
</P>
<A NAME="eolPage145"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2017/02/21/0001193125-17-050543_G481013EX10_118.JPG" ALT="LOGO">
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	IN WITNESS WHEREOF, the parties have executed this Second amendment by their duly authorized representatives, effective as
	of the Effective Date.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Agreed and accepted:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TR>
<TD WIDTH="4%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="41%">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD WIDTH="5%">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD WIDTH="4%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="42%">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID ; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" COLSPAN="3">
	SAFC, INC
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="3">
	SEATTLE GENETICS, INC.
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID ; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	By
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; BORDER-BOTTOM:1PX SOLID #000000; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	/s/ Mike Smith
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	By
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; BORDER-BOTTOM:1PX SOLID #000000; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	/s/ Vaughn B. Himes
</P>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID ; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	Name
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; BORDER-BOTTOM:1PX SOLID #000000; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Mike Smith
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	Name
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; BORDER-BOTTOM:1PX SOLID #000000; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Vaughn B. Himes
</P>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID ; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<A NAME="FIS_UNIDENTIFIED_TABLE_53"></A>
	Title
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; BORDER-BOTTOM:1PX SOLID #000000; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Site Director
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	Title
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; BORDER-BOTTOM:1PX SOLID #000000; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	EVP
</P>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID ; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	Date
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; BORDER-BOTTOM:1PX SOLID #000000; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	November 22, 2016
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	Date
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; BORDER-BOTTOM:1PX SOLID #000000; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	December 2, 2016
</P>
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
</TABLE>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="50%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="48%">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID ; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	CONFIDENTIAL
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" ALIGN="RIGHT">
	Page 3 of 3
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately
	with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
</P>
</EFX_EXHIBIT_10>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage146"></A>
<A NAME="D481013DEX1029_HTM"></A>
<EFX_EXHIBIT_10>
<A NAME="FIS_EXHIBIT_10_3"></A>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="RIGHT">
<B>
	Exhibit 10.29
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
	Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	TENTH AMENDMENT
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	TO DEVELOPMENT AND SUPPLY AGREEMENT
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Effective as of the date of the last signature below, AbbVie Inc. (the successor in interest to Abbott Laboratories&#146; research-based
	pharmaceuticals business), a Delaware corporation having a principal place of business at 1 N Waukegan Road, North Chicago, IL 60064 (&#147;
<B>
<I>
	AbbVie
</I>
</B>
	&#148;), and Seattle Genetics, Inc., a Delaware corporation having a principal place of
	business at 21823 &#150; 30
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	th
</SUP>
	Drive Southeast in Bothell, Washington 98021 (&#147;
<B>
<I>
	Seattle Genetics
</I>
</B>
	&#148;) (individually the &#147;
<B>
<I>
	Party
</I>
</B>
	&#148; or collectively the
	&#147;
<B>
<I>
	Parties
</I>
</B>
	&#148;) agree to the following terms and conditions as set forth below (this &#147;
<B>
<I>
	Tenth Amendment
</I>
</B>
	&#148;). Capitalized terms used but not defined herein shall have the meaning ascribed to them in the
	Agreement (as defined below).
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	WHEREAS,
</B>
	the Parties entered into a Development and Supply Agreement with an Effective Date of
	February&nbsp;23, 2004 for the manufacture of a chimeric anti-CD30 AC10 monoclonal antibody known as cAC10 Bulk Drug Substance (the &#147;
<B>
<I>
	Original Agreement
</I>
</B>
	&#148;), which also constitutes the antibody component of SGN-35, and the
	Parties subsequently entered into nine amendments to the Original Agreement and, collectively, the Original Agreement and those nine amendments are hereinafter referred to as the &#147;
<B>
<I>
	Agreement
</I>
</B>
	&#148;;
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	WHEREAS,
</B>
	Abbott Laboratories (&#147;
<B>
<I>
	Abbott
</I>
</B>
	&#148;) and AbbVie entered into a Separation and Distribution Agreement dated
	as of November&nbsp;28, 2012 (the &#147;
<B>
<I>
	Separation and Distribution Agreement
</I>
</B>
	&#148;), which provided for, among other things, the separation of Abbott&#146;s research-based pharmaceuticals business from its other business by the
	contribution from Abbott to AbbVie of certain assets, the assumption of AbbVie of certain Liabilities (as defined in the Separation and Distribution Agreement) from Abbott, the distribution by Abbott of AbbVie common stock to Abbott shareholders,
	and the execution and delivery of certain agreements in order to facilitate and provide for the foregoing, in each case subject to the terms and conditions set forth therein;
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	WHEREAS
</B>
	, in connection with the Separation and Distribution Agreement, Abbott assigned, transferred and conveyed all of its rights and
	obligations under the Agreement to AbbVie and AbbVie accepted and assumed all rights and obligations of Abbott under the Agreement as further set forth below; and
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	WHEREAS
</B>
	, the Parties desire to further amend the Agreement as herein provided as of the date of the last signature below.
</P>
<A NAME="eolPage147"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	NOW, THEREFORE,
</B>
	in consideration of the mutual covenants and agreements contained here and
	for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows:
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	1.
<U>
	Incorporation of the Agreement
</U>
	. All capitalized terms which are used but not otherwise defined herein shall have the same meanings as set forth in the Agreement, and the Agreement, to the extent not inconsistent with this Tenth Amendment, is
	incorporated herein by this reference as though the same was set forth in its entirety. To the extent any terms and provisions of the Agreement are inconsistent with this Tenth Amendment, such terms and provisions shall be deemed superseded by the
	Tenth Amendment. Except as specifically set forth herein, the Agreement shall remain in full force and effect and its provisions shall be binding on the Parties.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	2.
<U>
	Amendment of the Agreement
</U>
	. The Agreement is hereby amended as follows:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	a.
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Any reference to &#147;Abbott&#148; in the Agreement is hereby replaced by &#147;AbbVie.&#148;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	b.
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Section&nbsp;1.33 of the Agreement is hereby deleted in its entirety and replaced with the following:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	&#147;1.33 &#147;
<B>
	[*]
</B>
	&#148; means, for (i)&nbsp;Contract Years [*] of Bulk Drug Substance, and (ii)&nbsp;all remaining Contract Years
	during the Term, [*] of Bulk Drug Substance.&#148;
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	c.
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Any reference to &#147;[*]&#148; in the Agreement is hereby deleted and replaced with &#147;[*]&#148; and corresponding references are amended accordingly.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	d.
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Section&nbsp;1.55 of the Agreement is hereby deleted in its entirety and replaced with the following:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	&#147;1.55 &#147;[*]&#148; means, for (i)&nbsp;Contract Years [*] thru and including Contract Year [*], [*] of Bulk Drug Substance per
<B>
	[*]
</B>
	or (ii)&nbsp;beginning in any Contract Year in which [*] and for every Contract Year thereafter,
<B>
	[*]
</B>
	of Bulk Drug Substance per [*]&#148;
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	e.
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Section&nbsp;1.56 of the Agreement is hereby added as follows:
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	&#147;1.56
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	&#147;Seattle Genetics ADCETRIS Territory&#148; means the United States and Canada.&#148;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	f.
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Section&nbsp;7.1 of the Agreement is hereby amended to include three additional paragraphs at the end of Section&nbsp;7.1 as follows:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	&#147;Through [*], and except for Bulk Drug Substance produced by the Second Source in accordance with the above provisions in this
	Section&nbsp;7.1: (i)&nbsp;AbbVie shall, and shall [*], manufacture and deliver Bulk Drug Substance for the [*], in accordance with the terms of this Agreement, for the benefit of Seattle Genetics or, as mutually agreed upon between the Parties from
	time to time, its designee, and (ii)&nbsp;Seattle Genetics shall [*] purchase, in accordance with this Section&nbsp;7.1 and the terms of this Agreement, from AbbVie [*] for the [*], in [*] pursuant to Section&nbsp;9.9 and [*], provided AbbVie is
	able to supply Bulk Drug Substance in accordance with this Section&nbsp;7.1 and with Article 9.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	[*] = Certain confidential information
	contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
</P>
<A NAME="eolPage148"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	[*], notwithstanding anything to the contrary in the above provisions in this Section&nbsp;7.1,
	Seattle Genetics and/or its designee shall have the [*] so long as Seattle Genetics fulfills [*] pursuant to Section&nbsp;9.9 of the Agreement, to [*]. For the sake of clarity, notwithstanding the foregoing, Seattle Genetics and/or its designee
	shall be permitted to [*] in anticipation of the [*]. In the event the [*], this Agreement shall remain in full force and effect and Seattle Genetics shall continue to meet all of its obligations under the Agreement, including but not limited to
	fulfilling its [*] pursuant to Section&nbsp;9.9 of the Agreement.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	AbbVie acknowledges and approves of [*] (doing business as [*]) as the
	[*] and sole &#147;designee&#148; as referenced in this Section&nbsp;7.1.&#148;
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	g.
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Section&nbsp;9.4 of the Agreement is hereby deleted in its entirety and replaced with the following:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	&#147;9.4
<U>
	Rolling Forecast
</U>
	. [*] of each Calendar Quarter, Seattle Genetics shall provide to AbbVie a rolling [*] forecast of its
	requirements of Bulk Drug Substance to be supplied by AbbVie (&#147;
<U>
	Rolling Forecast
</U>
	&#148;). [*].&#148;
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	h.
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	The first full sentence of Section&nbsp;9.9 of the Agreement is hereby deleted in its entirety and replaced with the following:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	&#147;9.9 [*]. Seattle Genetics shall [*] for each Contract Year commencing in the [*].&#148;
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The remaining sentences in Section&nbsp;9.9 of the Agreement are unchanged.
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	i.
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Section&nbsp;12.1 of the Agreement is hereby deleted in its entirety and replaced with the following:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	&#147;12.1
<U>
	Term
</U>
	. This Agreement shall become effective as of the Effective Date, and unless sooner terminated hereunder, shall continue
	in effect through and including December&nbsp;31, 2025 (the &#147;
<U>
	Term
</U>
	&#148;). THE TERM SHALL AUTOMATICALLY BE EXTENDED ONE (1)&nbsp;YEAR TO DECEMBER 31, 2026, UNLESS EITHER PARTY PROVIDES WRITTEN NOTICE TO THE OTHER PARTY BY JUNE 30, 2024
	THAT IT ELECTS NOT TO HAVE THE TERM BE SO EXTENDED.&#148;
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	3.
<U>
	Bulk Drug Substance Pricing
</U>
	. Exhibit D shall hereby be deleted in its
	entirety and be replaced by the new Exhibit D attached to this Tenth Amendment.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	[*] = Certain confidential information
	contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
</P>
<A NAME="eolPage149"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	4.
<U>
	Effectuation
</U>
	. The amendment to the Agreement contemplated by this Tenth Amendment shall
	be deemed effective as of the last date written below upon the full execution of this Tenth Amendment and without any further action required by the Parties hereto. There are no conditions precedent or subsequent to the effectiveness of this Tenth
	Amendment. All terms and conditions set forth in the Agreement that are not amended hereby shall remain in full force and effect. Any term of this Tenth Amendment may be amended with the written consent of both Parties. From the date hereof, any
	reference to the Agreement shall be deemed to refer to the Agreement as amended by this Tenth Amendment.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	5.
<U>
	Counterparts
</U>
	. This
	Tenth Amendment may be executed in one or more counterparts, each of which shall be deemed to be an original, but all of which together shall constitute one and the same instrument. One or more counterparts of this Tenth Amendment may be delivered
	by facsimile, with the intention that delivery by such means shall have the same effect as delivery of an original counterpart thereof.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	6.
<U>
	Entire Agreement
</U>
	. This Tenth Amendment is the product of both Parties, and together with the Agreement and exhibits thereto,
	constitute the entire agreement between the Parties pertaining to the subject matter hereof, and merge all prior negotiations and drafts of the Parties with regard to the transactions contemplated herein.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	[*] = Certain confidential information
	contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
</P>
<A NAME="eolPage150"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	IN WITNESS WHEREOF,
</B>
	the Parties have caused this Tenth Amendment to be executed by their
	duly authorized officers as of the date of the last signature set forth below.
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TR>
<TD WIDTH="4%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="41%">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD WIDTH="5%">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD WIDTH="4%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="42%">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID ; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" COLSPAN="3">
<B>
	ABBVIE INC.
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="3">
<B>
	SEATTLE GENETICS, INC.
</B>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID ; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	By:
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; BORDER-BOTTOM:1PX SOLID #000000; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	/s/ Keith Kentala
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	By:
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; BORDER-BOTTOM:1PX SOLID #000000; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	/s/ Clay B. Siegall
</P>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID ; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	Name:
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; BORDER-BOTTOM:1PX SOLID #000000; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Keith Kentala
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	Name:
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; BORDER-BOTTOM:1PX SOLID #000000; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Clay B. Siegall
</P>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID ; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	Title:
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; BORDER-BOTTOM:1PX SOLID #000000; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	VP, Operations Commercial Development
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	Title:
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; BORDER-BOTTOM:1PX SOLID #000000; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	President &amp; CEO
</P>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID ; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	Date:
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; BORDER-BOTTOM:1PX SOLID #000000; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	12/23/2016
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	Date:
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; BORDER-BOTTOM:1PX SOLID #000000; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	12/26/2016
</P>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:12PT; MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	[*] = Certain confidential information
	contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
</P>
<A NAME="eolPage151"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
<U>
	EXHIBIT D
</U>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	[*]
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Subject to adjustments made pursuant to the paragraphs set
	forth below, [*] includes [*] but excludes the following associated costs: (i)[*]; and (ii)&nbsp;[*] uniquely related to the ongoing [*] manufacture of Bulk Drug Substance.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Parties agree the [*] as listed in this Exhibit D does [*], which may require [*]. During the course of the Term, the Parties shall [*] regarding the [*],
	which may result in a cost per gram [*]. If AbbVie cannot implement a [*], the [*] for [*] will [*] as noted above.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	AbbVie may [*] above due to [*] if
	such [*] are demonstrated to be [*].
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	AbbVie may [*], effective [*] of each [*]. [*] shall be effective for deliveries of [*] beginning [*] of each [*].
	Such adjustment shall not exceed the [*] of the most recent [*] period of which figures are available in the [*], issued by the Bureau of Labor Statistics, U.S. Department of Labor. Beginning [*], the [*] will be the [*] or the [*].
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Prices to be paid are applicable to [*], and are not intended to apply on an [*]. For example, if Seattle Genetics [*] and [*] during a particular [*],
	Seattle Genetics shall pay a price equal to [*] purchased during such [*].
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	[*] = Certain confidential information
	contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
</P>
</EFX_EXHIBIT_10>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage152"></A>
<A NAME="D481013DEX1035_HTM"></A>
<EFX_EXHIBIT_10>
<A NAME="FIS_EXHIBIT_10_4"></A>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="RIGHT">
<B>
	Exhibit 10.35
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	SEATTLE GENETICS, INC.
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
<U>
	AMENDED AND RESTATED 2000 EMPLOYEE STOCK PURCHASE PLAN
</U>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Adopted by the Board of Directors: November&nbsp;16, 2000
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Approved by the Stockholders: February&nbsp;14, 2001
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Amended and Restated by the Board of Directors: February&nbsp;1, 2011
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Amended and Restated by the Board of Directors: February&nbsp;11, 2011
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Approved by the Stockholders: May&nbsp;20, 2011
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Amended and Restated by the Board of Directors: February&nbsp;9, 2015
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Approved by the Stockholders: May&nbsp;15, 2015
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Amended and Restated by the Board of Directors: November&nbsp;11, 2016
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The following constitute the provisions of the Amended and Restated 2000 Employee Stock Purchase Plan of Seattle Genetics, Inc.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	1.&nbsp;
<B>
<U>
	Purpose
</U>
	.
</B>
	&nbsp;The purpose of the Plan is to provide employees of the Company and its Designated Subsidiaries with an
	opportunity to purchase Common Stock of the Company. It is the intention of the Company to have the Plan qualify as an &#147;Employee Stock Purchase Plan&#148; under Section&nbsp;423 of the Code. The provisions of the Plan shall, accordingly, be
	construed so as to extend and limit participation in a manner consistent with the requirements of that section of the Code.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	2.&nbsp;
<B>
<U>
	Definitions
</U>
</B>
	.
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(a)&nbsp;
<B>
	&#147;
<U>
	Board
</U>
	&#148;
</B>
	&nbsp;means the Board of Directors of the Company.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(b)&nbsp;
<B>
	&#147;
<U>
	Code
</U>
	&#148;
</B>
	&nbsp;means the Internal Revenue Code of 1986, as amended.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(c)&nbsp;
<B>
	&#147;
<U>
	Common Stock
</U>
	&#148;
</B>
	&nbsp;means the Common Stock of the Company.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(d)&nbsp;
<B>
	&#147;
<U>
	Company
</U>
	&#148;
</B>
	&nbsp;means Seattle Genetics, Inc., a Delaware corporation.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(e)&nbsp;
<B>
	&#147;
<U>
	Committee
</U>
	&#148;
</B>
	&nbsp;means a committee of one (1)&nbsp;or more members of the Board to whom authority has been
	delegated by the Board in accordance with Section&nbsp;13(c).
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(f)&nbsp;
<B>
	&#147;
<U>
	Compensation
</U>
	&#148;
</B>
	&nbsp;means total cash
	compensation received by an Employee from the Company or a Designated Subsidiary. By way of illustration, but not limitation, Compensation includes regular compensation such as salary, wages, overtime, shift differentials, bonuses (other than
	bonuses offered in connection with, and as an inducement for, the commencement of employment), commissions and incentive compensation, but excludes relocation payments or reimbursements, expense reimbursements, tuition or other reimbursements,
	automobile allowances, housing allowances, cash payments in lieu of sick or vacation time benefits and income realized as a result of participation in any stock option, stock purchase, or similar plan of the Company or any Designated Subsidiary.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(g)&nbsp;
<B>
	&#147;
<U>
	Continuous Status as an Employee
</U>
	&#148;
</B>
	&nbsp;means the absence of any interruption or termination of service
	as an Employee. Continuous Status as an Employee shall not be considered interrupted in the case of (i)&nbsp;sick leave; (ii)&nbsp;military leave; (iii)&nbsp;any other leave of absence approved by the Administrator, provided that such leave is for a
	period of not more than 90 days, unless reemployment upon the expiration of such leave is guaranteed by contract or statute, or unless provided otherwise pursuant to Company policy adopted from time to time; or (iv)&nbsp;in the case of transfers
	between locations of the Company or between the Company and its Designated Subsidiaries.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(h) &#147;
<B>
<U>
	Contributions
</U>
</B>
	&#148;
	means all amounts credited to the account of a participant pursuant to the Plan.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(i)&nbsp;
<B>
	&#147;
<U>
	Corporate
	Transaction
</U>
	&#148;
</B>
	&nbsp;means any of the following, unless the Board provides otherwise: (i)&nbsp;an acquisition of the Company by another entity by means of any transaction or series of related transactions (including, without limitation,
	any reorganization, merger or consolidation but excluding any merger effected exclusively for the purpose of changing the domicile of the Company), (ii)&nbsp;a sale of all or substantially all of the
</P>
<A NAME="eolPage153"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	assets of the Company, so long as in either (i)&nbsp;or (ii)&nbsp;above, the Company&#146;s stockholders of record immediately prior to such transaction will, immediately after such transaction,
	hold less than fifty percent (50%)&nbsp;of the voting power of the surviving or acquiring entity or (iii)&nbsp;any other event specified by the Board; provided, however, that no Corporate Transaction (or any analogous term) shall be deemed to occur
	upon announcement or commencement of a tender offer or upon a &#147;potential&#148; takeover or upon shareholder approval of a merger or other transaction, in each case without a requirement that the Corporate Transaction actually occur.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(j) &#147;
<B>
<U>
	Designated Subsidiaries
</U>
</B>
	&#148; means the Subsidiaries which have been designated by the Board from time to time in its
	sole discretion as eligible to participate in the Plan.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(k)
<B>
	&#147;
<U>
	Director
</U>
</B>
	&#148; means a member of the Board.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(l) &#147;
<B>
<U>
	Employee
</U>
</B>
	&#148; means any person, including an Officer, who is customarily employed for at least twenty (20)&nbsp;hours
	per week and more than five (5)&nbsp;months in a calendar year by the Company or one of its Designated Subsidiaries. However, service solely as a Director, or payment of a fee for such services, shall not cause a Director to be considered an
	&#147;Employee&#148; for purposes of the Plan.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(m) &#147;
<B>
<U>
	Exchange Act
</U>
</B>
	&#148; means the Securities Exchange Act of 1934, as
	amended.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(n) &#147;
<B>
<U>
	Offering Date
</U>
</B>
	&#148; means the first business day of each Offering Period of the Plan.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(o) &#147;
<B>
<U>
	Offering Period
</U>
</B>
	&#148; means a period of approximately six (6)&nbsp;months commencing on or about February&nbsp;1 and
	August&nbsp;1 of each year (or at such other time or times as may be determined by the Board of Directors).
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(p)
	&#147;
<B>
<U>
	Officer
</U>
</B>
	&#148; means a person who is an officer of the Company within the meaning of Section&nbsp;16 of the Exchange Act and the rules and regulations promulgated thereunder.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(q) &#147;
<B>
<U>
	Plan
</U>
</B>
	&#148; means this Amended and Restated 2000 Employee Stock Purchase Plan.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(r) &#147;
<B>
<U>
	Purchase Date
</U>
</B>
	&#148; means the last day of each Offering Period of the Plan.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(s) &#147;
<B>
<U>
	Purchase Price
</U>
</B>
	&#148; means with respect to an Offering Period an amount equal to 85% of the Fair Market Value (as
	defined in Section&nbsp;7(b) below) of a Share of Common Stock on the Offering Date or on the Purchase Date, whichever is lower.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(t)
	&#147;
<B>
<U>
	Securities Act
</U>
</B>
	&#148; means the Securities Act of 1933, as amended.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(u) &#147;
<B>
<U>
	Share
</U>
</B>
	&#148; means a share
	of Common Stock, as adjusted in accordance with Section&nbsp;18 of the Plan.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(v) &#147;
<B>
<U>
	Subsidiary
</U>
</B>
	&#148; means a
	corporation, domestic or foreign, as such term is defined in Section&nbsp;424(f) of the Code, whether or not such corporation now exists or is hereafter organized or acquired by the Company or a Subsidiary.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(w) &#147;
<B>
<U>
	Trading Day
</U>
</B>
	&#148; means any day on which the exchange(s) or market(s) on which shares of Common Stock are listed,
	including the Nasdaq Global Select Market, the Nasdaq Global Market, or the Nasdaq Capital Market, is open for trading.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	3.&nbsp;
<B>
<U>
	Eligibility
</U>
	.
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(a) Any person who has been an Employee for a continuous period of at least thirty (30)&nbsp;days ending on the Offering Date of a given
	Offering Period shall be eligible to participate in such Offering Period under the Plan, subject to the requirements of Section&nbsp;5(a) and the limitations imposed by Section&nbsp;423(b) of the Code. Each person who first becomes an Employee
	during an Offering Period shall not be eligible to participate in such Offering Period, but shall be eligible to participate in subsequent Offering Periods.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(b) Any provisions of the Plan to the contrary notwithstanding, no Employee shall be granted an option under the Plan (i)&nbsp;if, immediately
	after the grant, such Employee (or any other person whose stock would be attributed to such Employee pursuant to Section&nbsp;424(d) of the Code) would own capital stock of the Company and/or hold outstanding options to purchase stock possessing
	five percent (5%)&nbsp;or more of the total combined voting
</P>
<A NAME="eolPage154"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	power or value of all classes of stock of the Company or of any subsidiary of the Company, or (ii)&nbsp;if such option would permit his or her rights to purchase stock under all employee stock
	purchase plans (described in Section&nbsp;423 of the Code) of the Company and its Subsidiaries to accrue at a rate which exceeds Twenty-Five Thousand Dollars ($25,000) of the Fair Market Value (as defined in Section&nbsp;7(b) below) of such stock
	(determined on the Offering Date of such option) for each calendar year in which such option is outstanding at any time.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	4.&nbsp;
<B>
<U>
	Offering Periods
</U>
	.
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(a)&nbsp;
<B>
<U>
	Offering Periods
</U>
	.
</B>
	&nbsp;The Plan shall be implemented by a series of Offering Periods of approximately six
	(6)&nbsp;months duration, with new Offering Periods commencing on or about February&nbsp;1 and August&nbsp;1 of each year (or at such other time or times as may be determined by the Board of Directors). The Plan shall continue until terminated in
	accordance with Section&nbsp;19 hereof. The Board of Directors of the Company shall have the power to change the duration and/or the frequency of Offering Periods with respect to future offerings without stockholder approval if such change is
	announced at least fifteen (15)&nbsp;days prior to the scheduled beginning of the first Offering Period to be affected. Notwithstanding the foregoing, if any Offering Date falls on a day that is not a Trading Day, then such Offering Date shall
	instead fall on the next subsequent Trading Day.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(b)&nbsp;
<B>
<U>
	Purchase Dates
</U>
	.
</B>
	&nbsp;The Purchase Date of an Offering Period
	commencing on February&nbsp;1 shall be the next July&nbsp;31 and the Purchase Date of an Offering Period commencing on August&nbsp;1 shall be the next January&nbsp;31. The Board of Directors of the Company shall have the power to change the
	frequency of Purchase Dates with respect to future purchases without stockholder approval if such change is announced at least fifteen (15)&nbsp;days prior to the scheduled beginning of the first Offering Period to be affected. Notwithstanding the
	foregoing, if any Purchase Date falls on a day that is not a Trading Day, then such Purchase Date shall instead fall on the immediately preceding Trading Day.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	5.&nbsp;
<B>
<U>
	Participation
</U>
	.
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(a) An eligible Employee may become a participant in the Plan by completing the electronic enrollment process designated by the Company during
	the open enrollment period prescribed by the Company. The electronic enrollment interface shall require the participant to specify the percentage of the participant&#146;s Compensation (subject to Section&nbsp;6 below) to be paid as Contributions
	pursuant to the Plan. Once an Employee affirmatively enrolls in an Offering Period and authorizes payroll deductions, the Employee automatically shall be enrolled for all subsequent Offering Periods until he or she elects to withdraw from an
	Offering Period pursuant to Section&nbsp;10 or terminates his or her participation in the Plan.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(b) Payroll deductions shall commence on
	the first payroll paid following the Offering Date and shall end on the last payroll paid on or prior to the Purchase Date to which the election is applicable, unless sooner terminated by the participant as provided in Section&nbsp;10.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	6.&nbsp;
<B>
<U>
	Method of Payment For Purchase of Shares
</U>
	.
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(a) This Plan shall be operated as a payroll deduction plan.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(b) A participant shall elect to have payroll deductions made on each payday during an Offering Period in an amount not less than one
	percent&nbsp;(1%) and not more than twenty percent (20%)&nbsp;(or such other maximum percentage as the Board may establish from time to time before an Offering Date) of such participant&#146;s Compensation on each payday during the Offering Period.
	All payroll deductions made by a participant shall be credited to his or her account under the Plan. Once a participant is participating in the Plan on a payroll deduction basis, he or she may not make any additional payments into such account.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Notwithstanding the foregoing or anything to the contrary herein, due to certain payroll deductions and withholdings, a participant&#146;s
	Contributions on any payday during an Offering Period may be less than the percentage of Compensation that the participant elected to have contributed to the Plan on such payday. On each payday during an Offering Period, a participant&#146;s
	Contributions shall be deducted from the participant&#146;s Compensation after deducting any (i)&nbsp;amounts elected to be deferred by the participant under any qualified cash or deferred arrangement described in Section&nbsp;401(k) of the Code or
	other deferred compensation program or arrangement established by the Company or a Designated Subsidiary, (ii)&nbsp;payments for coverage under any Company or Designated Subsidiary health insurance plan or other employee benefit plan,
	(iii)&nbsp;contributions to any Company or Designated Subsidiary
</P>
<A NAME="eolPage155"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	flexible spending account plan, (iv)&nbsp;other pre-tax deductions, (v)&nbsp;other deductions designated by the Company or a Designated Subsidiary, and (vi)&nbsp;applicable tax withholding. As a
	result, a participant may not be able to make Contributions on any payday during an Offering Period at the percentage of Compensation that the participant elected to have contributed to the Plan on such payday, and in such event, neither the Company
	nor any Designated Subsidiary shall have the obligation to make up for any difference between the participant&#146;s actual Contributions on such payday and the percentage of Compensation that the participant elected to have contributed to the Plan
	on such payday.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(c) A participant may discontinue his or her participation in the Plan as provided in Section&nbsp;10 or, on one occasion
	only during an Offering Period may decrease the rate of his or her Contributions with respect to the Offering Period to a rate not lower than one percent (1%), by authorizing a change in the payroll deduction rate in the manner designated in the
	Company&#146;s electronic ESPP interface. Any change in the rate of Contributions pursuant to this Section&nbsp;6(c) shall be effective as soon as administratively possible, but in no event later than thirty (30)&nbsp;days after the date the change
	is authorized. A participant may not increase the rate of his or her Contributions with respect to the Offering Period during an Offering Period.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(d) Notwithstanding the foregoing, to the extent necessary to comply with Section&nbsp;423(b)(8) of the Code and Section&nbsp;3(b), a
	participant&#146;s payroll deductions may be decreased by the Company to 0% at any time during an Offering Period. Payroll deductions shall re-commence at the rate provided in such participant&#146;s election at the beginning of the first Offering
	Period which is scheduled to end in the following calendar year, unless terminated by the participant as provided in Section&nbsp;10. In addition, a participant&#146;s payroll deductions may be decreased by the Company to 0% at any time during an
	Offering Period in order to avoid unnecessary payroll contributions as a result of application of the maximum share limit set forth in Section&nbsp;7(a), or as a result of the limitations set forth in Section&nbsp;3(b), in which case payroll
	deductions shall re-commence at the rate provided in such participant&#146;s election at the beginning of the next Offering Period, unless terminated by the participant as provided in Section&nbsp;10.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(e) At the time the option is exercised, in whole or in part, or at the time some or all of the Company&#146;s Common Stock issued under the
	Plan is disposed of, the participant must make adequate provision for the Company&#146;s federal, state, or other tax withholding obligations, if any, which arise upon the exercise of the option or the disposition of the Common Stock. At any time,
	the Company may, but shall not be obligated to, withhold from the participant&#146;s compensation the amount necessary for the Company to meet applicable withholding obligations, including any withholding required to make available to the Company
	any tax deductions or benefits attributable to sale or early disposition of Common Stock by the participant.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	7.&nbsp;
<B>
<U>
	Grant of
	Option
</U>
	.
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(a) Subject to the final sentence of this Section&nbsp;7(a), on the Offering Date of each Offering Period, each eligible
	Employee participating in such Offering Period shall be granted an option to purchase on each Purchase Date a number of Shares of the Company&#146;s Common Stock determined by dividing such Employee&#146;s Contributions accumulated prior to such
	Purchase Date and retained in the participant&#146;s account as of the Purchase Date by the applicable Purchase Price. Notwithstanding the above, the maximum number of Shares an Employee may purchase during each Offering Period shall be 2,000 Shares
	(subject to any adjustment pursuant to Section&nbsp;18 below), and provided further that such purchase shall be subject to the limitations set forth in Sections 3(b) and 12.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(b) If the Common Stock is listed on any established stock exchange or traded on any established market, the fair market value of the
	Company&#146;s Common Stock on a given date (the &#147;
<U>
	Fair Market Value
</U>
	&#148;) shall be the closing price of the Common Stock as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the Common
	Stock) on the date of determination, as reported in such source as the Board deems reliable. Unless otherwise provided by the Board, if there is no closing sales price for the Common Stock on the date of determination, then the Fair Market Value
	shall be the closing selling price (or closing bid if no sales were reported) on the last preceding date for which such quotation exists. In the absence of such markets for the Common Stock, the Fair Market Value shall be determined by the Board in
	good faith.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	8.&nbsp;
<B>
<U>
	Exercise of Option
</U>
	.
</B>
	&nbsp;Unless a participant withdraws from the Plan as provided in Section&nbsp;10,
	his or her option for the purchase of Shares will be exercised automatically on each Purchase Date of an Offering Period, and the maximum number of full Shares subject to the option will be purchased at the applicable Purchase Price with the
	accumulated Contributions in his or her account. No fractional Shares shall be issued. The Shares purchased upon exercise of an option hereunder shall be deemed to be transferred to the participant on the Purchase Date. During his or her lifetime, a
	participant&#146;s option to purchase Shares hereunder is exercisable only by him or her.
</P>
<A NAME="eolPage156"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	9.&nbsp;
<B>
<U>
	Delivery
</U>
	.
</B>
	&nbsp;As promptly as practicable after each Purchase Date of each
	Offering Period, the Company shall arrange the delivery to each participant, as appropriate, of the Shares purchased upon exercise of his or her option. No fractional Shares shall be purchased; any payroll deductions accumulated in a
	participant&#146;s account which are not sufficient to purchase a full Share shall be retained in the participant&#146;s account for the subsequent Offering Period, subject to earlier withdrawal by the participant as provided in Section&nbsp;10
	below. Any other amounts left over in a participant&#146;s account after a Purchase Date shall be returned to the participant.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	10.&nbsp;
<B>
<U>
	Voluntary Withdrawal; Termination of Employment
</U>
	.
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(a) A participant may withdraw all but not less than all the Contributions credited to his or her account under the Plan at any time prior to
	each Purchase Date by giving notice to the Company through the Company&#146;s electronic ESPP interface (or such other method as the Company may specify) at least ten days prior to the Purchase Date. All of the participant&#146;s Contributions
	credited to his or her account will be paid to him or her promptly after receipt of his or her notice of withdrawal and his or her option for the current period will be automatically terminated, and no further Contributions for the purchase of
	Shares will be made during the Offering Period.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(b) Upon termination of the participant&#146;s Continuous Status as an Employee prior to
	the Purchase Date of an Offering Period for any reason, including retirement or death, the Contributions credited to his or her account will be returned to him or her or, in the case of his or her death, to the person or persons entitled thereto
	under Section&nbsp;14, and his or her option will be automatically terminated.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(c) In the event an Employee fails to remain in Continuous
	Status as an Employee of the Company for at least twenty (20)&nbsp;hours per week during the Offering Period in which the employee is a participant, he or she will be deemed to have elected to withdraw from the Plan and the Contributions credited to
	his or her account will be returned to him or her and his or her option terminated.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(d) A participant&#146;s withdrawal from an offering
	will not have any effect upon his or her eligibility to participate in a succeeding offering or in any similar plan which may hereafter be adopted by the Company.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	11.&nbsp;
<B>
<U>
	Interest
</U>
	.
</B>
	&nbsp;No interest shall accrue on the Contributions of a participant in the Plan.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	12.&nbsp;
<B>
<U>
	Stock
</U>
	.
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(a) Subject to adjustment as provided in Section&nbsp;18, the maximum number of Shares which shall be made available for sale under the Plan
	shall be 1,896,190 Shares. If any option granted under the Plan shall for any reason terminate without having been exercised, the shares of Common Stock not purchased under such option shall again become available for issuance under the Plan. If the
	Board determines that, on a given Purchase Date, the number of shares with respect to which options are to be exercised may exceed (i)&nbsp;the number of shares of Common Stock that were available for sale under the Plan on the Offering Date of the
	applicable Offering Period, or (ii)&nbsp;the number of shares available for sale under the Plan on such Purchase Date, the Board may in its sole discretion provide (x)&nbsp;that the Company shall make a pro rata allocation of the Shares of Common
	Stock available for purchase on such Offering Date or Purchase Date, as applicable, in as uniform a manner as shall be practicable and as it shall determine in its sole discretion to be equitable among all participants exercising options to purchase
	Common Stock on such Purchase Date, and continue all Offering Periods then in effect, or (y)&nbsp;that the Company shall make a pro rata allocation of the shares available for purchase on such Offering Date or Purchase Date, as applicable, in as
	uniform a manner as shall be practicable and as it shall determine in its sole discretion to be equitable among all participants exercising options to purchase Common Stock on such Purchase Date, and terminate any or all Offering Periods then in
	effect pursuant to Section&nbsp;19 below. The Company may make pro rata allocation of the Shares available on the Offering Date of any applicable Offering Period pursuant to the preceding sentence, notwithstanding any authorization of additional
	Shares for issuance under the Plan by the Company&#146;s stockholders subsequent to such Offering Date.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(b) The participant shall have no
	interest or voting right in Shares covered by his or her option until such option has been exercised.
</P>
<A NAME="eolPage157"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(c) Shares to be delivered to a participant under the Plan will be registered in the name of the
	participant or in the name of the participant and his or her spouse.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	13.&nbsp;
<B>
<U>
	Administration
</U>
	.
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(a) The Board shall administer the Plan unless and until the Board delegates administration of the Plan to a Committee or Committees, as
	provided in Section&nbsp;13(c).
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(b) The Board shall have the power, subject to, and within the limitations of, the express provisions of
	the Plan:
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:13%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(i) To determine how and when options to purchase Shares shall be granted and the provisions of each Offering Period (which
	need not be identical).
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:13%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(ii) To designate from time to time which Subsidiaries of the Company shall be eligible to participate in the
	Plan.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:13%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(iii) To construe and interpret the Plan and options, and to establish, amend and revoke rules and regulations for its
	administration. The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan, in a manner and to the extent it shall deem necessary or expedient to make the Plan fully effective.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:13%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(iv) To settle all controversies regarding the Plan and options granted under it.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:13%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(v) To amend, suspend or terminate the Plan at any time as provided in Section&nbsp;19.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:13%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(vi) Generally, to exercise such powers and to perform such acts as it deems necessary or expedient to promote the best interests of the
	Company and its Subsidiaries and to carry out the intent that the Plan be treated as an Employee Stock Purchase Plan.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:13%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(vii) To adopt
	such procedures and sub-plans as are necessary or appropriate to permit participation in the Plan by Employees who are foreign nationals or employed outside the United States.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(c) The Board may delegate some or all of the administration of the Plan to a Committee or Committees. If administration is delegated to a
	Committee, the Committee shall have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to delegate to a subcommittee any of the
	administrative powers the Committee is authorized to exercise (and references in this Plan to the Board shall thereafter be to the Committee or subcommittee), subject, however, to such resolutions, not inconsistent with the provisions of the Plan,
	as may be adopted from time to time by the Board. The Board may retain the authority to concurrently administer the Plan with the Committee and may, at any time, revest in the Board some or all of the powers previously delegated. Whether or not the
	Board has delegated administration of the Plan to a Committee, the Board shall have the final power to determine all questions of policy and expediency that may arise in the administration of the Plan.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(d) All determinations, interpretations and constructions made by the Board in good faith shall not be subject to review by any person and
	shall be final, binding and conclusive on all persons.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	14.&nbsp;
<B>
<U>
	Designation of Beneficiary
</U>
	.
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(a) A participant may file a written designation of a beneficiary who is to receive any Shares and cash, if any, from the participant&#146;s
	account under the Plan in the event of such participant&#146;s death subsequent to the end of an Offering Period but prior to delivery to him or her of such Shares and cash. In addition, a participant may file a written designation of a beneficiary
	who is to receive any cash from the participant&#146;s account under the Plan in the event of such participant&#146;s death prior to the Purchase Date of an Offering Period. If a participant is married and the designated beneficiary is not the
	spouse, spousal consent shall be required for such designation to be effective.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(b) Such designation of beneficiary may be changed by the
	participant (and his or her spouse, if any) at any time by written notice. In the event of the death of a participant and in the absence of a beneficiary validly designated under the Plan who is living at the time of such participant&#146;s death,
	the Company shall deliver such
</P>
<A NAME="eolPage158"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Shares and/or cash to the executor or administrator of the estate of the participant, or if no such executor or administrator has been appointed (to the knowledge of the Company), the Company, in
	its discretion, may deliver such Shares and/or cash to the spouse or to any one or more dependents or relatives of the participant, or if no spouse, dependent or relative is known to the Company, then to such other person as the Company may
	designate.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	15.&nbsp;
<B>
<U>
	Transferability
</U>
	.
</B>
	&nbsp;Neither Contributions credited to a participant&#146;s account nor any rights
	with regard to the exercise of an option or to receive Shares under the Plan may be assigned, transferred, pledged or otherwise disposed of in any way (other than by will, the laws of descent and distribution, or as provided in Section&nbsp;14) by
	the participant. Any such attempt at assignment, transfer, pledge or other disposition shall be without effect, except that the Company may treat such act as an election to withdraw funds in accordance with Section&nbsp;10.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	16.&nbsp;
<B>
<U>
	Use of Funds
</U>
	.
</B>
	&nbsp;All Contributions received or held by the Company under the Plan may be used by the Company for any
	corporate purpose, and the Company shall not be obligated to segregate such Contributions. Proceeds from the sale of shares of Common Stock pursuant to options granted under the Plan shall constitute general funds of the Company.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	17.&nbsp;
<B>
<U>
	Reports
</U>
	.
</B>
	&nbsp;Individual accounts will be maintained for each participant in the Plan. Statements of account will be
	given to participating Employees at least annually, which statements will set forth the amounts of Contributions, the per Share Purchase Price, the number of Shares purchased and the remaining cash balance, if any.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	18.&nbsp;
<B>
<U>
	Adjustments Upon Changes in Capitalization; Corporate Transactions
</U>
	.
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(a)&nbsp;
<B>
<U>
	Adjustment
</U>
	.
</B>
	&nbsp;Subject to any required action by the stockholders of the Company, the number of Shares covered by each
	option under the Plan which has not yet been exercised and the number of Shares which have been authorized for issuance under the Plan but have not yet been placed under option (collectively, the &#147;
<U>
	Reserves
</U>
	&#148;), as well as the maximum
	number of shares of Common Stock which may be purchased by a participant in an Offering Period, the number of shares of Common Stock set forth in Section&nbsp;12(a) above, and the price per Share of Common Stock covered by each option under the Plan
	which has not yet been exercised, shall be proportionately adjusted for any increase or decrease in the number of issued Shares resulting from a stock split, reverse stock split, stock dividend, dividend in property other than cash, liquidating
	dividend, combination, exchange or reclassification of the Common Stock (including any such change in the number of Shares of Common Stock effected in connection with a change in domicile of the Company), or any other increase or decrease in the
	number of Shares effected without receipt of consideration by the Company (through merger, consolidation, reorganization, recapitalization, change in corporate structure or other similar transaction); provided however that conversion of any
	convertible securities of the Company shall not be deemed to have been &#147;effected without receipt of consideration.&#148; Such adjustment shall be made by the Board, whose determination in that respect shall be final, binding and conclusive.
	Except as expressly provided herein, no issue by the Company of shares of stock of any class, or securities convertible into shares of stock of any class, shall affect, and no adjustment by reason thereof shall be made with respect to, the number or
	price of Shares subject to an option.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(b)&nbsp;
<B>
<U>
	Corporate Transactions
</U>
	.&nbsp;
</B>
	In the event of a dissolution or liquidation of
	the Company, any Offering Period then in progress will terminate immediately prior to the consummation of such action, unless otherwise provided by the Board. In the event of a Corporate Transaction, each option outstanding under the Plan shall be
	assumed or an equivalent option shall be substituted by the successor corporation or a parent or Subsidiary of such successor corporation. In the event that the successor corporation refuses to assume or substitute for outstanding options, the
	Offering Period then in progress shall be shortened and a new Purchase Date shall be set (the &#147;
<U>
	New Purchase Date
</U>
	&#148;), as of which date the Offering Period then in progress will terminate. The New Purchase Date shall be on or before
	the date of consummation of the transaction and the Board shall notify each participant in writing, at least ten (10)&nbsp;days prior to the New Purchase Date, that the Purchase Date for his or her option has been changed to the New Purchase Date
	and that his or her option will be exercised automatically on the New Purchase Date, unless prior to such date he or she has withdrawn from the Offering Period as provided in Section&nbsp;10. For purposes of this Section&nbsp;18, an option granted
	under the Plan shall be deemed to be assumed, without limitation, if, at the time of issuance of the stock or other consideration upon a Corporate Transaction, each holder of an option under the Plan would be entitled to receive upon exercise of the
	option the same number and kind of shares of stock or the same amount of property, cash or securities as such holder would have been entitled to receive upon the occurrence of the transaction if the holder had been, immediately prior to the
	transaction, the holder of the number of Shares of Common Stock covered by the option at such time (after giving effect to any adjustments in the number of Shares
</P>
<A NAME="eolPage159"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	covered by the option as provided for in this Section&nbsp;18); provided however that if the consideration received in the transaction is not solely common stock of the successor corporation or
	its parent (as defined in Section&nbsp;424(e) of the Code), the Board may, with the consent of the successor corporation, provide for the consideration to be received upon exercise of the option to be solely common stock of the successor corporation
	or its parent equal in Fair Market Value to the per Share consideration received by holders of Common Stock in the transaction.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Board
	may, if it so determines in the exercise of its sole discretion, also make provision for adjusting the Reserves, as well as the price per Share of Common Stock covered by each outstanding option, in the event that the Company effects one or more
	reorganizations, recapitalizations, rights offerings or other increases or reductions of Shares of its outstanding Common Stock, and in the event of the Company&#146;s being consolidated with or merged into any other corporation.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	19.&nbsp;
<B>
<U>
	Amendment or Termination
</U>
	.
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(a) The Board may at any time and for any reason terminate or amend the Plan. Except as provided in Section&nbsp;18, no such termination of the
	Plan may affect options previously granted, provided that the Plan or an Offering Period may be terminated by the Board on a Purchase Date or by the Board&#146;s setting a new Purchase Date with respect to an Offering Period then in progress if the
	Board determines that termination of the Plan and/or the Offering Period is in the best interests of the Company and the stockholders. Except as provided in Section&nbsp;18 and in this Section&nbsp;19, no amendment to the Plan shall make any change
	in any option previously granted which adversely affects the rights of any participant. In addition, to the extent necessary to comply with Rule 16b-3 under the Exchange Act, or under Section&nbsp;423 of the Code (or any successor rule or provision
	or any applicable law or regulation), the Company shall obtain stockholder approval in such a manner and to such a degree as so required.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(b) Without stockholder consent and without regard to whether any participant rights may be considered to have been adversely affected, the
	Board (or its Committee) shall be entitled to change the Offering Periods, limit the frequency and/or number of changes in the amount withheld during an Offering Period, establish the exchange ratio applicable to amounts withheld in a currency other
	than U.S. dollars, permit payroll withholding in excess of the amount designated by a participant in order to adjust for delays or mistakes in the Company&#146;s processing of properly completed withholding elections, establish reasonable waiting
	and adjustment periods and/or accounting and crediting procedures to ensure that amounts applied toward the purchase of Common Stock for each participant properly correspond with amounts withheld from the participant&#146;s Compensation, and
	establish such other limitations or procedures as the Board (or its Committee) determines in its sole discretion advisable which are consistent with the Plan.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	20.&nbsp;
<B>
<U>
	Notices
</U>
	.
</B>
	&nbsp;All notices or other communications by a participant to the Company under or in connection with the Plan
	shall be deemed to have been duly given when received in the form specified by the Company at the location, or by the person, designated by the Company for the receipt thereof.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	21.&nbsp;
<B>
<U>
	Conditions Upon Issuance of Shares
</U>
	.
</B>
	&nbsp;Shares shall not be issued with respect to an option unless the exercise of
	such option and the issuance and delivery of such Shares pursuant thereto shall comply with all applicable provisions of law, domestic or foreign, including, without limitation, the Securities Act, the Exchange Act, the rules and regulations
	promulgated thereunder, applicable state securities laws and the requirements of any stock exchange upon which the Shares may then be listed, and shall be further subject to the approval of counsel for the Company with respect to such compliance.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	As a condition to the exercise of an option, the Company may require the person exercising such option to represent and warrant at the
	time of any such exercise that the Shares are being purchased only for investment and without any present intention to sell or distribute such Shares if, in the opinion of counsel for the Company, such a representation is required by any of the
	aforementioned applicable provisions of law.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	22.&nbsp;
<B>
<U>
	Effective Date
</U>
	.
</B>
	&nbsp;The Plan became effective on May&nbsp;20, 2011.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	23.&nbsp;
<B>
<U>
	Miscellaneous Provisions
</U>
	.
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(a) A participant shall not be deemed to be the holder of, or to have any of the rights of a holder with respect to, Shares subject to options
	unless and until the participant&#146;s Shares acquired upon exercise of options under the Plan are recorded in the books of the Company (or its transfer agent).
</P>
<A NAME="eolPage160"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(b) The Plan does not constitute an employment contract. Nothing in the Plan shall in any way
	alter the at will nature of an Employee&#146;s employment or be deemed to create in any way whatsoever any obligation on the part of any Employee to continue in the employ of the Company or a Subsidiary, or on the part of the Company or a Subsidiary
	to continue the employment of an Employee.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(c) The provisions of the Plan shall be governed by the laws of the State of Washington
	without resort to that state&#146;s conflicts of laws rules.
</P>
</EFX_EXHIBIT_10>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage161"></A>
<A NAME="D481013DEX1056_HTM"></A>
<EFX_EXHIBIT_10>
<A NAME="FIS_EXHIBIT_10_5"></A>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="RIGHT">
<B>
	Exhibit 10.56
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Executive Officer Compensation Information
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The following table sets forth the annual base salary rates for 2016 and 2017 for the executive officers of Seattle Genetics, Inc. (the
	&#147;Company&#148;), in each case based on full-time employment status. The table below also sets forth the bonuses awarded to the Company&#146;s executive officers for the 2016 fiscal year under the Company&#146;s 2016 Senior Executive Annual
	Bonus Plan. The 2017 target bonuses (based on a percentage of annual base pay as of December&nbsp;31, 2016) for the Company&#146;s executive officers under the Company&#146;s Senior Executive Annual Bonus Plan are also set forth in the table below.
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_54"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="53%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="6%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="6%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="6%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="6%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM" NOWRAP>
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:52.85PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Name and Title
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2016&nbsp;Annual
<BR>
	Base&nbsp;Salary&nbsp;Rate
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2016
<BR>
	Bonus
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2017
<BR>
	Annual
<BR>
	Base&nbsp;Salary
<BR>
	Rate
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2017&nbsp;Target
<BR>
	Bonus&nbsp;Percentage
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Clay B. Siegall, Ph.D.
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	855,750
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	985,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	890,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	100
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	President&nbsp;&amp; Chief Executive Officer
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Todd E. Simpson
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	476,900
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	269,500
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	493,600
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	50
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Chief Financial Officer
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Eric L. Dobmeier
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	535,615
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	261,800
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	555,706
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	50
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Chief Operating Officer
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Jonathan Drachman
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	512,200
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	294,600
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	531,450
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	50
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Chief Medical Officer and Executive Vice President, Research and Development
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Vaughn Himes
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	460,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	246,900
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	478,400
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	50
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Chief Technical Officer
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Darren Cline
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	440,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	221,700
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	454,300
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	45
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Executive Vice President, Commercial
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_55"></A>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Director Compensation Information
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The following table sets forth the compensation components for non-employee members of the Company&#146;s Board of Directors for 2016 and 2017,
	including equity awards.
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="74%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="6%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="6%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM" NOWRAP>
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:79.70PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Compensation Element
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2016
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2017
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	General Board Service &#150; Cash Retainer
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	50,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	50,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
<U>
	General Board Service &#150; Equity
</U>
</I>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Initial Grant &#150; Number of Options
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	13,275
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	14,250
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Initial Grant &#150; Number of Restricted Stock Units
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	5,310
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	5,750
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Annual Grant &#150; Number of Shares
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	9,260
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	9,260
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Annual Grant &#150; Number of Restricted Stock Units
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3,700
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3,700
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
<U>
	Chair Service &#150; Annual Retainer
</U>
</I>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Lead Director
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	25,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	25,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Audit
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	20,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	20,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Compensation
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	15,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	15,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Nominating&nbsp;&amp; Governance
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	10,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	10,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
<U>
	Committee Member Service &#150; Annual Retainer
</U>
</I>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Audit
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	10,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	10,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Compensation
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	8,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	8,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Nominating&nbsp;&amp; Governance
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	5,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	5,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
</EFX_EXHIBIT_10>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage162"></A>
<A NAME="D481013DEX211_HTM"></A>
<EFX_EXHIBIT_21>
<A NAME="FIS_EXHIBIT_21"></A>
<EFX_SUBSIDIARIES>
<A NAME="FIS_SUBSIDIARIES"></A>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="RIGHT">
<B>
	Exhibit 21.1
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Subsidiaries of Seattle Genetics, Inc.
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="51%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD WIDTH="47%">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM" NOWRAP>
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:20.00PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Name
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Jurisdiction of Incorporation
</B>
</P>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	SeaGen Canada Inc.
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Canada
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	Seattle Genetics UK, Limited
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	England and Wales
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	SeaGen International GmbH
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Switzerland
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	SeaGen International Holdings, Inc.
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	United States
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	SeaGen US Holdings, Inc.
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	United States
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	SeaGen, Inc.
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	United States
</TD>
</TR>
</TABLE>
</EFX_SUBSIDIARIES>
</EFX_EXHIBIT_21>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage163"></A>
<A NAME="D481013DEX231_HTM"></A>
<EFX_EXHIBIT_23>
<A NAME="FIS_EXHIBIT_23"></A>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="RIGHT">
<B>
	Exhibit 23.1
</B>
</P>
<EFX_EXPERTS_CONSENT>
<A NAME="FIS_EXPERTS_CONSENT"></A>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<U>
	CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
</U>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-212688, 333-204331,
<FONT STYLE="WHITE-SPACE:NOWRAP">
	333-197992,
</FONT>
	333-188446, 333-176144, 333-168672, 333-148188, 333-56670) of Seattle Genetics, Inc., and the Registration Statement on Form S-3 (No. 333-206846) of our report dated February 21, 2017 relating to
	the financial statements and the effectiveness of internal control over financial reporting, which is incorporated in this Annual Report on Form 10-K.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	/s/ PricewaterhouseCoopers LLP
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Seattle, Washington
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	February 21, 2017
</P>
</EFX_EXPERTS_CONSENT>
</EFX_EXHIBIT_23>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage164"></A>
<A NAME="D481013DEX311_HTM"></A>
<EFX_EXHIBIT_31>
<A NAME="FIS_EXHIBIT_31"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Exhibit 31.1
</B>
</FONT>
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION"></A>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	CERTIFICATIONS
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	I, Clay B. Siegall, certify that:
</FONT>
</P>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1.
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	I have reviewed this Annual Report on Form 10-K of Seattle Genetics, Inc.;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2.
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
	light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	3.
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial
	condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	4.
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The registrant&#146;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act
	Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	a)
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
	information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	b)
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
	reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	c)
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the
	disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	d)
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal
	quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	5.
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The registrant&#146;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
	registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions):
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	a)
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely
	affect the registrant&#146;s ability to record, process, summarize and report financial information; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	b)
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial
	reporting.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Date: February&nbsp;21, 2017
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<DIV ALIGN="RIGHT">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">
<TR>
<TD WIDTH="100%">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX;BORDER-BOTTOM:1PX SOLID #000000" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	/s/ Clay B. Siegall&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Clay B. Siegall
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Chief Executive Officer
</I>
</FONT>
</P>
</TD>
</TR>
</TABLE>
</DIV>
</EFX_CERTIFICATION>
</EFX_EXHIBIT_31>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage165"></A>
<A NAME="D481013DEX312_HTM"></A>
<EFX_EXHIBIT_31>
<A NAME="FIS_EXHIBIT_31_2"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Exhibit 31.2
</B>
</FONT>
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION_2"></A>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	CERTIFICATIONS
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	I, Todd E. Simpson, certify that:
</FONT>
</P>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	1.
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	I have reviewed this Annual Report on Form 10-K of Seattle Genetics, Inc.;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	2.
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
	light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	3.
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial
	condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	4.
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The registrant&#146;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act
	Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	a)
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
	information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	b)
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
	reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	c)
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the
	disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	d)
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal
	quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	5.
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The registrant&#146;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
	registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions):
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	a)
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely
	affect the registrant&#146;s ability to record, process, summarize and report financial information; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	b)
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial
	reporting.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Date: February&nbsp;21, 2017
</FONT>
</P>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<DIV ALIGN="RIGHT">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">
<TR>
<TD WIDTH="100%">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX;BORDER-BOTTOM:1PX SOLID #000000" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	/s/ Todd E. Simpson&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Todd E. Simpson
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Chief Financial Officer
</I>
</FONT>
</P>
</TD>
</TR>
</TABLE>
</DIV>
</EFX_CERTIFICATION>
</EFX_EXHIBIT_31>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage166"></A>
<A NAME="D481013DEX321_HTM"></A>
<EFX_EXHIBIT_32>
<A NAME="FIS_EXHIBIT_32"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Exhibit 32.1
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	SEATTLE GENETICS, INC.
</B>
</FONT>
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION_3"></A>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	CERTIFICATION PURSUANT TO
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	18 U.S.C. SECTION 1350,
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	AS ADOPTED PURSUANT TO
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In connection with the Annual Report of Seattle Genetics, Inc. (the &#147;Company&#148;) on Form 10-K for the year ended
	December&nbsp;31, 2016, as filed with the Securities and Exchange Commission on the date hereof (the &#147;Report&#148;), I, Clay B. Siegall, Chief Executive Officer of the Company, certify, pursuant to Rule 13a-14(b) under the Securities Exchange
	Act of 1934, as amended (the &#147;Exchange Act&#148;), and 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:
</FONT>
</P>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(1)
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The Report fully complies with the requirements of Section&nbsp;13(a) or 15(d) of the Exchange Act; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(2)
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">
<TR>
<TD WIDTH="100%">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	/s/ Clay B. Siegall
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Clay B. Siegall
</FONT>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="BOTTOM">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Chief Executive Officer
</I>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	February&nbsp;21, 2017
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Seattle
	Genetics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.
</FONT>
</P>
</EFX_CERTIFICATION>
</EFX_EXHIBIT_32>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage167"></A>
<A NAME="D481013DEX322_HTM"></A>
<EFX_EXHIBIT_32>
<A NAME="FIS_EXHIBIT_32_2"></A>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="RIGHT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	Exhibit 32.2
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	SEATTLE GENETICS, INC.
</B>
</FONT>
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION_4"></A>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	CERTIFICATION PURSUANT TO
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	18 U.S.C. SECTION 1350,
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	AS ADOPTED PURSUANT TO
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX" ALIGN="CENTER">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<B>
	SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX; TEXT-INDENT:4%">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	In connection with the Annual Report of Seattle Genetics, Inc. (the &#147;Company&#148;) on Form 10-K for the year ended
	December&nbsp;31, 2016, as filed with the Securities and Exchange Commission on the date hereof (the &#147;Report&#148;), I, Todd E. Simpson, Chief Financial Officer of the Company, certify, pursuant to Rule 13a-14(b) under the Securities Exchange
	Act of 1934, as amended (the &#147;Exchange Act&#148;), and 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:
</FONT>
</P>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(1)
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The Report fully complies with the requirements of Section&nbsp;13(a) or 15(d) of the Exchange Act; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="4%">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	(2)
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:12PX;MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">
<TR>
<TD WIDTH="100%">
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX;BORDER-BOTTOM:1PX SOLID #000000">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	/s/ Todd E. Simpson
</FONT>
</P>
</TD>
</TR>
<TR STYLE="PAGE-BREAK-INSIDE:AVOID">
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	Todd E. Simpson
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PX;MARGIN-BOTTOM:1PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
<I>
	Chief
	Financial Officer
</I>
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	February&nbsp;21, 2017
</FONT>
</P>
<P STYLE="MARGIN-TOP:6PX;MARGIN-BOTTOM:0PX">
<FONT STYLE="FONT-FAMILY:TIMES NEW ROMAN" SIZE="2">
	This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Seattle
	Genetics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.
</FONT>
</P>
</EFX_CERTIFICATION>
</EFX_EXHIBIT_32>

<!-- FOOTER LOGO -->
</BODY>
</HTML>
